A VISUAL REFERENCE ATLAS

Immunology Guide

Expanded edition · 47 scenes covering 95 mediators plus 126 cells, antibodies, complement components, acute-phase markers, biologic agents and precision therapies. The 95 mediators are drawn across Scenes 1–18 as their structural folds — shown at the specific cell and receptor on which they act, with every intracellular cascade traced to its output and every feedback loop drawn as a closed, traceable path — and catalogued by source cell, function, receptor and signalling class; Scenes 19–38 add the T- and B-cell subsets, the immunoglobulins and Fc receptors, complement, the neutrophil and the acute-phase markers, Scenes 39–43 the biologic and targeted agents that act on them and their effect on the tests, and Scenes 44–47 the precision therapies for inborn errors of immunity.

JAK–STAT signalling NF-κB signalling GPCR / chemotaxisReceptor tyrosine kinaseDeath receptor / cytotoxic Feedback loop

The legend precedes the numbered scenes, which are arranged in sequence: Scenes 1–6 trace the innate response into the adaptive T-helper axes and out to the tissue via chemokine gradients; Scenes 7–18 add the alarmins, the other interferons, regulatory brakes and decoys, barrier and gp130 cytokines, growth factors, B-cell and cytotoxic signals, and the remaining chemokines; Scenes 19–34 then show the cells themselves (every T- and B-cell subset, the immunoglobulins and their Fc receptors, the three complement pathways with their regulators and receptors, and the neutrophil from marrow to resolution), and Scenes 35–38 the acute-phase response that turns those cytokine signals into the CRP, ESR, ferritin and procalcitonin on a results sheet; Scenes 39–43 present the biologic and targeted agents that block those mediators and their effect on each of the tests above, and Scenes 44–47 the precision therapies, immunoglobulin replacement, prophylaxis and vaccination in inborn errors of immunity. Written explanations of every scene are collected in the text guide near the end, separate from the diagrams.

Legend explaining the icon language used throughout the atlas Defines five cytokine molecule shapes by structural fold, three intracellular cascade types, and the arrow conventions for induction, inhibition, and feedback loops. Molecule shapes (by structural fold) Four-helix bundle Most interleukins, IFNs, GM-CSF TNF-family trimer TNF-alpha, TNF-beta/LTA IL-1 family trefoil IL-1a, IL-1b, IL-18, IL-1RA Chemokine fold All chemokines (CC, CXC, C, CX3C) Cystine-knot dimer IL-17 family Intracellular cascades nuc JAK-STAT: receptor → JAK-P → STAT dimer → nucleus → gene NF-kB nuc NF-kB: receptor → adaptor (MyD88/ TRAF/Act1) → NF-kB → gene G directional migration GPCR: 7TM receptor → G-protein → cell crawls up the gradient SOCS: a STAT-induced brake that shuts its own cascade down Arrows Induces / activates Inhibits / blocks ↻ Feedback loop (follow it all the way around) Docking site — where a molecule meets its receptor
1Innate alarm and the regulatory brake
Innate activation via NF-kB, with IL-1RA and IL-10/STAT3 as regulatory brakes TNF-alpha and TNF-beta bind TNFR1/2 and signal through TRADD/TRAF2 (TNFR2 binds TRAF2 directly) to NF-kB. IL-1-alpha and IL-1-beta bind the shared IL-1 receptor and signal through MyD88/IRAK to NF-kB. IL-18 binds its own receptor and signals through a separate MyD88/IRAK adaptor to the same NF-kB. Together these pathways induce pro-inflammatory genes including IL-6, GM-CSF and chemokines; with TLR or CD40 signals the same cell also makes IL-12 and IL-27. IL-1RA blocks the IL-1 receptor. IL-10 signals through a separate JAK1/TYK2/STAT3 pathway to induce a suppressive gene programme that represses NF-kB target-gene transcription and destabilizes pro-inflammatory mRNAs. nucleus Macrophage / dendritic cell TNF-alpha TNF-beta / LTA IL-1 beta IL-1 alpha IL-1RA (antagonist, no signal) IL-18 IL-10 TNFR1/2 IL-1R (shared receptor) IL-18R IL-10R TRADD/TRAF2 MyD88/IRAK MyD88/IRAK NF-kB pro-inflammatory genes suppressive genes IL-10 → STAT3 → represses NF-kB target genes Secreted outputs IL-6 → Scene 4 (Th17) GM-CSF → Scene 5 IL-12 p70 → Scene 2 * IL-27 dual role, Scenes 2 and 4 * IL-8, GRO-a, MCP-1... → Scene 6 Site of interaction: macrophage / dendritic cell surface and cytoplasm TNF-alpha and TNF-beta signal identically downstream of the adaptor; they share TNFR1/TNFR2 * IL-12 p70 and IL-27 also require TLR or CD40 signals; TNF or IL-1 alone induces them poorly
2The Th1 amplification core
The Th1 amplification core: IL-12 and IL-23 share IL-12Rbeta1 while IL-27 uses WSX-1/gp130; IL-18 synergizes via NF-kB; IFN-gamma closes a positive feedback loop to the macrophage and a negative feedback loop via IL-18BP A macrophage secretes IL-12 and IL-27 which bind to a T or NK cell alongside IL-23 and IL-18. IL-12 signals through JAK2/TYK2 to STAT4, IL-23 through JAK2/TYK2 to STAT3, IL-27 through JAK1/JAK2/TYK2 to both STAT1 (early) and STAT3 (late), and IL-18 through MyD88/NF-kB. IL-12, IL-18, and early IL-27 converge on the IFN-gamma gene. Late IL-27 restrains the IL-23/Th17 output, mainly through STAT1 and by inducing IL-10. The T cell secretes IFN-gamma, which loops back to the macrophage to amplify IL-12 transcription and separately induces IL-18 binding protein, which neutralizes free IL-18. Macrophage / DC (from Scene 1) IFNGR IL-12 gene ↑ IL-18BP gene IL-18BP protein neutralizes IL-18 T cell / NK cell IL-18 (from Scene 1) IL-18R MyD88/IRAK NF-kB IL-12 p70 IL-12Rb1/b2 JAK2/TYK2 STAT4 IL-23 IL-23R/IL-12Rb1 JAK2/TYK2 STAT3 IL-27 WSX-1/gp130 JAK1/2, TYK2 early: STAT1 later: +STAT3 early → T-bet later → IL-10 gene IL-27 (late, via STAT1 + IL-10) restrains the IL-23/Th17 output T-bet / IFN-gamma gene (IL-12 + IL-18 + early IL-27 converge here) RORgt / IL-17 gene → Scene 4 (Th17) IL-10 gene IFN-gamma ↻ positive feedback: IFN-gamma amplifies IL-12 transcription IFN-gamma ⊣ Th2 (→ Scene 3) IL-4 ⊣ Th1 (from Scene 3) Site of interaction: T-cell and NK-cell surface (IL-12R, IL-23R, IL-27R, IL-18R) and macrophage cytoplasm (IFN-gamma feedback)
3Th2 / allergic axis
Th2 and allergic axis cytokines acting on epithelium, eosinophils, mast cells, and sensory neurons IL-4 and IL-13 bind to epithelial cells and signal through STAT6 to induce mucus, eotaxin and periostin genes; in T and B cells the same STAT6 drives GATA3 and the IgE switch. IL-5 signals through JAK1/JAK2/STAT5 on eosinophils. IL-9 signals through JAK1/JAK3/STAT5 on mast cells. IL-31 signals through JAK1/JAK2/STAT3 on sensory neurons to drive itch genes. IFN-gamma from the Th1 core suppresses this axis, and IL-4 reciprocally suppresses Th1. Epithelial / Th2 effector cell IL-4 IL-13 IL-4Ra + gamma-c (type I) / IL-4Ra + IL-13Ra1 (type II) JAK1/JAK3 (type I) or JAK1/2/TYK2 (type II) STAT6 mucus / eotaxin / periostin genes (in T / B cells: GATA3, IgE switch) induces Eotaxin → Scene 6 Eosinophil IL-5 shares beta-c with GM-CSF JAK1/JAK2 STAT5 eosinophil differentiation genes Mast cell IL-9 shares gamma-c with IL-2 family JAK1/JAK3 STAT5 mast cell growth genes Sensory neuron (DRG) IL-31 IL-31RA + OSMRb JAK1/JAK2 STAT3 itch signalling (TRPV1/TRPA1) IFN-gamma suppresses Th2 (from Scene 2) IL-4 suppresses Th1 (→ Scene 2) Sites of interaction: epithelium (IL-4/IL-13), eosinophil (IL-5), mast cell (IL-9), sensory neuron (IL-31)
4Th17 axis
Th17 axis: IL-6, IL-23, and IL-21 converge on STAT3; IL-21 forms an autocrine feedback loop; IL-17A signals via Act1/NF-kB while IL-22 signals via JAK/STAT3 on the same epithelial cell A Th17 cell integrates IL-6, IL-23, and IL-21 signals through STAT3 to maintain RORgt expression. It secretes IL-17A, IL-22, and IL-21. IL-21 loops back autocrine to amplify the same cell and also signals a B cell through JAK1/JAK3/STAT3. IL-17A signals an epithelial cell through Act1/TRAF6/NF-kB to induce neutrophil chemokines, while IL-22 signals the same epithelial cell through JAK1/TYK2/STAT3 to induce antimicrobial peptides. IL-27 from Scene 2 restrains this whole axis. Th17 cell IL-6 IL-23 (full receptor detail: Scene 2) IL-21R (autocrine) STAT3 (shared node) RORgt / Th17 identity genes IL-27 restrains (from Scene 2) IL-17A IL-22 IL-21 ↻ autocrine loop IL-21 acts directly on the B cell, not on the epithelium Epithelial / stromal cell IL-17A binds here IL-22 binds here IL-17RA/RC Act1/TRAF6 NF-kB neutrophil chemokines (IL-8, GRO-a) → Scene 6 IL-22R1/IL-10R2 JAK1/TYK2 STAT3 antimicrobial peptide genes B cell IL-21 binds IL-21R + γc JAK1/JAK3 STAT3 antibody / plasma cell genes Sites of interaction: Th17 cell (autocrine), epithelium (IL-17A + IL-22 side by side), B cell (IL-21)
5Survival signals and antiviral defence
Homeostatic survival cytokines, type I interferon, hepatocyte acute-phase response, and myeloid growth factor signalling IL-2, IL-7, and IL-15 signal through JAK1/JAK3/STAT5 on lymphocytes for survival and proliferation, with IL-15 shown trans-presented by a dendritic cell. IFN-alpha signals through JAK1/TYK2 to form the STAT1/STAT2/IRF9 ISGF3 complex, inducing antiviral genes. IL-6 signals hepatocytes through JAK1/JAK2/TYK2/STAT3 to induce acute-phase proteins. GM-CSF signals myeloid progenitors through JAK2/STAT5. Presenting DC Lymphocyte (+IL-9 on mast cells, same STAT5 — Scene 3) IL-2 IL-7 IL-15 held on IL-15Ra trans-presented, not secreted freely shared gamma-c receptor chain JAK1/JAK3 STAT5 survival & proliferation genes Any nucleated cell IFN-alpha IFNAR1 + IFNAR2 JAK1, TYK2 STAT1/STAT2 + IRF9 (ISGF3 complex) antiviral ISGs also activates NK cells Hepatocyte (liver) IL-6 IL-6Rα + gp130 JAK1/2, TYK2 STAT3 acute-phase genes (CRP, fibrinogen) Myeloid progenitor GM-CSF shares beta-c with IL-5 JAK2 STAT5 granulocyte/macrophage genes Sites: lymphocyte (IL-2/7/15), any nucleated cell (IFN-alpha), hepatocyte (IL-6), myeloid progenitor (GM-CSF)
6Chemokine gradients
Chemokine gradients drive directional leukocyte migration via GPCR signalling, distinct from the JAK-STAT and NF-kB cascades in earlier scenes Neutrophils follow IL-8 and GRO-alpha gradients, monocytes and NK cells follow MCP-1, MIP-1-alpha, and MIP-1-beta, eosinophils follow Eotaxin and RANTES, and Th1 cells follow IP-10, which is itself induced by IFN-gamma from Scene 2. Each migrating cell senses the gradient through a G-protein coupled receptor rather than a JAK-STAT pathway. SDF1-alpha/CXCL12 signals through CXCR4 to retain cells in the bone marrow niche rather than recruiting them toward inflammation. site of infection Blood vessel Neutrophil IL-8 / GRO-a (IL-17A-induced, Scene 4) Monocyte / NK cell MCP-1 / MIP-1a / MIP-1b Eosinophil Eotaxin / RANTES (IL-5/IL-4 support this axis, Scene 3) Th1 cell IP-10 / CXCL10 induced by IFN-gamma, Scene 2 Bone marrow niche Stromal niche cell SDF1a stem cell retained CXCR4 signalling here retains haematopoietic stem cells in the marrow niche — constitutive, homeostatic, and directionally opposite to the inflammatory gradients above, although it uses the same GPCR mechanism.
Legend additions for Scenes 7–18
Additional icons used in Scenes 7 to 18 Adds molecule shapes for soluble decoy receptors, small growth factors, perforin, granzymes and HMGB1; the receptor-tyrosine-kinase and death-receptor cascades; and the marks used in the chemokine receptor matrices. Additional molecule shapes (Scenes 7–18) Soluble receptor / decoy IL-12p40, sCD137, sFas Small growth-factor fold EGF, TGFα; also drawn for IL-16 Perforin monomer polymerizes into a pore Serine protease granzymes A and B HMG-box protein HMGB1 Additional cascades and marks PI3K / AKT, RAS / MAPK Receptor tyrosine kinase: ligand dimerizes the receptor, which cross-phosphorylates (P) FADD caspase-8 caspase-3 apoptosis Death receptor (Fas, DR4/DR5). The Y-shaped stem marks any membrane receptor, including TNF-receptor-family members (BAFF-R, BCMA, CD40). signal that is not sent (decoy or blockade) agonist antagonist non-GPCR receptor Chemokine receptor matrices (Scenes 16–17) Colours of the new cell outlines follow the cascade: purple JAK-STAT, amber NF-κB, olive receptor tyrosine kinase, red death receptor / cytotoxic granule, grey decoy, teal chemokine GPCR. Ligand colours follow the family, as in Scenes 1–6. Shared folds: the β-trefoil also draws IL-33 and FGF-2; the cystine knot also draws IL-25, PDGF and VEGF-A. IL-16 (a PDZ-domain protein) reuses the small-fold glyph. The TNF-family trimer also draws BAFF, APRIL, CD40L, 4-1BBL, FasL and TRAIL. Each panel lists, under the cell, the cells that make the mediator.
7Epithelial alarmins and damage signals
Epithelial alarmins and damage signals: IL-33, IL-25, TSLP and HMGB1 IL-33 binds ST2 with IL-1RAcP on ILC2 and Th2 cells and signals through MyD88/IRAK to NF-κB, inducing IL-5 and IL-13; soluble ST2 is a decoy. IL-25 (IL-17E) binds IL-17RA with IL-17RB and signals through Act1/TRAF6 to NF-κB in ILC2 and Th2 memory cells. TSLP binds TSLPR with IL-7R-alpha on dendritic cells and signals through JAK1/JAK2 mainly to STAT5; in DCs OX40L is induced via NF-kB and CCL17 via STAT6, so the DC primes Th2 cells. HMGB1 released from necrotic or activated cells binds RAGE or, in its disulfide form, TLR4 on macrophages, signalling through MyD88 to NF-κB for TNF-alpha and IL-6 release. ILC2 / Th2 cell (also mast cells, basophils, ST2+ Tregs) IL-33 ST2 + IL-1RAcP soluble ST2 (sST2) is a decoy MyD88 / IRAK NF-κB • IL-5, IL-13 genes • eosinophils, mucus (Scene 3) Made by: airway and gut epithelium, endothelium, fibroblastic reticular cells; stored in the nucleus, released on necrosis or mechanical stress Inflammatory ILC2 / Th2 memory cell IL-25 (IL-17E) IL-17RA + IL-17RB Act1 / TRAF6 NF-κB • IL-4, IL-5, IL-13 genes • goblet-cell hyperplasia, helminth expulsion Made by: intestinal tuft cells, airway epithelium; also Th2 cells, mast cells, eosinophils Dendritic cell (also ILC2, mast cells, basophils, itch neurons) TSLP TSLPR (CRLF2) + IL-7Rα JAK1 / JAK2 STAT5 (main TSLP signal) • OX40L (NF-κB) · CCL17/TARC (STAT6) • DC primes Th2 cells Made by: airway, skin (keratinocyte) and gut epithelium; also mast cells, DCs, fibroblasts Macrophage / dendritic cell HMGB1 RAGE; TLR4 (disulfide form) fully reduced HMGB1 + CXCL12 instead acts on CXCR4 (chemotaxis) TLR4 → MyD88 RAGE → MAPK NF-κB • TNF-α, IL-6 genes • innate alarm (Scene 1) Made by: any necrotic cell (passive release); activated macrophages, monocytes, DCs, NK cells (active secretion) Sites of interaction: ILC2 / Th2 cells (IL-33, IL-25), dendritic cell (TSLP), macrophage (HMGB1)
8Interferons beyond IFN-α: type I and type III
Type I interferons IFN-beta and IFN-omega versus type III interferons IL-28A and IL-29 IFN-beta and IFN-omega bind IFNAR1/IFNAR2, present on almost every nucleated cell, and signal through JAK1/TYK2 to the ISGF3 complex (STAT1:STAT2:IRF9), inducing antiviral interferon-stimulated genes. Among them is IRF7, which amplifies further IFN-alpha/beta production: a positive feedback loop. IL-28A (IFN-lambda2) and IL-29 (IFN-lambda1) bind a different receptor, IFNLR1 with IL-10R2, which is largely restricted to barrier epithelium and hepatocytes, but reach the same JAK1/TYK2 to ISGF3 programme. Any nucleated cell IFNβ IFNAR1 + IFNAR2 highest-affinity type I IFN JAK1 / TYK2 ISGF3 (STAT1 : STAT2 : IRF9) antiviral ISGs, incl. IRF7 IRF7 → more IFN-α/β in virus-sensing cells (+ feedback) Made by: fibroblasts, epithelial cells, macrophages and DCs (first IFN after IRF3 activation); also pDCs Any nucleated cell IFNω IFNAR1 + IFNAR2 JAK1 / TYK2 ISGF3 (STAT1 : STAT2 : IRF9) • antiviral ISGs • (same programme as IFN-α, Scene 5) Made by: leukocytes: pDCs and monocytes, co-produced with IFN-α Barrier epithelial cell / hepatocyte (also neutrophils, pDCs) IL-28A (IFN-λ2) IFNLR1 + IL-10R2 JAK1 / TYK2 ISGF3 (STAT1 : STAT2 : IRF9) • antiviral ISGs • barrier protection, less systemic inflammation Made by: airway and gut epithelial cells, hepatocytes, pDCs and DCs Barrier epithelial cell / hepatocyte (also neutrophils, pDCs) IL-29 (IFN-λ1) IFNLR1 + IL-10R2 JAK1 / TYK2 ISGF3 (STAT1 : STAT2 : IRF9) • antiviral ISGs • (same programme as IL-28A) Made by: epithelial cells, hepatocytes, pDCs and DCs (IFNL1 is a pseudogene in mice) Type I IFN · IFNAR1 + IFNAR2 (almost every nucleated cell) Type III IFN (IFN-λ) · IFNLR1 + IL-10R2 (barrier cells) Sites of interaction: any nucleated cell (type I); barrier epithelium and hepatocytes (type III)
9Regulatory brakes and soluble decoys
Regulatory brakes and soluble decoys: IL-12p40, IL-35, sCD137 and sFas Free IL-12p40 and its homodimer occupy IL-12R-beta1, the chain shared by the IL-12 and IL-23 receptors, without activating JAK-STAT, so they compete with IL-12 and IL-23. IL-35 from regulatory T and B cells binds IL-12R-beta2 and gp130 on effector T cells and signals through JAK1/JAK2 to a STAT1:STAT4 heterodimer; it suppresses proliferation and Th17, and converts the target into an IL-35-producing iTr35 cell, so that suppression is self-propagating. Soluble CD137 captures 4-1BB ligand so 4-1BB co-stimulation of CD8 T cells is not engaged. Soluble Fas captures Fas ligand so Fas-mediated apoptosis is not triggered. T cell / NK cell IL-12p40 (free p40 / p80) occupies IL-12Rβ1 IL-12Rβ1 (shared by IL-12R and IL-23R) no JAK2 / TYK2 → STAT activation competes with IL-12 (STAT4) / IL-23 (STAT3) Made by: activated macrophages, monocytes, DCs, neutrophils; p40 is made in large excess over IL-12p70 (p80 antagonism shown mainly in mice) Conventional (effector) T cell IL-35 (p35 + EBI3) IL-12Rβ2 + gp130 (on T cells) (or homodimers of either chain) JAK1 / JAK2 STAT1 : STAT4 • ↓ proliferation, ↓ Th17 • converts the cell to an IL-35-producing iTr35 new iTr35 cells make IL-35 (infectious tolerance) Made by: regulatory T cells (firmly in mice; inducible iTr35 in humans), regulatory B cells CD8 T cell 4-1BBL sCD137 captured 4-1BBL cannot reach 4-1BB 4-1BB (CD137) left unengaged TRAF1/2 → NF-κB not sent less CD8 T-cell expansion and survival Made by: activated T cells and NK cells (alternatively spliced form), some tumours; serum marker of T-cell activation Activated lymphocyte / Fas+ target cell FasL sFas captured FasL cannot reach Fas Fas (CD95) left unengaged FADD → caspase-8 not triggered Fas-mediated apoptosis prevented Made by: activated lymphocytes and many tissues (exon-skipping splice variant) IL-12-family brakes Soluble decoy receptors Dashed red blunt arrow = receptor occupied (IL-12p40) or ligand kept from its receptor by capture (sCD137, sFas); dashed grey box = the signal that is not sent. sCD137 is soluble 4-1BB; sFas is soluble CD95.
10Barrier-tissue and gp130-family cytokines
Barrier-tissue cytokines IL-17F, IL-20 and IL-24, and gp130-family cytokines IL-11 and LIF IL-17F binds IL-17RA/IL-17RC on epithelial cells and fibroblasts and signals through Act1/TRAF6 to NF-κB and C/EBP-beta, inducing neutrophil chemokines, G-CSF and beta-defensins more weakly than IL-17A. IL-20 and IL-24 bind IL-20R1/IL-20R2 or IL-22R1/IL-20R2 on keratinocytes and signal through JAK1/TYK2 to STAT3, driving proliferation; IL-24 also lowers filaggrin. IL-11 binds IL-11R-alpha with a gp130 homodimer on fibroblasts and signals through JAK1 (with JAK2, TYK2) to STAT3, with ERK-dependent fibrotic signalling; fibroblasts both make and respond to IL-11, an autocrine loop. LIF binds LIFR with gp130 and signals through JAK1 (with JAK2, TYK2) to STAT3 for mouse ES-cell self-renewal, implantation and acute-phase proteins. Epithelial cell / fibroblast IL-17F IL-17RA + IL-17RC (homodimer or IL-17A/F heterodimer) Act1 / TRAF6 NF-κB NF-κB, C/EBPβ • CXCL1, CXCL5, G-CSF, β-defensins • weaker than IL-17A (Scene 4) Made by: Th17 cells, γδ T cells, ILC3, MAIT cells; some epithelial cells Keratinocyte IL-20 IL-20R1 + IL-20R2 or IL-22R1 + IL-20R2 JAK1 / TYK2 STAT3 keratinocyte proliferation, antimicrobial peptides Made by: keratinocytes, monocytes, macrophages, DCs Keratinocyte IL-24 IL-20R1 + IL-20R2 or IL-22R1 + IL-20R2 JAK1 / TYK2 STAT3 • keratinocyte proliferation • ↓ filaggrin (IL-13-induced; atopic-dermatitis barrier defect) Made by: keratinocytes, Th2 and Th17 cells, monocytes, melanocytes Fibroblast (also MK progenitors) IL-11 IL-11Rα + gp130 homodimer JAK1 (JAK2, TYK2) STAT3 (+ SHP2 → ERK) fibroblast activation, fibrosis (ERK-dependent) autocrine: fibroblasts make and respond to IL-11 Made by: fibroblasts (TGF-β-induced, major), bone-marrow stroma, epithelial cells, osteoblasts Stem cell / hepatocyte / neuron LIF LIFR + gp130 JAK1 (JAK2, TYK2) STAT3 • mouse ES-cell self-renewal • implantation • acute-phase proteins • neuron survival Made by: activated T cells, monocytes, fibroblasts, astrocytes, endometrium, bone-marrow stroma Barrier tissue: IL-17 family · IL-20 subfamily (IL-10 family) IL-6 / gp130 family Sites of interaction: epithelium and fibroblasts (IL-17F), keratinocytes (IL-20, IL-24), fibroblasts (IL-11), stem cells, hepatocytes, neurons (LIF)
11Haematopoietic growth factors
Haematopoietic growth factors: IL-3, G-CSF, TPO via JAK-STAT; M-CSF, IL-34, SCF and Flt-3 ligand via receptor tyrosine kinases IL-3 binds IL-3R-alpha (CD123) with the common beta chain and signals through JAK2 to STAT5 in progenitors, basophils and mast cells. G-CSF binds a G-CSFR homodimer on neutrophil precursors and signals through JAK1/JAK2 to STAT3. Thrombopoietin binds MPL on megakaryocytes and stem cells and signals through JAK2 to STAT5. M-CSF and IL-34 share the receptor tyrosine kinase CSF1R on monocytes and macrophages; SCF binds KIT on mast cells and stem cells; Flt-3 ligand binds FLT3 on dendritic-cell progenitors. These receptor tyrosine kinases dimerize, cross-phosphorylate and signal through PI3K/AKT and RAS/MAPK. Progenitor / basophil / mast cell IL-3 IL-3Rα (CD123) + βc (CD131) βc shared with IL-5 and GM-CSF JAK2 STAT5 • multilineage progenitor growth • basophil / mast-cell growth and priming • pDC survival Made by: activated T cells (Th2), mast cells, basophils, NK cells Neutrophil precursor G-CSF G-CSFR (CSF3R) homodimer JAK1 / JAK2 STAT3 (also STAT5) • neutrophil production, release, survival • stem-cell mobilization Made by: monocytes, macrophages, endothelium, fibroblasts, epithelium (strongly IL-17-induced, Scene 4) Megakaryocyte / stem cell TPO MPL (TPO receptor) JAK2 STAT5 (also STAT3) • megakaryocyte growth → platelets • stem-cell quiescence Made by: liver hepatocytes (constant output); plasma level set by platelet MPL clearance; also kidney, marrow stroma Monocyte / macrophage M-CSF IL-34 CSF1R (c-FMS) shared by both ligands; IL-34 also binds PTPRZ1 PI3K / AKT, ERK • macrophage survival, proliferation, differentiation • IL-34: Langerhans cells, microglia Made by: M-CSF: fibroblasts, osteoblasts, endothelium, marrow stroma; IL-34: keratinocytes, neurons, splenic stroma Mast cell / stem cell SCF (KIT ligand) KIT (CD117) PI3K / AKT, MAPK, (STAT) • mast-cell development, survival, activation • stem-cell maintenance Made by: marrow stroma and endothelium, fibroblasts, keratinocytes, airway epithelium and smooth muscle Dendritic-cell progenitor Flt-3 Ligand FLT3 (CD135) PI3K / AKT, RAS / MAPK, STAT5 • cDC and pDC development • early progenitor expansion Made by: bone-marrow stroma, T cells, endothelium (membrane and soluble forms) Cytokine receptors · JAK-STAT Receptor tyrosine kinases Sites of interaction: bone-marrow progenitors and their descendants; tissue mast cells and macrophages
12Tissue growth factors and angiogenesis
Tissue growth factors and angiogenesis: EGF and TGF-alpha, FGF-2, PDGF-AA, PDGF-AB/BB and VEGF-A EGF and TGF-alpha share EGFR on epithelial cells and keratinocytes. FGF-2 binds FGFR with heparan sulfate on fibroblasts and endothelium. PDGF-AA binds the PDGFR-alpha homodimer on fibroblasts and oligodendrocyte precursors; PDGF-BB binds all three PDGFR dimers and PDGF-AB binds alpha-alpha and alpha-beta, recruiting pericytes and smooth muscle. VEGF-A binds VEGFR2 with neuropilin-1 on endothelial cells, while VEGFR1 acts as a high-affinity sink. Each receptor is a tyrosine kinase that dimerizes and signals through RAS/MAPK, PI3K/AKT and PLC-gamma. Epithelial cell / keratinocyte EGF TGFα EGFR (ErbB1) shared by both ligands RAS / MAPK, PI3K / AKT, PLCγ • epithelial proliferation, migration • wound re-epithelialization • airway MUC5AC mucus Made by: EGF: salivary and Brunner’s glands, kidney, platelets, macrophages; TGFα: macrophages, keratinocytes, epithelium, eosinophils (ADAM17-shed) Fibroblast / endothelial cell FGF-2 (basic FGF) FGFR1–4 + heparan sulfate RAS / MAPK, PI3K, PLCγ • angiogenesis • fibroblast growth • wound healing • airway smooth-muscle growth Made by: fibroblasts, endothelium, macrophages, mast cells, smooth muscle (released on injury: no signal peptide) Fibroblast / oligodendrocyte precursor PDGF-AA PDGFRα homodimer (αα) PI3K, PLCγ, RAS / MAPK • fibroblast / OPC proliferation • alveolar myofibroblasts Made by: platelets (α-granules), macrophages, epithelial cells, astrocytes, smooth muscle Pericyte / smooth-muscle cell / fibroblast PDGF-AB/BB PDGFRαα, αβ, ββ BB binds all three; AB binds αα and αβ PI3K, PLCγ, RAS / MAPK • pericyte and smooth-muscle recruitment to vessels • fibroblast chemotaxis • airway remodelling Made by: platelets (major), macrophages, endothelium, smooth muscle Endothelial cell VEGF-A VEGFR2 (KDR) + neuropilin-1 VEGFR1 (FLT1): high-affinity sink PLCγ / ERK, PI3K / AKT / eNOS • angiogenesis • vascular permeability (oedema) • endothelial survival Made by: hypoxic epithelial and tumour cells (HIF-1α), macrophages, keratinocytes, mast cells, eosinophils, neutrophils, platelets Sites of interaction: epithelium and skin (EGFR), fibroblasts and vessel wall (FGFR, PDGFR), endothelium (VEGFR2)
13TNF superfamily: B-cell survival and co-stimulation
TNF-superfamily B-cell signals: BAFF, APRIL and soluble CD40 ligand BAFF binds BAFF-R on transitional and mature naive B cells; this degrades TRAF3, freeing NIK to activate the non-canonical NF-κB pathway (p52/RelB) and B-cell survival genes. APRIL binds BCMA on long-lived plasma cells and TACI on B cells, activating canonical and non-canonical NF-κB for plasma-cell survival and IgA switching. Soluble CD40 ligand binds CD40 on B cells, recruiting TRAF2/3/5/6 to canonical and non-canonical NF-κB and driving class switching and germinal-centre responses. Transitional / mature naive B cell BAFF (BLyS) BAFF-R (BR3) BAFF also binds TACI and BCMA TRAF3 degraded → NIK freed NF-κB non-canonical NF-κB (p52 / RelB) • B-cell survival genes • excess BAFF rescues autoreactive B cells Made by: monocytes, macrophages, DCs, neutrophils, lymphoid stromal cells, epithelium (strongly interferon-induced) Long-lived plasma cell / B cell APRIL BCMA (plasma cell); TACI (B cell) plus heparan sulfate proteoglycans TRAFs NF-κB canonical + non-canonical NF-κB • long-lived plasma-cell survival (BCMA) • T-independent IgA switching (TACI) Made by: monocytes, macrophages, DCs, neutrophils, eosinophils and osteoclasts in the marrow plasma-cell niche; gut epithelium B cell (also DC, endothelium) sCD40L (soluble CD154) CD40 also αIIbβ3 and Mac-1 integrins TRAF2 / 3 / 5 / 6 NF-κB canonical + non-canonical NF-κB • class switching, germinal centres (mainly via membrane CD40L) • DC licensing (IL-12, Scene 2) Made by: activated CD4 T cells (shed from the membrane) and platelets (most circulating sCD40L); mast cells, basophils Sites of interaction: naive B cells (BAFF), plasma cells in the marrow niche (APRIL), B cells, DCs and endothelium (CD40L)
14Death ligands and cytotoxic granules
Death ligands and cytotoxic granules: soluble FasL, TRAIL, perforin, granzyme B and granzyme A Soluble Fas ligand binds Fas and TRAIL binds DR4 or DR5; both recruit FADD and caspase-8, which activates caspase-3 and apoptosis (soluble FasL is weakly cytotoxic compared with membrane FasL and is mainly chemotactic). Perforin released from cytotoxic granules inserts into the target membrane in a calcium-dependent manner and polymerizes into pores through which granzymes enter. Granzyme B cleaves BID to tBID, permeabilizing mitochondria, and directly activates caspase-3 and -7. Granzyme A causes caspase-independent death by a mechanism that is not settled; cleavage of the SET complex with single-strand DNA nicks, and cleavage of gasdermin B with pyroptosis in gasdermin-B-expressing cells, have both been proposed. Activated lymphocyte / Fas+ target cell sFasL (soluble CD95L) Fas (CD95) FADD caspase-8 caspase-3 weak apoptosis (sFasL mainly chemotactic) Made by: shed by metalloproteinases from activated CTLs, NK cells and Th1 cells; constitutive at immune-privileged sites Virus-infected / transformed cell TRAIL (Apo2L) DR4 (TRAIL-R1), DR5 (TRAIL-R2) decoys DcR1, DcR2, OPG FADD caspase-8 caspase-3 apoptosis of virus-infected or transformed cells; also NF-κB Made by: NK cells (especially liver), CTLs, pDCs, monocytes, neutrophils (strongly interferon-induced) Target cell Perforin inserts into the target membrane Ca²⁺-dependent (ring = pore) polymerizes into pores granzymes enter the cytosol → next panels Made by: CD8 CTLs, NK cells, NKT and γδ T cells, CD4 CTLs Target cell Granzyme B enters through perforin pores cleaves BID → tBID → MOMP (cytochrome c release), and directly activates caspase-3 and -7 rapid apoptosis Made by: CTLs, NK cells; also pDCs, B cells, basophils, mast cells, keratinocytes Target cell Granzyme A enters through perforin pores proposed: SET-complex cleavage → single-strand DNA nicks; gasdermin B cleavage in GSDMB+ cells (e.g. epithelium) caspase-independent death (mechanism disputed); proposed pyroptosis in GSDMB+ cells Reported, and contested: extracellular induction of IL-1β, IL-6 and TNF-α from monocytes Made by: CTLs, NK cells, γδ T cells (one of the two most abundant, with granzyme B) Death-receptor ligands Cytotoxic granule (killer cell → target cell) Site of interaction: the infected, transformed or activated target cell; perforin and granzymes are delivered across the immune synapse
15CXC chemokines: neutrophil recruiters and interferon-induced T-cell recruiters
CXC chemokines: ENA-78 and GCP-2 recruit neutrophils via CXCR2 and CXCR1; MIG and I-TAC recruit Th1, CTL and NK cells via CXCR3 Each lane shows a responding leukocyte sensing a chemokine gradient through a G-protein-coupled receptor and migrating toward the cells that make the chemokine. ENA-78 (CXCL5) acts on CXCR2 and GCP-2 (CXCL6) on CXCR1 and CXCR2, both recruiting neutrophils; ENA-78 is induced by IL-1, TNF and IL-17, GCP-2 by IL-1 and TNF. MIG (CXCL9) is predominantly IFN-gamma-induced and I-TAC (CXCL11) is induced by IFN-gamma plus type I interferon; both act on CXCR3 on Th1 cells, CTLs and NK cells. Responding cell · chemokine receptor Chemokine · where it is made · what it does ENA-78 (CXCL5) Made by: type II alveolar epithelium, platelets, monocytes, endothelium, fibroblasts; IL-1 / TNF / IL-17-induced Does: neutrophil recruitment, angiogenesis; competes for the erythrocyte DARC (ACKR1) sink Neutrophil CXCR2 GCP-2 (CXCL6) Made by: fibroblasts, airway and gut epithelium, macrophages, chondrocytes (IL-1 / TNF-induced) Does: neutrophil chemotaxis and degranulation; direct antimicrobial activity; angiogenesis Neutrophil CXCR1 + CXCR2 MIG (CXCL9) Made by: macrophages, DCs, endothelium, keratinocytes; predominantly IFN-γ-induced (IFN-γ: Scene 2) Does: recruits effector T and NK cells into inflamed tissue; angiostatic Th1 cell / CTL / NK cell CXCR3 I-TAC (CXCL11) Made by: monocytes, endothelium, keratinocytes, astrocytes; induced by IFN-γ plus type I IFN Does: the most potent (highest-affinity) CXCR3 agonist; effector T-cell recruitment; also scavenged by the atypical receptor ACKR3 Th1 cell / CTL / NK cell CXCR3 These receptors signal by the mechanism shown in Scene 6: each couples to a Gi protein, which activates PI3K, Rho GTPases and Ca²⁺ flux, and the cell migrates up the gradient. The neutrophil lanes extend the IL-8 and GROα entries of Scene 6, and the CXCR3 lanes extend the IP-10 entry.
16Inflammatory CC chemokines: shared receptors
Inflammatory CC chemokines MCP-2, MCP-3, MIP-1-delta and MPIF-1 and the receptors CCR1, CCR2, CCR3 and CCR5 they engage CC chemokines are promiscuous: one chemokine engages several receptors and each receptor responds to several chemokines. MCP-2 (CCL8) acts on CCR1, CCR2, CCR3 and CCR5; MCP-3 (CCL7) on CCR1, CCR2 and CCR3; MIP-1-delta (CCL15) on CCR1 and CCR3; MPIF-1 (CCL23) on CCR1. The receptor determines which cells are recruited: CCR1 and CCR2 mainly monocytes and memory T cells, CCR3 eosinophils and basophils, CCR5 Th1 cells, CTLs, NK cells and macrophages. MCP-3 also binds CCR5 as an antagonist. Chemokine · where it is made · main effect Receptor on the responding cell CCR1 monocytes, memory T cells, DCs CCR2 classical monocytes, memory T, NK CCR3 eosinophils, basophils, Th2 cells CCR5 Th1, CTL, NK cells, macrophages MCP-2 (CCL8) Made by: fibroblasts, monocytes, endothelium (interferon-induced) Recruits monocytes, T and NK cells, eosinophils, basophils (mouse CCL8 also acts on CCR8: IL-5+ Th2 cells in skin) MCP-3 (CCL7) Made by: monocytes, fibroblasts, platelets, mast cells, keratinocytes Broad recruiter; with CCL2, drives monocyte egress from marrow MIP-1δ (CCL15) Made by: monocytes, macrophages, intestinal and lung epithelium Recruits monocytes, neutrophils, lymphocytes, eosinophils; potency rises after N-terminal trimming MPIF-1 (CCL23) Made by: monocytes, macrophages, DCs (enhanced by IL-4 / IL-13) Recruits monocytes and resting T cells; inhibits myeloid progenitor growth; angiogenic binds and signals: the cell migrates toward this chemokine binds but blocks the receptor (antagonist) Each row shows which cells one chemokine can recruit, and each column shows every chemokine to which a cell type responds. All four receptors are Gi-coupled GPCRs (Scene 6).
17Allergic-tissue chemokines: eosinophil, Th2 and Treg recruiters
Eotaxin-2, Eotaxin-3, MCP-4, TARC, MDC, I-309 and IL-16 and the receptors they engage on eosinophils, Th2 cells and Tregs Eotaxin-2 (CCL24) and Eotaxin-3 (CCL26) act on CCR3 on eosinophils, basophils and Th2 cells; Eotaxin-3 also binds and blocks CCR1, CCR2 and CCR5. MCP-4 (CCL13) acts on CCR1, CCR2 and CCR3. TARC (CCL17) and MDC (CCL22) act on CCR4 on Th2 cells, Tregs and skin-homing T cells. I-309 (CCL1) acts on CCR8 on Tregs and Th2 cells. IL-16 is not a chemokine: it binds CD4 and recruits CD4 T cells, monocytes and eosinophils. Chemokine · where it is made · main effect Receptor on the responding cell CCR1 monocytes, memory T, DCs CCR2 classical monocytes, memory T, NK CCR3 eosinophils, basophils, Th2 CCR4 Th2, Treg, skin-homing T CCR5 Th1, CTL, NK, macrophages CCR8 Tregs, Th2 cells CD4 CD4 T cells, monocytes, eosinophils Eotaxin-2 (CCL24) Made by: IL-4-conditioned monocytes and macrophages, DCs, airway epithelium, fibroblasts Eosinophil and basophil chemotaxis Eotaxin-3 (CCL26) Made by: oesophageal and airway epithelium, keratinocytes, endothelium (IL-4 / IL-13 / STAT6) Eosinophil and basophil recruitment in chronic Th2 inflammation MCP-4 (CCL13) Made by: endothelium, airway epithelium, fibroblasts, monocytes (IL-1 / TNF plus IL-4 / IL-13) Eosinophil, basophil, monocyte and T-cell chemotaxis TARC (CCL17) Made by: DCs (incl. Langerhans and TSLP-conditioned DCs, Scene 7), keratinocytes, endothelium Recruits Th2, Treg and skin-homing (CLA+) T cells MDC (CCL22) Made by: DCs, IL-4-conditioned macrophages, activated B cells Recruits Th2 and Treg cells; Treg recruitment into tumours I-309 (CCL1) Made by: activated monocytes / macrophages, mast cells, Th2 cells, endothelium Recruits CCR8+ Tregs (skin, tumours) and Th2 cells; enhances Treg suppression IL-16 (not a chemokine) Made by: CD8 T cells (preformed), CD4 T cells, mast cells, eosinophils, airway epithelium Chemoattracts CD4+ cells (CD4 with CD9; Lck signalling); induces CD25 (IL-2Rα) binds and signals: the cell migrates toward this chemokine binds but blocks the receptor (antagonist) non-GPCR receptor (CD4) Eotaxin-3 is the dominant IL-4 / IL-13 / STAT6-induced epithelial eotaxin (Scene 3) and also acts on CX3CR1. Serum TARC is the best-validated biomarker of atopic-dermatitis severity.
18Homing and positioning chemokines: tissue addresses
Homeostatic and tissue-address chemokines: 6Ckine, MIP-3-beta, BCA-1, MIP-3-alpha, CTACK, CCL28, lymphotactin and fractalkine Homeostatic chemokines direct cells to specific tissues. 6Ckine (CCL21) and MIP-3-beta (CCL19) draw CCR7+ naive T cells and mature DCs into the lymph-node T zone. BCA-1 (CXCL13) draws CXCR5+ B cells and Tfh cells into follicles. MIP-3-alpha (CCL20) draws CCR6+ Th17 cells, Tregs, immature DCs and B cells to epithelia and Peyer’s patches. CTACK (CCL27) draws CCR10+ memory T cells to skin; CCL28 draws CCR10+ IgA plasmablasts to mucosa and milk. Lymphotactin (XCL1) from CD8 T and NK cells draws XCR1+ cDC1. Fractalkine (CX3CL1), anchored on inflamed endothelium, captures CX3CR1+ cells. Migrating cell · receptor → migrates up the gradient Chemokine · where it is made · where it sends the cell 6Ckine (CCL21, SLC) Made by: lymph-node high endothelial venules, T-zone fibroblastic reticular cells, lymphatic endothelium Sends cells to: lymph-node T zone; DCs travel along lymphatics Naive / central-memory T cell; mature DC CCR7 MIP-3β (CCL19, ELC) Made by: T-zone fibroblastic reticular cells, mature DCs Sends cells to: lymph-node T zone, bringing T cells and DCs together (unlike CCL21, it internalizes CCR7) Naive T cell; mature DC CCR7 BCA-1 (CXCL13, BLC) Made by: follicular DCs and marginal reticular cells; human Tfh cells; stroma of ectopic follicles Sends cells to: B-cell follicles and germinal centres; ectopic lymphoid structures B cell; Tfh cell CXCR5 MIP-3α (CCL20, LARC) Made by: gut follicle-associated, skin and airway epithelium (IL-1β / TNF / IL-17-induced) and Th17 cells Sends cells to: epithelial surfaces and Peyer’s patches (β-defensin-2 is also reported to bind CCR6) Th17, Treg, immature DC, B cell CCR6 CTACK (CCL27) Made by: keratinocytes (constitutive; increased by TNF-α / IL-1β) Sends cells to: skin CLA+ memory T cell (incl. skin Tregs) CCR10 CCL28 (MEC) Made by: mucosal and glandular epithelium (salivary, colon, airway, lactating breast); also directly antimicrobial Sends cells to: mucosa, salivary gland and milk (IgA plasmablasts); mucosa (eosinophils) IgA plasmablast; eosinophil CCR10 (plasmablast) · CCR3 (eosinophil) Lymphotactin (XCL1) Made by: activated CD8 T cells, NK cells, NKT and γδ T cells Sends cDC1 to: the XCL1-making CD8 T / NK cell (e.g. in tumours), strengthening cross-priming; also positions thymic XCR1+ DCs for Treg development Cross-presenting cDC1 (XCR1+) XCR1 Fractalkine (CX3CL1) Made by: inflamed endothelium (TNF / IL-1 / IFN-γ-induced), neurons, epithelium, DCs; membrane-anchored on a mucin stalk, shed by ADAM10/17 Sends cells to: inflamed vessel wall (firm capture without selectin rolling); in the brain, holds microglia beside neurons Patrolling monocyte, NK, effector CD8 T CX3CR1 All act through Gi-coupled GPCRs; fractalkine is the only one here that also works as a membrane-anchored adhesion molecule. Lymphotactin acts in the opposite direction: a lymphocyte recruits a dendritic cell.
19CD4 effector T-helper subsets: what induces each and what each makes
CD4 effector T-helper subsets Th1, Th2, Th17, Th9 and Th22: inducing cytokines, defining transcription factors, output cytokines and cross-regulation A naive CD4 T cell becomes one of five effector subsets according to the cytokines present when it is primed. IL-12 with IL-18 drives STAT4 and T-bet for Th1, whose output is IFN-gamma, TNF-alpha, lymphotoxin-alpha, IL-2 and the IL-10 that limits it. IL-4 drives STAT6 and GATA3 for Th2, whose output is IL-4, IL-5, IL-13, IL-9, IL-31, IL-10 and GM-CSF. IL-1-beta with IL-6 and IL-23 (TGF-beta is permissive at low dose; its obligate role is established in mouse but contested in humans) drives STAT3 and ROR-gamma-t for Th17, whose output is IL-17A, IL-17F, IL-22, IL-21, GM-CSF and TNF-alpha. IL-4 with TGF-beta drives PU.1 and IRF4 for Th9, making IL-9, IL-10 and IL-21. IL-6 with TNF-alpha and aryl-hydrocarbon-receptor ligands drives AHR with STAT3 for Th22, making IL-22 and TNF-alpha without IL-17. Each subset also lists its homing receptors, its function and its clinical correlate. The lanes underneath draw the cross-regulation the atlas states: IFN-gamma suppresses Th2 and Th17, and IL-4 suppresses Th1. Induced / maintained by IL-12p70 IL-18 IFNγ IL-27 ⊣ IL-4 Th1 CD4 helper 1 T-bet (TBX21), with STAT4 / STAT1 Markers: CD4, CXCR3, CCR5, IL-12Rβ2, IL-18R Homing: CXCR3, CCR5 → inflamed Th1 tissue Makes IFNγ TNFα TNFβ IL-2 IL-10 Does: Macrophage activation, IgG1 and IgG3 class switching, delayed-type hypersensitivity Clinical: Mendelian susceptibility to mycobacterial disease (IL12B, IL12RB1, IFNGR1/2, STAT1); driver of granulomatous inflammation Induced / maintained by IL-4 TSLP IL-33 IL-17E/IL-25 ⊣ IFNγ ⊣ IL-27 Th2 CD4 helper 2 GATA3, with STAT6 / STAT5 Markers: CD4, CRTH2 (DP2), CCR4, ST2, IL-17RB; the allergen-specific pathogenic effector "Th2A" subset is CRTH2+ CD161+ CD27− IL-17RB+ with high CD49d Homing: CCR4, CCR3, CRTH2 → allergic tissue, skin and airway Makes IL-4 IL-5 IL-13 IL-9 IL-31 IL-10 GM-CSF Does: IgE class switching, eosinophilia, mucus, smooth-muscle and barrier changes of allergic disease Clinical: Atopic dermatitis, allergic asthma, food allergy, eosinophilic oesophagitis; Th2A frequency falls with successful oral or sublingual immunotherapy and with naturally acquired tolerance; target of dupilumab (IL-4Rα) and anti-IL-5 agents Induced / maintained by IL-1β IL-6 IL-23 TGF-β IL-21 ⊣ IFNγ ⊣ IL-4 ⊣ IL-27 ⊣ IL-35 Th17 CD4 helper 17 RORγt (RORC), with STAT3 Markers: CD4, CCR6, IL-23R, CD161 Homing: CCR6 → epithelium, gut and skin (CCL20) Makes IL-17A IL-17F IL-22 IL-21 GM-CSF TNFα Does: Neutrophil recruitment and antifungal/antibacterial defence at barriers; autoimmune tissue inflammation Clinical: STAT3 LOF (hyper-IgE), IL17RA / IL17RC / IL17F / ACT1 (TRAF3IP2) and RORC defects and STAT1 GOF cause chronic mucocutaneous candidiasis (RORC also brings mycobacterial susceptibility); CARD9 deficiency causes invasive and CNS fungal disease; in APECED (AIRE) neutralizing anti-IL-17 and anti-IL-22 autoantibodies produce the same candidiasis; target of anti-IL-17 and anti-IL-23 agents Induced / maintained by IL-4 TGF-β IL-17E/IL-25 TSLP Th9 CD4 helper 9 PU.1 (SPI1) with IRF4, BATF and GATA3 Markers: No defining surface phenotype in humans; identified by IL-9 secretion; GATA3 is required alongside PU.1, IRF4 and BATF, although PU.1 blocks the full Th2 programme Homing: CCR3, CCR6 → airway and gut mucosa Makes IL-9 IL-10 IL-21 Does: Mast-cell accumulation and IL-9-dependent allergic inflammation; antihelminth and antitumour effects shown in mouse models. A differentiation state rather than a stable lineage; IL-9 output is lost on restimulation Clinical: Contributes to asthma and food-allergy mast-cell burden; no monogenic human disease defined Induced / maintained by IL-6 TNFα AHR ligands Th22 CD4 helper 22 AHR with STAT3 (no master TF) Markers: CD4, CCR10 with CCR4/CCR6, no IL-17A Homing: CCR10 with CCR4 → skin Makes IL-22 TNFα Does: Keratinocyte antimicrobial peptides, proliferation and wound repair without the IL-17 neutrophil programme Clinical: Expanded in psoriasis and in atopic dermatitis (IL-22 correlates with severity) Cross-talk stated in this scene ⊣ IFN-γ from Th1 suppresses Th2 ⊣ IL-4 from Th2 suppresses Th1 ⊣ IFN-γ suppresses Th17 IL-4 is needed for Th9 as well as Th2 (Scene 3) Chip colours follow the mediator's cascade class in the catalogue; a dashed red chip with ⊣ marks a signal that suppresses this subset. TGF-β is named as a co-signal for Th17, Th9 and induced Tregs but is not one of the 95 catalogued mediators, and nor is IL-26, a human Th17 and Th22 product. Each subset's own output cytokines are drawn in their own scenes: Scene 2 (Th1), Scene 3 (Th2), Scene 4 (Th17), Scene 10 (IL-22 family). One cross-talk is deliberately not drawn as a lane because it does not run between two of these cells: Th2 IL-13 induces IL-24 in the keratinocyte, an IL-20-family partner of the IL-22 that Th22 cells make (Scene 10).
20Regulatory and follicular CD4 T cells
Follicular and regulatory CD4 subsets: Tfh, Tfr, thymic and peripheral Tregs and Tr1 cells Tfh cells are driven in humans mainly by IL-12 on the current working model — the human inducer is not settled, and the mouse requirement for IL-6 does not appear to hold in humans — with IL-21 as an autocrine amplifier, through STAT3 with STAT4 to Bcl-6; they carry CXCR5 into the follicle and deliver IL-21, IL-4 and CD40 ligand to the germinal-centre B cell. Tfr cells are FoxP3 regulatory cells that acquire Bcl-6 and CXCR5 and limit the size and output of that germinal centre. Thymic (natural) Tregs depend on IL-2 and STAT5 for FoxP3 stability and suppress through IL-10, IL-35 and CTLA-4. Peripherally induced Tregs are converted in the gut by TGF-beta with retinoic acid and IL-2, and carry alpha-4-beta-7 and CCR9 back to the mucosa; this is the population oral tolerance and oral immunotherapy depend on. Tr1 cells have no FoxP3 — and whether they are a distinct lineage at all is unsettled, since many cells including Th1, Th2, Th17 and B cells make IL-10: IL-27 and IL-10 drive c-Maf and Blimp-1, and they suppress through large amounts of IL-10. Induced / maintained by IL-12p70 IL-21 IL-6 ICOS-L Tfh follicular helper T cell Bcl-6, with STAT3 Markers: CD4, CXCR5, PD-1, ICOS, Bcl-6, CD57 on germinal-centre Tfh, low CCR7 Homing: CXCR5 → B-cell follicle (CXCL13), CCR7 low Makes IL-21 IL-4 CD40L IL-10 BCA-1 Does: Germinal-centre formation, affinity maturation and class switching; its IL-21 and IL-4 determine the isotype Clinical: CD40LG deficiency (X-linked hyper-IgM), ICOS, CD40, IL21 and IL21R defects abolish or severely impair germinal centres; NFKB1/NFKB2 and activated-PI3K-delta syndrome dysregulate Tfh; circulating Tfh expanded in autoantibody disease Induced / maintained by IL-2 TGF-β ⊣ IL-21 Tfr follicular regulatory T cell FoxP3 with Bcl-6 Markers: CD4, CD25, FoxP3, CXCR5, PD-1 Homing: CXCR5 → germinal centre Makes IL-10 IL-35 Does: Limits germinal-centre size and output; restraint of autoantibody (and of IgE, shown in mouse) is mediated by CTLA-4, IL-10 and IL-2 consumption Clinical: CTLA-4 haploinsufficiency and LRBA deficiency, in which follicular regulation fails, cause germinal-centre hyperplasia with autoantibodies; FOXP3 mutation (IPEX) eliminates the entire Treg compartment Induced / maintained by IL-2 IL-15 ⊣ IL-6 nTreg thymic (natural) regulatory T cell FoxP3 (demethylated TSDR), with STAT5, Helios Markers: CD4, CD25 high, CD127 low, FoxP3, CTLA-4 Homing: CCR4, CCR8 → skin and inflamed tissue; CCR7 for nodes Makes IL-10 IL-35 Does: Dominant peripheral tolerance: suppresses effector T cells, B cells and antigen-presenting cells through CTLA-4-mediated CD80/CD86 transendocytosis, IL-2 consumption by high-affinity CD25, IL-10 and TGF-β, CD39/CD73 adenosine generation, and granzyme-mediated killing Clinical: FOXP3 mutation causes IPEX; CD25 (IL2RA), CTLA-4, LRBA, STAT5B, IL2RB, BACH2 and DEF6 defects cause Treg-deficient autoimmunity with enteropathy Induced / maintained by TGF-β IL-2 Retinoic acid ⊣ IL-6 pTreg / iTreg peripherally induced regulatory T cell FoxP3 with an incompletely demethylated TSDR Markers: CD4, FoxP3, α4β7, CCR9; Helios is often low but is a disputed marker of peripheral origin Homing: α4β7 and CCR9 → gut lamina propria Makes IL-10 IL-35 Does: Tolerance to food and microbial antigens at mucosal surfaces. TGF-β-induced FOXP3 in human cells is often transient and not necessarily suppressive, so a FoxP3-positive cell is not necessarily regulatory Clinical: Central to oral tolerance and to the proposed mechanism of oral immunotherapy Induced / maintained by IL-27 IL-10 IL-21 Tr1 type 1 regulatory T cell (FoxP3-negative) c-Maf with Blimp-1 (no FoxP3) Markers: CD4, IL-10 high with IFN-γ (the defining human cytokine pattern); LAG-3 with CD49b is the proposed Tr1 signature but both are induced on activated conventional CD4 cells, so it is not specific in humans Homing: CCR5, CXCR3 and gut homing receptors → inflamed mucosa Makes IL-10 IFNγ Granzyme B Does: IL-10-dependent suppression without FoxP3; granzyme-mediated killing of APCs Clinical: IL10, IL10RA and IL10RB defects cause very-early-onset inflammatory bowel disease; Tr1 induction is a goal of allergen immunotherapy Follicular (germinal-centre) CD4 cells Regulatory CD4 cells Cross-talk stated in this scene ⊣ Tfh IL-21 restricts Tfr proliferation, lowering CD25 and IL-2 responsiveness (Bcl-6-dependent) ⊣ Tfr limits Tfh help and germinal-centre output ⊣ Treg IL-10 and CTLA-4 restrain Tfh and APC co-stimulation Treg consumption of IL-2, with TGF-β, favours peripheral Treg conversion A solid chip outline is one of the 95 catalogued mediators; a dotted outline is a signal named elsewhere in this atlas but not catalogued, which is how TGF-β, retinoic acid and ICOS-L are drawn here. A dashed red chip with ⊣ marks a signal that suppresses the subset. The B-cell side of the Tfh interaction is drawn in Scene 25, and the isotype each help signal selects in Scene 26. IL-2 is not drawn as a suppressive chip here; although it is needed for Treg survival, it represses Bcl-6 and so restrains the follicular programme.
21CD8 T-cell subsets: effector, memory, resident and regulatory
CD8 T-cell subsets: cytotoxic Tc1, Tc2 and Tc17 effectors, stem-cell-like and central memory, effector memory and Temra, tissue-resident memory, and CD8 regulatory cells A naive CD8 T cell primed by a cross-presenting cDC1 with IL-12 and type I interferon becomes a Tc1 cytotoxic lymphocyte: T-bet with Eomes and Runx3, delivering perforin, granzymes A and B, Fas ligand, IFN-gamma and TNF-alpha. In IL-4-rich conditions the same cell becomes Tc2 and in IL-6 with IL-23 it becomes Tc17. IL-7 and IL-15 maintain stem-cell-like and central-memory cells through STAT5 and Tcf-1; persistent antigen with IL-15 gives effector-memory and terminally differentiated Temra cells; and TGF-beta with local IL-15 holds tissue-resident memory cells in place through Hobit, CD69 and CD103. CD8 regulatory cells suppress rather than kill. Induced / maintained by IL-12p70 IFNα2 IL-2 IL-15 CD8 Tc1 (CTL) cytotoxic T lymphocyte, type 1 T-bet with Eomes and Runx3 Markers: CD8, CXCR3, CD107a on degranulation, granzyme/perforin loaded Homing: CXCR3, CCR5 → infected tissue Makes IFNγ TNFα Perforin Granzyme A Granzyme B sFasL Lymphotactin Does: Kills virus-infected and tumour cells; provides IFN-γ to the Th1 axis Clinical: Perforin (PRF1), UNC13D, STX11 and STXBP2 defects cause familial HLH; CD8 CTLs are the effectors of checkpoint-inhibitor responses Induced / maintained by IL-4 (Tc2) IL-6 (Tc17) IL-23 (Tc17) IL-1β (Tc17) CD8 Tc2 / Tc17 type 2 and type 17 cytotoxic CD8 subsets GATA3 (Tc2) or RORγt (Tc17) Markers: CD8 with CRTH2 (Tc2) or CCR6 and CD161 (Tc17) Homing: CRTH2 and CCR4 (Tc2); CCR6 (Tc17) Makes IL-4 IL-5 IL-13 IL-17A IL-22 GM-CSF Granzyme B Does: Tc2 contributes IL-4, IL-5 and IL-13 in allergic tissue; Tc17 contributes IL-17A with weaker cytotoxicity Clinical: Tc2 cells are found in atopic dermatitis and eosinophilic oesophagitis; Tc17 in psoriasis Induced / maintained by IL-7 IL-15 CD8 Tscm / Tcm stem-cell-like and central-memory CD8 T cells Tcf-1 (TCF7) with Bcl-6, Id3 Markers: Tcm: CD8, CD45RO+, CCR7+, CD62L+, CD127+. Tscm: CD45RA+ CD45RO− CCR7+ CD62L+ CD27+ with CD95+ and CD122+, a naive-like surface phenotype with memory function Homing: CCR7 and CD62L → lymph node Makes IL-2 IFNγ Does: Long-lived recall capacity: proliferation and replenishment of the effector pool on re-exposure Clinical: IL7R defects cause T−B+NK+ SCID; the memory pool on which vaccine responses depend Induced / maintained by IL-15 IL-18 CD8 Tem / Temra effector-memory and terminally differentiated CD8 T cells T-bet high, Tcf-1 low Markers: CD8, CD45RA re-expression (Temra), CD57, CD28 low, CX3CR1 Homing: CX3CR1 and CCR5; no CCR7 → blood and tissue Makes IFNγ Perforin Granzyme B TNFα Does: Immediate cytotoxic effector function in blood and tissue, with limited proliferation Clinical: Accumulate with CMV carriage and age; Temra expansion is a marker of immune senescence Induced / maintained by TGF-β IL-15 IL-33 TNFα CD8 Trm tissue-resident memory CD8 T cell Runx3 with Blimp-1 and KLF2 downregulation; Hobit (ZNF683) is the mouse residency determinant and is variably expressed in human Trm Markers: CD8, CD69 (the most consistent human marker), CD103 on many but not all (liver and some lung Trm are CD103−), CD49a, CXCR6, low S1PR1 / KLF2 Homing: retained by CD69 and CD103; CXCR6; S1PR1 low → tissue residence Makes IFNγ Granzyme B TNFα Does: Local first-line defence at skin, lung and gut; rapid IFN-γ and granule release without recirculating Clinical: Mediate fixed-drug eruption and recurrent herpes lesions; contribute to mucosal protection after infection and vaccination, as shown chiefly in mouse models Induced / maintained by IL-10 IL-15 TGF-β Treg (CD8) CD8 regulatory T cell FoxP3 or Helios (subset-dependent) Markers: Human: CD8+CD28− suppressors, HLA-E-restricted CD8 Tregs, or KIR+ CD8 T cells; FoxP3 in a minority. CD8+CD122+ is the mouse-defined population Homing: CCR7 and CXCR5 on the follicular-suppressing subset Makes IL-10 Granzyme B Does: Suppresses effector T cells and follicular responses, partly by killing activated targets Clinical: Human biology remains incompletely defined; of interest in autoimmunity and transplantation Effector CD8 subsets Memory CD8 subsets Regulatory Cross-talk stated in this scene Repeated antigen with IL-15 drives Tc1 cells toward effector memory and Temra TGF-β and local IL-15 convert effector CD8 cells into tissue-resident memory Memory cells refill the cytotoxic effector pool on re-exposure ⊣ CD8 regulatory cells suppress effector CD8 and follicular responses The killing machinery these cells deliver — perforin pores, granzymes A and B and Fas ligand — is drawn step by step in Scene 14. IL-15 is trans-presented on IL-15Rα rather than secreted freely (Scene 5). Homing receptors determine where each subset is found.
22Innate-like T cells and NK cells
Innate-like lymphocytes: invariant NKT cells, MAIT cells, gamma-delta T cells and NK cells These lymphocytes respond within hours, before conventional T cells are primed. Invariant NKT cells recognise lipid presented by CD1d through an invariant T-cell receptor and, with IL-12 and IL-18, release IFN-gamma, IL-4 and IL-13 together, so they shape the response that follows. MAIT cells recognise riboflavin metabolites presented by MR1 and can also be triggered by IL-12 with IL-18 alone, without any receptor signal, making IFN-gamma, IL-17A and IL-22 at mucosa. Gamma-delta T cells do not require MHC presentation and supply early IL-17 or IFN-gamma at epithelial surfaces. NK cells are shown alongside for comparison: IL-15 keeps them alive, IL-12 and IL-18 trigger IFN-gamma, and CD16 allows bound IgG to direct their killing, linking antibody to cellular cytotoxicity. Developed and activated by IL-12p70 IL-18 IL-15 CD1d-lipid iNKT invariant natural killer T cell PLZF (ZBTB16), with T-bet, GATA3 or RORγt by subset Markers: Vα24-Jα18 TCR, CD1d-tetramer+, CD161, often CD4− CD8− Homing: CXCR6 → liver sinusoids; CCR4 and CCR6 to tissue Makes IFNγ IL-4 IL-13 IL-2 TNFα IL-10 GM-CSF CD40L Granzyme B Does: Very rapid cytokine release that shapes the response before conventional T cells arrive; activates dendritic cells. IL-17A derives only from a rare NKT17 subset, prominent in mouse Clinical: Reduced in some primary immunodeficiencies (e.g. XLP, SAP/SH2D1A deficiency); iNKT-derived IL-4 has been proposed, chiefly on mouse evidence, to contribute to early allergic sensitization Developed and activated by IL-12p70 IL-18 IL-7 IL-23 MR1-metabolite MAIT mucosal-associated invariant T cell PLZF with RORγt and T-bet Markers: Vα7.2 TCR, CD161 high, CD26 high, MR1-tetramer+ Homing: CCR6 and CXCR6 → gut, lung and liver Makes IFNγ TNFα IL-17A IL-22 Granzyme B Does: Antibacterial and antifungal defence at mucosa; can respond to IL-12 + IL-18 without a TCR signal Clinical: Depleted in HIV and in cystic-fibrosis airways; low MAIT numbers accompany several inborn errors of immunity Developed and activated by IL-23 IL-1β IL-15 IL-18 IL-7 Phosphoantigen γδ T cell gamma-delta T cell RORγt (IL-17 subset) or T-bet (IFN-γ subset) Markers: TCR γδ, Vδ2 (blood) or Vδ1 (tissue), NKG2D, CD27 (which separates functional subsets) Homing: CCR6 and CCR2 (IL-17 subset); skin and gut epithelium (Vδ1) Makes IFNγ IL-17A IL-17F TNFβ Perforin Granzyme B IL-22 Does: Early IFN-γ or IL-17 at epithelial surfaces; cytotoxicity against stressed cells; keratinocyte repair Clinical: Expanded in CMV infection and in some leukaemias; in mouse, γδ T cells are a major early IL-17 source before Th17 cells appear, whereas human γδ cells produce IL-17 only rarely (chiefly tissue Vδ1) and are dominated by IFN-γ and cytotoxic output Developed and activated by IL-15 IL-12p70 IL-18 IFNα2 NK cell natural killer cell — the prototype cytotoxic group 1 ILC, shown for comparison with innate-like T cells T-bet with Eomes, on an ID2 and NFIL3-dependent ILC programme Markers: CD56, CD16, NKp46, no CD3 Homing: CXCR3 and CX3CR1 (CD56dim blood); CCR7 and CXCR4 (CD56bright, nodes and marrow) Makes IFNγ TNFα Perforin Granzyme A Granzyme B Lymphotactin GM-CSF Does: Kills cells lacking MHC class I or coated with IgG (CD16-mediated); provides early IFN-γ Clinical: Classical and functional NK deficiency (GATA2, MCM4, FCGR3A) predisposes to severe herpesvirus disease; CD16 links NK killing to IgG Cross-talk stated in this scene iNKT CD40L and IFN-γ license dendritic cells, which in turn activate NK cells — an indirect route All four use the cytotoxic machinery of Scene 14 and the IL-12 / IL-18 pairing of Scene 2, and the IFN-γ they release feeds the same IL-12 / Th1 loop as Scene 2 — the one lane drawn below is an indirect route, in which iNKT cells license dendritic cells and the dendritic cell activates the NK cell. PLZF (ZBTB16) is the shared developmental transcription factor of the innate-like T-cell lineages. NK cells carry no T-cell receptor and are included for comparison only.
23Which cytokine acts on which lymphocyte subset
Cytokine-to-subset action matrix: which lymphocyte each major cytokine acts on, which subsets suppress it, and which subsets make it Each row shows every lymphocyte subset on which one cytokine acts, and each column every cytokine to which that subset responds or which it produces. A filled teal circle means the cytokine acts on that subset, a red blocked circle means it suppresses that subset, and a blue square means that subset is a source of the cytokine; a square with a teal centre means both. IL-2 is the clearest example of a cytokine that both supports its producer and sustains the regulatory cells that restrain it. Every mark in this matrix is an interaction stated elsewhere in this atlas: in Scenes 19 to 22 for the subsets, in Scenes 2 to 5 for the cytokine cascades, or in the mediator catalogue. Cytokine · where it is made · what it does to lymphocytes Lymphocyte subset acted on (●), suppressed (⊖) or producing it (■) Th1 T-bet, IFN-γ Th2 GATA3, IL-4/5/13 Th17 RORγt, IL-17/IL-22 Treg FoxP3 (and Tr1) Tfh Bcl-6, B-cell help CD8 CTL cytotoxic effector Innate-like / ILC / NK iNKT, MAIT, γδ, NK, ILC2 B cell naive → GC → plasma cell IL-2 Made by: activated T cells (Th1 and naive-derived effectors) Expands effector T cells and is essential for Treg survival and FoxP3 stability, but through STAT5 it represses Bcl-6, so it restrains Th17 and Tfh IL-4 Made by: Th2 cells, iNKT cells, mast cells, basophils, Tfh cells Drives Th2 and Th9, suppresses Th1 and Th17, and switches B cells to IgE and IgG4 IL-6 Made by: macrophages, fibroblasts, epithelium, endothelium With IL-1β and IL-23 initiates Th17 (TGF-β is permissive), drives Tfh, blocks Treg induction, and with IL-21 drives plasmablasts IL-12p70 Made by: activated macrophages and cDC1 dendritic cells The Th1 and cytotoxic signal: STAT4 → T-bet → IFN-γ IL-21 Made by: Tfh cells, Th17 cells, iNKT cells The central B-cell help cytokine: germinal centres, class switching and plasmablasts; autocrine for Th17 and Tfh; opposes induced Treg conversion IL-23 Made by: activated macrophages and dendritic cells Expands and stabilizes the IL-17-producing subsets (it does not initiate them) IFNγ Made by: Th1 cells, CD8 CTLs, NK cells, iNKT and γδ T cells Amplifies Th1 and macrophage killing; suppresses Th2 and Th17; drives IgG switching IL-10 Made by: Tregs, Tr1 and Breg cells, macrophages, Th2 and Th1 cells A broadly acting inhibitory cytokine: suppresses Th1, Th17 and antigen presentation; drives IgG4 with IL-4 IL-15 Made by: monocytes, dendritic cells, epithelium (trans-presented on IL-15Rα) Survival and memory signal for CD8 and innate-like lymphocytes; no effect on B cells TSLP / IL-33 / IL-25 Made by: airway, skin and gut epithelium (and tuft cells for IL-25) Epithelial alarmins that initiate and sustain the Th2 and ILC2 programme (Scene 7); within this column the target is ILC2, not MAIT or NK BAFF / APRIL Made by: neutrophils, monocytes, dendritic cells, stromal cells B-cell survival: BAFF for transitional and naive cells, APRIL for plasma cells and IgA switching TGF-β (not one of the 95 catalogued mediators) Made by: Tregs, platelets, epithelium, macrophages With IL-6 permits Th17, with retinoic acid induces Tregs, retains tissue-resident CD8 cells, and selects IgA IL-27 Made by: activated macrophages and dendritic cells Supports early Th1, then restrains Th17 and Th2 and drives IL-10-producing Tr1 cells IL-35 Made by: regulatory T and B cells (mouse evidence; human data limited) Suppresses effector T cells and converts them into further IL-35 producers CD40 ligand Made by: Tfh and other activated T cells (membrane form); platelets (soluble) The licensing signal for class switching and germinal centres; also licenses dendritic cells to make IL-12, which is how it reaches Th1 cells indirectly acts on this cell (induces or supports it) suppresses this cell made by this cell both: made by this cell and acts back on it made by this cell and also suppresses it no effect stated in this atlas This matrix is the lymphocyte counterpart of the chemokine-receptor matrices in Scenes 16 and 17. It serves as the index to the subset scenes: a cytokine row points to the subsets whose cards carry that cytokine as an inducing chip or an output chip. A small grey dot means no effect is stated in this atlas, not that none exists. TGF-β is included because it is a co-signal on five of the subset cards, even though it is not one of the 95 catalogued mediators.
24B-cell subsets before the germinal centre
B-cell subsets before the germinal centre: transitional, naive follicular, marginal-zone, B-1 and regulatory B cells A B cell leaving the marrow is a transitional cell: it survives only if tonic B-cell-receptor signalling is matched by BAFF through BAFF-R, which is the last checkpoint against autoreactivity. Surviving cells become naive follicular B cells, held in the follicle by CXCL13 and kept alive by BAFF, and these are the cells that start T-dependent germinal-centre responses. Marginal-zone B cells sit in the spleen and respond to polysaccharide without T-cell help, using the B-cell receptor together with Toll-like receptors and complement receptor CD21, which is why they protect against encapsulated bacteria and why that protection is missing in young children and after splenectomy. B-1 cells make natural polyreactive IgM without immunization. Regulatory B cells are defined by their IL-10 output rather than by a lineage transcription factor. Survival and activation signals BAFF BCR (tonic) Transitional B cell T1 / T2 transitional B cell Remains BCR-dependent; no change in lineage master TF Markers: CD19, CD24 high, CD38 high, CD10+, IgM high, IgD low (T1), becoming IgD+ (T2) Homing: spleen (via blood), then follicle on CXCR5 Makes no cytokine output Does: Last checkpoint against autoreactivity before the naive pool; T2 cells can enter follicles Clinical: Expanded in common variable immunodeficiency and after rituximab; reduced BAFF-R function blocks the transitional-to-naive step Survival and activation signals BAFF sCD40L Naive follicular B cell mature naive B cell (IgM+ IgD+) Pax5 with EBF1 (B-lineage identity) Markers: CD19, CD20, CD27−, IgM+, IgD+, CD21+, CD23+ Homing: lymph-node and splenic follicles (CXCR5 → CXCL13) Makes no cytokine output Does: The pool from which T-dependent germinal-centre responses arise Clinical: Target of anti-CD20 therapy; excess BAFF permits survival of autoreactive naive cells (belimumab target) Survival and activation signals BAFF APRIL Notch2 TLR + CD21 Marginal-zone B cell splenic marginal-zone B cell Pax5 with a Notch2-driven programme (mouse-established) Markers: CD19, CD27+, IgM high, IgD low, CD21 high, CD1c+ Homing: splenic marginal zone (S1PR1 vs CXCR5 shuttling) Makes IL-10 Does: Rapid T-independent IgM (and some IgG2) against encapsulated bacteria Clinical: Absent or non-functional after splenectomy and immature in young children, with resulting susceptibility to pneumococcus and poor polysaccharide vaccine responses Survival and activation signals IL-5 BCR (tonic) TLR B-1 cell B-1a / B-1b cell (innate-like) Pax5 with high Bhlhe41 (mouse-defined) Markers: Mouse: CD19 high, CD5+ (B-1a), CD43+, IgM high, IgD low. A proposed human equivalent (CD20+CD27+CD43+CD70−) is contested; human CD5+ B cells are activated or transitional cells and do not correspond to mouse B-1a Homing (mouse): pleural and peritoneal cavities and gut lamina propria; no human cavity pool defined Makes IL-10 Does: Spontaneous "natural" polyreactive IgM and some IgA, without immunization Clinical: Human counterpart remains debated; the source of natural IgM, including isohaemagglutinins Survival and activation signals IL-21 sCD40L IL-6 IFNα2 TLR ligands Regulatory B cell (Breg) IL-10-producing regulatory B cell No unique master TF; defined by IL-10 output Markers: Human: CD19+CD24 high CD38 high transitional, or CD24 high CD27+ memory Homing: spleen, blood, inflamed tissue Makes IL-10 IL-35 Granzyme B Does: Suppresses Th1 and Th17 responses and supports Tregs, mainly through IL-10 (and IL-35) Clinical: Reduced IL-10+ B cells in several autoimmune diseases; the allergen-specific human BR1 population (IL-10+ CD73− CD25+ CD71+) preferentially secretes IgG4 and expands during successful allergen immunotherapy and in beekeepers T-dependent (follicular) route T-independent / innate-like Regulatory Cross-talk stated in this scene Transitional cells that pass the checkpoint become naive follicular B cells At the T2 transitional stage the lineage bifurcates: Notch2/DLL1 in the spleen (mouse-established), with BCR specificity, commits some to the marginal zone Transitional, memory and plasmablast-like cells can all become regulatory B cells Chips show survival and activation signals only: the chemokines that position these cells — CXCL13 for the follicle, CXCL12 for the marrow — are on each card's homing line instead. BAFF and APRIL are drawn as ligands on their receptors in Scene 13; the germinal-centre fate of the follicular B cell continues in Scene 25. CD21 (CR2) is the complement receptor that lowers the B-cell activation threshold, drawn with the other complement receptors in Scene 32.
25The germinal centre and antibody-secreting cells
The germinal-centre reaction: dark-zone mutation, light-zone selection, and the memory, plasmablast and long-lived plasma-cell outputs Inside the germinal centre a B cell alternates between the dark zone, where AID mutates its immunoglobulin genes, and the light zone, where it must capture antigen from follicular dendritic cells and obtain help from a Tfh cell. That help is CD40 ligand plus IL-21, and it has two effects: it maintains the survival of the cell and it selects the isotype, since IL-21 and IFN-gamma favour IgG, IL-4 and IL-13 favour IgE and IgG4, and TGF-beta with APRIL favours IgA. Cells that receive little help become memory B cells; those that receive the most become plasmablasts, and the plasmablasts that reach a CXCL12 marrow niche with APRIL, BAFF and IL-6 become long-lived plasma cells that sustain serum antibody for years. Because long-lived plasma cells lack CD20, anti-CD20 treatment leaves existing antibody titres largely unchanged. Signals it needs sCD40L IL-21 Antigen on FDC Germinal-centre B cell dark-zone and light-zone GC B cell Bcl-6, which blocks differentiation during somatic hypermutation; exit results from mutual antagonism with Blimp-1 and a rise in IRF4 Markers: CD19, CD38+, CD10+, IgD−, CD77 (dark zone), Fas/CD95+ Homing: germinal centre; shuttling between dark and light zones on CXCR4 and CXCR5 Makes no cytokine output Does: Somatic hypermutation in the dark zone, selection on follicular-dendritic-cell antigen in the light zone, and class switching Clinical: AICDA and UNG defects cause hyper-IgM with giant germinal centres; the cell of origin of most B-cell lymphomas Signals it needs sCD40L IL-21 BAFF Memory B cell class-switched and IgM memory B cell Loss of Bcl-6; Bach2 prevents differentiation into a plasma cell Markers: CD19, CD27+, IgD− (switched) or IgM+IgD+ CD27+ (IgM memory); CD21low CD38low and T-bet+ CD11c+ IgD−CD27− "double-negative" (DN2) cells are the two clinically tracked abnormal compartments Homing: blood, spleen and marginal zone; mucosa for IgA memory Makes no cytokine output Does: Rapid, high-affinity recall: re-enters germinal centres or becomes a plasmablast within days Clinical: Switched memory (CD27+IgD−) counts classify CVID (EUROclass), where severely reduced switched memory B cells are associated with splenomegaly and granulomatous disease and an expanded CD21low subset with splenomegaly; DN2 cells expand in lupus and chronic infection; IgM memory loss follows splenectomy Signals it needs IL-21 IL-6 sCD40L Plasmablast short-lived antibody-secreting cell Blimp-1 (PRDM1) and IRF4, with XBP1 Markers: CD19 low or positive, CD20−, CD27 high, CD38 high, CD138 variable, Ki-67+ Homing: medullary cords, then marrow or mucosa on CXCR4 Makes IgM IgG1 IgA1 IgE Does: The early antibody response, days after exposure; the cells remain proliferative and migratory Clinical: Blood plasmablast counts rise about a week after vaccination; expanded in IgG4-related disease Signals it needs APRIL BAFF IL-6 Long-lived plasma cell bone-marrow (and mucosal) plasma cell Blimp-1 with XBP1 (Pax5 off) Markers: CD38 high, CD138+, CD20−, surface Ig low; the long-lived, titre-maintaining marrow fraction is CD19-negative, while CD19+ plasma cells are shorter-lived Homing: bone-marrow survival niche; mucosal lamina propria for IgA Makes IgG1 IgG2 IgG3 IgG4 IgA1 IgA2 Does: Maintains serum antibody titres for years without antigen; the source of steady-state IgG Clinical: Not depleted by anti-CD20 (no CD20), so titres persist after rituximab; anti-BCMA agents target it in myeloma Cross-talk stated in this scene Low Tfh help → memory B cell Strong Tfh help (CD40L + IL-21) → plasmablast A CXCL12+ marrow niche with APRIL, BAFF and IL-6 → long-lived plasma cell On re-exposure, memory B cells become plasmablasts within days Either antibody-secreting cell can make any isotype: the chips name the isotypes each is typically found producing, and IgE-secreting cells are mostly short-lived, which is why IgE sits on the plasmablast rather than the long-lived card. Which isotype the Tfh help selects is set out in Scene 26 and the isotypes themselves in Scene 27. AID (AICDA) performs both somatic hypermutation and class switching, which is why its loss gives hyper-IgM with large germinal centres. The CXCL12 and CXCL13 gradients that position these cells are in Scene 18.
26Class switching: which signal selects which isotype
Class-switch recombination: the cytokine and co-stimulatory signals that select each immunoglobulin isotype Class switching requires two signals: a CD40 signal (or, without T cells, a TACI signal from BAFF or APRIL) to open the switch region, and a cytokine to select the isotype. IL-4 and IL-13 through STAT6 open the epsilon and gamma-4 regions, so they select IgE and IgG4; IL-10 added to IL-4 shifts the balance from IgE toward IgG4, as occurs during successful allergen immunotherapy. IFN-gamma selects IgG1 and IgG3 and suppresses IgE. IL-21 drives IgG generally and, with IL-4, restrains IgE. TGF-beta with APRIL or BAFF selects IgA, and gut retinoic acid favours IgA2. Polysaccharide acting through TACI without T-cell help gives IgM and IgG2. AID (AICDA) performs the recombination itself, so without AID or CD40 ligand the cell remains restricted to IgM. Switch signal · where it comes from · what it does Isotype the signal selects (●) or suppresses (⊖) IgM default, no switch IgD rare switch, airway IgG1 protein antigens IgG2 polysaccharide IgG3 early antiviral IgG4 chronic exposure IgA1 serum and upper airway IgA2 lower gut, secretions IgE allergy, helminths CD40L + antigen (no cytokine) From: Tfh and other activated T cells, through CD40 on the B cell Opens the switch regions and licenses AID but selects no isotype; without it the cell cannot switch from IgM (X-linked hyper-IgM) IL-4 or IL-13 (+ CD40L) From: Th2, Tfh, iNKT cells, mast cells and basophils (STAT6) Selects IgE and IgG4; the signal dupilumab interrupts at IL-4Rα IL-4 with IL-10 (+ CD40L) From: Tr1 and regulatory cells during prolonged antigen exposure Shifts the same B cell from IgE toward IgG4 — the blocking-antibody pattern of allergen immunotherapy IFNγ (+ CD40L) From: Th1 cells, CD8 CTLs, NK cells (STAT1) Selects IgG1 and IgG3 for opsonization and complement fixation, and contributes to IgG2; suppresses IgE IL-21 (+ CD40L) From: Tfh cells in the germinal centre (STAT3) The general IgG-promoting and plasmablast signal; it also supports the IgA switch, and with IL-4 it restrains IgE TGF-β with APRIL or BAFF From: mucosal dendritic cells and stroma, acting through TACI Selects IgA, with or without T-cell help; the mucosal default (TGF-β also damps IgE, though TGF-β is not one of the 95 catalogued mediators) Retinoic acid (gut) From: CD103+ gut dendritic cells converting dietary vitamin A Imprints gut homing and favours the IgA switch, with a skew toward the protease-resistant IgA2 in the distal gut Polysaccharide through TACI (T-independent) From: encapsulated bacteria acting on marginal-zone and IgM-memory B cells Gives IgM and IgG2 without germinal centres — the response that matures late in childhood drives the switch to this isotype suppresses this isotype permits the switch without selecting an isotype no effect stated in this atlas This is the step between Scene 25 (where Tfh help is delivered) and Scene 27 (what each isotype then does). CD40 ligand is drawn as a ring rather than a filled circle because it licenses switching without choosing an isotype. The IgD switch is atypical: a non-canonical recombination from Sμ to the σδ switch-like region in tonsil and upper-airway mucosa, driven by IL-2 and IL-21 with APRIL or BAFF through TACI rather than by CD40. Sequential switching is common: many IgE-producing cells pass through IgG1 first, which is why IgE and IgG4 to the same allergen so often move together.
27Immunoglobulin isotypes: levels, complement and Fc receptors
The nine immunoglobulin isotypes: typical serum level, half-life, complement activation and which Fc receptors each engages Each isotype is defined by what its constant region can do. IgM is the strongest classical-complement activator because one bound pentamer presents several C1q binding sites at once. Among the IgG subclasses the order is IgG3 then IgG1, with IgG2 weak and IgG4 inactive; the same order holds for the activating Fc gamma receptors, except that IgG2 binds appreciably only to the H131 allotype of FcγRIIa. IgG4 preferentially engages the inhibitory receptor FcγRIIb and, because it exchanges half-molecules and is functionally monovalent, cross-links antigen poorly, which makes it a blocking antibody. IgA engages FcαRI on neutrophils and is carried into secretions by pIgR, but does not use the classical pathway. IgE engages FcεRI on mast cells and basophils, where it persists for weeks. All four IgG subclasses are recycled by FcRn, which is what gives them their long half-life and carries them across the placenta. Isotype · typical adult serum level and half-life · complement and switch signal Complement activation and Fc receptor engagement Classical complement C1q binding FcγRI (CD64) high-affinity IgG FcγRIIa (CD32a) phagocytosis FcγRIIb (CD32b) inhibitory FcγRIII (CD16) NK ADCC FcRn half-life, placenta FcεRI / CD23 mast cell, B cell FcαRI (IgA) / pIgR pIgR also carries pentameric IgM IgM Typical adult serum 0.4–2.3 g/L; the only isotype produced in quantity by the newborn (cord IgM above ~0.2 g/L suggests intrauterine infection). Serum half-life about 5 days by turnover studies, although some texts give up to 10 Classical pathway: strongest activator; one surface-bound pentamer in the staple conformation can fix C1. Switch signal: none required (default isotype) IgD Trace: mean adult serum about 0.03 g/L with a laboratory upper limit around 0.15 g/L, often undetectable; not useful as a routine quantitative test. Serum half-life about 3 days Does not activate complement. Switch signal: non-canonical class switch from Sμ to the σδ switch-like region in tonsil and upper-airway mucosa; AID-dependent, largely T-independent, promoted by IL-2 and IL-21 with APRIL or BAFF through TACI IgG1 Typical adult serum 4.9–11.4 g/L (about 60–65% of total IgG). Serum half-life about 21 days (FcRn-dependent) Classical pathway: good activator (second only to IgG3). Switch signal: IL-21 and IFN-γ with CD40L IgG2 Typical adult serum 1.5–6.4 g/L (about 20–30% of total IgG); the last subclass to mature; it is low through early childhood and continues to rise through adolescence, so an age-specific rather than an adult range is required. Polysaccharide antibody responses, rather than the IgG2 level itself, mature first: they are poor before about 2 years and mature over the next few years. Serum half-life about 21 days Classical pathway: weak activator. Switch signal: T-independent polysaccharide with TACI (APRIL/BAFF); IFN-γ contributes IgG3 Typical adult serum 0.2–1.1 g/L (about 5–8% of total IgG). Serum half-life about 7 days, shorter than the other subclasses because Arg435 in its Fc binds FcRn with lower affinity Classical pathway: strongest IgG activator. Switch signal: IFN-γ with CD40L (and IL-21) IgG4 Typical adult serum 0.08–1.4 g/L (about 1–4% of total IgG); the widest and most skewed of the subclass ranges. Serum half-life about 21 days Does not activate complement (and blocks activation by other isotypes on the same antigen). Switch signal: IL-4 / IL-13 with IL-10 and CD40L IgA1 About 85–90% of serum IgA; total serum IgA typically 0.7–4.0 g/L in adults and much lower through early childhood. Serum half-life about 6 days Does not activate the classical pathway; aggregated IgA can engage the alternative pathway weakly. Switch signal: TGF-β with APRIL / BAFF (TACI) and IL-21; retinoic acid in the gut IgA2 About 10–15% of serum IgA, but the majority (about 60%) of colonic secretory IgA. Serum half-life about 6 days Does not activate the classical pathway; whether aggregated IgA2 engages the alternative pathway is not established; it is reported for aggregated IgA generally, whereas some sources report IgA1 as positive and IgA2 as negative. Switch signal: TGF-β with APRIL / BAFF (TACI); gut retinoic acid favours IgA2 IgE Typical adult total IgE 0–100 kU/L (about 0.0002 g/L, roughly 240 µg/L); the least abundant isotype. Cord-blood total IgE is usually under 0.5 kU/L (median about 0.3 kU/L in one large series); maternal blood contamination of a cord sample is excluded by measuring cord IgA, which does not cross the placenta, rather than inferred from the IgE value. Values rise through childhood, so age-specific ranges are required. Serum half-life about 2 days free, but around two weeks once bound to FcεRI on tissue mast cells Does not activate complement. Switch signal: IL-4 or IL-13 with CD40L (STAT6 → ε germline transcript) binds / activates binds but inhibits (or blocks activation) no effect stated in this atlas Only the receptors most used in practice are columned here; IgM also engages FcμR and the Fcα/μ receptor, which are not shown. Every range here is a typical adult figure for orientation only: reference ranges are laboratory-specific and strongly age-specific. In children, IgG falls to a physiological nadir around 3 to 6 months as maternal IgG is cleared, polysaccharide antibody responses are poor before about 2 years and mature over the next few years while IgG2 itself keeps rising through adolescence, IgA rises slowly through the first decade, and total IgE rises through childhood; results are therefore interpreted against an age-matched range from the reporting laboratory.
28Fc receptors: how antibody becomes cellular action
Fc receptors and transport receptors: which antibody each binds, which cells carry it, and what it does The cellular effector functions of an antibody depend on engagement of its Fc by a receptor. FcγRI is the one high-affinity IgG receptor, so it is largely occupied by circulating IgG; it appears on neutrophils only after IFN-gamma or G-CSF, which is why neutrophil CD64 is used as a marker of bacterial infection. FcγRIIa is the main phagocytic receptor, and its H131 allotype is effectively the only human receptor that binds IgG2, which is relevant to defence against pneumococcus. FcγRIIb is the only inhibitory Fc receptor and the only one B cells carry, so IgG immune complexes suppress further antibody production. FcγRIIIa on NK cells is the antibody-dependent killing receptor. FcεRI holds IgE on mast cells for weeks and triggers immediate hypersensitivity, while CD23 regulates how much IgE is made. FcαRI enables IgA to activate neutrophils. FcRn and pIgR do not signal: they transport, which accounts for the three-week half-life of IgG and puts secretory IgA on the mucosal surface. Binds IgG1 IgG3 IgG4 FcγRI (CD64) FCGR1A — the only high-affinity IgG receptor High affinity — binds monomeric IgG On: Monocytes, macrophages and dendritic cells constitutively; neutrophils only after induction by IFN-γ or G-CSF Downstream phagocytosis ADCC Does: Binds monomeric IgG1 and IgG3 (and IgG4) with high affinity, so it is occupied by circulating IgG at rest; phagocytosis, ADCC and antigen presentation Clinical: Neutrophil CD64 rises within hours of bacterial infection and is used as a sepsis marker, especially in neonates Binds IgG1 IgG2 IgG3 FcγRIIa (CD32a) FCGR2A — activating, with the H131/R131 polymorphism Low affinity — needs immune complexes On: Neutrophils, monocytes, macrophages, platelets, eosinophils Downstream phagocytosis NETs Does: The main phagocytic receptor for IgG-opsonized particles; the H131 allotype is the only human FcγR that binds IgG2 efficiently Clinical: The R131 allotype mediates poor uptake of IgG2-opsonized pneumococcus and is associated with invasive pneumococcal disease; FcγRIIa on platelets mediates heparin-induced thrombocytopenia Binds IgG1 IgG3 IgG4 FcγRIIb (CD32b) FCGR2B — the only inhibitory Fc receptor Inhibitory — the only ITIM Fc receptor On: B cells (the only FcγR they express), mast cells and basophils, macrophages, neutrophils, eosinophils, dendritic cells; the B1 form on B cells and mast cells, the B2 form on the myeloid cells Downstream ⊣ B-cell activation Does: Raises the activation threshold: co-ligated with the BCR by IgG immune complexes it inhibits B-cell activation, so IgG exerts negative feedback on its own production Clinical: Loss of FcγRIIb function predisposes to lupus; its engagement is a proposed component of the mechanism of high-dose IVIG Binds IgG1 IgG3 FcγRIII (CD16) FCGR3A (CD16a, transmembrane) and FCGR3B (CD16b, GPI-anchored) Low affinity — CD16a signals, CD16b captures On: CD16a on NK cells, macrophages and monocyte subsets; CD16b on neutrophils only Downstream ADCC Does: CD16a is the ADCC receptor: IgG-coated targets are killed by NK cells. CD16b is the most abundant neutrophil Fc receptor and captures immune complexes Clinical: FCGR3A V158F has been associated with response to rituximab and other IgG1 antibody therapies in some, but not all, studies; CD16a deficiency causes severe herpesvirus disease with normal NK numbers; CD16b is shed on neutrophil activation Binds IgE FcεRI MS4A2 / FCER1A — the high-affinity IgE receptor Very high affinity — holds IgE for weeks On: Mast cells and basophils as a four-chain αβγ2 receptor; dendritic cells, monocytes and eosinophils as a three-chain αγ2 form Downstream degranulation Does: Retains IgE on the cell surface for weeks; allergen cross-linking of bound IgE triggers immediate degranulation (histamine, tryptase) and then leukotrienes, prostaglandins and Th2 cytokines Clinical: The receptor of immediate hypersensitivity, and therefore of anaphylaxis and of the skin-prick and basophil activation tests; omalizumab lowers free IgE, and FcεRI density falls in parallel, which accounts for an onset of action over weeks Binds IgE FcεRII (CD23) FCER2 — the low-affinity IgE receptor (a C-type lectin, not an Ig-superfamily FcR) Low affinity — a C-type lectin On: B cells, follicular dendritic cells, monocytes, eosinophils, airway epithelium Downstream ⊣ IgE synthesis sCD23 can raise it Does: Regulates the quantity of IgE produced and transports IgE-bound allergen for presentation; the soluble shed form can raise or lower IgE production depending on the site of cleavage Clinical: Lumiliximab (anti-CD23) has been evaluated in clinical trials in asthma; the soluble form rises in allergic disease and chronic lymphocytic leukaemia Binds IgA1 IgA2 FcαRI (CD89) FCAR — the myeloid IgA receptor Complexed IgA activates, monomeric IgA inhibits On: Neutrophils (the dominant site), monocytes, macrophages, eosinophils Downstream phagocytosis burst Does: Confers effector function on IgA: complexed IgA triggers phagocytosis, respiratory burst and neutrophil extracellular traps, while monomeric IgA through the same receptor is inhibitory Clinical: IgA immune complexes acting on CD89 drive the neutrophil injury of IgA vasculitis (Henoch–Schönlein purpura) and IgA nephropathy Binds IgG1 IgG2 IgG3 IgG4 IgA1 IgA2 IgM FcRn and pIgR FCGRT (with β2-microglobulin) and PIGR — the transport receptors Transport, not signalling On: FcRn on endothelium, monocytes, syncytiotrophoblast and epithelium; pIgR on the basolateral face of mucosal and glandular epithelium Downstream recycling secretory IgA Does: FcRn rescues IgG and albumin from lysosomal degradation, which accounts for the three-week half-life of IgG, and transports maternal IgG across the placenta. pIgR transports dimeric IgA (and pentameric IgM) into secretions, with the secretory component remaining attached Clinical: FcRn accounts for third-trimester placental IgG transfer and for the IgG half-life that determines IVIG dosing intervals; FcRn blockers (efgartigimod) shorten IgG half-life in autoantibody disease; pIgR delivers the secretory IgA that is absent from serum-only measurements IgG receptors (FcγR) IgE receptors IgA receptor Transport (IgG and IgA) Cross-talk stated in this scene ⊣ FcγRIIb raises the threshold for every activating FcγR on the same cell ⊣ CD23 feedback lowers IgE production, so less IgE is available to arm FcεRI ITAM receptors activate through Syk; the single ITIM receptor, FcγRIIb, inhibits through SHIP-1. The isotype each receptor binds is the column key of Scene 27, and the neutrophil functions these receptors trigger are drawn in Scene 34.
29Complement: the classical and lectin pathways
Classical and lectin pathways of complement: recognition, C4 and C2 cleavage, and the shared C3 convertase Both pathways reach the same enzyme by different recognition molecules. In the classical pathway C1q binds the Fc of antibody already bound to a surface — IgM in its staple conformation, or IgG3 and IgG1 — and the conformational change activates C1r and then C1s. In the lectin pathway mannose-binding lectin, a ficolin or collectin-11 binds microbial carbohydrate directly and activates MASP-2, with MASP-1 assisting. Either protease then cleaves C4 to C4b, which binds the surface covalently, and cleaves C2 to C2a, and C4b with C2a is the classical and lectin C3 convertase, C4b2a. That enzyme cleaves C3 into the opsonin C3b and the anaphylatoxin C3a. C1 inhibitor is the principal inhibitor of both initial proteases, which is why its loss causes bradykinin angioedema rather than uncontrolled complement activation, and C4b-binding protein and DAF dissociate the convertase. Recognition First protease Cleaves C4 and C2 C3 convertase Output Classical pathway Antibody on a surface IgM in the staple conformation, or IgG3 > IgG1 (IgG2 weakly, IgG4 not at all); also CRP and apoptotic-cell surfaces C1 complex C1q + C1r₂C1s₂, calcium-dependent C1q from monocytes, macrophages and dendritic cells — not liver C1q bends → C1r → C1s C1s (classical) or MASP-2 (lectin) cleaves C4, then C2 C4 → C4b (binds the surface covalently) + C4a C2 → C2a + C2b C4b2a The classical and lectin C3 convertase Serum C4 about 0.1–0.4 g/L (some laboratories 0.16–0.48), C2 about 0.02 g/L C3 → C3b + C3a C3b: opsonin and convertase builder (Scene 30) C3a: mast-cell and basophil anaphylatoxin Lectin pathway Microbial carbohydrate Mannose and N-acetylglucosamine read by MBL, ficolin-1/2/3 or collectin-11 MBL 0.5–3 mg/L, genotype-driven MASP-1 and MASP-2 Carried on the recognition molecule MASP-2 cleaves C4, then C2 — the lectin equivalent of C1s MASP-1 activates MASP-2 and also cleaves C2; MASP-3 activates pro-factor D Regulators C1 inhibitor (SERPING1) Traps C1r, C1s and MASP-1/2 — and plasma kallikrein and factor XIIa, which is why its loss gives bradykinin angioedema Antigenic 0.15–0.35 g/L; function under 50% supports HAE C4BP, MCP (CD46), DAF (CD55) DAF and C4BP both dissociate the convertase; C4BP and MCP are also cofactors for factor I, which cleaves C4b to C4c and C4d same C4 and C2 cleavage blocks C1r and C1s and MASP-1 / MASP-2 decay and cofactor Low C4 with low C3 indicates classical-pathway consumption (lupus, cryoglobulinaemia, immune complexes). Low C4 with a normal C3 is the hereditary-angioedema pattern. A normal C4 does not exclude angioedema with normal C1 inhibitor. Naming: by the current consensus C2a is the larger catalytic fragment, so the convertase is written C4b2a; some literature writes C4b2b for the same enzyme. C4a is released at the same step but has no classical anaphylatoxin receptor, binding neither C3aR nor C5aR1. The alternative pathway that amplifies the C3b made here is Scene 30.
30Complement: the alternative pathway, amplification and the terminal pathway
The alternative pathway: tick-over, the amplification loop, the C5 convertase and the membrane attack complex The alternative pathway needs no recognition molecule. C3 hydrolyses spontaneously in plasma — tick-over — and the resulting C3(H2O) binds factor B, which factor D cleaves to Bb. Any C3b that lands on a surface does the same, so C3bBb cleaves more C3 to more C3b: an amplification loop that properdin stabilizes five- to ten-fold and that factor H, factor I, DAF and MCP inhibit on host surfaces. Because of this loop the alternative pathway produces the large majority of C3b and of downstream membrane attack complex even when the classical pathway initiated the response. When a second C3b joins the convertase it becomes a C5 convertase — C3bBb3b, or C4b2a3b on the classical side — and C5 is cleaved into C5a, the most potent anaphylatoxin and neutrophil chemoattractant, and C5b, which recruits C6, C7, C8 and multiple C9 into the membrane attack complex. CD59 blocks that final step on host cells. Spontaneous start Factor D cleaves factor B Amplification loop C5 convertase Membrane attack complex Alternative pathway C3 tick-over C3 hydrolyses spontaneously in plasma to C3(H₂O); surface-bound C3b from any pathway does the same Serum C3 0.9–1.8 g/L Factor D cleaves factor B Factor B binds C3b first; factor D (adipsin, from adipocytes) cleaves it to Bb + Ba Factor D 1–2 mg/L: rate-limiting C3bBb + properdin The alternative C3 convertase, stabilized five- to ten-fold by properdin — the only positive regulator (5–25 mg/L, X-linked) C3bBb3b A second C3b converts the C3 convertase into a C5 convertase (C4b2a3b on the classical side) C5b-9 pore C5b + C6 + C7 insert, then C8 and many C9 Lyses Neisseria; sublytic MAC activates endothelium and NLRP3 Amplification More C3 → more C3b The loop that makes most of the C3b in any response, whichever pathway started it C5 → C5a + C5b C5a: neutrophil chemotaxis, adhesion, degranulation and burst; mast-cell activation C5aR1 is a Gi-coupled GPCR Host-surface brakes Host-surface brakes Factor H recognizes host sialic acid and glycosaminoglycans. DAF (CD55), CR1 (CD35) and factor H dissociate the C3 and C5 convertases; MCP (CD46) and CR1 are instead factor-I cofactors. Factor H 0.2–0.7 g/L Factor I With factor H, MCP or CR1, cleaves C3b to iC3b (the CR3 ligand), which can no longer build a convertase; the second cut to C3dg needs CR1 specifically. 0.03–0.06 g/L CD59 Blocks C9 recruitment, so C5b-8 never becomes a pore decay the C3 and C5 convertases Low C3 with a normal C4 points to alternative-pathway activation: C3 nephritic factor, factor H or factor I defect, gain-of-function factor B, or post-infectious glomerulonephritis. Screening grid: absent CH50 with normal AH50 → C1, C2 or C4. Normal CH50 with absent AH50 → factor D, factor B or properdin. Both absent → C3 or a terminal component. Complement function is labile in vitro, so samples should be separated promptly and stored at −70 °C. Terminal-pathway and properdin deficiency present as recurrent Neisseria infection, often with unusual serogroups; C5 blockade with eculizumab or ravulizumab creates the same acquired risk, so MenACWY and MenB vaccination is required at least two weeks before the first dose. C9 deficiency is common in Japan and relatively mild, because C5b-8 retains some lytic activity.
31Complement regulators and the deficiency states that follow
Complement regulators: C1 inhibitor, factor H, factor I, the membrane regulators and CD59 — what each restrains and what happens when it fails Complement is a cascade without an intrinsic termination step, so its regulators are required to restrict it from host tissue, and deficiency of each produces a characteristic phenotype. C1 inhibitor blocks C1r, C1s and the MASPs, but it is also the principal inhibitor of plasma kallikrein and factor XIIa, which is why its deficiency causes bradykinin angioedema rather than infection. Factor H distinguishes host surfaces by their sialic acid and glycosaminoglycans and dissociates the alternative convertase; its C-terminal mutations cause atypical haemolytic uraemic syndrome while loss of its N-terminal regulatory function causes C3 glomerulopathy. Factor I permanently inactivates C3b and C4b, and its loss depletes C3. The membrane regulators DAF and MCP perform the same functions on the cell surface, and CD59 blocks the last step of the membrane attack complex — the two GPI-anchored ones are lost together in paroxysmal nocturnal haemoglobinuria. Production rises with IFNγ Androgens C1 inhibitor SERPING1 (C1-INH) Inhibits C1r, C1s, MASP-1, MASP-2, kallikrein, factor XIIa Serum / assay: Typical adult antigenic level 0.15–0.35 g/L with function above about 68% of normal; a function under 50% supports hereditary angioedema and 50–68% is indeterminate and should be repeated. Type II disease has a normal antigenic level and low function, so the functional assay is always required Made by: Hepatocytes mainly; also monocytes and endothelium Does: Serpin that inactivates C1r/C1s and MASP-1/2, and is the principal inhibitor of plasma kallikrein and factor XIIa; its loss therefore causes bradykinin angioedema rather than a complement-deficiency syndrome Clinical: Hereditary angioedema types I and II: low C4 between attacks is the best screening test, with a normal C3; acquired C1-INH deficiency (low C1q) accompanies lymphoproliferative disease. Hereditary angioedema with normal C1-INH (F12, PLG, ANGPT1, KNG1, MYOF) is a recognized diagnostic difficulty, since C4 and C1-INH are both normal and the low-C4 screen is uninformative. Attacks do not respond to antihistamines, corticosteroids or adrenaline: on-demand treatment includes C1-INH concentrate, icatibant and ecallantide (marketed in the United States but not in Canada), and first-line long-term prophylaxis includes plasma-derived C1-INH concentrate, lanadelumab and berotralstat, with danazol a second-line option that is not recommended in children and adolescents before Tanner stage V Production rises with IFNγ IL-6 Factor H CFH (with the CFHR proteins) Decay acceleration of C3bBb plus factor-I cofactor activity Serum / assay: Typical adult serum 0.2–0.7 g/L; measured with C3, factor I and anti-factor-H antibodies when C3 is low in isolation Made by: Hepatocytes mainly; also retinal pigment epithelium, endothelium and platelets locally Does: The principal fluid-phase and host-surface inhibitor of the alternative pathway: accelerates decay of C3bBb and acts as a cofactor for factor I to cleave C3b; it recognizes host sialic acid and glycosaminoglycans, which is the basis on which host surfaces are spared Clinical: Loss-of-function CFH variants and anti-factor-H autoantibodies (often with CFHR1/3 deletion) cause atypical haemolytic uraemic syndrome; the Y402H variant is a major age-related macular degeneration risk allele; complete deficiency results in complete consumption of C3. The phenotype follows the genotype: aHUS mutations cluster in the C-terminal surface-recognition domains (SCR19-20), while C3 glomerulopathy follows loss of N-terminal regulatory function or CFH–CFHR hybrid genes. Eculizumab is first-line for aHUS, and anti-factor-H-antibody disease additionally requires plasma exchange and immunosuppression Production rises with IL-6 IFNγ Factor I CFI C3b → iC3b with factor H, MCP or CR1; the second cleavage of iC3b to C3c plus C3dg (the CR2 ligand) requires CR1 specifically; factor H and MCP cannot serve as cofactors for it Serum / assay: Typical adult serum 0.03–0.06 g/L Made by: Hepatocytes; also monocytes and endothelium Does: The protease that permanently inactivates C3b to iC3b and C4b to C4c/C4d, using factor H, C4BP, CR1 or MCP as cofactor Clinical: Factor I deficiency results in C3 depletion (secondary C3 deficiency) and susceptibility to pyogenic infection; partial defects cause atypical haemolytic uraemic syndrome Production rises with IL-6 (C4BP) TNFα (DAF, MCP) IL-1β (DAF, MCP) C4BP / MCP / DAF C4BPA (C4b-binding protein), CD46 (MCP), CD55 (DAF) Decay acceleration (DAF) and factor-I cofactor activity (C4BP, MCP) Serum / assay: Membrane regulators are measured by flow cytometry (the PNH panel), not by serum level Made by: C4BP from hepatocytes; MCP (CD46) and DAF (CD55) on almost every host cell membrane Does: Prevent activation on host surfaces: C4BP is the cofactor for C4b (weakly for C3b) and MCP for both C3b and C4b; DAF dissociates both C3 convertases Clinical: CD46 loss of function causes atypical haemolytic uraemic syndrome; an acquired somatic PIGA mutation in an expanded haematopoietic stem-cell clone eliminates DAF and CD59 together in paroxysmal nocturnal haemoglobinuria, where the haemolysis is predominantly CD59-dependent; isolated inherited CD55 loss instead causes CHAPLE disease (protein-losing enteropathy with thrombosis), treated with terminal-pathway blockade (pozelimab). CD46-associated aHUS has the best renal and post-transplant prognosis of the aHUS genotypes Production rises with TNFα (endothelium) CD59 CD59 (protectin, MAC-inhibitory protein) Prevents conversion of C5b-8 to a C5b-9 pore Serum / assay: Measured by flow cytometry (FLAER / CD55 and CD59 on red cells and granulocytes) Made by: GPI-anchored on essentially all host cells, including red cells Does: Blocks C9 recruitment so the membrane attack complex cannot complete on host membranes Clinical: Isolated inherited CD59 deficiency causes haemolysis with childhood neuropathy; with CD55 loss in PNH it causes the intravascular haemolysis that eculizumab prevents Fluid phase: classical and lectin Fluid phase: alternative pathway Host-surface and C4b / C3b regulators Cross-talk stated in this scene Factor H is the cofactor that lets factor I cleave C3b DAF (within this card) and CD59 are the GPI-anchored pair, so PNH removes them together Every figure here is a typical adult value for orientation: ranges are laboratory-specific, and neonatal complement levels are roughly half to two-thirds of adult levels, so age-matched ranges are required in children. Where these regulators act in the cascade is drawn in Scenes 29 and 30.
32Complement receptors: how complement signals to cells
Complement receptors CR1, CR2, CR3 and CR4 and the anaphylatoxin receptors: which fragment each reads and what the cell then does A complement fragment acts on a cell only through a receptor that recognises it, and the fragment present determines which cells respond. Intact C3b is recognised by CR1, which erythrocytes use to transport immune complexes to liver and spleen and phagocytes use to ingest them. Once factor I has cleaved C3b, the iC3b that remains is the ligand for CR3 and CR4, the main phagocytic integrins, so the cleavage step transfers the particle from one receptor to another. The final fragment, C3d, is recognised by CR2 on B cells, where it lowers the activation threshold by one to three orders of magnitude in model systems — the point at which innate complement directly amplifies an antibody response. The anaphylatoxin receptors C3aR and C5aR1 are G-protein-coupled receptors of the same family as the chemokine receptors in Scene 6, and C5aR1 on the neutrophil couples complement activation to neutrophil recruitment. Binds this fragment C3b C4b CR1 (CD35) CR1 — complement receptor 1 Phagocytosis with FcγR co-signalling; regulator activity on the same molecule Serum / assay: Red-cell CR1 copy number is measured in research settings; low in lupus, partly acquired Made by: Erythrocytes (the largest pool), neutrophils, monocytes, macrophages, B cells, follicular dendritic cells, podocytes Does: Immune-complex clearance: red-cell CR1 transports C3b/C4b-coated complexes to liver and spleen; on phagocytes it binds C3b and C4b for ingestion; it is also a factor-I cofactor and decay accelerator Clinical: Low erythrocyte CR1 impairs immune-complex clearance in lupus; CR1 is the Plasmodium falciparum rosetting receptor Binds this fragment iC3b CR3 / CR4 ITGAM/ITGB2 (CD11b/CD18, Mac-1) and ITGAX/ITGB2 (CD11c/CD18) Inside-out activation by C5a and chemokines; outside-in signalling → phagocytosis, oxidative burst Serum / assay: Measured as CD18/CD11b expression by flow cytometry in the evaluation of leukocyte adhesion deficiency Made by: Neutrophils, monocytes, macrophages, NK cells, dendritic cells (CR4) Does: The main phagocytic receptor for iC3b-opsonized particles; also the neutrophil adhesion integrin for firm arrest on endothelium Clinical: CD18 deficiency (leukocyte adhesion deficiency type 1) causes delayed cord separation, absent pus formation, severe bacterial infection with a high blood neutrophil count; the ITGAM R77H variant is an established lupus risk allele Binds this fragment C3d C3dg iC3b CR2 (CD21) CR2 — complement receptor 2 CD19 phosphorylation → PI3K with BCR signalling Serum / assay: Assessed by flow cytometry; CD21-low B cells are a recognized CVID phenotype Made by: B cells and follicular dendritic cells Does: Lowers the B-cell activation threshold by one to three orders of magnitude in model systems (reported 10- to 1000-fold): C3d on antigen co-ligates CR2 with the BCR (the CD19/CD21/CD81 complex); FDC CR2 retains antigen in germinal centres Clinical: Human CR2 deficiency is very rare: the first reported patient presented with CVID-like hypogammaglobulinaemia and poor vaccine responses, and a second had a milder phenotype; CD21 is the Epstein–Barr-virus receptor, which links complement to EBV entry Binds this fragment C3a → C3aR C5a → C5aR1 / C5aR2 C3aR / C5aR1 C3AR1 and C5AR1 (CD88); with C5aR2 (C5L2) Gi-coupled GPCRs → PI3K, Rho GTPases, Ca²⁺ flux (the same signalling pathway as the chemokine receptors of Scene 6) Serum / assay: Not a serum measurement; receptor expression falls on neutrophils during sepsis Made by: Neutrophils, monocytes, macrophages, mast cells, basophils, eosinophils; also epithelium and endothelium Does: Convert complement activation into cell behaviour: chemotaxis, adhesion, degranulation and oxidative burst, and mast-cell mediator release Clinical: Avacopan (C5aR1 antagonist) is approved for ANCA-associated vasculitis; C5aR1 blockade spares the membrane-attack complex, unlike anti-C5 Fragment receptors (C3b → iC3b → C3d) Anaphylatoxin GPCRs Cross-talk stated in this scene Factor I cleaves C3b to iC3b, transferring the particle from CR1 to CR3 and CR4 A further cut leaves C3d, the B-cell ligand C5a activates CR3 from inside the cell, enabling firm adhesion and ingestion In the cross-talk lanes below, the filled dot marks the source and the arrowhead the target. C5aR2 (C5L2) is not G-protein-coupled: it modulates the C5a response rather than signalling through Gi like C3aR and C5aR1. The fragment sequence C3b → iC3b → C3dg/C3d is the same one drawn in Scene 30; factor I makes each cut, and the second cut needs CR1 specifically. CR3 is also the adhesion integrin of Scene 33, which is why one molecule serves both firm arrest on endothelium and ingestion of an opsonized organism.
33Neutrophil regulation: production, release, recruitment and resolution
The neutrophil life cycle: G-CSF-driven production, the CXCR4/CXCR2 release switch, recruitment to tissue, and resolution by efferocytosis Neutrophil numbers are regulated at four points. G-CSF drives production in the marrow, with GM-CSF, IL-3 and stem-cell factor; it takes about six days from myeloblast to mature cell, and G-CSF shortens that. Roughly ninety per cent of the body's neutrophils then reside in the marrow reserve, held there by stromal CXCL12 acting on CXCR4; G-CSF lowers CXCL12 and raises the CXCR2 ligands IL-8, GRO-alpha and ENA-78, so the balance shifts and cells are released. In tissue, TNF-alpha and IL-1-beta induce selectins and the same chemokines on endothelium, and C5a is generated by complement activation; the neutrophil rolls, activates its integrins from the inside, arrests on LFA-1 and CR3 and transmigrates. It then undergoes apoptosis and is ingested by macrophages, which shifts them toward IL-10 and TGF-beta production and ends the response. The number of neutrophils cleared is itself sensed: when few apoptotic neutrophils are being ingested, IL-23 rises, IL-17 follows, and IL-17 drives more G-CSF — the loop that explains why neutropenia raises G-CSF. Production in marrow Retention and release Recruitment to tissue Resolution Feedback Neutrophil Granulopoiesis GMP progenitors under G-CSF with GM-CSF, IL-3 and SCF About 6 days myeloblast → mature cell C/EBPα steady state, C/EBPβ emergency Marrow reserve About 90% of the body's neutrophils held by stromal CXCL12 on CXCR4 Released when G-CSF lowers CXCL12 and raises CXCR2 ligands Rolling → arrest → diapedesis Selectins and PSGL-1 for rolling; IL-8, GRO-α, ENA-78 and C5a activate integrins from the inside; LFA-1 and CR3 (CD11b/CD18) bind ICAM-1 Apoptosis and efferocytosis Hours to about a day in blood (estimates vary), longer in tissue. Macrophages detect phosphatidylserine through MerTK, bridged by Gas6 and protein S; C1q and C3b bridge separately to CR1, CR3 and calreticulin-LRP1 IL-23 → IL-17 → G-CSF Successful efferocytosis suppresses IL-23. When few apoptotic neutrophils are ingested, IL-23 rises, IL-17 follows (γδ T, ILC3, MAIT) and IL-17 raises G-CSF — so neutropenia raises G-CSF Drivers G-CSF, GM-CSF, IL-3, SCF G-CSFR → JAK2 / STAT3 KIT and GM-CSFR for the others CXCR4 ⇄ CXCR2 balance CXCL12 holds, CXCR2 ligands release Both are Gi-coupled GPCRs TNF-α, IL-1β on endothelium Induce E- and P-selectin and the CXCR2 chemokines; C5a adds the complement arm Efferocytosis → IL-10, TGF-β Also the lipid class switch to lipoxins, resolvins and protectins Where it fails Severe congenital neutropenia ELANE (commonest), HAX1, G6PC3, SRP54, GFI1, JAGN1, VPS45, WAS gain of function; promyelocyte arrest G-CSF-responsive; MDS/AML cumulative incidence about 22% at 15 years on G-CSF (SCNIR), the annual risk plateauing near 2.3%/year after 10 years — so counts and marrow are monitored WHIM syndrome Gain-of-function CXCR4 keeps cells in the marrow: myelokathexis Mavorixafor (oral; FDA 2024, 12 years and over) raises counts; plerixafor releases them acutely Leukocyte adhesion deficiency LAD-1 (ITGB2/CD18): delayed cord separation, no pus; LAD-2 (SLC35C1): glycosylation, Bombay phenotype; LAD-3 (FERMT3): bleeding too Failed clearance Apoptotic cells that are not cleared become autoantigen — the C1q-deficiency route to lupus (Scene 29) efferocytosis suppresses IL-23; the loop operates when few apoptotic neutrophils are cleared IL-17-driven G-CSF returns to the marrow and raises production — the loop that closes the cycle Each step has its own disease: severe congenital neutropenia at production, WHIM syndrome at release, the leukocyte adhesion deficiencies at recruitment, and failed clearance of apoptotic cells in lupus. Grey dotted tethers mark which step a disease breaks; dashed red blunt arrows mean inhibition, as in Scenes 29 to 31. The chemokines named here are drawn as gradients in Scenes 6 and 15, C5a in Scene 30, and what the neutrophil does once it arrives in Scene 34. Blood neutrophil counts rise or fall for two different reasons: a true change in production, or redistribution between the marrow reserve and the marginated and circulating pools. Adrenaline raises the count by demargination within minutes; corticosteroids raise it over hours by demargination, marrow release and reduced egress into tissue.
34Neutrophil function: opsonins, the burst, granules and NETs
What the neutrophil does on arrival: antibody and complement opsonins, phagocytosis, the oxidative burst, granule release, NETs and resolution A neutrophil is a far less efficient killer of anything that is not opsonized — it recognizes some targets directly, fungal beta-glucan through Dectin-1 and CR3 among them — so antibody and complement largely determine what it ingests. IgG is recognised by FcγRIIa and FcγRIIIb, and FcγRI appears only after IFN-gamma or G-CSF, which is why neutrophil CD64 rises in bacterial infection. C3b is recognised by CR1 and, after factor I has cleaved it, iC3b by CR3 — and C5a activates that same CR3 from inside the cell, so complement supplies both the activating signal and the opsonized target. Ingestion assembles the NADPH oxidase on the phagosome, and the primary, secondary and tertiary granules discharge into it. When the target cannot be ingested the cell can release a neutrophil extracellular trap instead, which traps organisms but also externalizes the autoantigens of several diseases. Finally the cell undergoes apoptosis and is cleared by efferocytosis, which actively resolves the response rather than merely halting it. Triggered by (⊣ = delays this step instead) IgG1 IgG3 IgA1 C3b iC3b C5a IFNγ G-CSF GM-CSF Opsonin recognition what decides whether a neutrophil ingests something Receptors are already on the surface Receptors: FcγRIIa (CD32a), FcγRIIIb (CD16b, GPI-anchored and lacking an ITAM; it signals through FcγRIIa and CR3), FcγRI (CD64, induced by IFN-γ or G-CSF), FcαRI (CD89) for IgA, CR1 (CD35) for C3b, CR3 (CD11b/CD18) for iC3b Signal: ITAM → Syk → PI3K and PKC; C5a and chemokines activate CR3 by inside-out signalling Does: Binds opsonized organisms and extends the membrane around them; unopsonized organisms are largely not recognized, so antibody and complement determine which organisms a neutrophil can kill Clinical: Neutrophil CD64 rises within hours of bacterial infection and is used as a sepsis marker, especially in neonates; IgA complexes acting on CD89 drive the neutrophil injury of IgA vasculitis Triggered by (⊣ = delays this step instead) IFNγ GM-CSF TNFα C5a Phagocytosis and killing opsonin-dependent ingestion, oxidative burst and granules Granule contents are preformed Receptors: FcγRIIa (CD32a), FcγRIIIb (CD16b, GPI-anchored and lacking an ITAM; it signals through FcγRIIa and CR3), FcγRI (CD64, induced by IFN-γ or G-CSF), FcαRI (CD89) for IgA, CR1 (CD35), CR3 (CD11b/CD18), C5aR1, fMLP receptor Signal: ITAM → Syk → PI3K and PKC → p47phox, p67phox, p40phox and Rac2 assemble on the membrane flavocytochrome gp91phox (NOX2) with p22phox Releases IL-8 TNFα BAFF IL-1RA IL-1β Does: Ingests opsonized organisms into a phagosome, assembles NADPH oxidase for superoxide, and discharges primary (myeloperoxidase, elastase), secondary (lactoferrin) and tertiary (gelatinase, MMP-9) granules into it Clinical: Chronic granulomatous disease (CYBB, NCF1, NCF2, CYBA, NCF4, CYBC1/EROS) abolishes the burst and predisposes to Staphylococcus aureus, Serratia, Burkholderia cepacia complex, Nocardia and Aspergillus infection with sterile granulomas and colitis (the former catalase-positive rule has been experimentally refuted). Dihydrorhodamine flow cytometry is the diagnostic test and identifies X-linked carriers by its bimodal pattern; residual oxidase activity predicts survival. Myeloperoxidase deficiency is usually benign but gives a falsely abnormal DHR result, because dihydrorhodamine oxidation is itself MPO-dependent; the NBT test remains normal Triggered by (⊣ = delays this step instead) IL-8 C5a TNFα NET formation neutrophil extracellular traps ROS- and PAD4-dependent Receptors: Downstream of FcγR, CR3, C5aR1 and TLR signalling Signal: ROS and PAD4 → chromatin decondensation → extracellular release Does: Releases chromatin bearing elastase, myeloperoxidase and histones, which traps extracellular organisms; also a source of autoantigen and a driver of thrombosis Clinical: NETs externalize MPO and PR3 (the ANCA antigens) and DNA and nucleosomes in lupus, whereas citrullinated histones from the same process are a source of the ACPA antigens of rheumatoid arthritis; NET clearance depends on DNase I and DNASE1L3, and DNASE1L3 loss causes lupus and hypocomplementaemic urticarial vasculitis. NOX2-deficient (CGD) neutrophils form NETs poorly, a defect corrected by gene therapy. NETs also contribute to immunothrombosis in sepsis and severe COVID-19 Triggered by (⊣ = delays this step instead) ⊣ GM-CSF ⊣ G-CSF ⊣ IL-8 Resolution and clearance apoptosis, efferocytosis and the end of the response Efferocytosis, not transcription Receptors: Phosphatidylserine on the apoptotic neutrophil recognized by macrophage MerTK (bridged by Gas6 and protein S) and by scavenger receptors; C1q and C3b bridge separately to CR1, CR3 and calreticulin-LRP1 Signal: Efferocytosis → macrophage IL-10 and TGF-β, suppressing IL-23 Releases IL-10 Does: Macrophages ingest apoptotic neutrophils (efferocytosis), which switches the macrophage to a TGF-β and IL-10 programme and terminates recruitment, while the eicosanoid class switch to lipoxins, resolvins and protectins actively terminates the response; when few apoptotic neutrophils are cleared in tissue, macrophage IL-23 production rises and induces IL-17 (largely from γδ T, ILC3 and MAIT cells), which in turn raises G-CSF Clinical: Failed apoptotic-cell clearance (C1q deficiency) causes lupus; the IL-23 / IL-17 / G-CSF loop accounts for the rise in G-CSF in neutropenia and for the mild reduction in neutrophil counts with anti-IL-17 agents Opsonin-driven killing Extracellular killing Ending the response Cross-talk stated in this scene Ingestion assembles the oxidase and empties granules into the phagosome When the target is too large to ingest, the cell releases a NET instead ⊣ Uncleared NETs and apoptotic cells become autoantigen instead of resolving Chip styles: a solid outline is one of the 95 catalogued mediators, a dotted outline is a complement fragment or other signal named elsewhere in this atlas, and a dashed red chip with ⊣ is a signal that delays the step rather than triggering it. The opsonins come from the antibody isotypes of Scene 27 and the complement fragments of Scene 30; the receptors that read them are in Scenes 28 and 32. Neutrophils also make cytokines, though far less than monocytes do.
35The hepatic acute-phase response: how a cytokine signal becomes a blood test
The acute-phase response: IL-6 and IL-1-beta reprogramme the hepatocyte, so that positive reactants rise and negative reactants fall Most inflammatory markers in clinical use are outputs of a single circuit. Infection, trauma, surgery or autoinflammation activates tissue macrophages and monocytes, which release IL-6, IL-1-beta and TNF-alpha, and the hepatocyte responds to IL-6 through IL-6R with gp130, JAK1 and STAT3 while IL-1-beta adds NF-kappa-B. The hepatocyte then reprogrammes its plasma-protein output extensively, though not uniformly: CRP, SAA and C3 are type 1 and respond to both signals, whereas fibrinogen and human haptoglobin are type 2 and respond to the IL-6/gp130 signal alone. CRP, serum amyloid A, fibrinogen, haptoglobin, ferritin, hepcidin, alpha-1 antitrypsin and ceruloplasmin rise, and albumin, transferrin and transthyretin fall at the same time and for the same reason. Several complement proteins are acute-phase reactants too, which is why a C3 or C4 can appear normal while it is being consumed. The whole response therefore depends on one signal: if IL-6 cannot reach the hepatocyte, or the hepatocyte cannot respond, the IL-6-dependent markers cannot rise: CRP, fibrinogen and so the ESR, haptoglobin and SAA. Two markers are exceptions: procalcitonin has its own drivers and still rises, and ferritin is driven by IL-1-beta, IFN-gamma and IL-18 as well, so it can still rise steeply. A rising ferritin against a flat CRP in a child on tocilizumab should be regarded as a genuine finding and not as an artefact. Trigger Cytokines released The hepatocyte What changes in the blood Acute-phase axis Infection, trauma, surgery, autoinflammation Tissue macrophages and monocytes sense the insult (Scene 1) Inflammasome activation in the periodic fevers does the same IL-6, IL-1β, TNF-α IL-6 is the dominant driver; IL-1β and TNF-α add to it IL-11 and LIF use the same gp130 receptor (Scene 10) Hepatocyte IL-6R + gp130 → JAK1 → STAT3 IL-1β → NF-κB One signal, a coordinated switch of plasma-protein synthesis Positive reactants rise: CRP · SAA · fibrinogen · haptoglobin · ferritin · hepcidin · α1-antitrypsin · ceruloplasmin Complement C3, C4, factor B, MBL and C1 inhibitor are acute-phase proteins too — so a normal C3 or C4 does not exclude ongoing consumption (Scenes 29–31) α1-antitrypsin and ceruloplasmin are named here but are not catalogued in this atlas Falling, and not rising at all No IL-6 signal, no acute phase IL-6 blockade (tocilizumab, sarilumab) abolishes the CRP response IL6R, IL6ST or STAT3 loss-of-function does the same So does liver failure Procalcitonin is the exception — it still rises when IL-6 is blocked (Scene 36) Albumin · transferrin · transthyretin · retinol-binding protein Suppressed by the same IL-6 and TNF-α signal. A low albumin or transthyretin here is a marker of inflammation, not nutrition; a low transferrin is not iron overload Timing Kinetics of each marker SAA is among the fastest hepatic reactants (up to ~1000-fold, as can CRP) CRP: rises by 4–6 h, peaks 36–50 h, t½ ~19 h Fibrinogen and ferritin: over days RBP falls first (t½ ~12 h), then transthyretin (t½ ~2 d); albumin slowest (t½ ~20 d) synthesis switched down removes the whole response The markers are interpreted as a set and over time. CRP reflects current synthesis, a fibrinogen-driven ESR reflects the preceding days, and an albumin falling with them indicates a systemic rather than local response. The cytokines in the second column are drawn in Scene 1 (IL-1β, TNF-α) and Scenes 4 and 5 (IL-6) and Scene 10 (the rest of the gp130 family); the complement proteins named here have their own cards in Scenes 29 to 31. CRP, SAA, procalcitonin and fibrinogen are set out marker by marker in Scene 36, the ESR in Scene 37, and the iron axis in Scene 38.
36The markers in common use: CRP, SAA, procalcitonin and fibrinogen
CRP, serum amyloid A, procalcitonin and fibrinogen: what induces each, what it does, its kinetics, and its interpretation These four differ sufficiently that measuring them together is more informative than measuring any one of them. CRP is made only by the hepatocyte, only on an IL-6 signal, and its half-life is fixed at about nineteen hours, so the level reflects the current rate of synthesis; it also has a function, binding phosphocholine on damaged membranes and on pneumococcus and then activating complement through C1q, which makes it an antibody-independent opsonin. Serum amyloid A rises faster and falls faster, and can rise about 1000-fold in a day, as can CRP; when it remains elevated it is the protein that becomes AA amyloid, which is why it, rather than CRP, is the marker of adequate treatment between attacks of a periodic fever. Procalcitonin is induced by bacterial products and suppressed by interferon, which is why it separates bacterial from viral illness better than CRP, and it is the only one of the four that remains informative under IL-6 blockade. Fibrinogen rises slowly and is the protein that drives the ESR. Induced by IL-6 IL-1β CRP C-reactive protein (CRP); a pentameric short pentraxin Level: Typical adult under about 5 mg/L (laboratories quote 3, 5 or 8); high-sensitivity CRP is the same analyte on a lower-range assay, interpreted as under 1 (low), 1–3 (average) and over 3 mg/L (high) for cardiovascular risk; the 2003 AHA/CDC statement that defined those bands specifies the average of two samples about two weeks apart and regards a value over 10 mg/L as an indication to seek an acute cause rather than as a risk category Kinetics: Half-life about 19 hours and constant, so the level reflects the current rate of synthesis: it begins to rise by 4–6 hours, doubles roughly every 8 hours, peaks at 36–50 hours, and falls rapidly once the stimulus ceases Does: Binds phosphocholine exposed on damaged membranes, on apoptotic cells and on the pneumococcal C-polysaccharide, then activates the classical complement pathway through C1q and opsonizes the target for FcγRI and FcγRIIa; it is an antibody-independent opsonin Clinical: A CRP over about 100 mg/L favours bacterial infection or an abscess, and viral illness is usually lower, but no cut-off separates them reliably and the threshold is population-specific: paediatric febrile-infant rules use the markers only as components of a complete rule. Step-by-Step classifies an infant as low risk only if the child appears well, is older than 21 days, has a negative urine leukocyte esterase, PCT under 0.5 µg/L, CRP 20 mg/L or below and ANC 10 ×10⁹/L or below, so the CRP and PCT thresholds alone do not stratify risk; neonatal sepsis screens use 10 mg/L. Because CRP lags the stimulus by hours, a low value sampled early does not exclude bacterial infection. Newborns have a physiological rise over the first 24–48 hours of life, parallel to PCT, and that response is gestational-age dependent (preterm infants mount a lower and shorter rise), so a neonatal CRP requires both an hour-of-life and a gestation-matched reference. Negative findings are equally informative: CRP remains relatively low in many lupus flares (serositis excepted), which assists in distinguishing flare from infection; it cannot rise during IL-6 blockade, in IL6R or STAT3 defects, or in liver failure, so a normal CRP in those settings provides no information about infection Induced by IL-1β IL-6 TNFα SAA serum amyloid A (SAA1/SAA2) Level: Typical adult under about 10 mg/L, but the assay is not universally available Kinetics: Among the fastest of the acute-phase rises: up to about 1000-fold within roughly 24 hours, as can CRP, and on serial measurement it rises earlier and falls more rapidly than CRP (human SAA half-life figures are not well established, so the comparison is kinetic rather than pharmacokinetic) Does: An apolipoprotein that redistributes cholesterol during inflammation and recruits monocytes; chronically raised SAA is the precursor protein of AA amyloid, which deposits in kidney, gut and liver Clinical: The clinically relevant marker in the periodic fevers: sustained SAA elevation in untreated familial Mediterranean fever, TRAPS or CAPS causes AA amyloidosis, so where the assay is available it is used to confirm that colchicine or anti-IL-1 treatment is adequate between attacks; a normal CRP between attacks does not establish that inflammation is controlled Induced by, suppressed by IL-1β TNFα IL-6 ⊣ IFNγ ⊣ IFNα2 Procalcitonin procalcitonin (PCT), the prohormone of calcitonin (CALCA) Level: typical adult under 0.1 µg/L; above about 0.5 µg/L suggests bacterial infection and above 2 µg/L suggests sepsis. In the first days of life it is interpreted against an hour-of-life nomogram (see the note below) Kinetics: Half-life about 24 hours; it rises within 3–6 hours and peaks at about 6–24 hours, so it rises earlier than CRP and falls predictably when the infection is treated Does: No established physiological role at these concentrations; it is used as a marker because bacterial products induce it whereas interferon suppresses it Clinical: Discriminates bacterial from viral infection better than CRP and is the only marker in this group that IL-6 blockade does not abolish, so it remains interpretable on tocilizumab. It is also raised without infection after major surgery, trauma, burns, cardiac arrest and in medullary thyroid carcinoma Induced by IL-6 Fibrinogen fibrinogen (FGA / FGB / FGG) — a type 2 acute-phase protein Level: Typical adult 2–4 g/L; rises to 6–10 g/L in sustained inflammation; neonatal values are lower than adult, and in a child with systemic JIA a fibrinogen of ≤3.6 g/L is classified as abnormally low in the 2016 MAS criteria because the acute-phase response would be expected to have raised it Kinetics: Slow: rises over 24–48 hours and falls over days to weeks, which accounts for the lag of the ESR behind the CRP in both directions Does: The protein that bridges red cells into rouleaux, so it, not CRP, is the principal determinant of the ESR (Scene 37); and the clotting substrate for thrombin. It is a type 2 acute-phase gene, which is why it responds to IL-6 alone: IL-1β and TNF-α add nothing to the IL-6 effect and IL-1β transiently antagonises it at the promoter, unlike CRP, SAA and C3, which are type 1 and respond to both Clinical: Because fibrinogen determines the ESR, any condition in which it is consumed or not produced (disseminated intravascular coagulation, liver failure, congenital hypo- or dysfibrinogenaemia, thrombolysis) can suppress the ESR despite active inflammation Type 1: IL-6 with IL-1β (and TNF-α for SAA) Bacterial products via these cytokines; IFN suppresses Type 2: IL-6 alone Cross-talk stated in this scene Both respond to the same IL-6 signal, but SAA rises sooner and falls faster Fibrinogen and CRP rise together; only fibrinogen raises the ESR (Scene 37) Every level here is a typical adult figure for orientation only: cut-offs are assay-specific, and paediatric interpretation differs. Procalcitonin is the clearest case: healthy newborns have a large physiological peak at about 24 hours of life (roughly the 18–36 hour window), with a 95th centile near 20 µg/L in term infants — far above the adult bacterial cut-off — returning to the adult range by about 48–72 hours on the classic term nomograms, though some series show a slower fall. In preterm infants it resolves later still and the peak magnitude is disputed, so gestation as well as hour of life has to be matched; the catalogue entry gives the series. CRP's complement activation through C1q is the same step drawn in Scene 29.
37The ESR: what it measures, what moves it, and how it differs from CRP
The erythrocyte sedimentation rate: a physical index driven by fibrinogen and immunoglobulin, with its own confounders and its own timing The ESR is not a protein and not a cytokine: it is the distance red cells fall in a vertical tube in one hour. They fall faster when plasma proteins bridge them into stacks, and the protein that does most of that bridging is fibrinogen, with immunoglobulin second. This accounts for most of the behaviour of the test. Because fibrinogen is an IL-6-driven acute-phase protein that takes a day or two to rise and days to weeks to fall, the ESR lags the CRP in both directions. Because anything that changes red cells or plasma proteins changes sedimentation, the ESR can be high with no inflammation at all — in anaemia, in pregnancy, with age, and in any hypergammaglobulinaemia — and it can remain low despite genuine inflammation when fibrinogen is consumed or red-cell shape prevents rouleaux. When the ESR is interpreted with the CRP, the discordances are themselves informative. Driven by Fibrinogen Immunoglobulin (IgM > IgG, IgA; paraprotein) What the ESR measures Westergren method: millimetres fallen in one hour Rouleaux formation, not inflammation itself Level: age- and sex-dependent — adult men under about 15 mm/h and women under about 20 mm/h below age 50, about 20 and 30 mm/h above it. The age ÷ 2 (men) and (age + 10) ÷ 2 (women) correction is for adults only: children run about 0–13 mm/h to age 12 (newborns 0–2 mm/h), with adult limits from around puberty Kinetics: rises over 24–48 hours and falls over days to weeks, lagging the CRP in both directions Red cells carry a negative surface charge that keeps them apart; bridging proteins — fibrinogen most of all, immunoglobulin next — overcome it so the cells stack into rouleaux and sediment faster Clinical: It is an indirect index of plasma protein composition. That makes it useful for following a slow process and poor for detecting a fast one Higher in, with no inflammation Anaemia Pregnancy Older age Female sex Obesity Hypergammaglobulinaemia Renal failure Raised without inflammation the common reasons for a high ESR in a well patient Fewer red cells, or more plasma protein Anaemia raises it (fewer cells fall faster); polycythaemia lowers it Rises with female sex, older age, pregnancy, obesity and renal failure Any polyclonal or monoclonal rise in IgG, IgA or IgM raises the ESR — myeloma, chronic infection, HIV, autoimmune disease and chronic liver disease among them. IgE and IgD are present at too low a concentration to affect it, so a high ESR in hyper-IgE or hyper-IgD disease reflects the inflammation, not the immunoglobulin Clinical: An ESR over 100 mm/h is significant on its own. In a child it suggests osteomyelitis or septic arthritis, Kawasaki disease, systemic JIA, inflammatory bowel disease or occult infection; in an adult the differential also includes myeloma or another malignancy, giant-cell arteritis and tuberculosis Held down by, despite inflammation Low fibrinogen Sickle cells Spherocytes Polycythaemia Hyperviscosity (very high IgM) Extreme leukocytosis Delayed sample Held down despite inflammation when a normal ESR is falsely reassuring No fibrinogen, or cells that do not stack Disseminated intravascular coagulation, liver failure and congenital hypo- or dysfibrinogenaemia remove the bridging protein Sickle cells, spherocytes and marked microcytosis do not form rouleaux; polycythaemia and extreme leukocytosis slow sedimentation; and a monoclonal IgM high enough to raise viscosity slows it too, the same IgM that promotes rouleaux at lower concentrations; and a sample left standing for hours loses rouleaux and gives a falsely low result The test is also technique-sensitive: a tilted tube, a warm room or a sample left standing for hours all change the result Clinical: In a child with sickle-cell disease or with DIC, a normal ESR is uninformative and the CRP should be used CRP and ESR together what each discordance usually means Different proteins, different clocks High CRP with a normal ESR: inflammation that started within the last day High ESR with a normal CRP: inflammation that is resolving, a paraprotein, polyclonal hypergammaglobulinaemia or anaemia Both high: established inflammation. Both normal with a convincing history: consider a process the acute phase does not report, or an inability to mount it at all (IL-6 blockade, or IL6R or STAT3 loss-of-function, or liver failure) Clinical: In lupus the pair is classically discordant — the ESR tracks the flare while the CRP stays comparatively low, so a high CRP in lupus should raise the question of infection or serositis rather than flare alone What the test is Why it can mislead Reading it with the CRP Cross-talk stated in this scene The ESR follows fibrinogen, so it reflects the preceding day or two rather than the current hour Fibrinogen, the principal determinant of the ESR, has its own card in Scene 36, and the IL-6 signal that raises it is in Scene 35. Because IL-6 blockade lowers fibrinogen, tocilizumab normalises the ESR as well as the CRP — on that treatment neither test can be used to detect infection, and procalcitonin remains informative.
38What inflammation does to iron: hepcidin, ferritin and the anaemia of inflammation
The iron axis in inflammation: IL-6 drives hepcidin, hepcidin removes ferroportin, and iron is locked away from the erythron Inflammation withholds iron through the same IL-6 signal that raises CRP. IL-6 acting through STAT3 on the hepatocyte raises hepcidin, and hepcidin binds and degrades ferroportin, the only way iron leaves a cell. With ferroportin gone, dietary iron cannot cross the enterocyte and recycled iron cannot leave the macrophage, so serum iron and transferrin saturation fall while iron accumulates inside macrophages. Ferritin rises at the same time for two separate reasons — inflammation raises its transcription and stored iron raises its translation — and transferrin falls because it is a negative acute-phase protein. The result is the anaemia of inflammation, and the practical consequence is that the usual iron panel loses its usual interpretation: a normal or high ferritin does not exclude iron deficiency, a low transferrin is not iron overload, and oral iron is poorly effective until the inflammation itself is treated. The signal The hormone The gate, and the ferritin it explains The result, and how to read the panel Iron axis IL-6 on the hepatocyte The same STAT3 signal that raises CRP (Scene 35) BMP6 → SMAD1/5/8 senses iron stores in parallel Hepcidin (HAMP) The master iron hormone Rises within hours of an IL-6 signal Suppressed by erythroferrone when the marrow demands iron Ferroportin degraded Hepcidin binds ferroportin (SLC40A1) and has it internalized Ferroportin is the only exporter of iron from enterocytes and macrophages Anaemia of inflammation Serum iron low Transferrin saturation low Transferrin low (a negative reactant) Ferritin normal or high Normocytic, becoming microcytic late Reading the iron panel Ferritin rises for two reasons Iron trapped inside the cell by the loss of ferroportin raises its translation through the iron-responsive element, while IL-6 and IL-1β raise its transcription — two unrelated reasons for the same ferritin to rise Which tests remain informative Soluble transferrin receptor still reflects iron supply when CRP is raised — but it also rises with any expanded erythropoiesis (haemolysis, thalassaemia) and falls in marrow hypoplasia and CKD Transferrin saturation is lowered by inflammation itself, so a low TSAT does not prove deficiency Ferritin is raised by inflammation: with raised CRP, a ferritin under 30 µg/L below five years and under 70 µg/L from five years still means deficiency — WHO bands the 70 figure from five years up, not adults only which explains the pattern of the panel When CRP is raised, the soluble transferrin receptor (or the sTfR/log-ferritin index) is more informative than ferritin or transferrin saturation, because inflammation lowers the saturation on its own. A ferritin of 500 µg/L or more (HLH-2004), or over 684 µg/L with any two of a low platelet count (≤181 ×10⁹/L), a raised AST (>48 U/L), raised triglycerides (>1.76 mmol/L) or a low fibrinogen (≤3.6 g/L) in a febrile child with systemic JIA (2016 MAS criteria), should prompt consideration of haemophagocytosis or macrophage activation syndrome rather than iron stores; values in the thousands to tens of thousands are typical in established HLH but are not the classification threshold. The IL-6 signal is the one drawn in Scene 35, and ferritin, hepcidin and transferrin each have a card in the acute-phase catalogue. Erythropoietic drive opposes this axis through erythroferrone, which suppresses hepcidin — which is why the anaemia of inflammation is a restriction of supply rather than a failure of the marrow itself.
39Type 2 and allergic disease: the agents, and what each one does to the tests
Anti-IgE, anti-IL-4Rα, anti-IL-13, anti-IL-5, anti-IL-5Rα, anti-TSLP and anti-IL-31RA: where each one cuts the type 2 pathway Every agent on this scene blocks a mediator that already has a card in this atlas, so the downstream consequences are the ones the earlier scenes draw. They differ in the level of the pathway at which they act. Omalizumab acts at the final step, on IgE already produced. Dupilumab blocks the shared IL-4Rα chain and so removes IL-4 and IL-13 together; the anti-IL-13 antibodies remove only IL-13. The anti-IL-5 agents act on the eosinophil, and benralizumab depletes it rather than withdrawing its survival signal. Tezepelumab is the only one acting above the type 2 cytokines, at the epithelial alarmin, which is why it is effective without a type 2 phenotype. Each card also records the effect that changes management: what the agent does to the tests. Two of these are counter-intuitive and are a common source of error: total IgE rises on omalizumab, and the eosinophil count rises in the first months of dupilumab. Blocks (⊣) or supplies ⊣ IgE Omalizumab omalizumab (Xolair) — humanised anti-IgE IgG1 What it does to the tests: Total IgE rises, often several-fold, and remains elevated for a year or more: the assay measures omalizumab–IgE complexes as well as free IgE, so a rising total IgE on treatment is expected and is not treatment failure. Free IgE is the analyte that falls, and it is not routinely available. Blood eosinophils fall modestly. Skin prick tests and basophil activation tests become unreliable while surface IgE is depleted, and specific IgE in serum is unaffected by the drug but is interpreted against a distorted total. Made uninterpretable: Total IgE and skin prick testing. For asthma, nasal polyps and food allergy the dose and interval are determined from the pre-treatment total IgE and body weight, so the baseline must be recorded before the first dose and a total IgE measured on treatment cannot be used to revise the dose. Chronic spontaneous urticaria is the exception: dosing is fixed at 150 or 300 mg every four weeks and requires neither value, so treatment should not be delayed to obtain them. If skin testing is required, it must precede treatment or follow a washout of several months. How it works: Binds the Cε3 domain of free IgE at the site used by FcεRI, so IgE can no longer bind to mast cells and basophils; receptor-bound IgE is not displaced, so the effect results from the slow loss of surface IgE as receptors turn over, and FcεRI density on basophils and mast cells falls over weeks Clinical: Carries a boxed warning for anaphylaxis, which has occurred after a first dose and after more than a year of uneventful treatment: it is administered in a healthcare setting with observation, and for the food-allergy indication an adrenaline auto-injector is prescribed. Licensed for allergic asthma from 6 years, chronic spontaneous urticaria from 12 years, chronic rhinosinusitis with nasal polyps in adults, and, in the USA only, for IgE-mediated food allergy from one year, where it raises the reaction threshold rather than conferring tolerance, so avoidance continues. Also used off-label as adjunctive cover during oral immunotherapy build-up. Blocks (⊣) or supplies ⊣ IL-4 ⊣ IL-13 Dupilumab dupilumab (Dupixent) — human anti-IL-4Rα IgG4 What it does to the tests: Blood eosinophils often rise in the first weeks to months and then decline; this is the expected result of blocking eotaxin-driven tissue recruitment while IL-5-driven marrow release continues, so the cells remain in the circulation. A rise does not represent treatment failure and is not by itself an indication for discontinuation; a sustained count over about 1.5 × 10⁹/L, and any count with new systemic symptoms, requires evaluation for eosinophilic granulomatosis with polyangiitis or hypereosinophilic disease. FeNO and total IgE fall slowly over months. TARC (CCL17) falls and correlates with atopic-dermatitis activity. CRP and ESR are unaffected and remain interpretable. Made uninterpretable: Blood eosinophils in the first months, and total IgE as a measure of disease activity. How it works: Binds IL-4Rα, so it blocks the type I receptor (IL-4Rα + γc, used by IL-4 alone) and the type II receptor (IL-4Rα + IL-13Rα1, used by both IL-4 and IL-13): a single antibody blocks the entire STAT6 arm of type 2 immunity Clinical: Atopic dermatitis from 6 months, eosinophilic asthma from 6 years, chronic rhinosinusitis with nasal polyps from 12 years, eosinophilic oesophagitis from 1 year and 15 kg, chronic spontaneous urticaria from 2 years in the USA but only from 12 years in Canada, allergic fungal rhinosinusitis from 6 years with prior sino-nasal surgery and bullous pemphigoid in adults in the USA only, and prurigo nodularis and COPD with type 2 inflammation in adults. Head and neck erythema and conjunctivitis are the characteristic adverse effects; arthralgia and psoriasiform eruptions are recognised. Blocks (⊣) or supplies ⊣ IL-13 Tralokinumab, lebrikizumab tralokinumab (Adbry/Adtralza) and lebrikizumab (Ebglyss) — anti-IL-13 IgG4 What it does to the tests: Changes are in the same direction as with dupilumab but are smaller: FeNO and TARC fall, and eosinophils change little. Conjunctivitis occurs but less often than with dupilumab. How it works: Neutralise IL-13 itself rather than the shared receptor chain, so IL-4 signalling through the type I receptor remains intact; the blockade is narrower than that of dupilumab Clinical: Atopic dermatitis in adolescents from 12 years and in adults; the adolescent tralokinumab dose is twice as high in Canada as in the USA (see the licensing note). Useful where dupilumab-associated conjunctivitis or head-and-neck erythema is limiting, since IL-4 signalling is preserved. Blocks (⊣) or supplies ⊣ IL-5 Mepolizumab, reslizumab mepolizumab (Nucala) and reslizumab (Cinqair) — anti-IL-5 IgG What it does to the tests: Blood eosinophils fall by roughly 80–90% within weeks but do not reach zero; tissue eosinophils fall more slowly. CRP, ESR and IgE are unaffected. A persistently normal eosinophil count on treatment does not establish tissue control. Made uninterpretable: The blood eosinophil count as a measure of disease activity, since on treatment it reflects the drug effect. How it works: Neutralise circulating IL-5, so eosinophil production, release from the marrow and survival in tissue all fall; the cells are not killed directly, so the count falls but is not abolished Clinical: Mepolizumab: severe eosinophilic asthma from 6 years, hypereosinophilic syndrome from 12 years in the USA but adults only in Canada, and eosinophilic granulomatosis with polyangiitis, chronic rhinosinusitis with nasal polyps and COPD in adults. Reslizumab is intravenous and adults only. Baseline eosinophil count predicts response, so it must be measured before the first dose. Blocks (⊣) or supplies ⊣ IL-5 Benralizumab benralizumab (Fasenra) — afucosylated anti-IL-5Rα IgG1 What it does to the tests: Blood eosinophils fall to zero by the first on-treatment measurement at four weeks (and within about a day in the bronchoscopy studies of the mechanism) and remain at zero; depletion is complete, unlike that with the anti-IL-5 antibodies. Basophils also fall. A zero eosinophil count is the expected on-treatment finding and is not in itself a cause for concern, but the count can no longer be used diagnostically, including for the eosinophilia that would otherwise indicate drug reaction, parasitic infection or adrenal insufficiency. Made uninterpretable: The eosinophil count, for the duration of treatment. How it works: Binds IL-5Rα, the receptor on the eosinophil, and not the cytokine: the target shown for this entry is IL-5 because the eosinophil is not a catalogued entity in this reference, but the drug leaves IL-5 itself in the circulation and depletes the cell that responds to it. Because the Fc is afucosylated and binds FcγRIIIa with very high affinity, it recruits NK-cell antibody-dependent cellular cytotoxicity: the eosinophil is killed rather than deprived of its survival signal. Basophils, which also express IL-5Rα, are depleted with them Clinical: Severe eosinophilic asthma from 6 years in the USA but adults only in Canada, hypereosinophilic syndrome from 12 years (Canada also requires 40 kg), and eosinophilic granulomatosis with polyangiitis in adults. Strongyloides should be screened for and treated before initiation, as with any agent that depletes eosinophils. Blocks (⊣) or supplies ⊣ TSLP Tezepelumab tezepelumab (Tezspire) — human anti-TSLP IgG2 What it does to the tests: Blood eosinophils, FeNO and total IgE all fall. IL-5 and IL-13 in blood fall. Airway hyperresponsiveness falls, an effect not reliably achieved by the other agents. How it works: Blocks TSLP at the origin of the epithelial alarmin cascade, upstream of the type 2 cytokines, so it is effective in asthma independent of eosinophil count or allergic status; it is the only type 2 agent that is not restricted to a type 2 phenotype Clinical: Severe asthma from 12 years regardless of phenotype, including low-eosinophil disease, and chronic rhinosinusitis with nasal polyps from 12 years in the USA but adults only in Canada. Because it acts upstream of IL-5 and IL-13, it attenuates several of the markers used to phenotype the patient, so phenotyping must precede treatment. Blocks (⊣) or supplies ⊣ IL-31 Nemolizumab nemolizumab (Nemluvio) — anti-IL-31RA IgG2 What it does to the tests: No reliable effect on eosinophils, IgE or the acute-phase markers, so there is no characteristic laboratory change to monitor. Arthralgia, myalgia and headache are the labelled adverse reactions. How it works: Blocks the IL-31 receptor A chain on sensory neurons, keratinocytes and immune cells, interrupting the itch signal rather than the inflammation that produced it Clinical: Prurigo nodularis in adults, and atopic dermatitis from 12 years. Because it targets the itch pathway specifically, the skin signs can lag the symptomatic response. At the antibody At the IL-4 / IL-13 axis At the eosinophil Above the cytokines, and at the itch Cross-talk stated in this scene Blocking IL-4 and IL-13 raises the blood eosinophil count; blocking IL-5 lowers it Tezepelumab acts above IL-5 and IL-13, so it lowers the markers of both The targets are the mediators of Scenes 2, 3 and 7 and the IgE of Scene 27; the eosinophil recruitment these agents interrupt is the eotaxin axis of Scenes 6 and 17. Dupilumab raising the blood eosinophil count while it treats the disease is consistent with the mechanism drawn here: IL-5-driven release from the marrow continues while eotaxin-driven entry into tissue is blocked, so the cells remain in the circulation, where they are counted. Thresholds for stopping are clinical, not numerical.
40TNF, IL-1 and IL-6 blockade: the agents that suppress the acute-phase response
Etanercept, the anti-TNF monoclonals, anakinra, canakinumab, rilonacept, tocilizumab, sarilumab and siltuximab These are the agents that act on the three cytokines Scene 35 draws as the drivers of the hepatic acute-phase response, so they share one consequence: they lower the markers used to detect infection. The degree differs. TNF and IL-1 blockade blunt the response. IL-6 blockade abolishes it, so the CRP cannot rise; this is among the most consequential laboratory interactions described here. Procalcitonin is the exception and is preserved, because bacterial products induce it through pathways that do not need IL-6. Within TNF blockade the agents are not interchangeable: etanercept is a decoy receptor that also binds lymphotoxin-α, binds transmembrane TNF without sustained cross-linking, and is ineffective in granulomatous bowel disease, in which the monoclonal antibodies are effective. Blocks (⊣) or supplies ⊣ TNFα ⊣ TNFβ Etanercept etanercept (Enbrel) — soluble TNFR2 (p75) — Fc fusion protein What it does to the tests: CRP, ESR, SAA and fibrinogen all fall, and so does the platelet count; the anaemia of inflammation improves, so haemoglobin rises. Ferritin falls. Because it attenuates the entire acute-phase response, a normal CRP on treatment cannot be used to exclude infection. Anti-nuclear and anti-dsDNA antibodies appear in a minority without clinical lupus. Made uninterpretable: CRP and ESR as infection markers. How it works: A decoy receptor rather than an antibody: it binds soluble TNF-α and lymphotoxin-α (TNF-β), which the monoclonal antibodies do not. It binds transmembrane TNF without the sustained cross-linking produced by the monoclonal antibodies, which is the usual, although not established, explanation for its lack of efficacy in granulomatous bowel disease and its lower rate of tuberculosis reactivation Clinical: Carries the class boxed warning: serious infection including tuberculosis (testing for latent disease is required before and during treatment), invasive fungal infection (histoplasmosis, coccidioidomycosis and pneumocystosis, where the histoplasma antigen test may be negative), and lymphoma and other malignancies, some fatal, reported in children and adolescents treated with TNF blockers. Screening for latent tuberculosis and hepatitis B is required before initiation. Licensed in the USA for polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis from 2 years and for paediatric plaque psoriasis from 4 years; in Canada for polyarticular juvenile idiopathic arthritis from 4 to 17 years after an inadequate response to a disease-modifying antirheumatic drug and for chronic severe paediatric plaque psoriasis from 4 to 17 years, with no juvenile psoriatic arthritis indication. The paediatric dose in both countries is 0.8 mg/kg weekly to a maximum of 50 mg. In adults it is licensed in both countries for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and plaque psoriasis. It is not effective in Crohn disease, uveitis or sarcoidosis, which is the clearest example in this class that two drugs against the same cytokine are not interchangeable. Blocks (⊣) or supplies ⊣ TNFα Infliximab, adalimumab, golimumab, certolizumab infliximab (Remicade), adalimumab (Humira), golimumab (Simponi), certolizumab pegol (Cimzia) — anti-TNF-α monoclonals What it does to the tests: As for etanercept with respect to the acute-phase markers: CRP, ESR, SAA, fibrinogen, ferritin and the platelet count all fall, and the anaemia of inflammation improves. Faecal calprotectin falls in bowel disease. Anti-drug antibodies develop, particularly with infliximab, and drug levels with anti-drug antibodies are the standard means of investigating loss of response; concomitant methotrexate reduces them. Made uninterpretable: CRP and ESR as infection markers. How it works: Neutralise TNF-α only, and bind transmembrane TNF with sustained cross-linking, which delivers reverse signalling and, for the IgG1 agents, complement- and cell-mediated killing of TNF-bearing cells. This accounts for their efficacy in granulomatous disease, in which etanercept is not effective, and for their higher tuberculosis risk Clinical: Carries the same class boxed warning as etanercept (serious infection including tuberculosis, invasive fungal infection, and lymphoma and other malignancies reported in children and adolescents). These agents carry the higher tuberculosis risk, as described above, so latent tuberculosis and hepatitis B screening before initiation, with repeat tuberculosis testing on treatment, is of particular importance. Licensed across Crohn disease, ulcerative colitis, juvenile idiopathic arthritis, uveitis and hidradenitis; Behçet disease is not a labelled indication for any of the four agents in Canada or the USA, so that use is off-label. The paediatric licences differ by country. Infliximab: Crohn disease from 9 years in Canada and from 6 years in the USA, and ulcerative colitis from 6 years in both. Adalimumab: polyarticular juvenile idiopathic arthritis from 2 years and ulcerative colitis from 5 years in both countries; Crohn disease from 13 years and 40 kg in Canada but from 6 years in the USA; hidradenitis suppurativa from 12 years, dosed from 30 kg, in both; and uveitis from 2 years, as chronic non-infectious anterior uveitis with methotrexate in Canada and as non-infectious intermediate, posterior and panuveitis in the USA. Golimumab: polyarticular juvenile idiopathic arthritis from 2 years by the intravenous route in both countries, with ulcerative colitis from 15 kg by the subcutaneous route and paediatric psoriatic arthritis from 2 years by the intravenous route in the USA only; the subcutaneous product has no paediatric indication in Canada. Certolizumab: polyarticular juvenile idiopathic arthritis from 2 years in the USA, with no paediatric indication in Canada. Certolizumab has the least placental transfer (negligible in most infants at birth and low in the remainder), so it is the agent that can be continued latest in pregnancy; the IgG1 agents cross from the second trimester, and a live vaccine in an exposed infant, in practice rotavirus or BCG, is deferred, usually to 6 months. Blocks (⊣) or supplies ⊣ IL-1α ⊣ IL-1β Anakinra anakinra (Kineret) — recombinant human IL-1 receptor antagonist What it does to the tests: CRP, SAA, ferritin and the ESR fall rapidly, often within days; the response is sufficiently rapid to be used diagnostically in suspected macrophage activation syndrome and in the periodic fevers. Neutropenia occurs in a few per cent and requires monitoring. Injection-site reactions are almost universal early in treatment and subsequently resolve. Made uninterpretable: CRP and SAA as infection markers. How it works: The recombinant form of the natural antagonist catalogued in this reference as IL-1RA: it occupies IL-1R1 without signalling, so it blocks both IL-1-α and IL-1-β; this is broader than the anti-IL-1β antibodies, which is relevant where IL-1α drives the disease Clinical: Licensed in the US for NOMID (neonatal-onset multisystem inflammatory disease) and for deficiency of the IL-1 receptor antagonist (DIRA) with no age or weight floor in either indication. The DIRA cohort started treatment from one month of age, which is relevant because DIRA presents in the neonatal period: the only practical lower bound is the prefilled syringe, which cannot deliver under 20 mg. Rheumatoid arthritis is the adult indication. The floor of 8 months and 10 kg is the European figure and is also the Health Canada NOMID floor, stated in the Canadian indication itself, so in Canada it governs. See the licensing note. Its wide use in systemic JIA and Still disease, macrophage activation syndrome, colchicine-resistant familial Mediterranean fever and recurrent pericarditis is off-label in the US, although well supported and recommended in the 2025 inborn-errors practice parameter for several inflammasome disorders (Scene 45). The short half-life of 4 to 6 hours is an advantage in an acutely unwell child; its effect ceases within a day of discontinuation. Blocks (⊣) or supplies ⊣ IL-1β Canakinumab, rilonacept canakinumab (Ilaris) — anti-IL-1β IgG1; rilonacept (Arcalyst) — IL-1 Trap, which also binds IL-1RA What it does to the tests: CRP and SAA fall to normal and remain normal; SAA is the marker used to confirm that control is adequate between attacks in the periodic fevers, because a normal CRP alone does not establish it. Ferritin falls. Neutropenia is less common than with anakinra. Made uninterpretable: CRP and SAA as infection markers. How it works: Canakinumab neutralises IL-1β only and has a half-life of 22.9 to 25.7 days, so it provides sustained control with monthly dosing. Rilonacept is a fusion of the IL-1R1 and IL-1RAcP extracellular domains to an Fc, trapping IL-1β with high affinity, IL-1α with lower affinity and the natural antagonist IL-1RA as well, dosed weekly Clinical: US labelling: canakinumab covers CAPS from 4 years, limited to familial cold autoinflammatory syndrome and Muckle-Wells syndrome, Still disease including systemic JIA from 2 years and 7.5 kg, and familial Mediterranean fever, TRAPS and hyper-IgD syndrome / mevalonate kinase deficiency in adult and paediatric patients without a stated age; in the USA the 2-year floor applies to Still disease and not to CAPS, and the two are readily transposed. Canadian labelling: CAPS from 2 years, dosed from 15 kg, naming familial cold autoinflammatory syndrome and Muckle-Wells syndrome and permitting use in NOMID/CINCA with the statement that improvement in central nervous system symptoms has not been confirmed; TRAPS, hyper-IgD syndrome / mevalonate kinase deficiency and familial Mediterranean fever, not recommended under 2 years; and Still disease including systemic JIA from 2 years and over 9 kg. In the EU canakinumab is licensed for CAPS from 2 years and 7.5 kg. Rilonacept is licensed in the USA from 12 years for CAPS (familial cold autoinflammatory syndrome and Muckle-Wells syndrome) and for recurrent pericarditis, and for maintenance of remission in deficiency of the IL-1 receptor antagonist from 10 kg; it is not authorised in Canada. The long half-life that makes canakinumab convenient is a disadvantage if infection supervenes. Blocks (⊣) or supplies ⊣ IL-6 Tocilizumab, sarilumab tocilizumab (Actemra) and sarilumab (Kevzara) — anti-IL-6R IgG1 What it does to the tests: CRP falls to normal within days and cannot be relied on to rise during treatment, irrespective of the clinical state; the same applies to ESR (through fibrinogen), SAA, haptoglobin, fibrinogen and ferritin. This is among the most consequential laboratory interactions described in this reference: a normal CRP in a child on tocilizumab provides almost no information about infection. Procalcitonin is the least affected and is the preferred marker for monitoring, because bacterial products induce CALCA through pathways that do not require IL-6; this rests, however, on observational data in cytokine release syndrome and COVID-19 rather than on the label, and procalcitonin also rises in non-infectious cytokine release syndrome, so it is the best available marker rather than a specific one. Neutropenia is common and is not usually infection-related. Transaminases rise. Lipids rise. Hepcidin falls, so the anaemia of inflammation improves and iron studies become interpretable. Measured total IL-6 rises on receptor blockade, because the cytokine is no longer cleared through its receptor; a high IL-6 on tocilizumab reflects the pharmacological effect of the drug and not failure of disease control, and for this reason interpretation in this reference is based on the treatment rather than the measured level. Made uninterpretable: CRP, ESR, SAA, fibrinogen, haptoglobin and ferritin, for the duration of treatment. Procalcitonin, clinical assessment and imaging are used instead. How it works: Block the IL-6 receptor, so both classical signalling (membrane IL-6R on hepatocytes and leucocytes) and trans-signalling (soluble IL-6R on any gp130-bearing cell) are inhibited. Because the hepatocyte acute-phase programme is IL-6-dependent, blockade abolishes the laboratory acute-phase response Clinical: The two are not interchangeable in children. Tocilizumab covers systemic JIA and polyarticular JIA from 2 years, giant-cell arteritis and rheumatoid arthritis in both countries. For CAR T-cell-induced cytokine release syndrome the US licence is from 2 years, whereas the Canadian indication follows the populations of the authorised CAR T-cell products and safety and efficacy are stated not to be established under 3 years. For COVID-19 in hospitalised patients receiving systemic corticosteroids the US licence is from 2 years and the Canadian licence is for adults only. Sarilumab has no systemic JIA indication; its only paediatric licence is polyarticular JIA at 63 kg and above, in the USA, with no paediatric indication in Canada, and it holds no giant-cell arteritis, cytokine release syndrome or COVID-19 indication. Bowel perforation is the characteristic serious risk and presents without the CRP rise that would normally accompany it; abdominal pain on tocilizumab requires imaging rather than repeat CRP measurement. Blocks (⊣) or supplies ⊣ IL-6 Siltuximab siltuximab (Sylvant) — chimeric anti-IL-6 IgG1 What it does to the tests: Identical to tocilizumab: CRP, ESR, fibrinogen, haptoglobin and ferritin are all suppressed and uninterpretable; procalcitonin is preserved. Made uninterpretable: CRP, ESR and the other IL-6-driven acute-phase markers. How it works: Neutralises IL-6 itself rather than its receptor, so the same acute-phase consequences follow; it does not bind viral IL-6, and it is therefore used in HHV-8-negative rather than HHV-8-associated Castleman disease Clinical: Idiopathic multicentric Castleman disease in adults; safety and efficacy in children are not established; it is not used in HHV-8-associated disease, because it does not bind viral IL-6. The same loss of infection markers as with tocilizumab applies. TNF: a decoy receptor and the monoclonals are not the same drug IL-1: broad (anakinra) or IL-1β-selective IL-6: the acute-phase response is abolished Cross-talk stated in this scene Receptor block or cytokine block — the same consequences for the markers Both lower ferritin and SAA; only the IL-6 agents abolish the CRP entirely The hepatic programme these agents interrupt is Scene 35, the individual markers are Scene 36, the ESR is Scene 37 and the iron axis is Scene 38. On IL-6 blockade, procalcitonin, the clinical picture and imaging are relied upon; a normal CRP indicates only that the drug is acting. Hepcidin falls with IL-6 blockade, so the anaemia of inflammation improves and iron studies become interpretable again; this is the one setting in this atlas where a blocking agent restores a test rather than removing one.
41IL-12, IL-23, IL-17 and the cell-directed agents
Ustekinumab, the p19-selective anti-IL-23 agents, the IL-17 agents, abatacept, rituximab and belimumab The p40 of ustekinumab is shared by IL-12 and IL-23, so it blocks the Th1 axis and the Th17 axis at once; the p19 agents block IL-23 alone and leave IL-12 intact. The IL-17 agents act one step further down, and the adverse effects follow from the pathways drawn here: IL-17 drives the epithelial antimicrobial programme, so mucocutaneous candidiasis is the acquired phenocopy of inherited IL-17 pathway defects, and IL-17 drives G-CSF, so neutrophil counts fall mildly. The cell-directed agents do not target a cytokine at all. Abatacept withholds the costimulatory second signal; rituximab removes CD20-positive B cells but spares the long-lived plasma cell, which is why immunoglobulin falls slowly and IgM falls first; belimumab removes the BAFF survival signal from the newly made B-cell pool. Blocks (⊣) or supplies ⊣ IL-12p40 ⊣ IL-12p70 ⊣ IL-23 Ustekinumab ustekinumab (Stelara) — anti-p40 IgG1 What it does to the tests: CRP and ESR fall where they were elevated by disease activity. No characteristic haematological change. The combined IL-12 and IL-23 blockade resembles inherited IL-12Rβ1 deficiency, so mycobacterial and salmonella susceptibility is the theoretical concern, although it is rarely observed in practice. How it works: Binds the p40 subunit shared by IL-12 and IL-23, so it blocks both the Th1 axis (IL-12 → STAT4 → IFN-γ) and the Th17 axis (IL-23 → STAT3 → IL-17); a single antibody thus blocks two pathways, which accounts for the difference between its infection profile and that of the p19-selective agents Clinical: In the USA: plaque psoriasis from 6 years, psoriatic arthritis from 6 years, and Crohn disease and ulcerative colitis from 2 years, dosed from 10 kg; the US paediatric licence thus covers all four indications and not psoriasis alone. In Canada the paediatric licence is for plaque psoriasis alone, from 6 to 17 years where other systemic therapy or phototherapy has given inadequate control or is not tolerated; psoriatic arthritis, Crohn disease and ulcerative colitis are adult indications. Blockade of IL-12 as well as IL-23 distinguishes it from the newer p19 agents; the p19 agents are at least as effective in psoriasis, so the broader blockade is no longer regarded as a clinical advantage. Blocks (⊣) or supplies ⊣ IL-23 Guselkumab, risankizumab, tildrakizumab guselkumab (Tremfya), risankizumab (Skyrizi), tildrakizumab (Ilumya) — anti-IL-23 p19 IgG1 What it does to the tests: CRP and ESR fall where they were elevated by disease activity. Candida infection is less frequent than with the IL-17 agents: IL-23 blockade leaves IL-17 signalling at the receptor intact and spares the IL-17 already produced by differentiated and innate sources, rather than removing the cytokine itself. How it works: Bind the p19 subunit unique to IL-23, leaving IL-12 and the Th1 axis intact; the blockade is narrower than that of ustekinumab and targets the relevant cytokine, since IL-23 maintains pathogenic Th17 cells after their induction Clinical: The three are not equivalent: risankizumab covers plaque psoriasis, psoriatic arthritis, Crohn disease and ulcerative colitis, guselkumab the same four indications in both countries, but tildrakizumab is licensed in adults only, for plaque psoriasis in Canada and for plaque psoriasis and psoriatic arthritis in the USA. Guselkumab and risankizumab hold paediatric licences for plaque psoriasis and psoriatic arthritis from 6 years: guselkumab in Canada with weight-banded doses from 12 kg to under 40 kg and the adult dose from 40 kg, but in the USA only at 40 kg or more; risankizumab in both countries at 55 mg under 40 kg and 150 mg at 40 kg or more. The bowel indications of both, and all tildrakizumab indications, are adult only. Preferred over ustekinumab in psoriasis on efficacy, and the preserved IL-12 arm is a theoretical safety advantage. Blocks (⊣) or supplies ⊣ IL-17A ⊣ IL-17F Secukinumab, ixekizumab, bimekizumab, brodalumab secukinumab (Cosentyx) and ixekizumab (Taltz) — anti-IL-17A; bimekizumab (Bimzelx) — anti-IL-17A and IL-17F; brodalumab (Siliq) — anti-IL-17RA What it does to the tests: Mild falls in the neutrophil count are expected and follow from the IL-23 / IL-17 / G-CSF loop: reduced IL-17 lowers G-CSF and therefore the neutrophil count; this does not represent drug toxicity and is rarely clinically significant. CRP and ESR fall with disease control. How it works: Neutralise IL-17A (and, for bimekizumab, IL-17F as well; brodalumab blocks the receptor and therefore A, F, C, E and the A/F heterodimer). IL-17 induces epithelial antimicrobial peptides, CXCL8 and G-CSF, so its blockade predictably impairs mucosal antifungal defence Clinical: Secukinumab has the widest paediatric licence of any agent in these scenes. In the USA: plaque psoriasis from 6 years, psoriatic arthritis from 2 years, enthesitis-related arthritis from 4 years, and ankylosing spondylitis and hidradenitis from 12 years. In Canada: plaque psoriasis, enthesitis-related arthritis and juvenile psoriatic arthritis from 6 years, with ankylosing spondylitis, non-radiographic axial spondyloarthritis and hidradenitis in adults only. Ixekizumab covers psoriasis from 6 years in both countries; bimekizumab and brodalumab are adults only. Mucocutaneous candidiasis is the characteristic adverse effect and is the acquired phenocopy of inherited IL-17 pathway defects (IL17RA, IL17F, ACT1, and the chronic mucocutaneous candidiasis of STAT1 gain-of-function and AIRE autoantibodies). With respect to inflammatory bowel disease the class is not uniform: for secukinumab, ixekizumab and bimekizumab new or worsening disease is a labelled caution rather than a contraindication, so an effective drug need not be withheld from a child with quiescent disease, whereas for brodalumab Crohn disease is a contraindication. Brodalumab also carries a boxed warning for suicidal ideation and behaviour including completed suicides, and is available only through a restricted programme. Blocks (⊣) or supplies ⊣ Th1 (costimulation withheld) ⊣ Th17 (costimulation withheld) ⊣ Tfh (costimulation withheld) Abatacept abatacept (Orencia) — CTLA-4-Ig fusion protein What it does to the tests: No characteristic laboratory change; CRP and ESR fall with disease control. T-dependent vaccine responses are attenuated, so serological protection cannot be assumed and post-vaccination titres should be measured. Made uninterpretable: Vaccine serology as proof of protection. How it works: Binds CD80 and CD86 on antigen-presenting cells, so the CD28 costimulatory second signal is not delivered and T cells are not fully activated; it acts at the initiation of the response rather than on any single cytokine Clinical: In the USA: polyarticular JIA from 2 years (subcutaneously from 2 years, intravenously from 6 years), psoriatic arthritis from 2 years, rheumatoid arthritis in adults, and prophylaxis of acute graft-versus-host disease from 2 years. In Canada: polyarticular JIA from 6 years by intravenous infusion only, with no paediatric subcutaneous indication, rheumatoid arthritis and psoriatic arthritis in adults, and prophylaxis of acute graft-versus-host disease from 6 years. In inborn errors of immunity it is the precision agent for CTLA-4 haploinsufficiency and LRBA deficiency, where it replaces the deficient CTLA-4 inhibitory function (Scene 46). Live vaccines should not be given with it or within three months of stopping, and it should not be combined with a TNF inhibitor. Because it attenuates rather than abolishes responses, infection risk is lower than with the cytokine blockers. Blocks (⊣) or supplies ⊣ Transitional B cell (cell depleted) ⊣ Naive follicular B cell (cell depleted) ⊣ Memory B cell (cell depleted) ⊣ Germinal-centre B cell (cell depleted) Rituximab rituximab (Rituxan/MabThera) — chimeric anti-CD20 IgG1 What it does to the tests: B cells are depleted from the blood within days and return at 6 to 12 months. IgM falls first and to the greatest extent; IgG falls later and in a minority remains low for years (persistent hypogammaglobulinaemia, more likely with repeated courses, with prior immunosuppression, and in children). Specific antibody titres fall. Vaccine responses are lost while B cells are absent, so immunisation must precede treatment by at least 4 weeks where possible, and live vaccines are contraindicated. Late-onset neutropenia can occur months after the last dose. Made uninterpretable: Vaccine serology, B-cell-dependent diagnostic testing, and any attempt to diagnose an antibody deficiency while the drug is active; the immunological evaluation must precede treatment. How it works: Depletes CD20-positive B cells from the pre-B stage to the memory B cell by complement-dependent and antibody-dependent killing. CD20 is lost as the cell differentiates into an antibody-secreting cell (it is low and variable on plasmablasts and absent from long-lived plasma cells), so existing antibody is initially spared and the fall in immunoglobulin is gradual; the long-lived plasma cell compartment maintains vaccine-derived antibody Clinical: Carries a boxed warning with four parts: fatal infusion reactions, most often with the first infusion; severe and sometimes fatal mucocutaneous reactions; hepatitis B reactivation, which makes screening mandatory; and progressive multifocal leukoencephalopathy, including fatal cases, which is the risk of greatest importance to disclose when obtaining consent from a family. Licensed in the USA for mature B-cell non-Hodgkin lymphoma and mature B-cell acute leukaemia from 6 months, for ANCA-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis) from 2 years, and in adults for non-Hodgkin lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis and pemphigus vulgaris. In Canada the reference product is licensed in adults only, for non-Hodgkin lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis and induction of remission in granulomatosis with polyangiitis and microscopic polyangiitis; it has no paediatric indication and no pemphigus vulgaris indication, so those uses are off-label in Canada. Used off-label in both countries for nephrotic syndrome, autoimmune cytopenias and neuromyelitis optica. Immunoglobulins and B-cell numbers should be measured before each course and monitored afterwards. Blocks (⊣) or supplies ⊣ BAFF Belimumab belimumab (Benlysta) — human anti-BAFF (BLyS) IgG1 What it does to the tests: Naive and transitional B cells fall over months; memory B cells and plasma cells are relatively spared, so immunoglobulins fall only modestly. Anti-dsDNA titres fall and complement C3 and C4 rise towards normal as consumption diminishes; this is one of the few agents listed that raises complement levels. How it works: Neutralises soluble BAFF, the survival factor on which transitional and naive B cells depend, so the autoreactive transitional cells that normally die at that checkpoint are not rescued; the effect is selective pressure on the newly formed B-cell pool rather than depletion Clinical: Systemic lupus erythematosus from 5 years and lupus nephritis from 5 years in both countries. The licensed routes differ: in Canada paediatric lupus nephritis is treated by the intravenous route only, subcutaneous use in lupus nephritis being restricted to adults, while subcutaneous use in paediatric systemic lupus erythematosus is from 15 kg; in the USA subcutaneous dosing from 15 kg is licensed from 5 years for both indications. The complement and anti-dsDNA response is used to monitor treatment. IL-12 and IL-23: shared subunit or selective IL-17: predictable candidiasis risk Cell-directed: costimulation, CD20 and BAFF Cross-talk stated in this scene Same pathway, different breadth: p40 blockade covers IL-12 with IL-23, p19 blockade does not Removal of the B cell or of its survival factor: different magnitude of effect on IgG The subsets these agents act on are Scenes 19 to 25, the B-cell life cycle is Scenes 24 and 25, and the immunoglobulins are Scene 27. Two rules follow from the B-cell agents: the immunological evaluation and the vaccinations must precede rituximab, because an antibody deficiency cannot be diagnosed and a vaccine cannot be answered while B cells are absent; and inflammatory bowel disease is a labelled caution for secukinumab, ixekizumab and bimekizumab but a true contraindication for brodalumab, which also carries a boxed warning for suicidal ideation and behaviour.
42Interferon and complement blockade, and the JAK inhibitors
Anifrolumab, emapalumab, the C5, C3, factor B, factor D, C5aR1 and C1s agents, and the oral JAK inhibitors The complement agents are the clearest example in this reference of a drug reproducing an inherited phenotype by design. Blocking C5 reproduces the terminal-pathway deficiency phenotype, with a comparably high meningococcal risk and the same vaccination and prophylaxis obligations Scene 30 sets out — and vaccination does not remove the risk. The assay that changes indicates the site of the block. C5 is a terminal component, so blocking it markedly reduces CH50 and AH50 together while leaving C3 and C4 unchanged. The factor B and factor D inhibitors markedly reduce AH50 and spare CH50 — the mirror of classical-pathway blockade with sutimlimab, not of C5 blockade. Measured C3 rises substantially on pegcetacoplan, because the C3 the drug binds is no longer being consumed; a high C3 in this setting reflects the effect of treatment. Anifrolumab blocks the type I interferon receptor while emapalumab neutralises the cytokine itself, and emapalumab carries a specific interpretive pitfall: measured IFN-γ rises on treatment because the assay still detects the drug–cytokine complex, so CXCL9 is the marker to follow. The JAK inhibitors are not biologics, but they block every JAK-STAT cytokine in this atlas at once — and leave TNF, IL-1, IL-17 and IL-18, which do not use JAKs, unaffected. Blocks (⊣) or supplies ⊣ IFNα2 ⊣ IFNβ ⊣ IFNω Anifrolumab anifrolumab (Saphnelo) — anti-IFNAR1 IgG1 What it does to the tests: The 21-gene interferon signature is neutralised by at least 80% from about week 4 and through the first year, which is the pharmacodynamic measure reported in the label; where the assay is available it is the marker used for monitoring. Anti-dsDNA falls and C3 and C4 rise with disease control. Herpes zoster is the characteristic infection and respiratory viral infections are more frequent, which is the predictable consequence of type I interferon blockade. Made uninterpretable: The interferon signature as a measure of disease rather than of drug. How it works: Blocks the type I interferon receptor, so the type I interferons (the IFN-α subtypes, IFN-β, IFN-ω and the less-studied IFN-κ and IFN-ε) are blocked together. The interferon signature that defines a large subgroup of lupus is suppressed Clinical: Moderate-to-severe systemic lupus erythematosus in adults; no paediatric licence. Its mechanism is the converse of that of the type I interferonopathies (STING, TREX1, IFIH1), in which the same pathway is pathologically activated. Blocks (⊣) or supplies ⊣ IFNγ Emapalumab emapalumab (Gamifant) — anti-IFN-γ IgG1 What it does to the tests: CXCL9 (MIG) falls and is the marker used for monitoring; CXCL9 is interferon-induced and reflects IFN-γ activity better than ferritin. Total IFN-γ measured by immunoassay rises, because the drug–cytokine complex is still detected; this is expected and is not treatment failure. Ferritin, soluble CD25 and the transaminases fall with response. Made uninterpretable: Measured IFN-γ levels. CXCL9 is used instead. How it works: Neutralises free and receptor-bound IFN-γ, the cytokine that drives the macrophage activation of haemophagocytic lymphohistiocytosis; it is the only agent in this reference directed at that final common pathway Clinical: Licensed in the USA only; it is not authorised in Canada, where the submission was withdrawn by the sponsor in January 2021 before a decision was issued. Primary haemophagocytic lymphohistiocytosis refractory to, intolerant of or recurrent on conventional therapy, from birth, and also HLH / macrophage activation syndrome in known or suspected Still disease where glucocorticoids have failed or MAS has recurred, which makes it directly relevant to systemic JIA as described elsewhere in this reference. The label names the organisms favoured by neutralisation of IFN-γ as mycobacteria, herpes zoster and Histoplasma capsulatum: latent tuberculosis is evaluated and tested for before initiation and treated if present, and prophylaxis is given against herpes zoster, Pneumocystis jirovecii and fungal infection. Salmonella susceptibility is a feature of the inherited IFN-γ-axis phenotype rather than of this drug. Blocks (⊣) or supplies ⊣ C5 ⊣ C5a Eculizumab, ravulizumab, pozelimab eculizumab (Soliris) and ravulizumab (Ultomiris) — anti-C5; pozelimab (Veopoz) — anti-C5, licensed for CHAPLE disease alone What it does to the tests: CH50 and AH50 both become undetectable: C5 is a terminal component and both haemolytic assays require C5 to C9, so its blockade abolishes both; this finding confirms adequate blockade and does not indicate a complement deficiency. C3 and C4 are unchanged, because the blockade is distal to them, so a normal C3 and C4 on treatment provides no information about drug effect. Free eculizumab levels and the modified Ham test are used where available. LDH falls in paroxysmal nocturnal haemoglobinuria; extravascular haemolysis with C3 loading on red cells may continue. Made uninterpretable: CH50 as a test for complement deficiency, and C3/C4 as a measure of blockade. How it works: Bind C5 and prevent its cleavage, so neither the C5a anaphylatoxin nor the C5b that nucleates the membrane attack complex is generated. All upstream events (C3 cleavage, C3b opsonisation, the amplification loop) continue unaffected Clinical: Eculizumab and ravulizumab: paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome, and generalised myasthenia gravis and NMOSD in adults. Paediatric cover differs by agent and country: ravulizumab is licensed for both haemolytic indications from one month of age in both countries; eculizumab is licensed for both in children from 5 kg in Canada, whereas in the USA its paediatric use is established for atypical haemolytic uraemic syndrome and for generalised myasthenia gravis from 6 years, and paediatric safety and effectiveness in paroxysmal nocturnal haemoglobinuria are not established. Pozelimab is not interchangeable with them: its only licensed indication is CD55-deficient protein-losing enteropathy (CHAPLE disease) from one year of age, the condition described in this reference under the complement regulators, and it has none of the other three indications; it is licensed in the USA and is not authorised in Canada. All three carry a boxed warning for serious meningococcal infection and are available only through a restricted programme. The class creates an acquired terminal-pathway defect, so meningococcal ACWY and B vaccination at least two weeks before initiation, with antibiotic prophylaxis, is mandatory; these are the same precautions described in this reference for inherited C5 to C9 deficiency. Vaccination does not eliminate the risk; breakthrough meningococcal disease occurs in vaccinated patients. Blocks (⊣) or supplies ⊣ C3 Pegcetacoplan pegcetacoplan (Empaveli in Canada and the USA; Aspaveli elsewhere) — PEGylated C3-binding peptide What it does to the tests: Measured C3 rises steeply, which is the most common source of misinterpretation with this drug: with convertase cleavage blocked, C3 is no longer consumed, and drug-bound C3 accumulates. The label reports a mean rise from 94 mg/dL at baseline to 380 mg/dL by week 16 in paroxysmal nocturnal haemoglobinuria, and from 62 to 371 mg/dL by week 26 in C3 glomerulopathy. A C3 of several hundred mg/dL on this drug reflects the pharmacological effect of treatment and is neither an artefact nor evidence of a different diagnosis. CH50 and AH50 both fall. Haemoglobin rises further than on C5 blockade in paroxysmal nocturnal haemoglobinuria, because extravascular haemolysis is also prevented. Made uninterpretable: The C3 level as a measure of disease, and both pathway assays. How it works: Binds C3 and C3b, blocking cleavage at the level of the convertase itself, so it inhibits the alternative amplification loop as well as the terminal pathway; this proximal blockade also prevents the C3 loading responsible for extravascular haemolysis on C5 inhibitors Clinical: Carries a boxed warning for serious infection caused by encapsulated bacteria and is available only through a restricted programme. Licensed for paroxysmal nocturnal haemoglobinuria in adults, and for C3 glomerulopathy and primary immune-complex MPGN from 12 years. Blockade at C3 abolishes opsonisation as well as the terminal pathway, so the encapsulated-organism risk is broader than with C5 blockade: pneumococcal, meningococcal and Haemophilus influenzae type b vaccination are all required. Blocks (⊣) or supplies ⊣ Factor B ⊣ Factor D Iptacopan, danicopan iptacopan (Fabhalta) — factor B inhibitor; danicopan (Voydeya) — factor D inhibitor What it does to the tests: AH50 falls to near zero while CH50 is relatively preserved, the converse of classical-pathway blockade with sutimlimab, in which CH50 falls and C4 recovers. It is not the converse of C5 blockade: C5 is a terminal component and both haemolytic assays require C5 to C9, so a C5 inhibitor abolishes CH50 and AH50 together (Scene 30). Measured C3 also rises as consumption ceases (the iptacopan label reports 23 to 80 mg/dL by day 14 in C3 glomerulopathy), although less steeply than on pegcetacoplan. The near-zero AH50 is inferred from the pathway as described in this reference rather than taken from the label, which uses an alternative-pathway activity assay and plasma Bb as its pharmacodynamic markers. Made uninterpretable: AH50, and the C3 level as a measure of disease. How it works: Oral small molecules that block the alternative pathway specifically, at factor B or at factor D, the two components of the amplification loop, leaving the classical and lectin pathways functional Clinical: Adults only. Paroxysmal nocturnal haemoglobinuria (iptacopan as monotherapy, danicopan added to a C5 inhibitor for extravascular haemolysis), and C3 glomerulopathy for iptacopan in both countries, with IgA nephropathy for iptacopan in the USA only. Both carry a boxed warning for serious infection with encapsulated organisms and both are available only through a restricted programme; vaccination against meningococcus, pneumococcus and Haemophilus influenzae type b is required before initiation, as for any alternative-pathway blockade. Blocks (⊣) or supplies ⊣ C5a ⊣ C1r / C1s Avacopan, sutimlimab avacopan (Tavneos) — C5aR1 antagonist; sutimlimab (Enjaymo) — anti-C1s IgG4 What it does to the tests: Avacopan: no routine complement assay changes, since C5 cleavage is unaffected and CH50 remains normal; liver enzymes require scheduled monitoring. Sutimlimab: C4 rises towards normal as classical-pathway consumption ceases (the label reports a return to about 0.2 g/L within a week), and CH50 falls; haemolysis markers improve in cold agglutinin disease. Made uninterpretable: For sutimlimab, CH50 and C4 as measures of disease. How it works: Avacopan blocks C5aR1, the C5a receptor on the neutrophil, rather than C5a itself (the target shown is C5a because that is the catalogued entity), so the chemotactic and priming signal is lost while the membrane attack complex is preserved; the terminal-pathway infection risk is therefore not created. Sutimlimab blocks C1s and so inhibits the classical pathway at its first enzyme Clinical: Avacopan: ANCA-associated vasculitis in adults, where it allows steroid sparing; hepatotoxicity requiring scheduled liver-function monitoring, hepatitis B reactivation and angioedema are its labelled cautions. Sutimlimab: cold agglutinin disease in adults, licensed in the USA and not authorised in Canada; it carries the same encapsulated-organism requirement as the other complement agents, namely vaccination against Streptococcus pneumoniae, Haemophilus influenzae type b and Neisseria meningitidis serogroups A, C, W, Y and B at least two weeks before the first dose, because blockade of C1s abolishes classical-pathway opsonisation, and vaccination does not eliminate the risk. Avacopan is the only complement agent listed that does not create a terminal-pathway defect. Blocks (⊣) or supplies ⊣ IL-6 ⊣ IFNγ ⊣ IFNα2 ⊣ IL-4 ⊣ IL-13 ⊣ IL-2 ⊣ IL-23 JAK inhibitors tofacitinib (Xeljanz), baricitinib (Olumiant), upadacitinib (Rinvoq), abrocitinib (Cibinqo), ruxolitinib (Jakafi/Opzelura) — oral JAK inhibitors What it does to the tests: CRP and ESR fall through the IL-6/gp130 arm, so the same loss of infection markers as with tocilizumab applies, although less completely. Haemoglobin, neutrophils, lymphocytes and platelets all fall through the JAK2 arm (erythropoietin and thrombopoietin signalling) and the γc arm. NK and B-cell numbers fall. Lipids and CK rise. Herpes zoster reactivation is the characteristic infection and is the predictable consequence of simultaneous blockade of type I and type II interferon signalling. Made uninterpretable: CRP and ESR, partially, as infection markers. How it works: Not biologics, but agents that act on the same pathways at the intracellular side of the membrane: every cytokine in this reference that signals through JAK-STAT is blocked simultaneously, according to the JAK selectivity of the drug. Ruxolitinib and baricitinib are JAK1/2-selective, tofacitinib JAK1/3, upadacitinib and abrocitinib JAK1-selective; the TYK2 arm is blocked only partially by these agents, and the selective TYK2 inhibitor deucravacitinib is not included here. Cytokines that use other receptor families (TNF, IL-1, IL-17, IL-18) are not affected Clinical: Paediatric licences exist across the class and differ by country. Tofacitinib: polyarticular-course JIA and psoriatic arthritis from 2 years and 10 kg in the USA, with an oral solution for children under 40 kg; in Canada polyarticular JIA and juvenile psoriatic arthritis only in children of 40 kg or more, with the 5 mg tablet. Abrocitinib: atopic dermatitis from 12 years in both countries. Upadacitinib: atopic dermatitis from 12 years and 40 kg in both countries, with polyarticular JIA and psoriatic arthritis from 2 years in the USA only. Baricitinib: severe alopecia areata from 12 years in the USA, and adults only in Canada. Topical ruxolitinib: atopic dermatitis from 2 years and nonsegmental vitiligo from 12 years in both countries. Systemic ruxolitinib covers myelofibrosis, polycythaemia vera and acute and chronic graft-versus-host disease (from 12 years) in both countries, with haemophagocytic lymphohistiocytosis off-label. The class boxed warning covers serious infection, mortality from any cause, malignancy including lymphoma, major adverse cardiovascular events and thrombosis, and derives from an adult rheumatoid-arthritis safety trial in patients over 50 with a cardiovascular risk factor, so it applies to children with caution rather than directly. In inborn errors of immunity these are the precision agents for the JAK/STAT gain-of-function disorders and the interferonopathies (Scene 44): ruxolitinib or baricitinib for STAT1 gain-of-function, ruxolitinib or tofacitinib for STAT3 gain-of-function, baricitinib or tofacitinib for SOCS1 haploinsufficiency, and ruxolitinib, baricitinib or tofacitinib for CANDLE, SAVI, Aicardi-Goutières syndrome and USP18 deficiency. Interferon: type I, and IFN-γ Complement: the assay that changes indicates the block Every JAK-STAT cytokine at once Cross-talk stated in this scene C5 blockade leaves C3 unchanged; C3 blockade raises it, because it is no longer consumed Alternative-pathway blockade markedly reduces AH50 and spares CH50: the converse of classical-pathway blockade The complement cascade is Scenes 29 to 31 and the regulators are Scene 31; the interferon receptors are Scenes 5 and 8. The terminal-pathway agents create an acquired C5 to C9 defect, so meningococcal ACWY and B vaccination at least two weeks ahead and antibiotic prophylaxis are mandatory; the C3 and alternative-pathway agents remove opsonisation too, so pneumococcal and Hib cover is added; and sutimlimab carries the same obligation, because blocking C1s removes classical-pathway opsonisation. Avacopan is the exception — blocking the C5a receptor leaves the membrane attack complex intact and creates no terminal-pathway defect.
43Agents that act on the neutrophil, and the rule for reading any test on a biologic
CXCR4 antagonists, recombinant G-CSF, and the three questions to ask of any laboratory result in a patient on a biologic The two neutrophil agents act in opposite ways and correspond to the defects in Scene 33. Mavorixafor blocks CXCR4, so the neutrophils retained in the marrow by SDF-1 (CXCL12) are released; the count rises within hours because the cells are already present. Recombinant G-CSF acts in the opposite way for the opposite defect: it drives production. The rule card states the principle of which every other card on these five scenes is an instance. A test in a patient on a biologic answers one of three questions, and only the first concerns the patient: whether the test still reflects the disease, whether it now reflects the drug, or whether the drug has made it uninterpretable. The most frequent interpretive errors arise from answering the first when the answer is the second or the third. Blocks (⊣) or supplies ⊣ SDF-1 Mavorixafor, plerixafor mavorixafor (Xolremdi) and plerixafor (Mozobil in the USA; generic Plerixafor Injection in Canada) — CXCR4 antagonists What it does to the tests: The absolute neutrophil count and the lymphocyte count rise within hours of dosing, because the cells were present but retained in the marrow. A normal count on treatment therefore reflects release and not production. How it works: Block CXCR4, the receptor and not the ligand: the target shown for this entry is SDF-1 because that is the catalogued entity, but the drug binds CXCR4 and does not affect SDF-1 itself. CXCR4 retains mature neutrophils and stem cells in the marrow against the SDF-1 (CXCL12) gradient. Release from this retention is the treatment of WHIM syndrome, in which a truncated CXCR4 cannot be inactivated and the cells are retained; this myelokathexis is a defect of retention and not of production Clinical: Mavorixafor is licensed in the USA for WHIM syndrome from 12 years and is not authorised in Canada; plerixafor is licensed for stem-cell mobilisation, in adults in both countries and in Canada also in children from 1 year with lymphoma or solid malignant tumours, whereas paediatric safety and effectiveness are not established in the USA, and is used off-label in WHIM. In Canada the Mozobil brand was cancelled after marketing on 31 October 2025 and plerixafor is supplied as generic Plerixafor Injection. Both are teratogenic, so pregnancy must be excluded and contraception used. The 2025 inborn-errors practice parameter recommends both for WHIM with the blood count as the monitoring marker. The mechanism is the direct converse of the WHIM defect, which accounts for the rapidity of the response. Blocks (⊣) or supplies G-CSF Recombinant G-CSF filgrastim, pegfilgrastim, lenograstim — recombinant G-CSF What it does to the tests: The neutrophil count rises within 24 to 48 hours, with a left shift and toxic granulation that can be mistaken for sepsis. Alkaline phosphatase, LDH and uric acid rise. The CD64 index on neutrophils rises, so neutrophil CD64 as a sepsis marker is confounded during G-CSF treatment. Bone pain is common. Made uninterpretable: Neutrophil CD64 as a sepsis marker; the blood film, which has a reactive appearance as an expected effect of treatment. How it works: The only agent listed that supplies a cytokine rather than blocking one: recombinant G-CSF drives granulopoiesis, shortens marrow transit and releases the marrow reserve, which accounts for its efficacy in severe congenital neutropenia, in cyclic neutropenia and after chemotherapy Clinical: Severe chronic neutropenia, whether congenital, cyclic or idiopathic, and chemotherapy-induced neutropenia are the labelled uses of filgrastim in both countries; autoimmune neutropenia is not a labelled indication in either, and in Canada efficacy in autoimmune neutropenia of infancy is stated not to have been established, so that use is off-label. The labelled starting dose in congenital neutropenia is 12 micrograms/kg daily, as a single or divided dose, in Canada and 6 micrograms/kg twice daily in the USA; in cyclic or idiopathic neutropenia it is 5 micrograms/kg daily in both. Pegfilgrastim has no paediatric indication in Canada. In severe congenital neutropenia the long-term MDS/AML risk (about 22% at 15 years, with a hazard of about 2.3% per year after the first 10 years) is the reason for annual marrow surveillance, and a higher G-CSF requirement indicates higher risk; whether G-CSF causes the transformation or is a marker of the more severe underlying defect is not established. Reading any test on a biologic the three questions, in order 1. Whether the test still reflects the disease: it does only if the agent does not act on the pathway that generates it. CRP and ESR still reflect inflammation on omalizumab, dupilumab or an anti-IL-5 agent, because none of them touches the IL-6 axis. 2. Whether it now reflects the drug: a zero eosinophil count on benralizumab, a normal neutrophil count on mavorixafor, an undetectable CH50 on eculizumab and a rising total IgE on omalizumab are all measurements of the effect of treatment, not of the disease. 3. Whether the drug has made it uninterpretable: a CRP on tocilizumab, an eosinophil count on benralizumab, vaccine serology on rituximab, a measured IFN-γ on emapalumab: these cannot answer the clinical question, and another test is required. Two corollaries. Baseline tests are obtained first: omalizumab dosing needs a pre-treatment total IgE, anti-IL-5 response is predicted by a pre-treatment eosinophil count, and an antibody deficiency cannot be diagnosed after rituximab. When a marker is abolished, a replacement should be named rather than none: procalcitonin for CRP on IL-6 blockade, CXCL9 for IFN-γ on emapalumab, the clinical picture and imaging for everything else. How it works: Three questions, asked in that order, of every result in a patient on one of these agents Clinical: The recurring error this prevents is illustrated by a well-appearing child on tocilizumab with a normal CRP and abdominal pain, in whom the normal CRP reflects the drug and the pain a perforation. An abolished marker is not a reassuring marker. The neutrophil: release from the marrow, or increased production The rule that covers every agent on Scenes 39 to 43 Cross-talk stated in this scene Retention defect or production defect: the agent must match the defect Granulopoiesis, marrow retention and release, and the defects of each are Scenes 33 and 34; the markers are Scenes 35 to 38. The predictor on this page accepts an agent name directly and reports what this reference states about which mediators move, which tests follow them, and which tests are no longer interpretable.
44Precision medicine I: JAK/STAT gain-of-function and the interferonopathies
Constitutively active signalling: JAK inhibition as correction of a molecular defect rather than as immunosuppression The agents of Scenes 39 to 43 dampen a pathway that is functioning normally but excessively. This scene and the three that follow differ: they match an agent to a defect. In a JAK/STAT gain-of-function disorder the lesion is a signalling molecule that cannot be inactivated, so inhibiting the kinase above it is not suppression — it is restoration, and it is the only medical therapy that addresses the lesion short of transplant. The same drugs treat the type I interferonopathies, where the interferon axis is constitutively activated from the opposite end. Two features distinguish these decisions from those of the earlier scenes: a biomarker is named for each disorder, and the strength of the recommendation is stated — which here means acknowledging that there are no clinical trials in any of them and that the evidence is cohort and case-report level throughout. This is not a reason to withhold treatment, because early introduction can determine whether the disease resolves. Pathway driven, and lowered by treatment ⊣ IFNγ ⊣ IL-6 STAT1 gain-of-function the commonest cause of chronic mucocutaneous candidiasis, with autoimmunity, aneurysms and squamous carcinoma Agent: Ruxolitinib or baricitinib Follow: CXCL9, and Th17 cell numbers — the subset that STAT1 gain-of-function suppresses and that treatment should restore Graded: Conditional recommendation, moderate certainty Note: Fluconazole prophylaxis is recommended where candidal infection is frequent, but chronic mucocutaneous candidiasis may improve on a JAK inhibitor, and azole prophylaxis may then be discontinued; this is one of the few settings where treating the lesion lets a prophylactic be withdrawn. Coccidioidomycosis prophylaxis is advised in endemic regions. The candidiasis here is the same phenotype that IL-17 blockade produces as an adverse effect in Scene 41: one inherited, one acquired. Pathway driven, and lowered by treatment ⊣ IL-6 STAT3 gain-of-function early-onset multisystem autoimmunity, lymphoproliferation, enteropathy and short stature — not the hyper-IgE of STAT3 loss Agent: Ruxolitinib or tofacitinib Follow: Double-negative T cells Graded: Strong recommendation, moderate certainty — the strongest in this group Note: Tocilizumab is often used with the JAK inhibitor, since IL-6 drives STAT3; the two together blunt the CRP completely. STAT3 loss-of-function is a different disease (hyper-IgE syndrome, Scene 47 prophylaxis). Pathway driven, and lowered by treatment ⊣ IL-6 STAT4 and STAT5b gain-of-function rarer gain-of-function disorders of the same family Agent: Ruxolitinib Follow: IL-6 in STAT4 gain-of-function; the eosinophil count in STAT5b gain-of-function Graded: Conditional recommendation; certainty very low for STAT4 and low for STAT5b Note: The eosinophilia of STAT5b gain-of-function is the read-out to follow, and it is the same cell that the anti-IL-5 agents of Scene 39 remove for a different reason. Pathway driven, and lowered by treatment ⊣ IFNγ SOCS1 haploinsufficiency loss of the suppressor of cytokine signalling: the brake on the pathway rather than the kinase Agent: Baricitinib or tofacitinib Follow: CXCL9 Graded: Strong recommendation, low certainty Note: SOCS1 is a key physiological inhibitor of JAK-STAT signalling, so loss of one copy leaves the pathway active, the same end state as a gain-of-function in the kinase, reached from the opposite direction, and treated the same way. Pathway driven, and lowered by treatment ⊣ IFNα2 ⊣ IFNβ The type I interferonopathies USP18 deficiency, SAVI, Aicardi-Goutières syndrome and CANDLE Agent: Ruxolitinib, baricitinib or tofacitinib Follow: An interferon-activity score — the same measurement anifrolumab is followed on in lupus (Scene 42) Graded: Strong recommendation, low certainty Note: These are the inherited opposite of anifrolumab’s indication: type I interferon constitutively activated rather than blocked. Blocking the receptor is not the approach here — the JAK inhibitors act below it and cover both interferon arms. JAK/STAT gain-of-function SOCS1: the brake, not the kinase Type I interferonopathies Cross-talk stated in this scene Same drugs, two routes to the same excess interferon signalling SOCS1 is a key physiological inhibitor of the pathway that STAT1 gain-of-function leaves active Diseases, agents, biomarkers and gradings on this scene follow the 2025 Inborn Errors of Immunity Practice Parameter (Joint Task Force on Practice Parameters with the AAAAI, ACAAI and the Clinical Immunology Society; Orange and colleagues, Annals of Allergy, Asthma and Immunology 2026;136:426-493). The JAK-STAT cascades these agents act on are drawn in Scenes 2, 4, 5 and 11. CXCL9 is this atlas’s MIG, the interferon-induced chemokine of Scene 15, which is why it reads IFN-γ activity better than ferritin does; the Th17 cells counted in STAT1 gain-of-function are the subset of Scene 19. Dosing is taken from cohort experience, not from trials: ruxolitinib from about 15 mg/m² twice daily towards 30 mg/m² twice daily, maximum 25 mg twice daily; baricitinib 2 mg daily increased to 4 mg over 4 to 6 weeks, and 2 mg daily under 9 years. Doses are titrated every 4 to 6 weeks. Aciclovir prophylaxis is given for the herpesvirus risk, patients are reviewed every 4 to 6 months for opportunistic infection, cardiovascular and thromboembolic disease, malignancy and liver disease, and a blood count, liver panel and chemistry panel are monitored with viral PCR. Because these agents also block IL-6 signalling, the CRP is blunted here as it is on tocilizumab. Treatment is lifelong or until transplant. The inherited converse should be kept in mind: STAT1 loss-of-function lies on the opposite side of the same molecule and is treated with IFN-γ, not with a JAK inhibitor (Scene 46).
45Precision medicine II: the inflammasomopathies and IL-1 blockade
Anakinra, rilonacept and canakinumab matched to the defect that drives IL-1, with the markers that say whether it is controlled The periodic fevers and the other inflammasome disorders are among the clearest examples in medicine of a single cytokine accounting for a disease, and of its blockade being effective. The three agents are not interchangeable. Anakinra blocks IL-1α as well as IL-1β, clears in 4 to 6 hours and probably penetrates the central nervous system better, which makes it the agent for an acutely unwell child and for a diagnostic trial. Rilonacept traps IL-1β and, less avidly, IL-1α and the natural antagonist IL-1RA, with a half-life of about a week. Canakinumab neutralises IL-1β alone and has a half-life of 22.9 to 25.7 days, which permits infrequent dosing but prolongs its effect if infection supervenes. Because the response is so fast, a trial of IL-1 blockade is itself used diagnostically rather than accepting the morbidity of waiting for a molecular result. The principal marker is not the CRP but serum amyloid A, because sustained SAA between attacks is what becomes AA amyloid, and a normal CRP does not prove the inflammation is controlled. Signal driving the disease, lowered by treatment ⊣ IL-1β ⊣ IL-1α CAPS familial cold autoinflammatory syndrome, Muckle-Wells syndrome and NOMID/CINCA, from NLRP3 Agent: Anakinra, rilonacept or canakinumab — all three Follow: CRP and serum amyloid A, the white cell and neutrophil count, and proteinuria Graded: Strong recommendation, high certainty — the best-evidenced indication on this scene Note: NOMID and deficiency of the IL-1 receptor antagonist are both FDA-approved anakinra indications; anakinra’s better central nervous system penetration is relevant in NOMID/CINCA, where the meninges and the inner ear are involved. Signal driving the disease, lowered by treatment ⊣ IL-1β TRAPS, familial Mediterranean fever and mevalonate kinase deficiency TNFRSF1A, MEFV and MVK — the other periodic fevers Agent: Canakinumab Follow: CRP and serum amyloid A, the white cell and neutrophil count, and proteinuria Graded: Strong recommendation, high certainty Note: In trials, baseline flares resolved in over 60% in TRAPS, over 80% in familial Mediterranean fever and 60% in mevalonate kinase deficiency, with more responding again on dose escalation; the 150-to-300 mg step is the figure reported for familial Mediterranean fever. In milder mevalonate kinase disease with normal markers between episodes, on-demand anakinra halved episode frequency or length without continuous treatment. Familial Mediterranean fever is treated here only when colchicine has failed. Signal driving the disease, lowered by treatment IL-1RA DIRA deficiency of the interleukin-1 receptor antagonist, from IL1RN Agent: Anakinra or rilonacept Follow: CRP and serum amyloid A Graded: Strong recommendation, moderate certainty Note: The most direct precision therapy in this reference: the disease is the absence of IL-1RA, and anakinra is recombinant IL-1RA, the molecule catalogued in Scene 1, given as replacement. Rilonacept is licensed for maintenance of remission from 10 kg. Signal driving the disease, lowered by treatment ⊣ IL-1β ⊣ IL-1α PAPA, FCAS2 and Majeed syndrome PSTPIP1, NLRP12 and LPIN2 Agent: Anakinra or canakinumab Follow: CRP and serum amyloid A Graded: Conditional recommendation, low certainty Note: Majeed syndrome presents as chronic recurrent multifocal osteomyelitis with congenital dyserythropoietic anaemia, and anakinra reduces both the markers and the sterile osteomyelitis. In NLRP12 disease febrile episodes improve but some patients relapse. Signal driving the disease, lowered by treatment ⊣ IL-1β ⊣ IL-1α NOCARH and FCAS4 CDC42 and NLRC4 — the inflammasome disorders that reach HLH Agent: Anakinra for NOCARH; canakinumab for FCAS4 Follow: CRP, serum amyloid A and ferritin — ferritin is added here because these two reach macrophage activation Graded: Conditional recommendation, low certainty Note: In NOCARH the markers, fever, rash, hepatosplenomegaly and growth improve, but the cytopenias respond less well, and severe disease with HLH features needs further therapy or transplant. This is where Scene 38’s ferritin thresholds and Scene 42’s emapalumab meet the inflammasome. The strongest evidence: CAPS and the periodic fevers The missing antagonist itself Rarer defects, weaker evidence Cross-talk stated in this scene Blocking IL-1, and replacing the antagonist that blocks it — anakinra does both Same cytokine, same drugs; the evidence, not the mechanism, is what differs Diseases, agents, biomarkers and gradings on this scene follow the 2025 Inborn Errors of Immunity Practice Parameter (Joint Task Force on Practice Parameters with the AAAAI, ACAAI and the Clinical Immunology Society; Orange and colleagues, Annals of Allergy, Asthma and Immunology 2026;136:426-493). IL-1α, IL-1β and the IL-1 receptor antagonist are all drawn in Scene 1; the acute-phase output these markers come from is Scenes 35 and 36, where serum amyloid A is set out as the marker of adequate treatment between attacks for exactly this reason. Children generally need higher doses than adults, and severe phenotypes need higher doses than mild ones: in familial Mediterranean fever, raising canakinumab from 150 mg to 300 mg every 4 weeks converted many partial responses into complete ones, and dose escalation improved response in TRAPS and mevalonate kinase deficiency too. IL-1 blockade also reduces proteinuria. Safety data in pregnancy and breastfeeding are limited for all three. Treatment is lifelong, with the exception noted on the mevalonate kinase card.
46Precision medicine III: the defect-specific agents
Leniolisib, CTLA-4–Ig, enzyme replacement, interferon gamma, fucose, and cobalamin and folate in the defects of their transport and metabolism: each agent matched to one defect These six are the clearest expression of what precision medicine means here: each is matched to a specific molecular lesion, and several correct it rather than compensate for it. Leniolisib was developed for a single disorder and, with interferon gamma-1b in chronic granulomatous disease (NEJM 1991, PMID 1846940), is one of two agents in this group supported by a randomised placebo-controlled trial. CTLA-4–Ig supplies the brake that CTLA-4 haploinsufficiency and LRBA deficiency have lost — the same molecule that, in Scene 41, is used to suppress a normal immune system. Interferon gamma is the mirror of emapalumab: a cytokine given rather than neutralised. The defects of cobalamin and folate transport and metabolism are the most important treatable mimics in this atlas: they can present with a picture resembling severe combined immunodeficiency and respond to vitamin replacement, most completely when treatment begins early. This is a reason to measure total plasma homocysteine, methylmalonic acid and folate before concluding that an infant with an SCID-like picture has SCID. Acts on (⊣) or supplies ⊣ IgM ⊣ Transitional B cell ⊣ Plasmablast ⊣ CD8 Tem / Temra Leniolisib leniolisib (Joenja) — oral selective PI3Kδ inhibitor For: Activated PI3K-delta syndrome, both APDS1 (PIK3CD gain-of-function) and APDS2 (PIK3R1 loss); from 4 years and 27 kg in the USA, but from 12 years and 45 kg in Canada, which requires both Follow: Serum IgM, which is characteristically high in APDS and falls markedly on treatment; transitional B cells; and CD8 and CD4 terminally differentiated effector memory (TEMRA) cells Graded: Strong recommendation, high certainty; one of two agents in this group, with interferon gamma-1b in chronic granulomatous disease (PMID 1846940), supported by a randomised placebo-controlled trial In practice: In the phase 3 trial, lymphadenopathy and spleen size fell, as did transitional B cells, CD38+ plasmablasts, switched and unswitched memory B cells, CD57+ senescent CD8 T cells and CD8 TEMRA cells, while total CD4 counts rose and CD4 TEMRA cells fell. Serum IgM fell markedly. A blood count and immunoglobulins are the monitoring specified in the label. Made uninterpretable: Serum IgM as a measure of disease rather than of treatment. How it works: The first drug developed for a single inborn error of immunity. In activated PI3K-delta syndrome a gain-of-function in PIK3CD, or loss of its regulatory subunit in PIK3R1, renders PI3Kδ constitutively active; leniolisib inhibits that catalytic subunit selectively and restores the lymphocyte compartment towards normal Notes: Fetal harm is possible, and medication interactions occur, so concurrent drugs should be reviewed. Treatment is lifelong. The randomised trial enrolled patients of 12 to 75 years, and the original 2023 licence followed it. The US licence was extended in September 2026 down to 4 years at 27 kg or more, with weight-banded dosing: 40 mg twice daily at 27 to under 38 kg, 50 mg twice daily at 38 to under 45 kg, and 70 mg twice daily at 45 kg and above and for all patients of 12 years and over. The Canadian licence was not extended: it remains 12 years and 45 kg, with only the 70 mg strength authorised, which is recorded as approved but not yet as marketed, and no weight bands (see the licensing note before an age is quoted). Children under 27 kg have no approved dose in either country; a US supplemental application for children of 4 years and over weighing 13 to under 27 kg has been accepted for priority review, with a target action date of 30 January 2027, and remains pending, so no dose can currently be quoted for that band. Acts on (⊣) or supplies ⊣ Tfh Abatacept, belatacept (CTLA-4–Ig) abatacept (Orencia) and belatacept (Nulojix) — CTLA-4-Ig fusion proteins For: CTLA-4 haploinsufficiency and LRBA deficiency: the lymphoproliferation, enteropathy, autoimmune cytopenias and interstitial lung disease of those disorders Follow: Circulating T follicular helper cells and soluble CD25, both of which fall on treatment in most patients Graded: Strong recommendation, moderate certainty In practice: Circulating Tfh and soluble CD25 fall. In LRBA deficiency with refractory interstitial lung disease, lung function improved within six months of initiation; chronic diarrhoea, lymphoproliferation and autoimmune cytopenias improved on long-term follow-up. The label specifies no monitoring blood tests. Made uninterpretable: Vaccine serology as proof of protection, as with abatacept in any indication. How it works: Replacement of a deficient inhibitory mechanism rather than suppression of a normal one. CTLA-4 competes with CD28 for CD80 and CD86; LRBA is required to recycle CTLA-4 rather than direct it to degradation, so loss of either leaves CD28 costimulation unopposed. A CTLA-4–Ig fusion protein supplies the missing competitor Notes: Live vaccines must not be given during treatment or within three months of stopping, and it should not be combined with a TNF inhibitor. Treatment is lifelong. It controls the disease and is not curative: transplantation remains the curative option in severe disease. Elapegademase elapegademase (Revcovi) — PEGylated recombinant bovine adenosine deaminase For: Adenosine deaminase deficiency, including ADA-SCID Follow: Plasma ADA activity and erythrocyte dAXP, with blood counts and lymphocyte subsets Graded: Strong recommendation, high certainty In practice: Lymphocyte and neutrophil counts rise and infections decrease; trough erythrocyte dAXP (deoxyadenosine nucleotides) falls below 0.02 mmol/L within 3 to 6 months, and a trough dAXP above 0.02 mmol/L is an indication for dose escalation. The US label specifies that trough erythrocyte dAXP is maintained below 0.02 mmol/L from two months after the start of treatment and monitored at least twice a year. Plasma ADA, erythrocyte dAXP, blood counts and lymphocyte subsets are measured at least every 6 months. Antibody function can wane on long-term therapy, in part from neutralising antibodies to the drug. How it works: Enzyme replacement rather than a signalling inhibitor. In adenosine deaminase deficiency the toxic substrates deoxyadenosine and dAXP accumulate and are toxic to lymphocytes; enzyme replacement clears them, and lymphocyte counts, neutrophil counts and infection frequency improve Notes: Licensed in the USA for adenosine deaminase severe combined immune deficiency in paediatric and adult patients; it is not authorised in Canada. Treatment is started as soon as absent enzyme activity is demonstrated, without awaiting the genetic result. Initial dosing in the parameter is 0.4 mg/kg/week intramuscularly, divided into two doses, for infants and 0.2 mg/kg/week for older children and adolescents, which may be given weekly; the label applies the same two figures to a different distinction (0.4 mg/kg/week, calculated on ideal or actual body weight, whichever is greater, and divided twice weekly for a minimum of 12 to 24 weeks until immune reconstitution, for any patient new to enzyme replacement irrespective of age, and 0.2 mg/kg/week as the minimum starting dose for those transitioning from pegademase at a weekly dose of 30 U/kg or less or of unknown size), so a late-diagnosed older child started at 0.2 would be underdosed. Treatment history as well as age should determine the dose. The dose is increased by 0.033 mg/kg/week if the trough plasma ADA remains under 30 mmol/h/L or trough dAXP exceeds 0.02 mmol/L; higher doses may be needed in ADA-associated pulmonary alveolar proteinosis or hepatitis. The parameter names vidarabine and deoxycoformycin as interacting; the label states that interaction potential has not been studied. Enzyme replacement does not fully reconstitute immunity, so antimicrobial prophylaxis and immunoglobulin replacement usually continue, and it is a bridging therapy to transplantation or gene therapy rather than definitive treatment. Acts on (⊣) or supplies IFNγ Interferon gamma-1b interferon gamma-1b (Actimmune) — recombinant human IFN-γ For: Chronic granulomatous disease as prophylaxis against all infections, and the Mendelian susceptibility to mycobacterial disease group: IL-12p40, IL-12Rβ1, IL-12Rβ2 and IL-23R deficiency, autosomal dominant partial IFN-γR1 or R2 deficiency, STAT1 loss-of-function, TYK2, IRF8 and ISG15 deficiency, and IFN-γ deficiency itself Follow: Clinical infection frequency; there is no validated laboratory marker of response Graded: Strong recommendation in chronic granulomatous disease with moderate certainty; strong with very low certainty in the IFN-γ-signalling defects In practice: Raised liver enzymes and renal toxicity are the laboratory adverse effects, with fever; liver enzymes, a chemistry panel and a blood count with differential are monitored. Treatment is lifelong or until transplant. How it works: The converse of emapalumab: a cytokine supplied rather than blocked. In chronic granulomatous disease it reduces the frequency and severity of serious infection without restoring the oxidative burst, and in the IFN-γ-axis defects it supplies or augments the signal that the defect has weakened Notes: Dosing is by body surface area, and the rule for small infants is the most frequent source of error: 50 micrograms/m² three times a week where the surface area is above 0.5 m², but 1.5 micrograms/kg per dose three times a week where it is 0.5 m² or below; a young infant dosed by the per-square-metre figure is substantially underdosed. In chronic granulomatous disease it is given alongside trimethoprim-sulfamethoxazole and itraconazole; in disseminated mycobacterial disease the per-square-metre dose is added to antimycobacterial therapy. It does not replace antimicrobial prophylaxis. It is licensed in the USA for chronic granulomatous disease, with paediatric use established from 1 year, and for severe malignant osteopetrosis, from 1 month; its use in Mendelian susceptibility to mycobacterial disease is off-label, and it is not authorised in Canada. Oral fucose oral L-fucose supplementation For: Leukocyte adhesion deficiency type II (SLC35C1), which also causes short stature, developmental delay and the Bombay blood phenotype Follow: The white cell count with differential: the persistent leucocytosis of a rolling defect falls as the ligands return Graded: Strong recommendation, low certainty; some but not all patients respond In practice: Selectin ligands reappear on neutrophils, the white cell count normalises and infections improve in responders. Discontinuation reverses both: the ligands are lost and the leucocytosis returns, which demonstrates the mechanism as clearly as the response itself. How it works: Direct supplementation of a deficient sugar. Leukocyte adhesion deficiency type II is a defect of GDP-fucose transport, so the selectin ligands on which rolling depends are not synthesised; oral fucose permits their synthesis, and the rolling step of Scene 33 is restored Notes: Not every patient responds, and the neurological features do not improve with the haematological ones. The white cell count is the practical measure of response to supplementation. Cobalamin and folate hydroxocobalamin, cyanocobalamin and high-dose intravenous folinic acid For: Transcobalamin II deficiency (TCN2); proton-coupled folate transporter deficiency (SLC46A1); MTHFD1 deficiency; and cblF disease (LMBRD1) Follow: Vitamin B12 and folate levels, total plasma homocysteine and methylmalonic acid, and the blood count Graded: Strong recommendation, low certainty In practice: The immunological abnormalities (low or absent T-cell proliferation, hypogammaglobulinaemia and impaired antibody responses) return to normal with treatment. The blood count, vitamin B12 and folate are monitored, together with total plasma homocysteine and methylmalonic acid. How it works: Several defects of vitamin B12 and folate transport or metabolism present with the features of severe combined immunodeficiency (poor T-cell proliferation to mitogen, hypogammaglobulinaemia and absent antibody responses) and respond to vitamin replacement, with the best outcomes when treatment begins early. They are the most important treatable mimics in this group Notes: TCN2 deficiency is treated with cyanocobalamin or hydroxocobalamin; SLC46A1 deficiency with high-dose intravenous folinic acid; MTHFD1 deficiency and cblF disease (LMBRD1) with hydroxocobalamin and folinic acid together. Treatment is lifelong. Total plasma homocysteine, methylmalonic acid and folate should be measured before a diagnosis of SCID is made in an infant with an SCID-like presentation. Correcting the signalling lesion Supplying what is missing: an enzyme, a cytokine Supplying what is missing: a sugar, a vitamin Cross-talk stated in this scene An enzyme and a cytokine: both supplied, both monitored on what they produce A cytokine supplied, and a sugar supplied — both replace what the defect cannot make Diseases, agents, biomarkers and gradings on this scene follow the 2025 Inborn Errors of Immunity Practice Parameter (Joint Task Force on Practice Parameters with the AAAAI, ACAAI and the Clinical Immunology Society; Orange and colleagues, Annals of Allergy, Asthma and Immunology 2026;136:426-493). Leniolisib’s read-outs are nodes in this atlas: serum IgM from Scene 27, transitional B cells from Scene 24 and plasmablasts from Scene 25, and the CD8 TEMRA compartment from Scene 21. The CD28 competition it restores is named here rather than drawn elsewhere, since this atlas catalogues secreted mediators rather than surface costimulatory pairs; the rolling step oral fucose rescues is in Scene 33; and the IFN-γ that interferon gamma-1b supplies is the cytokine of Scene 2, whose inherited pathway defects are what the MSMD indications are.
47The backbone: immunoglobulin replacement, prophylaxis, vaccination and cure
The treatment received by most patients, and the two rules that determine what a test can still answer Precision agents treat a minority of these patients. The majority receive immunoglobulin replacement, targeted prophylaxis and a modified vaccine schedule, and a few receive the only curative treatments there are. Each of the four carries a consequence for the laboratory that belongs with the rest of this atlas. Immunoglobulin replacement makes every IgG-based serology a measurement of the donor pool rather than of the patient — which is why the immunological evaluation must precede it. Prophylaxis is targeted at the organisms to which the specific defect confers susceptibility, which is the principle applied throughout this reference in reverse: the missing pathway predicts the infection. The vaccine rule is not "no vaccines": live replicating vaccines are withheld from severe defects, and non-live vaccines are given and are of value even where the antibody response will be poor. And transplant and gene therapy are the reason several agents on the previous scenes are described as treatment until transplant rather than as definitive therapy. Acts on (⊣) or supplies IgG1 IgG2 IgG3 IgG4 Immunoglobulin replacement immunoglobulin replacement therapy (IgRT) — intravenous or subcutaneous IgG For: Inborn errors with defective humoral immunity: X-linked agammaglobulinaemia, common variable immunodeficiency, class-switch recombination defects, combined immunodeficiencies and others in which antibody production or function is lost Follow: The serum IgG trough, with a blood count and chemistry panel Graded: Strong recommendation. Certainty moderate for the starting dose and the monitoring, high for the trough target, low for the recommendation that it is continuous and lifelong In practice: The starting dose is 400 to 600 mg/kg per month: intravenously every 3 to 4 weeks, or the same monthly dose divided into weekly or two-weekly subcutaneous infusions (the labelled conversion from the intravenous dose differs by product and by country: in the USA the weekly-equivalent intravenous dose is multiplied by 1.37 for Hizentra, Xembify and subcutaneous Gamunex-C and Gammagard Liquid and by 1.30 for Cuvitru and Cutaquig, to match bioavailability, and is unchanged for facilitated subcutaneous HyQvia; in Canada it is unchanged for Hizentra, Cuvitru and HyQvia, while the Canadian monographs of Xembify and Cutaquig, neither of which is recorded as marketed, apply 1.37 and 1.30; the figures of 1.35 and 1.53 are not labelled conversion factors, 1.53 being the mean individual dose adjustment in the US pharmacokinetic study of Hizentra). The target is a serum IgG above 800 mg/dL: pneumonia falls by about a quarter for every additional 100 mg/dL of trough, and a trough of 500 carries about five times the pneumonia rate of 1000, with no further benefit above 1000. IgG is measured every 6 to 12 months when stable, and monthly when there are breakthrough infections, in pregnancy, with protein loss, on immunosuppression, with significant weight change or where adherence is uncertain. The trough is sampled before the intravenous infusion; on subcutaneous dosing the level peaks at 3 to 5 days and steady state takes 4 to 6 months. Made uninterpretable: All IgG-based serology, including vaccine responses and infectious serology: the result reflects the donor pool and not the patient. Any assessment of antibody production must precede the first infusion or follow a washout. How it works: Not a cytokine therapy, but the treatment received by most patients with the antibody deficiencies described in this reference. It supplies pooled donor IgG and only IgG: it does not replace IgA or IgM, so mucosal protection is not restored and a low IgA is not corrected Notes: The population target is a minimum and not an individual goal: the dose is individualised to the level at which the individual patient ceases to have infections (the biologic trough), which in X-linked agammaglobulinaemia has ranged from 800 to 1300 mg/dL and in common variable immunodeficiency from 500 to 1700 mg/dL. Dose is adjusted for weight change beyond 5%. A low or absent IgA is not a contraindication, and the choice of route is a conditional recommendation made with the patient rather than part of the strong one. Treatment is continuous, and lifelong for most but not all patients: a planned trial off therapy is explicitly permitted in selected cases, specifically specific antibody deficiency in children and transient hypogammaglobulinaemia of infancy, which are the paediatric situations in which the question arises. Antimicrobial prophylaxis targeted antimicrobial prophylaxis in inborn errors of immunity For: Chronic granulomatous disease; SCID and congenital athymia; antibody deficiencies; terminal complement defects and asplenia; STAT3 and IL-6-pathway hyper-IgE syndrome; chronic mucocutaneous candidiasis (STAT1 gain-of-function, APECED, CARD9, IL-17 and IL-17R defects); Mendelian susceptibility to mycobacterial disease; combined immunodeficiency with severe T-cell defects Follow: Infection frequency; adherence and drug interactions are of greater importance than any laboratory measure Graded: Strong recommendation, high quality of evidence for the recommendation overall; the individual regimens range from strong with high certainty down to conditional with very low certainty In practice: Trimethoprim-sulfamethoxazole for chronic granulomatous disease, covering Staphylococcus aureus, Burkholderia, Nocardia and Serratia: 5 mg/kg of the trimethoprim component, with a maximum dose of 160 mg of trimethoprim twice daily; whether 5 mg/kg is a single or a total daily dose is not specified, and a 2018 review gives 5 mg/kg per day to a maximum of one double-strength tablet (160 mg of trimethoprim) daily. Prophylaxis reduces bacterial infections by approximately half. For Pneumocystis prophylaxis in SCID and congenital athymia the same agent is given two to three times a week (5 mg/kg, maximum 160 mg of trimethoprim), and in combined immunodeficiency with severe T-cell defects twice daily, as a conditional rather than a strong recommendation; pentamidine, atovaquone and dapsone are alternatives. Itraconazole for Aspergillus in chronic granulomatous disease: 5 mg/kg daily, to a maximum of 100 mg daily under 50 kg and 200 mg daily over 50 kg. The placebo-controlled trial, which enrolled patients aged 5 years and over, used fixed doses of 100 mg daily under 13 years of age or under 50 kg and 200 mg daily from 13 years or from 50 kg. Itraconazole has no paediatric indication in Canada or the USA; the oral solution is better absorbed than the tablets, which should be taken with a meal. Fluconazole for Candida at 3 mg/kg in SCID and congenital athymia, or 3 to 6 mg/kg/day in infants with SCID, and at 5 mg/kg in chronic mucocutaneous candidiasis and in hyper-IgE syndrome. In STAT3 hyper-IgE syndrome the named regimen is trimethoprim-sulfamethoxazole at 5 to 6 mg/kg/day of the trimethoprim component divided twice daily, with itraconazole added where pneumatoceles are present; coccidioidomycosis prophylaxis is advised in endemic regions for STAT3 hyper-IgE syndrome and STAT1 gain-of-function. Aciclovir for HSV and VZV, at 12.5 mg/kg twice daily in SCID and congenital athymia before immune reconstitution and at 20 to 40 mg/kg, to a maximum of 400 mg, twice daily in combined immunodeficiency with severe T-cell defects; ganciclovir or valganciclovir is used as treatment rather than as prophylaxis, for established CMV infection or for symptoms consistent with CMV infection while PCR results are pending. Azithromycin 5 mg/kg daily to a maximum of 250 mg, or 500 mg three days a week, for respiratory infection in antibody deficiency and for environmental mycobacteria in MSMD, with amoxicillin or trimethoprim-sulfamethoxazole as alternatives. Daily amoxicillin or penicillin in terminal complement defects and asplenia, to at least 5 years of age and able to be continued for life, particularly after an episode of sepsis; cephalexin or azithromycin is used in penicillin allergy, and an allergy evaluation is preferred before a second-line drug is adopted. Meningococcal and pneumococcal vaccination at diagnosis is at least as important as the antibiotic. Aciclovir should not be given concurrently with ganciclovir or valganciclovir. Perioperative decolonisation for Staphylococcus aureus is advised in chronic granulomatous disease, leukocyte adhesion deficiency and hyper-IgE syndrome. How it works: Prophylaxis in these disorders is directed at the organisms to which the specific defect confers susceptibility and is not given broadly. The correspondence between defect and organism follows the principle applied throughout this reference: the deficient pathway predicts the infection Notes: Where hypersensitivity to trimethoprim-sulfamethoxazole is suspected, desensitisation is preferred to discontinuation, since the alternatives provide incomplete coverage. The azoles interact with many drugs, including the agents in these scenes. Prophylaxis complements, and does not replace, immunoglobulin replacement or precision therapy. Vaccination in IEI live and non-live vaccines in IEI and their household contacts For: All inborn errors of immunity, and their household contacts Follow: Vaccine-specific antibody titres, where immunoglobulin replacement has not made them uninterpretable Graded: Strong recommendation to follow current public-agency and professional-society schedules, with low certainty, because those schedules change more rapidly than any practice parameter and supersede it In practice: All live viral vaccines, including live attenuated influenza and dengue, and all live bacterial vaccines (BCG, typhoid) are contraindicated in severe inborn errors: SCID, congenital athymia, combined immunodeficiency, IFN-α and IFN-γ deficiency, the IL-12 axis defects, antibody deficiencies and chronic granulomatous disease. Chronic granulomatous disease is a clinically important partial exception: the contraindication applies to live bacterial vaccines, and a child with CGD who is not immunosuppressed may receive live viral vaccines, so MMR and varicella are not withheld on the basis of the CGD diagnosis alone. Vaccine-strain rotavirus infection has occurred in newborns with SCID diagnosed before newborn screening, BCG has caused disseminated or localised granulomatous disease in SCID, IFN-γ-pathway defects and chronic granulomatous disease, and vaccine-strain rubella has been found in skin granulomas in ataxia-telangiectasia, combined immunodeficiency and also humoral defects. Isolated T-cell lymphopenia with preserved function is a distinct situation in which live vaccines may be given; the suggested thresholds are CD4 above 400/µL, CD8 above 200/µL, naive CD4 above 20% of CD4, and a protective tetanus response. In a patient who no longer requires immunoglobulin replacement (for example, in transient hypogammaglobulinaemia of infancy), catch-up live viral vaccines are deferred until 8 months after the last infusion (the ACIP interval for a replacement dose of 300–400 mg/kg before a measles- or varicella-containing vaccine), which is also the point at which serology again becomes interpretable. Made uninterpretable: Vaccine serology in any patient on immunoglobulin replacement. How it works: Vaccination is not contraindicated as a whole: live replicating vaccines are withheld in severe cellular, phagocytic or humoral defects, whereas non-live vaccines are given and are of value even where the antibody response is expected to be poor, because the T-cell response may be preserved Notes: Household contacts may receive live vaccines, with two exceptions: oral poliovirus vaccine and replication-competent smallpox/mpox vaccine. After a household infant has received oral rotavirus vaccine, hand washing after nappy changes is advised for a month. Contact with a blistering rash after varicella vaccination or shingles should be avoided. COVID-19 vaccination is strongly recommended including on immunoglobulin replacement, where T-cell and serological responses were better than expected; HPV vaccination is recommended for all patients with an inborn error of immunity from 9 to 45 years. The first dose of rotavirus vaccine must be given by 14 weeks and 6 days of age, with the series completed by 8 months, which is often before the immunological diagnosis is established; the question should therefore be resolved early rather than deferred by default. Meningococcal and pneumococcal vaccination is recommended at diagnosis in complement deficiency, asplenia and the TLR-pathway defects, alongside the antibiotic prophylaxis. Seasonal inactivated influenza vaccination is recommended with a standing on-demand antiviral prescription for exposure in patients of 3 months and over. With respect to grading, during immunoglobulin replacement the recommendations for mRNA COVID-19 and inactivated influenza vaccination are conditional with low certainty, and those for recombinant zoster and for HPV conditional with very low certainty, although the narrative text recommends them. Transplant and gene therapy allogeneic haematopoietic stem cell transplantation and ex vivo gene therapy For: Severe combined immunodeficiency and congenital athymia; severe combined and phagocyte defects; severe immune dysregulation; and selected disorders in which medical control is inadequate Follow: Lymphocyte subsets, chimerism and immune reconstitution testing after the procedure Graded: Strong recommendation with high certainty that SCID is treated by transplant or gene therapy; strong with moderate certainty for cultured thymus tissue implantation in congenital athymia; conditional with moderate certainty that it is done at an experienced centre In practice: Blood products given before or around transplant must be irradiated, leucoreduced and CMV-negative (not only CMV-safe), and lymphocyte-depleted; this requirement applies from the time a severe cellular defect is suspected and not from the time it is confirmed. How it works: The only curative options. All other treatments in Scenes 44 to 47 control a disease or replace a product; transplantation and gene therapy replace the defective cell itself, and several of the precision agents are accordingly described in the parameter as treatment until transplant rather than as definitive therapy Notes: Timing is among the most important determinants of outcome: survival exceeds 90% when SCID is identified by newborn screening, and transplantation before 3.5 months of age gives better outcomes than later transplantation; this is the rationale for newborn screening and the reason the procedure is urgent rather than elective. Thymus transplantation, rather than haematopoietic transplant, is the procedure for congenital athymia; in the USA allogeneic processed thymus tissue (Rethymic) has been licensed since 8 October 2021 for immune reconstitution in paediatric patients with congenital athymia, and is not indicated for severe combined immunodeficiency, while no such product is authorised in Canada. Gene therapy has been licensed in Europe for adenosine deaminase deficiency (Strimvelis, since May 2016) and in the USA for two further disorders: etuvetidigene autotemcel (Waskyra), approved on 9 December 2025 for Wiskott-Aldrich syndrome with a mutation in the WAS gene, from 6 months of age, where transplantation is appropriate and no suitable HLA-matched related donor is available; and marnetegragene autotemcel (Kresladi), given accelerated approval on 26 March 2026 for paediatric patients with severe leukocyte adhesion deficiency type I due to biallelic ITGB2 variants who have no HLA-matched sibling donor, with continued approval contingent on confirmatory evidence of clinical benefit. None of these gene therapies is authorised in Canada. The parameter lists ADA alongside X-linked SCID, Artemis deficiency and RAG1 deficiency as disorders in which it is accessed through open clinical trials, a statement that predates the two US approvals, so availability depends on location. Replace the product Prevent the infection Replace the cell Cross-talk stated in this scene Replacement and prophylaxis are given together, not as alternatives Replacement is lifelong unless the cell itself is replaced Diseases, agents, biomarkers and gradings on this scene follow the 2025 Inborn Errors of Immunity Practice Parameter (Joint Task Force on Practice Parameters with the AAAAI, ACAAI and the Clinical Immunology Society; Orange and colleagues, Annals of Allergy, Asthma and Immunology 2026;136:426-493). The IgG that replacement therapy supplies, and the FcRn recycling that gives it a three-week half-life, are Scenes 27 and 28; the terminal-complement and asplenia prophylaxis is the Neisseria pattern of Scene 30; the Pneumocystis and fungal cover follows the T-cell and phagocyte defects of Scenes 19 to 22 and 33 to 34. One rule applies to all four cards and to Scene 43: baseline tests are obtained first. An antibody deficiency cannot be diagnosed after immunoglobulin replacement has started, any more than it can after rituximab.

Mediator catalogue · where each is made and what it regulates

All 95 mediators, grouped by function. Made by lists the main producing cells (dominant source first); Regulates is the principal biological effect; Receptor → signalling names the receptor and the cascade class (chip colours match the cascade colours in the legend). Main scene gives the scene where the mediator is principally drawn; some also appear as outputs or cross-references in other scenes. Each mediator appears in one category only, even where it bridges two.

A–Z finder

Innate inflammatory mediators (IL-1 / TNF families, DAMPs) (6)

MediatorMade byRegulatesReceptor → signallingMain scene
IL-1α
IL1A
Epithelial cells, keratinocytes and endothelium (stored, active precursor released on necrosis); activated macrophagesSterile ‘first alarm’ after tissue damage; fever; endothelial adhesion molecules; induces IL-6 and chemokinesIL-1R1 + IL-1RAcP → MyD88 / IRAK4 / TRAF6 → NF-κB, MAPK
NF-κB family
Scene 1
IL-1β
IL1B
Monocytes, macrophages, DCs, neutrophils (pro-IL-1β cleaved by the NLRP3 inflammasome / caspase-1)Fever, acute-phase response (via IL-6), endothelial activation, neutrophil recruitment, Th17 differentiationIL-1R1 + IL-1RAcP → MyD88 / IRAK4 / TRAF6 → NF-κB, MAPK
NF-κB family
Scene 1
IL-18
IL18
Macrophages, DCs, keratinocytes, intestinal epithelium (caspase-1 processed; constitutive pro-form)With IL-12, drives IFN-γ from NK and Th1 cells; NK cytotoxicity; held in check by IL-18BPIL-18Rα + IL-18Rβ → MyD88 / IRAK → NF-κB
NF-κB family
Scene 1, 2
TNFα
TNF
Macrophages, monocytes, T cells, NK cells, mast cells (preformed in granules); shed from membrane by ADAM17Endothelial activation, fever, cachexia, granuloma maintenance, cell death via TNFR1TNFR1 (p55), TNFR2 (p75) → TRADD / TRAF2 / RIPK1 → NF-κB, MAPK; or caspase-8 death
NF-κB family
Scene 1
TNFβ
LTA (lymphotoxin-α)
Th1 cells, CD8 T cells, NK cells, B cells, ILC3Inflammation through the TNF receptors; as membrane LTα1β2, builds lymph nodes, Peyer’s patches and folliclesTNFR1, TNFR2, HVEM (and LTβR as LTα1β2) → TRADD / TRAF2 → NF-κB
NF-κB family
Scene 1
HMGB1
HMGB1
Passively released by any necrotic cell; actively secreted by activated macrophages, monocytes, DCs and NK cellsDamage signal: macrophage TNF-α / IL-6 release, DC maturation; reduced form joins CXCL12 to recruit leukocytesRAGE; TLR4 (disulfide form); CXCR4 when complexed with CXCL12 (reduced form) → TLR4 → MyD88 → NF-κB; RAGE → MAPK / NF-κB
NF-κB family
Scene 7

Epithelial alarmins (3)

MediatorMade byRegulatesReceptor → signallingMain scene
IL-33
IL33
Airway and gut epithelium, endothelium, fibroblastic reticular cells — stored in the nucleus, released on necrosis or mechanical stressActivates ILC2, Th2, mast cells, basophils, eosinophils and ST2+ Tregs → IL-5, IL-13; airway hyperresponsivenessST2 (IL1RL1) + IL-1RAcP; soluble ST2 is a decoy → MyD88 / IRAK → NF-κB, MAPK
NF-κB family
Scene 7
IL-17E/IL-25
IL25
Intestinal tuft cells, airway epithelium; also Th2 cells, mast cells, eosinophilsActivates ILC2 (especially inflammatory ILC2s) and Th2 memory cells → IL-4, IL-5, IL-13; anti-helminth tuft-cell circuitIL-17RA + IL-17RB → Act1 → TRAF6 → NF-κB
NF-κB family
Scene 7
TSLP
TSLP
Airway, skin (keratinocyte) and gut epithelium; also mast cells, DCs, fibroblastsConditions DCs (OX40L, CCL17) to prime Th2; activates ILC2, mast cells and basophils; acts on itch neuronsTSLPR (CRLF2) + IL-7Rα → JAK1 + JAK2 → STAT5
JAK-STAT
Scene 7

Regulatory cytokines and natural antagonists (3)

MediatorMade byRegulatesReceptor → signallingMain scene
IL-10
IL10
Tregs and Tr1 cells, macrophages (M2), Bregs, Th2 cells, DCs, mast cellsShuts down macrophage / DC cytokine production and MHC II; limits Th1 and Th17 inflammation; IgG4 switchingIL-10R1 + IL-10R2 → JAK1 / TYK2 → STAT3 → suppressive gene programme
JAK-STAT
Scene 1
IL-1RA
IL1RN
Monocytes, macrophages, neutrophils, hepatocytes (acute-phase), epitheliumBlocks IL-1α and IL-1β at IL-1R1 — the fastest brake on IL-1 inflammationIL-1R1 (occupies without recruiting IL-1RAcP) → Competitive block — no signal
Antagonist / decoy
Scene 1
IL-35
IL12A (p35) + EBI3
Regulatory T cells (firmly in mice; inducible ‘iTr35’ in humans), regulatory B cellsSuppresses effector T-cell proliferation and Th17; converts conventional T cells into IL-35-producing iTr35 cells; expands BregsIL-12Rβ2 + gp130 (also homodimers of either chain) → JAK1 / JAK2 → STAT1:STAT4 heterodimer
JAK-STAT
Scene 9

Th1 axis and the IL-12 family (4)

MediatorMade byRegulatesReceptor → signallingMain scene
IL-12p40
IL12B (p40 subunit; p40 homodimer ‘p80’)
Activated macrophages, monocytes, DCs, neutrophils — made in large excess over IL-12p70Shared subunit of IL-12 (p35+p40) and IL-23 (p19+p40); free p40 / p80 dampens both (shown mainly in mice; weak in humans)IL-12Rβ1 (as free p40 or p40 homodimer) → Occupies IL-12Rβ1 without STAT activation — competitive antagonist of IL-12 / IL-23 (mainly in mice)
Antagonist / decoy
Scene 9
IL-12p70
IL12A + IL12B
DCs, macrophages, monocytes, neutrophils (after TLR / CD40 signals)Th1 differentiation (T-bet), IFN-γ production by NK and T cells, cytotoxicityIL-12Rβ1 + IL-12Rβ2 → JAK2 / TYK2 → STAT4
JAK-STAT
Scene 2
IL-27
IL27 (p28) + EBI3
DCs, macrophages, monocytesEarly: T-bet and Th1 commitment; late: IL-10 from Tr1 cells, restrains Th17 and Th2IL-27Rα (WSX-1) + gp130 → JAK1 / JAK2 / TYK2 → STAT1 then STAT3
JAK-STAT
Scene 2
IFNγ
IFNG (type II IFN)
Th1 cells, CD8 T cells, NK and NKT cells, ILC1Macrophage activation (MHC II, microbicidal NO / ROS), IL-12 amplification, CXCL9/10/11, suppresses Th2 / Th17IFNGR1 + IFNGR2 → JAK1 / JAK2 → STAT1 homodimer (GAF)
JAK-STAT
Scene 2

Antiviral interferons (type I and type III) (5)

MediatorMade byRegulatesReceptor → signallingMain scene
IFNα2
IFNA2 (type I IFN)
Plasmacytoid DCs (dominant), any virus-infected cell, monocytesAntiviral ISGs, MHC I up-regulation, NK activation, DC maturation, B-cell responsesIFNAR1 + IFNAR2 → JAK1 / TYK2 → ISGF3 (STAT1:STAT2:IRF9)
JAK-STAT
Scene 5
IFNβ
IFNB1 (type I IFN)
Fibroblasts, epithelial cells, macrophages and DCs — the first IFN made after IRF3 activation; also pDCsAntiviral ISGs; primes IRF7 to amplify IFN-α production; antiproliferative and immunomodulatory effectsIFNAR1 + IFNAR2 (highest-affinity type I IFN) → JAK1 / TYK2 → ISGF3 → ISGs incl. IRF7
JAK-STAT
Scene 8
IFNω
IFNW1 (type I IFN)
Leukocytes — pDCs and monocytes (co-produced with IFN-α)Antiviral ISGs, with the same receptor and programme as IFN-αIFNAR1 + IFNAR2 → JAK1 / TYK2 → ISGF3
JAK-STAT
Scene 8
IL-28A
IFNL2 (IFN-λ2, type III IFN)
Epithelial cells (airway, gut), hepatocytes, pDCs and DCsAntiviral ISGs restricted to barrier epithelium, hepatocytes and a few leukocytes (neutrophils, pDCs) — protection with less systemic inflammationIFNLR1 + IL-10R2 → JAK1 / TYK2 → ISGF3
JAK-STAT
Scene 8
IL-29
IFNL1 (IFN-λ1, type III IFN)
Epithelial cells, hepatocytes, pDCs and DCs (IFNL1 is a pseudogene in mice)Same barrier-restricted antiviral programme as IL-28AIFNLR1 + IL-10R2 → JAK1 / TYK2 → ISGF3
JAK-STAT
Scene 8

Th2 / allergic effector cytokines (5)

MediatorMade byRegulatesReceptor → signallingMain scene
IL-4
IL4
Th2 and Tfh cells, basophils, mast cells, eosinophils, NKT cellsTh2 differentiation (GATA3), IgE and IgG4 class switching, alternatively activated macrophages, VCAM-1, suppresses Th1Type I: IL-4Rα + γc; type II: IL-4Rα + IL-13Rα1 → JAK1 / JAK3 (type I) or JAK1 / JAK2 / TYK2 (type II) → STAT6
JAK-STAT
Scene 3
IL-5
IL5
ILC2 (major), Th2 cells, mast cells, eosinophilsEosinophil production, release from marrow, survival and activationIL-5Rα + βc → JAK1 / JAK2 → STAT5 (also STAT1/3)
JAK-STAT
Scene 3
IL-9
IL9
Th9 and Th2 cells, ILC2, mast cellsMast-cell expansion and survival, mucus production, ILC2 survivalIL-9R + γc → JAK1 / JAK3 → STAT5 (also STAT1/3)
JAK-STAT
Scene 3
IL-13
IL13
Th2 cells, ILC2, mast cells, basophils, NKT cellsGoblet-cell mucus, airway hyperresponsiveness, epithelial eotaxin-3 and periostin, fibrosis, barrier disruptionIL-4Rα + IL-13Rα1 (IL-13Rα2 is a decoy) → JAK1 / JAK2 / TYK2 → STAT6
JAK-STAT
Scene 3
IL-31
IL31
Th2 cells (skin-homing), mast cells, macrophages, DCsItch via sensory (DRG) neurons; keratinocyte differentiation and barrierIL-31RA + OSMRβ → JAK1 / JAK2 → STAT3 (also STAT1/5)
JAK-STAT
Scene 3

Th17 axis and barrier-tissue (IL-17 / IL-20 subfamily) cytokines (7)

MediatorMade byRegulatesReceptor → signallingMain scene
IL-17A
IL17A
Th17 cells, γδ T cells, ILC3, MAIT cells, Tc17 cellsEpithelial and fibroblast CXCL1/5/8, G-CSF, antimicrobial peptides → neutrophilic inflammation; anti-Candida defenceIL-17RA + IL-17RC → Act1 → TRAF6 → NF-κB, C/EBPβ
NF-κB family
Scene 4
IL-17F
IL17F
Th17 cells, γδ T cells, ILC3, MAIT cells; some epithelial cellsSame programme as IL-17A but weaker: neutrophil chemokines (CXCL1, CXCL5), G-CSF, β-defensins; mucosal anti-Candida / anti-Staphylococcus defenceIL-17RA + IL-17RC (as homodimer or IL-17A/F heterodimer) → Act1 → TRAF6 → NF-κB, C/EBPβ
NF-κB family
Scene 10
IL-21
IL21
Tfh cells (major), Th17 cells, NKT cellsGerminal-centre B cells and plasma-cell differentiation; autocrine Th17 amplification; CD8 and NK cytotoxicityIL-21R + γc → JAK1 / JAK3 → STAT3 (also STAT1)
JAK-STAT
Scene 4
IL-22
IL22
Th22 and Th17 cells, ILC3, γδ T cellsEpithelial antimicrobial peptides, regeneration and barrier repair; hepatocyte acute-phase proteins; keratinocyte hyperplasiaIL-22R1 + IL-10R2 (IL-22BP is a soluble decoy) → JAK1 / TYK2 → STAT3
JAK-STAT
Scene 4
IL-23
IL23A (p19) + IL12B (p40)
DCs and macrophages (especially in skin and gut)Expands and stabilizes Th17 and ILC3; IL-17 and IL-22 productionIL-23R + IL-12Rβ1 → JAK2 / TYK2 → STAT3
JAK-STAT
Scene 2, 4
IL-20
IL20
Keratinocytes, monocytes, macrophages, DCsKeratinocyte proliferation and antimicrobial-peptide expression (epidermal hyperplasia); osteoclast formationIL-20R1 + IL-20R2 (type I) or IL-22R1 + IL-20R2 (type II) → JAK1 / TYK2 → STAT3
JAK-STAT
Scene 10
IL-24
IL24 (MDA-7)
Keratinocytes, Th2 and Th17 cells, monocytes, melanocytesKeratinocyte proliferation; IL-13-driven IL-24 lowers filaggrin (barrier defect in atopic dermatitis); tumour-suppressiveIL-20R1 + IL-20R2 or IL-22R1 + IL-20R2 → JAK1 / TYK2 → STAT3
JAK-STAT
Scene 10

Lymphocyte growth and survival (common gamma-chain) (3)

MediatorMade byRegulatesReceptor → signallingMain scene
IL-2
IL2
Activated CD4 (and CD8) T cells; small amounts from DCs and NKT cellsT-cell proliferation, Treg maintenance (CD25), NK activation, activation-induced cell deathIL-2Rα (CD25) + IL-2Rβ + γc → JAK1 / JAK3 → STAT5
JAK-STAT
Scene 5
IL-7
IL7
Thymic and bone-marrow stroma, lymph-node FRCs, intestinal epithelium, keratinocytesT-cell development, naive and memory T-cell survival, ILC developmentIL-7Rα + γc → JAK1 / JAK3 → STAT5
JAK-STAT
Scene 5
IL-15
IL15
Monocytes, macrophages, DCs, stromal and epithelial cells (trans-presented on IL-15Rα)NK, NKT, memory CD8 and intra-epithelial lymphocyte survival and proliferationIL-2Rβ + γc on the responding cell (IL-15 trans-presented on IL-15Rα) → JAK1 / JAK3 → STAT5
JAK-STAT
Scene 5

IL-6 / gp130 family (3)

MediatorMade byRegulatesReceptor → signallingMain scene
IL-6
IL6
Macrophages, DCs, T cells, fibroblasts, endothelium, adipocytes, muscleAcute-phase proteins (CRP, fibrinogen, hepcidin), fever, Th17 (with TGF-β), plasma-cell differentiationIL-6Rα (membrane or soluble ‘trans-signalling’) + gp130 → JAK1 / JAK2 / TYK2 → STAT3
JAK-STAT
Scene 4, 5
IL-11
IL11
Fibroblasts (TGF-β-induced, major), bone-marrow stroma, epithelial cells, osteoblastsFibroblast activation and fibrosis (autocrine), megakaryocyte maturation, bone remodelling, mucosal protectionIL-11Rα + gp130 homodimer → JAK1 (JAK2, TYK2) → STAT3; fibrotic programme largely ERK-dependent
JAK-STAT
Scene 10
LIF
LIF (leukemia inhibitory factor)
Activated T cells, monocytes, fibroblasts, astrocytes, endometrium, bone-marrow stromaMouse ES-cell self-renewal, embryo implantation, acute-phase proteins, neuronal survival, platelet formationLIFR + gp130 → JAK1 (JAK2, TYK2) → STAT3
JAK-STAT
Scene 10

Haematopoietic growth factors (8)

MediatorMade byRegulatesReceptor → signallingMain scene
IL-3
IL3
Activated T cells (Th2), mast cells, basophils, NK cellsMultilineage progenitor growth; basophil and mast-cell growth and priming (histamine release); pDC survivalIL-3Rα (CD123) + βc → JAK2 → STAT5
JAK-STAT
Scene 11
GM-CSF
CSF2
T cells (Th17 / ThGM), macrophages, endothelium, fibroblasts, alveolar epitheliumGranulocyte and macrophage production, alveolar-macrophage maturation (surfactant clearance), inflammatory DCsGM-CSFRα + βc → JAK2 → STAT5
JAK-STAT
Scene 5
G-CSF
CSF3
Monocytes, macrophages, endothelium, fibroblasts, epithelium (strongly IL-17-induced)Neutrophil production, release from marrow and survival; mobilizes stem cellsG-CSFR (CSF3R) homodimer → JAK1 / JAK2 → STAT3 (also STAT5)
JAK-STAT
Scene 11
M-CSF
CSF1
Fibroblasts, osteoblasts, endothelium, bone-marrow stroma, macrophages (constant circulating level)Monocyte / macrophage survival, proliferation and differentiation; osteoclasts (with RANKL); tissue-resident macrophagesCSF1R (c-FMS) → Receptor tyrosine kinase → PI3K / AKT, ERK
Receptor tyrosine kinase
Scene 11
IL-34
IL34
Keratinocytes, neurons, splenic red-pulp stromaDevelopment and maintenance of Langerhans cells and microgliaCSF1R (also PTPRZ1, syndecan-1) → Receptor tyrosine kinase → PI3K / AKT, ERK
Receptor tyrosine kinase
Scene 11
SCF
KITLG (stem cell factor, KIT ligand)
Bone-marrow stroma and endothelium, fibroblasts, keratinocytes, airway epithelium and smooth muscleStem-cell maintenance; mast-cell development, survival and activation; melanocytes and germ cellsKIT (CD117) → Receptor tyrosine kinase → PI3K / AKT, MAPK, (STAT)
Receptor tyrosine kinase
Scene 11
Flt-3 Ligand
FLT3LG
Bone-marrow stroma, T cells, endothelium (membrane and soluble forms)Dendritic-cell development (cDC and pDC), early progenitor expansion, NK cellsFLT3 (CD135) → Receptor tyrosine kinase → PI3K / AKT, RAS / MAPK, STAT5
Receptor tyrosine kinase
Scene 11
TPO
THPO (thrombopoietin)
Liver hepatocytes (constant production), kidney, marrow stromaMegakaryocyte growth and platelet production; stem-cell quiescence; plasma level set by platelet MPL clearanceMPL → JAK2 → STAT5 (also STAT3)
JAK-STAT
Scene 11

Tissue growth factors and angiogenesis (6)

MediatorMade byRegulatesReceptor → signallingMain scene
EGF
EGF
Salivary and Brunner’s glands, kidney, platelets, macrophages; abundant in saliva, milk and urineEpithelial proliferation and migration, wound healing, gut mucosal repair; airway goblet-cell (MUC5AC) mucusEGFR (ErbB1) → Receptor tyrosine kinase → RAS / MAPK, PI3K / AKT, PLCγ
Receptor tyrosine kinase
Scene 12
TGFα
TGFA
Macrophages, keratinocytes, epithelial cells, eosinophils (membrane precursor shed by ADAM17)Keratinocyte and epithelial proliferation, wound re-epithelialization, airway mucous metaplasiaEGFR (ErbB1) → Receptor tyrosine kinase → RAS / MAPK, PI3K / AKT
Receptor tyrosine kinase
Scene 12
FGF-2
FGF2 (basic FGF)
Fibroblasts, endothelium, macrophages, mast cells, smooth muscle (released on injury — no signal peptide)Angiogenesis, fibroblast proliferation, wound healing, airway smooth-muscle growthFGFR1–4 + heparan sulfate → Receptor tyrosine kinase → RAS / MAPK, PI3K, PLCγ
Receptor tyrosine kinase
Scene 12
PDGF-AA
PDGFA homodimer
Platelets (α-granules), macrophages, epithelial cells, astrocytes, smooth muscleFibroblast and oligodendrocyte-precursor proliferation; alveolar myofibroblast developmentPDGFRα homodimer → Receptor tyrosine kinase → PI3K, PLCγ, RAS / MAPK
Receptor tyrosine kinase
Scene 12
PDGF-AB/BB
PDGFA/PDGFB heterodimer; PDGFB homodimer
Platelets (major), macrophages, endothelium, smooth musclePericyte and smooth-muscle recruitment to vessels; fibroblast chemotaxis and proliferation; wound healing; airway remodellingPDGFRαα, PDGFRαβ, PDGFRββ (BB binds all three; AB binds αα and αβ) → Receptor tyrosine kinase → PI3K, PLCγ, RAS / MAPK
Receptor tyrosine kinase
Scene 12
VEGF-A
VEGFA
Hypoxic epithelial and tumour cells (HIF-1α), macrophages, keratinocytes, mast cells, eosinophils, neutrophils, plateletsAngiogenesis, vascular permeability (oedema), endothelial survival; airway vascular remodellingVEGFR2 (KDR) + neuropilin-1; VEGFR1 (FLT1) as a high-affinity sink → Receptor tyrosine kinase → PLCγ / ERK, PI3K / AKT / eNOS
Receptor tyrosine kinase
Scene 12

TNF superfamily: B-cell survival and co-stimulation (4)

MediatorMade byRegulatesReceptor → signallingMain scene
BAFF
TNFSF13B (BLyS)
Monocytes, macrophages, DCs, neutrophils, lymphoid stromal cells, epithelium (strongly interferon-induced)Survival of transitional and mature naive B cells; class switching via TACI; excess BAFF rescues autoreactive B cellsBAFF-R (BR3), TACI, BCMA → TRAF3 degradation → NIK → non-canonical NF-κB (p52 / RelB)
NF-κB family
Scene 13
APRIL
TNFSF13
Monocytes, macrophages, DCs, neutrophils, eosinophils and osteoclasts in the marrow plasma-cell niche, gut epitheliumLong-lived plasma-cell survival (BCMA); T-independent IgA class switching (TACI)TACI, BCMA (plus heparan sulfate proteoglycans) → TRAF → canonical and non-canonical NF-κB
NF-κB family
Scene 13
sCD40L
CD40LG (soluble CD154)
Activated CD4 T cells (shed from the membrane) and platelets (source of most circulating sCD40L); mast cells, basophilsB-cell class switching and germinal centres (via CD40); DC licensing (IL-12); endothelial activation; thrombus stabilityCD40 (also αIIbβ3 and Mac-1 integrins) → TRAF2/3/5/6 → canonical and non-canonical NF-κB
NF-κB family
Scene 13
sCD137
TNFRSF9 (soluble 4-1BB)
Activated T cells and NK cells (alternatively spliced), some tumoursDampens 4-1BB co-stimulation of CD8 T cells; serum marker of T-cell activationBinds 4-1BBL (CD137L) — decoy → No signal; blocks 4-1BB co-stimulation
Antagonist / decoy
Scene 9

Death ligands and cytotoxic effectors (6)

MediatorMade byRegulatesReceptor → signallingMain scene
sFasL
FASLG (soluble CD95L)
Shed (metalloproteinases) from activated CTLs, NK cells and Th1 cells; constitutive at immune-privileged sitesContraction of activated lymphocyte clones, removal of autoreactive lymphocytes; soluble form mainly chemotactic / non-apoptoticFas (CD95) → FADD → caspase-8 → caspase-3 (soluble form is a weak killer)
Death receptor
Scene 14
sFas
FAS (soluble CD95)
Activated lymphocytes and many tissues (exon-skipping splice variant)Inhibits FasL-induced apoptosisBinds FasL — decoy → No signal; blocks Fas-mediated apoptosis
Antagonist / decoy
Scene 9
TRAIL
TNFSF10 (Apo2L)
NK cells (especially liver), CTLs, pDCs, monocytes, neutrophils — strongly interferon-inducedKills virus-infected and transformed cells; NK immune surveillance; limits autoimmunityDR4 (TRAIL-R1), DR5 (TRAIL-R2); decoys DcR1, DcR2, OPG → FADD → caspase-8 → caspase-3; also NF-κB
Death receptor
Scene 14
Perforin
PRF1
CD8 CTLs, NK cells, NKT and γδ T cells, CD4 CTLsTarget-cell killing; removes antigen-presenting cells and so ends T-cell / macrophage activationInserts into the target-cell membrane (Ca²⁺-dependent) → Forms pores → delivers granzymes
Cytotoxic granule
Scene 14
Granzyme A
GZMA
CTLs, NK cells, γδ T cells (most abundant granzyme)Caspase-independent target death (pyroptosis in GSDMB+ cells); extracellularly induces IL-1β, IL-6, TNF-α from monocytesEnters through perforin pores (extracellular actions via unknown receptors) → Cleaves SET complex → single-strand DNA nicks (caspase-independent); cleaves gasdermin B
Cytotoxic granule
Scene 14
Granzyme B
GZMB
CTLs, NK cells; also pDCs, B cells, basophils, mast cells, keratinocytesRapid apoptosis of infected / tumour cells; extracellularly degrades matrix and barrier proteinsEnters through perforin pores → Cleaves BID and caspase-3/7 → mitochondrial apoptosis
Cytotoxic granule
Scene 14

Chemokines: neutrophil-recruiting (ELR+ CXC, CXCR1/2) (4)

MediatorMade byRegulatesReceptor → signallingMain scene
IL-8
CXCL8
Monocytes, macrophages, epithelium, endothelium, fibroblasts, keratinocytes, neutrophils (IL-1 / TNF / IL-17-induced)Neutrophil chemotaxis, adhesion and degranulation; angiogenesisCXCR1, CXCR2 → Gαi → PI3K, Rho GTPases, Ca²⁺ flux
Chemokine GPCR
Scene 6
GROα
CXCL1
Epithelium, keratinocytes, macrophages, endothelium, fibroblasts (strongly IL-17-induced)Neutrophil recruitment; angiogenesis; oligodendrocyte-precursor signallingCXCR2 → Gαi → PI3K, Rho GTPases, Ca²⁺ flux
Chemokine GPCR
Scene 6
ENA-78
CXCL5
Type II alveolar epithelium, platelets, monocytes, endothelium, fibroblasts (IL-1 / TNF / IL-17-induced)Neutrophil recruitment and angiogenesis; tunes plasma CXCL1/CXCL8 availability via the DARC (ACKR1) sinkCXCR2 → Gαi → PI3K, Rho GTPases, Ca²⁺ flux
Chemokine GPCR
Scene 15
GCP-2
CXCL6
Fibroblasts, airway and gut epithelium, macrophages, chondrocytes (IL-1 / TNF-induced)Neutrophil chemotaxis and degranulation; antimicrobial activity; angiogenesisCXCR1, CXCR2 → Gαi → PI3K, Rho GTPases, Ca²⁺ flux
Chemokine GPCR
Scene 15

Chemokines: interferon-induced (CXCR3) (3)

MediatorMade byRegulatesReceptor → signallingMain scene
IP-10
CXCL10
Monocytes, endothelium, keratinocytes, fibroblasts, epithelium — induced by IFN-γ and type I IFNRecruits Th1 cells, CTLs and NK cells; angiostaticCXCR3 → Gαi → PI3K, Ca²⁺ flux
Chemokine GPCR
Scene 6
MIG
CXCL9
Macrophages, DCs, endothelium, keratinocytes — predominantly IFN-γ-inducedRecruits Th1 cells, CTLs and NK cells into inflamed tissue; angiostaticCXCR3 → Gαi → PI3K, Ca²⁺ flux
Chemokine GPCR
Scene 15
I-TAC
CXCL11
Monocytes, endothelium, keratinocytes, astrocytes — induced by IFN-γ plus type I IFNMost potent CXCR3 agonist; effector T-cell recruitmentCXCR3 (highest affinity) → Gαi → PI3K, Ca²⁺ flux; ACKR3 = scavenger (no G-protein signal)
Chemokine GPCR
Scene 15

Chemokines: monocyte / lymphocyte-recruiting (CCR1, CCR2, CCR5) (8)

MediatorMade byRegulatesReceptor → signallingMain scene
MCP-1
CCL2
Monocytes, macrophages, endothelium, fibroblasts, epithelium, smooth muscleMonocyte egress from marrow and recruitment; memory T and NK cells; basophil histamine releaseCCR2 → Gαi → PI3K, Ca²⁺ flux
Chemokine GPCR
Scene 6
MCP-2
CCL8
Fibroblasts, monocytes, endothelium (interferon-induced)Recruits monocytes, T cells, NK cells, eosinophils, basophils; in mouse skin draws IL-5+ Th2 cells via CCR8CCR1, CCR2, CCR3, CCR5 (CCR8 in mice) → Gαi → PI3K, Ca²⁺ flux
Chemokine GPCR
Scene 16
MCP-3
CCL7
Monocytes, fibroblasts, platelets, mast cells, keratinocytesBroad recruiter: monocyte marrow egress (with CCL2), eosinophils, basophils, DCs, T and NK cellsCCR1, CCR2, CCR3 (CCR5 antagonist) → Gαi → PI3K, Ca²⁺ flux
Chemokine GPCR
Scene 16
MIP-1α
CCL3
Macrophages, DCs, T cells, NK cells, neutrophils, mast cellsRecruits monocytes, T cells, NK cells, DCs and eosinophils; osteoclast activation; inhibits stem-cell proliferationCCR1, CCR5 → Gαi → PI3K, Ca²⁺ flux
Chemokine GPCR
Scene 6
MIP-1β
CCL4
Macrophages, DCs, CD8 T cells, NK cellsRecruits CCR5+ T cells, NK cells and monocytes; blocks R5 HIV entryCCR5 → Gαi → PI3K, Ca²⁺ flux
Chemokine GPCR
Scene 6
MIP-1δ
CCL15 (leukotactin-1, HCC-2)
Monocytes, macrophages, intestinal and lung epitheliumRecruits monocytes, neutrophils, lymphocytes and eosinophils; potency rises after protease trimming of the N-terminusCCR1, CCR3 → Gαi → PI3K, Ca²⁺ flux
Chemokine GPCR
Scene 16
MPIF-1
CCL23 (MIP-3, CKβ8)
Monocytes, macrophages and DCs (boosted by IL-4 / IL-13)Recruits monocytes and resting T cells; inhibits myeloid progenitor proliferation (its namesake); angiogenicCCR1 → Gαi → PI3K, Ca²⁺ flux
Chemokine GPCR
Scene 16
RANTES
CCL5
Activated T cells (late), platelets (α-granules), epithelium, endothelium, fibroblasts, macrophagesRecruits T cells, monocytes, eosinophils, basophils, NK cells and DCsCCR1, CCR3, CCR5 → Gαi → PI3K, Ca²⁺ flux
Chemokine GPCR
Scene 6

Chemokines and chemoattractants: eosinophil / Th2 / Treg (CCR3, CCR4, CCR8, CD4) (8)

MediatorMade byRegulatesReceptor → signallingMain scene
Eotaxin
CCL11
Airway epithelium, fibroblasts, smooth muscle, endothelium, eosinophils (IL-4 / IL-13 / TNF-induced)Eosinophil, basophil and Th2 recruitment; with IL-5, eosinophil release from marrowCCR3 → Gαi → PI3K, Ca²⁺ flux
Chemokine GPCR
Scene 6
Eotaxin-2
CCL24
Activated (IL-4-conditioned) monocytes and macrophages, DCs, airway epithelium, fibroblastsEosinophil and basophil chemotaxis; resting T cellsCCR3 → Gαi → PI3K, Ca²⁺ flux
Chemokine GPCR
Scene 17
Eotaxin-3
CCL26
Epithelium (oesophageal, airway), keratinocytes, endothelium — strongly IL-4 / IL-13 / STAT6-inducedEosinophil and basophil recruitment; the dominant epithelial eotaxin in chronic Th2 inflammationCCR3 (also a CX3CR1 agonist and a CCR1, CCR2, CCR5 antagonist) → Gαi → PI3K, Ca²⁺ flux
Chemokine GPCR
Scene 17
MCP-4
CCL13
Endothelium, airway epithelium, fibroblasts, monocytes (IL-1 / TNF plus IL-4 / IL-13)Eosinophil, basophil, monocyte and T-cell chemotaxisCCR1, CCR2, CCR3 → Gαi → PI3K, Ca²⁺ flux
Chemokine GPCR
Scene 17
TARC
CCL17
DCs (incl. Langerhans and TSLP-conditioned DCs), keratinocytes, endothelium, bronchial epithelium; Reed–Sternberg cellsRecruits CCR4+ Th2, Treg and skin-homing (CLA+) T cellsCCR4 → Gαi → PI3K, Ca²⁺ flux
Chemokine GPCR
Scene 17
MDC
CCL22
DCs, macrophages (IL-4-conditioned), activated B cellsRecruits Th2 and Treg cells; Treg–DC contacts; Treg recruitment into tumoursCCR4 → Gαi → PI3K, Ca²⁺ flux
Chemokine GPCR
Scene 17
I-309
CCL1
Activated monocytes / macrophages, mast cells, activated T cells (Th2), endotheliumRecruits CCR8+ Tregs (especially in skin and tumours), Th2 cells and monocytes; enhances Treg suppressionCCR8 → Gαi → PI3K, Ca²⁺ flux
Chemokine GPCR
Scene 17
IL-16
IL16 (lymphocyte chemoattractant factor)
CD8 T cells (preformed, caspase-3 processed), CD4 T cells, mast cells, eosinophils, airway epithelium, B cellsChemoattractant for CD4+ T cells, monocytes and eosinophils; primes CD4 T cells (CD25); competes with HIV for CD4CD4 (with CD9) — not a GPCR → CD4-associated Lck signalling → migration, IL-2Rα (CD25) expression
Other (CD4)
Scene 17

Chemokines: homeostatic homing and tissue address (9)

MediatorMade byRegulatesReceptor → signallingMain scene
SDF-1
CXCL12
Bone-marrow CXCL12-abundant reticular (CAR) cells, osteoblasts, endothelium, lymph-node stromaStem-cell retention and homing, B-cell development, plasma-cell niches, germinal-centre dark zoneCXCR4 (ACKR3 = scavenger) → Gαi → PI3K, Ca²⁺ flux
Chemokine GPCR
Scene 6
6Ckine
CCL21 (SLC)
Lymph-node high endothelial venules and T-zone fibroblastic reticular cells; lymphatic endotheliumEntry of naive / central-memory T cells and mature DCs into lymph-node T zones; DC migration along lymphaticsCCR7 → Gαi → PI3K, Ca²⁺ flux; integrin activation
Chemokine GPCR
Scene 18
MIP-3β
CCL19 (ELC)
Lymph-node T-zone fibroblastic reticular cells, mature DCsT-cell / DC encounters in the T zone (with CCL21); unlike CCL21 it triggers CCR7 internalizationCCR7 → Gαi → PI3K, Ca²⁺ flux
Chemokine GPCR
Scene 18
BCA-1
CXCL13 (BLC)
Follicular DCs and marginal reticular cells; human Tfh cells; stroma of ectopic lymphoid folliclesHoming of B cells and Tfh cells to follicles; germinal-centre organization; ectopic lymphoid structuresCXCR5 → Gαi → PI3K, Ca²⁺ flux
Chemokine GPCR
Scene 18
MIP-3α
CCL20 (LARC)
Epithelium (gut follicle-associated, skin keratinocytes, airway) induced by IL-1β / TNF / IL-17; Th17 cellsRecruits CCR6+ Th17, Treg, immature DC and B cells to epithelia and Peyer’s patchesCCR6 (its only chemokine receptor; β-defensin-2 is also reported to bind CCR6) → Gαi → PI3K, Ca²⁺ flux
Chemokine GPCR
Scene 18
CTACK
CCL27
Keratinocytes (constitutive; increased by TNF-α / IL-1β)Skin homing of CLA+ CCR10+ memory T cells, including skin TregsCCR10 → Gαi → PI3K, Ca²⁺ flux
Chemokine GPCR
Scene 18
CCL28
CCL28 (MEC)
Mucosal and glandular epithelium (salivary, colon, airway, lactating mammary gland)Homing of IgA plasmablasts to mucosa and milk; CCR3+ eosinophils; direct antimicrobial activityCCR10, CCR3 → Gαi → PI3K, Ca²⁺ flux
Chemokine GPCR
Scene 18
Lymphotactin
XCL1
Activated CD8 T cells, NK cells, NKT and γδ T cellsDraws XCR1+ cross-presenting cDC1 to CD8 T cells, strengthening cross-priming; thymic Treg developmentXCR1 → Gαi → PI3K, Ca²⁺ flux
Chemokine GPCR
Scene 18
Fractalkine
CX3CL1
Inflamed endothelium (TNF / IL-1 / IFN-γ-induced), neurons, epithelium, DCsFirm capture and recruitment of CX3CR1+ patrolling monocytes, NK and effector CD8 T cells; neuron–microglia signallingCX3CR1 → Gαi + direct adhesion (membrane-anchored on a mucin stalk; ADAM10/17 shed)
Chemokine GPCR
Scene 18

Cells, antibodies, complement, acute-phase markers, biologic agents and precision therapies · catalogue

The 126 entities added in Scenes 19–47: every T- and B-cell subset, the nine immunoglobulin isotypes and their Fc receptors, the complement components, regulators and receptors, and the steps of the neutrophil life cycle from marrow to resolution, and the acute-phase markers. Made / induced by is what generates or produces it; Function and clinical correlate is what it does and what happens when it fails; Receptor → signalling names the receptor and cascade; Detail carries markers, homing, typical levels and cytokine control. Every level is a typical adult figure for orientation only — reference ranges are laboratory-specific and strongly age-specific, and paediatric values differ sharply from adult ones.

A–Z finder

Abatacept
Abatacept and belatacept in CTLA-4 and LRBA disease
Albumin
Anakinra
Anifrolumab
Antimicrobial prophylaxis
Avacopan and sutimlimab
B-1 cell
Belimumab
Benralizumab
C1 inhibitor
C1q
C1r / C1s
C2
C3
C3a
C3aR / C5aR1
C4
C4BP / MCP / DAF
C5
C5a
C6 / C7 / C8 / C9 (MAC)
Canakinumab and rilonacept
CD59
CD8 Tc1 (CTL)
CD8 Tc2 / Tc17
CD8 Tem / Temra
CD8 Trm
CD8 Tscm / Tcm
Cobalamin and folate in the transport defects
CR1 (CD35)
CR2 (CD21)
CR3 / CR4
CRP
Dupilumab
Eculizumab and ravulizumab
Elapegademase
Emapalumab
ESR
Etanercept
Factor B
Factor D
Factor H
Factor I
FcRn and pIgR
FcαRI (CD89)
FcγRI (CD64)
FcγRIIa (CD32a)
FcγRIIb (CD32b)
FcγRIII (CD16)
FcεRI
FcεRII (CD23)
Ferritin
Fibrinogen
G-CSF (filgrastim)
Germinal-centre B cell
Granulopoiesis
Guselkumab, risankizumab and tildrakizumab
Haptoglobin
Hepcidin
IgA1
IgA2
IgD
IgE
IgG1
IgG2
IgG3
IgG4
IgM
IL-1 blockade in the inflammasomopathies
Immune reconstitution: transplant and gene therapy
Immunoglobulin replacement
Infliximab, adalimumab and golimumab
iNKT
Interferon gamma-1b
Iptacopan and danicopan
JAK inhibitors
JAK inhibitors in JAK/STAT gain-of-function
Leniolisib
Long-lived plasma cell
MAIT
Marginal-zone B cell
Marrow retention and release
MASP-2
Mavorixafor and plerixafor
MBL
Memory B cell
Mepolizumab and reslizumab
Naive follicular B cell
Nemolizumab
NET formation
NK cell
nTreg
Omalizumab
Opsonin recognition
Oral fucose
Pegcetacoplan
Phagocytosis and killing
Plasmablast
Procalcitonin
Properdin
pTreg / iTreg
Recruitment to tissue
Regulatory B cell (Breg)
Resolution and clearance
Rituximab
SAA
Secukinumab, ixekizumab and bimekizumab
Siltuximab
Tezepelumab
Tfh
Tfr
Th1
Th17
Th2
Th22
Th9
Tocilizumab and sarilumab
Tr1
Tralokinumab and lebrikizumab
Transferrin and transthyretin
Transitional B cell
Treg (CD8)
Ustekinumab
Vaccination in inborn errors of immunity
γδ T cell

CD4 T-cell subsets (5)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
Th1
CD4 helper 1
CD4 effector subset
Naive CD4 T cell driven by IL-12 (+ IL-18) from macrophages and DC1s during intracellular infectionMacrophage activation, IgG1 and IgG3 class switching, delayed-type hypersensitivity
Mendelian susceptibility to mycobacterial disease (IL12B, IL12RB1, IFNGR1/2, STAT1); driver of granulomatous inflammation
IL-12R (IL-12Rβ1 + IL-12Rβ2); IFN-γR; CXCR3 for tissue entry → STAT4 (IL-12) and STAT1 (IFN-γ) → T-betDefining factor: T-bet (TBX21), with STAT4 / STAT1
Markers: CD4, CXCR3, CCR5, IL-12Rβ2, IL-18R
Homing: CXCR3, CCR5 → inflamed Th1 tissue
Makes: IFNγ, TNFα, TNFβ, IL-2, IL-10
Scene 19
Th2
CD4 helper 2
CD4 effector subset
Naive CD4 T cell driven by IL-4 (with TSLP-, IL-33- or IL-25-conditioned DCs) during allergen or helminth exposureIgE class switching, eosinophilia, mucus, smooth-muscle and barrier changes of allergic disease
Atopic dermatitis, allergic asthma, food allergy, eosinophilic oesophagitis; Th2A frequency falls with successful oral or sublingual immunotherapy and with naturally acquired tolerance; target of dupilumab (IL-4Rα) and anti-IL-5 agents
IL-4R (IL-4Rα + γc); ST2 and IL-17RB on memory Th2; CCR4 and CCR3 for tissue entry → STAT6 (IL-4) → GATA3; STAT5 (IL-2) supports itDefining factor: GATA3, with STAT6 / STAT5
Markers: CD4, CRTH2 (DP2), CCR4, ST2, IL-17RB; the allergen-specific pathogenic effector "Th2A" subset is CRTH2+ CD161+ CD27− IL-17RB+ with high CD49d
Homing: CCR4, CCR3, CRTH2 → allergic tissue, skin and airway
Makes: IL-4, IL-5, IL-13, IL-9, IL-31, IL-10, GM-CSF
Scene 19
Th17
CD4 helper 17
CD4 effector subset
Naive CD4 T cell driven in humans mainly by IL-1β with IL-6 and IL-23 (TGF-β is permissive at low dose; its obligate role is established in mouse but contested in humans), then stabilized by IL-23 and its own IL-21Neutrophil recruitment and antifungal/antibacterial defence at barriers; autoimmune tissue inflammation
STAT3 LOF (hyper-IgE), IL17RA / IL17RC / IL17F / ACT1 (TRAF3IP2) and RORC defects and STAT1 GOF cause chronic mucocutaneous candidiasis (RORC also brings mycobacterial susceptibility); CARD9 deficiency causes invasive and CNS fungal disease; in APECED (AIRE) neutralizing anti-IL-17 and anti-IL-22 autoantibodies produce the same candidiasis; target of anti-IL-17 and anti-IL-23 agents
IL-6R, IL-23R, IL-21R, IL-1R1; CCR6 for epithelial homing → STAT3 → RORγtDefining factor: RORγt (RORC), with STAT3
Markers: CD4, CCR6, IL-23R, CD161
Homing: CCR6 → epithelium, gut and skin (CCL20)
Makes: IL-17A, IL-17F, IL-22, IL-21, GM-CSF, TNFα
Scene 19
Th9
CD4 helper 9
CD4 effector subset
Naive CD4 T cell driven by IL-4 plus TGF-β (IL-25 and TSLP enhance it)Mast-cell accumulation and IL-9-dependent allergic inflammation; antihelminth and antitumour effects shown in mouse models. A differentiation state rather than a stable lineage; IL-9 output is lost on restimulation
Contributes to asthma and food-allergy mast-cell burden; no monogenic human disease defined
IL-4R, TGF-βR, IL-2R → STAT6 + SMAD → PU.1, IRF4Defining factor: PU.1 (SPI1) with IRF4, BATF and GATA3
Markers: No defining surface phenotype in humans; identified by IL-9 secretion; GATA3 is required alongside PU.1, IRF4 and BATF, although PU.1 blocks the full Th2 programme
Homing: CCR3, CCR6 → airway and gut mucosa
Makes: IL-9, IL-10, IL-21
Scene 19
Th22
CD4 helper 22
CD4 effector subset
Naive CD4 T cell driven by IL-6 and TNF-α with aryl-hydrocarbon-receptor ligands, in skin-draining nodesKeratinocyte antimicrobial peptides, proliferation and wound repair without the IL-17 neutrophil programme
Expanded in psoriasis and in atopic dermatitis (IL-22 correlates with severity)
IL-6R, TNFR; CCR4 + CCR10 for skin homing → STAT3 with AHRDefining factor: AHR (required for IL-22 but not lineage-restricted) with STAT3; no master transcription factor; best regarded as a differentiation state
Markers: CD4, CCR10 with CCR4/CCR6, no IL-17A
Homing: CCR10 with CCR4 → skin
Makes: IL-22, TNFα
Scene 19

CD4 regulatory and follicular subsets (5)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
Tfh
follicular helper T cell
CD4 helper for B cells
Naive CD4 T cell primed by dendritic cells (in humans mainly by IL-12 with TGF-β and IL-23, whereas IL-6 is the dominant inducer in mouse; IL-21 then provides autocrine amplification), then retained in the follicle by B-cell ICOS-L and by follicular-dendritic-cell CXCL13Germinal-centre formation, affinity maturation and class switching; its IL-21 and IL-4 determine the isotype
CD40LG deficiency (X-linked hyper-IgM), ICOS, CD40, IL21 and IL21R defects abolish or severely impair germinal centres; NFKB1/NFKB2 and activated-PI3K-delta syndrome dysregulate Tfh; circulating Tfh expanded in autoantibody disease
IL-6R, IL-21R, ICOS, CD40L on its surface; CXCR5 for follicle entry → STAT3 with STAT4 (human IL-12-driven) → Bcl-6Defining factor: Bcl-6, with STAT3
Markers: CD4, CXCR5, PD-1, ICOS, Bcl-6, CD57 on germinal-centre Tfh, low CCR7
Homing: CXCR5 → B-cell follicle (CXCL13), CCR7 low
Makes: IL-21, IL-4, sCD40L, IL-10, BCA-1
Scene 20
Tfr
follicular regulatory T cell
Regulatory subset
Treg that acquires CXCR5 and enters the follicle; thymic derivation and Bcl-6 dependence are established in mouse, while human follicular Tregs express Bcl-6 weakly and blood "circulating Tfr" are largely not germinal-centre-derivedLimits germinal-centre size and output; restraint of autoantibody (and of IgE, shown in mouse) is mediated by CTLA-4, IL-10 and IL-2 consumption
CTLA-4 haploinsufficiency and LRBA deficiency, in which follicular regulation fails, cause germinal-centre hyperplasia with autoantibodies; FOXP3 mutation (IPEX) eliminates the entire Treg compartment
IL-2R (CD25), CTLA-4, PD-1; CXCR5 → FoxP3 with Bcl-6Defining factor: FoxP3 with Bcl-6
Markers: CD4, CD25, FoxP3, CXCR5, PD-1
Homing: CXCR5 → germinal centre
Makes: IL-10, IL-35
Scene 20
nTreg
thymic (natural) regulatory T cell
Regulatory subset
Selected in the thymus on self antigen with IL-2; maintained peripherally by IL-2Dominant peripheral tolerance: suppresses effector T cells, B cells and antigen-presenting cells through CTLA-4-mediated CD80/CD86 transendocytosis, IL-2 consumption by high-affinity CD25, IL-10 and TGF-β, CD39/CD73 adenosine generation, and granzyme-mediated killing
FOXP3 mutation causes IPEX; CD25 (IL2RA), CTLA-4, LRBA, STAT5B, IL2RB, BACH2 and DEF6 defects cause Treg-deficient autoimmunity with enteropathy
IL-2R (CD25, high affinity), CTLA-4, TGF-βR; CCR4, CCR8 for tissue entry → STAT5 (IL-2) → FoxP3 stabilityDefining factor: FoxP3 (demethylated TSDR), with STAT5, Helios
Markers: CD4, CD25 high, CD127 low, FoxP3, CTLA-4
Homing: CCR4, CCR8 → skin and inflamed tissue; CCR7 for nodes
Makes: IL-10, IL-35
Scene 20
pTreg / iTreg
peripherally induced regulatory T cell
Regulatory subset
Naive CD4 T cell converted in the gut and other tissues by TGF-β with retinoic acid, IL-2 and short-chain fatty acidsTolerance to food and microbial antigens at mucosal surfaces. TGF-β-induced FOXP3 in human cells is often transient and not necessarily suppressive, so a FoxP3-positive cell is not necessarily regulatory
Central to oral tolerance and to the proposed mechanism of oral immunotherapy
TGF-βR, IL-2R, retinoic-acid receptor; CCR9 and α4β7 for gut homing → SMAD2/3 with STAT5 → FoxP3Defining factor: FoxP3 with an incompletely demethylated TSDR
Markers: CD4, FoxP3, α4β7, CCR9; Helios is often low but is a disputed marker of peripheral origin
Homing: α4β7 and CCR9 → gut lamina propria
Makes: IL-10, IL-35
Scene 20
Tr1
type 1 regulatory T cell (FoxP3-negative)
Regulatory subset
Repeated antigen exposure with IL-27 and IL-10 (tolerogenic DCs)IL-10-dependent suppression without FoxP3; granzyme-mediated killing of APCs
IL10, IL10RA and IL10RB defects cause very-early-onset inflammatory bowel disease; Tr1 induction is a goal of allergen immunotherapy
IL-10R, IL-27R (WSX-1 + gp130); LAG-3, CD49b and CTLA-4 on its surface → STAT1 and STAT3 (IL-27, IL-10) → c-Maf, Blimp-1Defining factor: c-Maf with Blimp-1 (no FoxP3)
Markers: CD4, IL-10 high with IFN-γ (the defining human cytokine pattern); LAG-3 with CD49b is the proposed Tr1 signature but both are induced on activated conventional CD4 cells, so it is not specific in humans
Homing: CCR5, CXCR3 and gut homing receptors → inflamed mucosa
Makes: IL-10, IFNγ, Granzyme B
Scene 20

CD8 T-cell subsets (6)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
CD8 Tc1 (CTL)
cytotoxic T lymphocyte, type 1
CD8 effector subset
Naive CD8 T cell primed by cross-presenting cDC1 with IL-12 and type I interferon, expanded by IL-2 and IL-15Kills virus-infected and tumour cells; provides IFN-γ to the Th1 axis
Perforin (PRF1), UNC13D, STX11 and STXBP2 defects cause familial HLH; CD8 CTLs are the effectors of checkpoint-inhibitor responses
TCR with CD8; IL-2R, IL-15R, IL-12R; CXCR3 and CCR5 for tissue entry → STAT4 / STAT5 → T-bet, Eomes, Runx3Defining factor: T-bet with Eomes and Runx3
Markers: CD8, CXCR3, CD107a on degranulation, granzyme/perforin loaded
Homing: CXCR3, CCR5 → infected tissue
Makes: IFNγ, TNFα, Perforin, Granzyme A, Granzyme B, sFasL, Lymphotactin
Scene 21
CD8 Tc2 / Tc17
type 2 and type 17 cytotoxic CD8 subsets
CD8 effector subset
CD8 T cell primed in IL-4-rich (Tc2) or IL-6 + IL-23-rich (Tc17) conditionsTc2 contributes IL-4, IL-5 and IL-13 in allergic tissue; Tc17 contributes IL-17A with weaker cytotoxicity
Tc2 cells are found in atopic dermatitis and eosinophilic oesophagitis; Tc17 in psoriasis
TCR with CD8; IL-4R (Tc2) or IL-23R and IL-6R (Tc17) → STAT6 → GATA3 (Tc2); STAT3 → RORγt (Tc17)Defining factor: GATA3 (Tc2) or RORγt (Tc17)
Markers: CD8 with CRTH2 (Tc2) or CCR6 and CD161 (Tc17)
Homing: CRTH2 and CCR4 (Tc2); CCR6 (Tc17)
Makes: IL-4, IL-5, IL-13, IL-17A, IL-22, GM-CSF, Granzyme B
Scene 21
CD8 Tscm / Tcm
stem-cell-like and central-memory CD8 T cells
CD8 memory subset
Survive after infection on IL-7 and IL-15, without antigenLong-lived recall capacity: proliferation and replenishment of the effector pool on re-exposure
IL7R defects cause T−B+NK+ SCID; the memory pool on which vaccine responses depend
IL-7R (CD127), IL-2Rβ + γc for IL-15; CCR7 and CD62L for node homing → STAT5 (IL-7, IL-15) → Bcl-2, Tcf-1Defining factor: Tcf-1 (TCF7) with Bcl-6, Id3
Markers: Tcm: CD8, CD45RO+, CCR7+, CD62L+, CD127+. Tscm: CD45RA+ CD45RO− CCR7+ CD62L+ CD27+ with CD95+ and CD122+, a naive-like surface phenotype with memory function
Homing: CCR7 and CD62L → lymph node
Makes: IL-2, IFNγ
Scene 21
CD8 Tem / Temra
effector-memory and terminally differentiated CD8 T cells
CD8 memory subset
Repeated or persistent antigen; maintained by IL-15Immediate cytotoxic effector function in blood and tissue, with limited proliferation
Accumulate with CMV carriage and age; Temra expansion is a marker of immune senescence
IL-15 (trans-presented) and IL-18R; CX3CR1 and CCR5; loss of CCR7 → STAT5 (IL-15) with T-bet highDefining factor: T-bet high, Tcf-1 low
Markers: CD8, CD45RA re-expression (Temra), CD57, CD28 low, CX3CR1
Homing: CX3CR1 and CCR5; no CCR7 → blood and tissue
Makes: IFNγ, Perforin, Granzyme B, TNFα
Scene 21
CD8 Trm
tissue-resident memory CD8 T cell
CD8 memory subset
Effector CD8 T cell retained in tissue by TGF-β and local IL-15Local first-line defence at skin, lung and gut; rapid IFN-γ and granule release without recirculating
Mediate fixed-drug eruption and recurrent herpes lesions; contribute to mucosal protection after infection and vaccination, as shown chiefly in mouse models
TGF-βR, IL-15R; CD103 (αEβ7) and CD69 mediate tissue retention → SMAD with STAT5; Hobit and Blimp-1Defining factor: Runx3 with Blimp-1 and KLF2 downregulation; Hobit (ZNF683) is the mouse residency determinant and is variably expressed in human Trm
Markers: CD8, CD69 (the most consistent human marker), CD103 on many but not all (liver and some lung Trm are CD103−), CD49a, CXCR6, low S1PR1 / KLF2
Homing: retained by CD69 and CD103; CXCR6; S1PR1 low → tissue residence
Makes: IFNγ, Granzyme B, TNFα
Scene 21
Treg (CD8)
CD8 regulatory T cell
Regulatory subset
CD8 T cell exposed to IL-10 and TGF-β or to Qa-1/HLA-E-restricted self peptideSuppresses effector T cells and follicular responses, partly by killing activated targets
Human biology remains incompletely defined; of interest in autoimmunity and transplantation
IL-10R, TGF-βR; HLA-E-restricted TCR on the best-defined human subset → STAT3 (IL-10) and SMAD2/3 (TGF-β)Defining factor: FoxP3 or Helios (subset-dependent)
Markers: Human: CD8+CD28− suppressors, HLA-E-restricted CD8 Tregs, or KIR+ CD8 T cells; FoxP3 in a minority. CD8+CD122+ is the mouse-defined population
Homing: CCR7 and CXCR5 on the follicular-suppressing subset
Makes: IL-10, Granzyme B
Scene 21

Innate-like T cells (4)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
iNKT
invariant natural killer T cell
Innate-like T cell
Thymic selection on CD1d-lipid by double-positive thymocytes with IL-15; activated within hours by CD1d-lipid plus IL-12 and IL-18Very rapid cytokine release that shapes the response before conventional T cells arrive; activates dendritic cells. IL-17A derives only from a rare NKT17 subset, prominent in mouse
Reduced in some primary immunodeficiencies (e.g. XLP, SAP/SH2D1A deficiency); iNKT-derived IL-4 has been proposed, chiefly on mouse evidence, to contribute to early allergic sensitization
Invariant TCR (Vα24-Jα18) on CD1d-lipid; IL-12R, IL-18R, IL-25R on subsets → TCR with STAT4 (IL-12); PLZF-dependent developmentDefining factor: PLZF (ZBTB16), with T-bet, GATA3 or RORγt by subset
Markers: Vα24-Jα18 TCR, CD1d-tetramer+, CD161, often CD4− CD8−
Homing: CXCR6 → liver sinusoids; CCR4 and CCR6 to tissue
Makes: IFNγ, IL-4, IL-13, IL-2, TNFα, IL-10, GM-CSF, sCD40L, Granzyme B
Scene 22
MAIT
mucosal-associated invariant T cell
Innate-like T cell
Selected on MR1-riboflavin metabolites; expanded by microbial exposure and maintained by IL-7 and IL-18Antibacterial and antifungal defence at mucosa; can respond to IL-12 + IL-18 without a TCR signal
Depleted in HIV and in cystic-fibrosis airways; low MAIT numbers accompany several inborn errors of immunity
Semi-invariant TCR (Vα7.2) on MR1; IL-12R, IL-18R, IL-7R, IL-23R; CCR6 and CXCR6 → TCR with STAT4 / STAT3; PLZF-dependent developmentDefining factor: PLZF with RORγt and T-bet
Markers: Vα7.2 TCR, CD161 high, CD26 high, MR1-tetramer+
Homing: CCR6 and CXCR6 → gut, lung and liver
Makes: IFNγ, TNFα, IL-17A, IL-22, Granzyme B
Scene 22
γδ T cell
gamma-delta T cell
Innate-like T cell
Thymic development without MHC restriction; peripheral Vγ9Vδ2 cells respond to phosphoantigens with IL-2, IL-15, IL-18 or IL-23Early IFN-γ or IL-17 at epithelial surfaces; cytotoxicity against stressed cells; keratinocyte repair
Expanded in CMV infection and in some leukaemias; in mouse, γδ T cells are a major early IL-17 source before Th17 cells appear, whereas human γδ cells produce IL-17 only rarely (chiefly tissue Vδ1) and are dominated by IFN-γ and cytotoxic output
γδ TCR engaging BTN2A1 directly, with phosphoantigen-sensing BTN3A1 as obligatory co-ligand (Vγ9Vδ2); NKG2D; IL-23R, IL-1R1 on the IL-17-producing subset → TCR with STAT3 (IL-23) or STAT4 (IL-12/IL-18)Defining factor: RORγt (IL-17 subset) or T-bet (IFN-γ subset)
Markers: TCR γδ, Vδ2 (blood) or Vδ1 (tissue), NKG2D, CD27 (which separates functional subsets)
Homing: CCR6 and CCR2 (IL-17 subset); skin and gut epithelium (Vδ1)
Makes: IFNγ, IL-17A, IL-17F, TNFβ, Perforin, Granzyme B, IL-22
Scene 22
NK cell
natural killer cell — the prototype cytotoxic group 1 ILC, shown for comparison with innate-like T cells
Innate effector
Marrow development on IL-15 with Flt-3L and SCF; activated by IL-12, IL-18 and type I interferonKills cells lacking MHC class I or coated with IgG (CD16-mediated); provides early IFN-γ
Classical and functional NK deficiency (GATA2, MCM4, FCGR3A) predisposes to severe herpesvirus disease; CD16 links NK killing to IgG
IL-15R (trans-presented), IL-12R, IL-18R; CD16 (FcγRIIIa) for antibody-dependent killing; NKG2D → STAT5 (IL-15) and STAT4 (IL-12) → T-bet, EomesDefining factor: T-bet with Eomes, on an ID2 and NFIL3-dependent ILC programme
Markers: CD56, CD16, NKp46, no CD3
Homing: CXCR3 and CX3CR1 (CD56dim blood); CCR7 and CXCR4 (CD56bright, nodes and marrow)
Makes: IFNγ, TNFα, Perforin, Granzyme A, Granzyme B, Lymphotactin, GM-CSF
Scene 22

B-cell subsets (9)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
Transitional B cell
T1 / T2 transitional B cell
B-cell developmental stage
Immature B cell leaving the marrow; survival depends on tonic BCR signalling plus BAFFLast checkpoint against autoreactivity before the naive pool; T2 cells can enter follicles
Expanded in common variable immunodeficiency and after rituximab; reduced BAFF-R function blocks the transitional-to-naive step
BCR (IgM high, IgD rising from low to high); BAFF-R; CD21 low → BAFF-R → non-canonical NF-κB (NIK); BCR → NF-κB, PI3KDefining factor: Remains BCR-dependent; no change in lineage master TF
Markers: CD19, CD24 high, CD38 high, CD10+, IgM high, IgD low (T1), becoming IgD+ (T2)
Homing: spleen (via blood), then follicle on CXCR5
Scene 24
Naive follicular B cell
mature naive B cell (IgM+ IgD+)
B-cell subset
Survival is maintained by BAFF through BAFF-R; CXCL13 retains the cell in the follicleThe pool from which T-dependent germinal-centre responses arise
Target of anti-CD20 therapy; excess BAFF permits survival of autoreactive naive cells (belimumab target)
BCR (IgM + IgD); BAFF-R, TACI; CD40; CXCR5, CCR7 → BAFF-R → non-canonical NF-κB; CD40 → canonical NF-κBDefining factor: Pax5 with EBF1 (B-lineage identity)
Markers: CD19, CD20, CD27−, IgM+, IgD+, CD21+, CD23+
Homing: lymph-node and splenic follicles (CXCR5 → CXCL13)
Scene 24
Marginal-zone B cell
splenic marginal-zone B cell
B-cell subset
Splenic population generated under Notch2/DLL1 signalling (established in mouse) with BAFF; responds to polysaccharide with little or no T-cell help. Human marginal-zone B cells carry mutated immunoglobulin V genes and overlap substantially with the IgM+IgD+CD27+ IgM-memory compartment, so a purely germinal-centre-independent origin is not establishedRapid T-independent IgM (and some IgG2) against encapsulated bacteria
Absent or non-functional after splenectomy and immature in young children, with resulting susceptibility to pneumococcus and poor polysaccharide vaccine responses
BCR with TLRs and complement receptor CD21 (CR2); TACI for APRIL and BAFF → BCR + TLR + CR2 co-signal → NF-κB; TACI → NF-κBDefining factor: Pax5 with a Notch2-driven programme (mouse-established)
Markers: CD19, CD27+, IgM high, IgD low, CD21 high, CD1c+
Homing: splenic marginal zone (S1PR1 vs CXCR5 shuttling)
Makes: IL-10
Scene 24
B-1 cell
B-1a / B-1b cell (innate-like)
B-cell subset
Self-renewing population of fetal/neonatal origin supported by IL-5; all of these features are established in mouse, and no equivalent human self-renewing cavity pool has been definedSpontaneous "natural" polyreactive IgM and some IgA, without immunization
Human counterpart remains debated; the source of natural IgM, including isohaemagglutinins
BCR (polyreactive, germline-near); IL-5R; TLRs → BCR tonic signalling with TLR → NF-κB; IL-5R → STAT5Defining factor: Pax5 with high Bhlhe41 (mouse-defined)
Markers: Mouse: CD19 high, CD5+ (B-1a), CD43+, IgM high, IgD low. A proposed human equivalent (CD20+CD27+CD43+CD70−) is contested; human CD5+ B cells are activated or transitional cells and do not correspond to mouse B-1a
Homing (mouse): pleural and peritoneal cavities and gut lamina propria; no human cavity pool defined
Makes: IL-10
Scene 24
Germinal-centre B cell
dark-zone and light-zone GC B cell
B-cell subset
Antigen plus Tfh help (CD40L and IL-21) after follicular entry; CXCL12 (dark zone) and CXCL13 (light zone) position itSomatic hypermutation in the dark zone, selection on follicular-dendritic-cell antigen in the light zone, and class switching
AICDA and UNG defects cause hyper-IgM with giant germinal centres; the cell of origin of most B-cell lymphomas
CD40 for T help; IL-21R; BCR for antigen capture; CXCR4 (dark zone) and CXCR5 (light zone) → CD40 → NF-κB; IL-21R → STAT3; AID (AICDA) mediates somatic hypermutation and class switchingDefining factor: Bcl-6, which blocks differentiation during somatic hypermutation; exit results from mutual antagonism with Blimp-1 and a rise in IRF4
Markers: CD19, CD38+, CD10+, IgD−, CD77 (dark zone), Fas/CD95+
Homing: germinal centre; shuttling between dark and light zones on CXCR4 and CXCR5
Scene 25
Memory B cell
class-switched and IgM memory B cell
B-cell subset
Germinal-centre output with lower Tfh help and intermediate affinity; maintained without antigenRapid, high-affinity recall: re-enters germinal centres or becomes a plasmablast within days
Switched memory (CD27+IgD−) counts classify CVID (EUROclass), where severely reduced switched memory B cells are associated with splenomegaly and granulomatous disease and an expanded CD21low subset with splenomegaly; DN2 cells expand in lupus and chronic infection; IgM memory loss follows splenectomy
BCR (switched IgG/IgA/IgE or IgM); CD40; TACI; BAFF-R → BCR with enhanced signalling (CD27, switched Ig tail) → NF-κB, PI3KDefining factor: Loss of Bcl-6; Bach2 prevents differentiation into a plasma cell
Markers: CD19, CD27+, IgD− (switched) or IgM+IgD+ CD27+ (IgM memory); CD21low CD38low and T-bet+ CD11c+ IgD−CD27− "double-negative" (DN2) cells are the two clinically tracked abnormal compartments
Homing: blood, spleen and marginal zone; mucosa for IgA memory
Scene 25
Plasmablast
short-lived antibody-secreting cell
Antibody-secreting cell
Strong BCR plus CD40L, IL-21 and IL-6; extrafollicular or germinal-centre derivedThe early antibody response, days after exposure; the cells remain proliferative and migratory
Blood plasmablast counts rise about a week after vaccination; expanded in IgG4-related disease
IL-6R, IL-21R; CXCR4 for migration to marrow and inflamed tissue; CXCR5 is lost → STAT3 (IL-6, IL-21) → Blimp-1, XBP1 secretory programmeDefining factor: Blimp-1 (PRDM1) and IRF4, with XBP1
Markers: CD19 low or positive, CD20−, CD27 high, CD38 high, CD138 variable, Ki-67+
Homing: medullary cords, then marrow or mucosa on CXCR4
Makes: IgM, IgG1, IgA1, IgE
Scene 25
Long-lived plasma cell
bone-marrow (and mucosal) plasma cell
Antibody-secreting cell
Germinal-centre derived; survival niche of CXCL12+ stromal cells with APRIL, BAFF and IL-6Maintains serum antibody titres for years without antigen; the source of steady-state IgG
Not depleted by anti-CD20 (no CD20), so titres persist after rituximab; anti-BCMA agents target it in myeloma
BCMA (APRIL, BAFF), IL-6R; CXCR4 retains the cell in the niche → BCMA → NF-κB survival; IL-6R → STAT3; no surface BCR signallingDefining factor: Blimp-1 with XBP1 (Pax5 off)
Markers: CD38 high, CD138+, CD20−, surface Ig low; the long-lived, titre-maintaining marrow fraction is CD19-negative, while CD19+ plasma cells are shorter-lived
Homing: bone-marrow survival niche; mucosal lamina propria for IgA
Makes: IgG1, IgG2, IgG3, IgG4, IgA1, IgA2
Scene 25
Regulatory B cell (Breg)
IL-10-producing regulatory B cell
Regulatory subset
BCR plus CD40 and TLR signals with IL-21, IL-6 and IFN-α; found among transitional, memory and plasmablast-like cellsSuppresses Th1 and Th17 responses and supports Tregs, mainly through IL-10 (and IL-35)
Reduced IL-10+ B cells in several autoimmune diseases; the allergen-specific human BR1 population (IL-10+ CD73− CD25+ CD71+) preferentially secretes IgG4 and expands during successful allergen immunotherapy and in beekeepers
CD40, TLRs, IL-21R; CD1d high on the transitional subset → CD40 and TLR → NF-κB → IL-10; STAT3Defining factor: No unique master TF; defined by IL-10 output
Markers: Human: CD19+CD24 high CD38 high transitional, or CD24 high CD27+ memory
Homing: spleen, blood, inflamed tissue
Makes: IL-10, IL-35, Granzyme B
Scene 24

Immunoglobulin isotypes (9)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
IgM
IGHM; pentamer (with J chain) in serum, monomer on the B-cell surface
Immunoglobulin
Naive and marginal-zone B cells, B-1 cells and plasmablasts, without class switching; T-independent responses includedFirst antibody of a primary response; agglutination and the strongest classical-complement activator; natural antibodies including isohaemagglutinins
Normal or raised in the class-switch-recombination defects still termed hyper-IgM syndromes (CD40LG, CD40, AICDA, UNG), in which IgM is often not elevated and the historical designation is misleading; absent or low, together with IgG, in agammaglobulinaemia; selective IgM deficiency is rare
Fcμ receptor (FCMR, on lymphocytes), Fcα/μR; pIgR carries pentameric IgM across mucosa; C1q is engaged only after antigen binding bends the pentamer out of its planar (star) form into the staple conformation → Switch signal: none required (default isotype)Level / assay: Typical adult serum 0.4–2.3 g/L; the only isotype produced in quantity by the newborn (cord IgM above ~0.2 g/L suggests intrauterine infection)
Serum half-life about 5 days by turnover studies, although some texts give up to 10
Classical pathway: strongest activator; one surface-bound pentamer in the staple conformation can fix C1
Scene 26, 27
IgD
IGHD; monomer, mostly membrane-bound
Immunoglobulin
Co-expressed with IgM on naive B cells by alternative splicing; a small amount is secreted, mainly by upper-airway plasma cells after class switching from IgM to IgDMarks the mature naive B cell; secreted IgD sensitizes basophils and mast cells and contributes to upper-airway immunity
Very high IgD with periodic fever suggests mevalonate-kinase deficiency (hyper-IgD syndrome), where the raised IgD is a marker rather than the cause
IgD receptor on basophils (galectin-9 has been proposed); no dedicated classical Fc receptor family → Switch signal: non-canonical class switch from Sμ to the σδ switch-like region in tonsil and upper-airway mucosa; AID-dependent, largely T-independent, promoted by IL-2 and IL-21 with APRIL or BAFF through TACILevel / assay: Trace: mean adult serum about 0.03 g/L with a laboratory upper limit around 0.15 g/L, often undetectable; not useful as a routine quantitative test
Serum half-life about 3 days
Does not activate complement
Scene 26, 27
IgG1
IGHG1
Immunoglobulin
Class-switched plasmablasts and long-lived plasma cells after T-dependent protein antigen; IL-21 with CD40L drives the switchDominant IgG of protein and vaccine responses; opsonization, toxin and virus neutralization, ADCC
Low IgG1 lowers total IgG; the main isotype measured in replacement therapy and in vaccine-response testing; crosses the placenta most efficiently
FcγRI (CD64, high affinity), FcγRIIa/IIb, FcγRIIIa; FcRn recycling and placental transfer → Switch signal: IL-21 and IFN-γ with CD40LLevel / assay: Typical adult serum 4.9–11.4 g/L (about 60–65% of total IgG)
Serum half-life about 21 days (FcRn-dependent)
Classical pathway: good activator (second only to IgG3)
Scene 26, 27
IgG2
IGHG2
Immunoglobulin
Plasma cells responding to polysaccharide, largely from marginal-zone and IgM-memory B cellsAntibody against encapsulated bacteria (pneumococcal and Haemophilus polysaccharide)
Selective IgG2 deficiency and poor polysaccharide responses present as recurrent sinopulmonary infection; an IgG2 level normal for age is required before a specific antibody deficiency is diagnosed
FcγRIIa (especially the H131 allotype); poor binding to FcγRI and FcγRIIIa; FcRn recycling → Switch signal: T-independent polysaccharide with TACI (APRIL/BAFF); IFN-γ contributesLevel / assay: Typical adult serum 1.5–6.4 g/L (about 20–30% of total IgG); the last subclass to mature; it is low through early childhood and continues to rise through adolescence, so an age-specific rather than an adult range is required. Polysaccharide antibody responses, rather than the IgG2 level itself, mature first: they are poor before about 2 years and mature over the next few years
Serum half-life about 21 days
Classical pathway: weak activator
Scene 26, 27
IgG3
IGHG3
Immunoglobulin
Class-switched plasma cells early in protein and viral responses; the first IgG subclass in the switch orderThe most potent IgG for complement activation and FcγR engagement; strong antiviral activity
Isolated IgG3 deficiency is reported with recurrent respiratory infection but is a finding of limited significance in isolation; its short half-life causes levels to fluctuate
FcγRI, FcγRIIa, FcγRIIIa (highest affinity of the subclasses); arginine at position 435 in the Fc, and not the long hinge, lowers FcRn affinity and shortens the half-life, and His435 allotypes behave like IgG1 → Switch signal: IFN-γ with CD40L (and IL-21)Level / assay: Typical adult serum 0.2–1.1 g/L (about 5–8% of total IgG)
Serum half-life about 7 days, shorter than the other subclasses because Arg435 in its Fc binds FcRn with lower affinity
Classical pathway: strongest IgG activator
Scene 26, 27
IgG4
IGHG4
Immunoglobulin
Plasma cells after prolonged or repeated antigen exposure with IL-4, IL-13 and especially IL-10 (and IL-21): the "modified Th2" settingNon-inflammatory blocking antibody: exchanges half-molecules so it becomes functionally monovalent and cannot cross-link
Rises during successful allergen immunotherapy and in beekeepers and cat-owners as a blocking antibody; serum IgG4 is not raised in all patients with IgG4-related disease: in a cohort of 125 patients only 51% of those with active disease had an elevated level, so a normal level does not exclude it; the raised IgG4 is probably a consequence of the chronic Th2 and IL-10 milieu rather than the driver of tissue injury
FcγRIIb (inhibitory) preferentially and FcγRI with intermediate affinity; measurable but weak at FcγRIIa, poor at FcγRIIIa; FcRn recycling → Switch signal: IL-4 / IL-13 with IL-10 and CD40LLevel / assay: Typical adult serum 0.08–1.4 g/L (about 1–4% of total IgG); the widest and most skewed of the subclass ranges
Serum half-life about 21 days
Does not activate complement (and blocks activation by other isotypes on the same antigen)
Scene 26, 27
IgA1
IGHA1; monomer in serum, dimer with J chain at mucosa
Immunoglobulin
Plasma cells in marrow and in systemic lymphoid tissue (serum IgA) and in upper-airway mucosa; TGF-β with APRIL, BAFF and IL-21 drives the switchThe dominant serum IgA and the main IgA of upper airway and nasal mucosa; neutralizes without inflammation
Selective IgA deficiency (total IgA under 0.07 g/L with normal IgG and IgM, over age 4) is the most common primary immunodeficiency; most patients with low serum IgA, with or without IgG anti-IgA antibodies, receive intravenous immunoglobulin without difficulty, although IgE anti-IgA antibodies have been associated with anaphylaxis and IgG anti-IgA antibodies with complement-mediated reactions, and a low or absent IgA in the setting of low IgG is not a contraindication to immunoglobulin replacement
FcαRI (CD89) on neutrophils, monocytes and eosinophils; pIgR transports the dimer across epithelium as secretory IgA; Fcα/μR → Switch signal: TGF-β with APRIL / BAFF (TACI) and IL-21; retinoic acid in the gutLevel / assay: About 85–90% of serum IgA; total serum IgA typically 0.7–4.0 g/L in adults and much lower through early childhood
Serum half-life about 6 days
Does not activate the classical pathway; aggregated IgA can engage the alternative pathway weakly
Scene 26, 27
IgA2
IGHA2; dimer with J chain at mucosa
Immunoglobulin
Mucosal plasma cells, especially in the colon and in secretions, under TGF-β with APRIL and retinoic acidThe protease-resistant mucosal IgA: its shorter hinge resists bacterial IgA1 proteases, so it dominates in the lower gut
Secretory IgA is the antibody of mucosal tolerance and protection; most IgA-deficient patients remain asymptomatic because IgM compensates at mucosal surfaces
FcαRI (CD89); pIgR for transport into secretions; binds the secretory component → Switch signal: TGF-β with APRIL / BAFF (TACI); gut retinoic acid favours IgA2Level / assay: About 10–15% of serum IgA, but the majority (about 60%) of colonic secretory IgA
Serum half-life about 6 days
Does not activate the classical pathway; whether aggregated IgA2 engages the alternative pathway is not established; it is reported for aggregated IgA generally, whereas some sources report IgA1 as positive and IgA2 as negative
Scene 26, 27
IgE
IGHE
Immunoglobulin
Plasma cells after IL-4 or IL-13 with CD40L (Tfh or Th2 help); often by sequential switching through IgG1Sensitizes mast cells and basophils for immediate hypersensitivity; defence against helminths
Very high IgE with eczema and infection suggests hyper-IgE syndrome (STAT3, DOCK8, PGM3, ZNF341, ERBIN, IL6ST / IL6R), and other causes of very high IgE include Netherton syndrome (SPINK5), Wiskott–Aldrich syndrome, Omenn or hypomorphic RAG disease, IPEX and CARD11 defects; omalizumab binds free IgE and lowers FcεRI density; total IgE is required for dosing in the indications dosed by IgE and body weight (such as allergic asthma and nasal polyps), whereas dosing in chronic spontaneous urticaria is fixed and independent of IgE
FcεRI (high affinity) as the four-chain receptor on mast cells and basophils, and as a three-chain form on monocytes, dendritic and Langerhans cells and some eosinophils, where it drives IgE-facilitated antigen presentation; FcεRII (CD23, low affinity) on B cells, which regulates IgE production → Switch signal: IL-4 or IL-13 with CD40L (STAT6 → ε germline transcript)Level / assay: Typical adult total IgE 0–100 kU/L (about 0.0002 g/L, roughly 240 µg/L); the least abundant isotype. Cord-blood total IgE is usually under 0.5 kU/L (median about 0.3 kU/L in one large series); maternal blood contamination of a cord sample is excluded by measuring cord IgA, which does not cross the placenta, rather than inferred from the IgE value. Values rise through childhood, so age-specific ranges are required
Serum half-life about 2 days free, but around two weeks once bound to FcεRI on tissue mast cells
Does not activate complement
Scene 26, 27

Fc receptors and immunoglobulin transport (8)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
FcγRI (CD64)
FCGR1A — the only high-affinity IgG receptor
Fc receptor
Monocytes, macrophages and dendritic cells constitutively; neutrophils only after induction by IFN-γ or G-CSFBinds monomeric IgG1 and IgG3 (and IgG4) with high affinity, so it is occupied by circulating IgG at rest; phagocytosis, ADCC and antigen presentation
Neutrophil CD64 rises within hours of bacterial infection and is used as a sepsis marker, especially in neonates
IgG1 and IgG3 ≫ IgG4; does not bind IgG2 → ITAM on the associated FcRγ chain → Syk → PI3K, PLCγ → phagocytosis and oxidative burstScene 28
FcγRIIa (CD32a)
FCGR2A — activating, with the H131/R131 polymorphism
Fc receptor
Neutrophils, monocytes, macrophages, platelets, eosinophilsThe main phagocytic receptor for IgG-opsonized particles; the H131 allotype is the only human FcγR that binds IgG2 efficiently
The R131 allotype mediates poor uptake of IgG2-opsonized pneumococcus and is associated with invasive pneumococcal disease; FcγRIIa on platelets mediates heparin-induced thrombocytopenia
Immune-complexed IgG1, IgG2 (H131 allotype), IgG3 → ITAM within its own cytoplasmic tail → Syk → phagocytosis, degranulation, NET formationScene 28
FcγRIIb (CD32b)
FCGR2B — the only inhibitory Fc receptor
Fc receptor
B cells (the only FcγR they express), mast cells and basophils, macrophages, neutrophils, eosinophils, dendritic cells; the B1 form on B cells and mast cells, the B2 form on the myeloid cellsRaises the activation threshold: co-ligated with the BCR by IgG immune complexes it inhibits B-cell activation, so IgG exerts negative feedback on its own production
Loss of FcγRIIb function predisposes to lupus; its engagement is a proposed component of the mechanism of high-dose IVIG
IgG immune complexes (preferentially IgG1 and IgG4) → ITIM → SHIP-1 → blocks PI3K and calcium signallingScene 28
FcγRIII (CD16)
FCGR3A (CD16a, transmembrane) and FCGR3B (CD16b, GPI-anchored)
Fc receptor
CD16a on NK cells, macrophages and monocyte subsets; CD16b on neutrophils onlyCD16a is the ADCC receptor: IgG-coated targets are killed by NK cells. CD16b is the most abundant neutrophil Fc receptor and captures immune complexes
FCGR3A V158F has been associated with response to rituximab and other IgG1 antibody therapies in some, but not all, studies; CD16a deficiency causes severe herpesvirus disease with normal NK numbers; CD16b is shed on neutrophil activation
IgG1 and IgG3 (the V158 allotype of CD16a binds more strongly) → CD16a: ITAM through FcRγ or CD3ζ → NK degranulation. CD16b: GPI-anchored, signals with CR3Scene 28
FcεRI
MS4A2 / FCER1A — the high-affinity IgE receptor
Fc receptor
Mast cells and basophils as a four-chain αβγ2 receptor; dendritic cells, monocytes and eosinophils as a three-chain αγ2 formRetains IgE on the cell surface for weeks; allergen cross-linking of bound IgE triggers immediate degranulation (histamine, tryptase) and then leukotrienes, prostaglandins and Th2 cytokines
The receptor of immediate hypersensitivity, and therefore of anaphylaxis and of the skin-prick and basophil activation tests; omalizumab lowers free IgE, and FcεRI density falls in parallel, which accounts for an onset of action over weeks
Monomeric IgE with very high affinity (KD ~10⁻¹⁰ M); it binds free IgE, and receptor density follows the IgE level → ITAM → Lyn and Syk → PLCγ and calcium flux → degranulation within minutesScene 28
FcεRII (CD23)
FCER2 — the low-affinity IgE receptor (a C-type lectin, not an Ig-superfamily FcR)
Fc receptor
B cells, follicular dendritic cells, monocytes, eosinophils, airway epitheliumRegulates the quantity of IgE produced and transports IgE-bound allergen for presentation; the soluble shed form can raise or lower IgE production depending on the site of cleavage
Lumiliximab (anti-CD23) has been evaluated in clinical trials in asthma; the soluble form rises in allergic disease and chronic lymphocytic leukaemia
IgE with low affinity (and CD21) → Not an ITAM receptor: acts by antigen capture, trafficking and feedback on IgE synthesis. IL-4 raises CD23 on B cells, which is the same signal that drives the IgE switch itself (Scene 26)Scene 28
FcαRI (CD89)
FCAR — the myeloid IgA receptor
Fc receptor
Neutrophils (the dominant site), monocytes, macrophages, eosinophilsConfers effector function on IgA: complexed IgA triggers phagocytosis, respiratory burst and neutrophil extracellular traps, while monomeric IgA through the same receptor is inhibitory
IgA immune complexes acting on CD89 drive the neutrophil injury of IgA vasculitis (Henoch–Schönlein purpura) and IgA nephropathy
IgA1 and IgA2 in complexes (monomeric IgA delivers an inhibitory signal) → ITAM on the associated FcRγ chain → Syk; monomeric binding instead produces inhibitory ITAM signallingScene 28
FcRn and pIgR
FCGRT (with β2-microglobulin) and PIGR — the transport receptors
Fc receptor
FcRn on endothelium, monocytes, syncytiotrophoblast and epithelium; pIgR on the basolateral face of mucosal and glandular epitheliumFcRn rescues IgG and albumin from lysosomal degradation, which accounts for the three-week half-life of IgG, and transports maternal IgG across the placenta. pIgR transports dimeric IgA (and pentameric IgM) into secretions, with the secretory component remaining attached
FcRn accounts for third-trimester placental IgG transfer and for the IgG half-life that determines IVIG dosing intervals; FcRn blockers (efgartigimod) shorten IgG half-life in autoantibody disease; pIgR delivers the secretory IgA that is absent from serum-only measurements
FcRn binds the IgG Fc at acidic pH and releases it at neutral pH; pIgR binds the J chain of dimeric IgA and pentameric IgM → Receptor-mediated recycling and transcytosis, not a signalling cascadeScene 28

Complement: classical pathway (2)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
C1q
C1QA / C1QB / C1QC (with C1r and C1s forms C1)
Complement
Monocytes, macrophages and dendritic cells (the main source; not mainly hepatocytes); immature DCs produce large amountsRecognition unit of the classical pathway: binds the Fc of bound IgM and IgG (IgG3 > IgG1 >> IgG2, with IgG4 not fixing C1q), CRP and apoptotic-cell surfaces
C1q deficiency confers the highest penetrance of lupus of any single-gene defect (around 90% in reported cases, although series are ascertainment-biased and a minority present with pyogenic infection alone), through failed apoptotic-cell clearance; acquired low C1q in hypocomplementaemic urticarial vasculitis
Binds surface-bound antibody and directly to apoptotic cells; signals through LAIR-1, calreticulin/CD91 and gC1qR (C1QBP); the former "C1qRp" (CD93) is no longer regarded as a C1q receptor → Conformational change activates C1r → C1sLevel / assay: About 0.1 g/L: clinical laboratory ranges are approximately 0.05–0.25 g/L, whereas complement-biochemistry tables quote 70–80 mg/L; measured when CH50 is absent
Cytokine control: Production falls with IL-6 and rises with IFN-γ in monocytes; glucocorticoids raise it
Scene 29
C1r / C1s
C1R / C1S serine proteases
Complement
Hepatocytes, with monocytes and fibroblastsThe catalytic component of C1: activated C1s cleaves C4 and then C2
C1r or C1s deficiency causes lupus-like disease; heterozygous C1R or C1S variants, presumed gain-of-function, cause periodontal Ehlers–Danlos syndrome
Held in the C1 complex as C1q with C1r₂C1s₂, assembled calcium-dependently; blocked by C1 inhibitor → Serine-protease cleavage of C4 → C4b + C4a, then C2Level / assay: Measured only indirectly (CH50 and component assays)
Cytokine control: Hepatic production rises in the acute-phase response (IL-6)
Scene 29

Complement: lectin pathway (2)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
MBL
MBL2 (mannose-binding lectin)
Complement
Hepatocytes (an acute-phase protein)Pattern recognition for mannose and N-acetylglucosamine on microbial surfaces; activates MASPs
MBL deficiency is a weak modifier rather than a disease in its own right; it is most relevant in combination with another defect, chemotherapy or infancy
Binds microbial carbohydrate; circulates in complex with MASP-1, MASP-2 and MASP-3 → MBL–MASP-2 cleaves C4 and C2 → the same C4b2a convertaseLevel / assay: Typical adult serum 0.5–3 mg/L but genotype-driven and very wide: about 5–10% of individuals have levels low enough to be classified as deficient, and more have low-intermediate levels, usually without disease
Cytokine control: Acute-phase: production rises with IL-6 and IL-1
Scene 29
MASP-2
MASP2 (MBL-associated serine protease 2); with MASP-1 and the ficolins/collectins
Complement
HepatocytesThe C4-cleaving protease of the lectin pathway, activated after MBL or ficolin binds a microbial surface
MASP-2 is encoded by MASP2, whereas the related MASP-1 and MASP-3 are encoded by MASP1; MASP-3 is the protease that activates pro-factor D, and MASP1 or COLEC11 (collectin-11) mutations cause 3MC syndrome. MASP-2 deficiency is reported with pneumococcal infection and inflammatory disease but is often clinically silent; ficolin-3 deficiency is more consistently associated with infection
Carried on MBL, ficolin-1/2/3 and collectin-11 → Cleaves C4 then C2 → C4b2a (MASP-1 assists by cleaving C2 and activating MASP-2)Level / assay: Measured by lectin-pathway functional assay rather than by concentration
Cytokine control: Hepatic acute-phase production with IL-6
Scene 29

Complement: the shared C4 and C2 step (2)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
C4
C4A and C4B (two loci, copy-number variable)
Complement
Hepatocytes mainly; also monocytes and macrophagesCleaved by C1s or MASP-2 to C4b, which binds the surface covalently and, with C2a, forms the classical/lectin C3 convertase
Low C4 with low C3 suggests classical-pathway consumption (lupus, cryoglobulinaemia, immune-complex disease); low C4 with normal C3 is the characteristic hereditary-angioedema pattern; C4A null alleles associate with lupus
C4b binds covalently to the activating surface; recognized by CR1 and inactivated by factor I with C4BP or MCP → C4 → C4b + C4a; C4b + C2a = C3 convertase (C4b2a). C4a is not a true anaphylatoxin (it binds neither C3aR nor C5aR1) but it is not inert: it signals through PAR1 and PAR4 on endothelium and platelets, raising permeability and linking complement to clottingLevel / assay: Typical adult serum 0.1–0.4 g/L; falls early in classical-pathway consumption
Cytokine control: Hepatic acute-phase protein: production rises with IL-6 and IFN-γ
Scene 29
C2
C2 serine protease
Complement
Hepatocytes; also monocytes and macrophagesCleaved on C4b to C2a, the catalytic subunit of the classical/lectin C3 convertase
The most common classical-pathway deficiency in individuals of European ancestry (about 1 in 20,000, mostly type I from a 28-base-pair deletion): pneumococcal sepsis in childhood and lupus-like disease, although around half of those affected remain asymptomatic and the lupus risk is far lower than with C1q or C4 deficiency
Binds C4b on the surface; decayed by DAF (CD55), CR1 and C4BP → C2 → C2a (with C4b) + C2b. Naming: by the current consensus C2a is the larger catalytic fragment and the enzyme is C4b2a; some literature follows the general a-small / b-large rule and writes C4b2b for the same convertaseLevel / assay: Typical adult serum about 0.02 g/L; absent in C2 deficiency with a very low CH50
Cytokine control: Hepatic production rises with IFN-γ and in the acute-phase response
Scene 29

Complement: central component (1)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
C3
C3 (the hub of all three pathways)
Complement
Hepatocytes (over 90% of plasma C3); also monocytes, macrophages, endothelium and epithelium locallyThe central component: cleaved to C3b (opsonin, convertase component) and C3a (anaphylatoxin); spontaneous tick-over initiates the alternative pathway
Low C3 with normal C4 indicates alternative-pathway activation (C3 nephritic factor, factor H or I defect, post-infectious glomerulonephritis); complete C3 deficiency causes severe pyogenic infection and immune-complex disease
C3b binds surfaces covalently and is recognized by CR1 (CD35) and by CRIg, the receptor on Kupffer and other tissue-resident macrophages that clears blood-borne opsonized organisms in the liver, binds C3b and iC3b, and additionally inhibits the alternative pathway; once factor I has cleaved it, iC3b is the ligand for CR3 and CR4; C3dg/C3d is recognized by CR2 on B cells and follicular dendritic cells → C3 → C3b + C3a; C3b + Bb = alternative C3 convertase (amplification loop)Level / assay: Typical adult serum 0.9–1.8 g/L; with C4, the most commonly measured complement protein
Cytokine control: Hepatic acute-phase protein: IL-6, IL-1 and TNF raise production, so C3 can appear normal during consumption
Scene 29, 30

Complement: anaphylatoxins (2)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
C3a
C3a anaphylatoxin (C3a des-Arg after carboxypeptidase N)
Complement
Released on cleavage of C3, at the site of activationMast-cell and basophil activation, smooth-muscle contraction and vascular permeability; also a chemoattractant for eosinophils and mast cells
Contributes to the vascular leak of sepsis and of transfusion and dialysis-membrane reactions
C3aR on mast cells, basophils, eosinophils, monocytes and epithelium; C3aR is also expressed on human neutrophils, but C3a, unlike C5a, is not an effective neutrophil chemoattractant, and in mouse models C3aR signalling restrains neutrophil mobilisation. C3a des-Arg is inactive at C3aR (it is acylation-stimulating protein, a metabolic mediator), whereas C5a des-Arg retains partial activity → C3aR is a Gi-coupled GPCR, like the chemokine receptors of Scene 6Level / assay: Measured as C3a des-Arg in activation studies, not in routine care; rises with any activation, including in vitro activation in an incorrectly handled sample
Cytokine control: Not transcriptionally regulated: its level follows C3 cleavage
Scene 29, 30
C5a
C5a anaphylatoxin (C5a des-Arg after carboxypeptidase N)
Complement
Released when the C5 convertase cleaves C5 at the activating surfaceThe most potent complement anaphylatoxin: neutrophil chemoattraction, adhesion, degranulation and oxidative burst; mast-cell activation; endothelial permeability
A major driver of neutrophil injury in sepsis and ANCA-associated vasculitis (avacopan blocks C5aR1); eculizumab prevents its formation by blocking C5 cleavage
C5aR1 (CD88) on neutrophils, monocytes, mast cells and epithelium; C5aR2 (C5L2) modulates the response → C5aR1 is a Gi-coupled GPCR → PI3K, Rho, Ca²⁺ flux, as for the neutrophil chemokine receptorsLevel / assay: Measured as C5a des-Arg in research settings; terminal-pathway activation is screened functionally (CH50/AH50) instead
Cytokine control: Not transcriptionally regulated: follows C5 cleavage
Scene 30, 33

Complement: alternative pathway (3)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
Factor B
CFB
Complement
Hepatocytes; also monocytes and macrophagesBinds surface C3b and is cleaved by factor D to Bb, forming the alternative C3 convertase C3bBb
Gain-of-function CFB variants cause atypical haemolytic uraemic syndrome and C3 glomerulopathy by stabilizing the convertase; complete deficiency is very rare (a few reported individuals) and causes Neisseria and pyogenic infection. Irrespective of the initiating pathway, the alternative-pathway amplification loop generates the large majority of C3b and of downstream C5b-9, so proximal inhibitors (iptacopan at factor B, pegcetacoplan at C3) also attenuate classical activation
Binds C3b on the activating surface; the convertase is stabilized by properdin → C3bB → C3bBb + Ba (factor D cleaves it)Level / assay: Typical adult serum about 0.2–0.4 g/L
Cytokine control: Hepatic acute-phase protein: production rises with IL-6, IL-1, TNF and IFN-γ
Scene 30
Factor D
CFD (adipsin)
Complement
Adipocytes are the dominant source (it is adipsin); also monocytesThe rate-limiting enzyme of the alternative pathway: cleaves factor B only when B is bound to C3b
Factor D deficiency causes recurrent Neisseria infection with a normal CH50 and an absent AH50; danicopan (Voydeya) inhibits factor D as an add-on for extravascular haemolysis in PNH, alongside iptacopan at factor B and pegcetacoplan at C3
Acts on C3b-bound factor B; circulates in active form, pro-factor D having been cleaved by MASP-3 (with MASP-1) → Cleaves C3bB → C3bBbLevel / assay: Typical adult serum about 1–2 mg/L; the lowest-concentration complement enzyme, and it is catalytically self-inhibited until it engages C3b-bound factor B; both properties account for its rate-limiting role
Cytokine control: TNF-α suppresses CFD transcription in cultured adipocytes, but circulating factor D correlates with fat mass and is higher, not lower, in obesity; it falls with lipoatrophy and weight loss
Scene 30
Properdin
CFP (factor P) — the only positive regulator
Complement
Neutrophils (released from secondary granules), monocytes and T cellsStabilizes the alternative C3 convertase five- to ten-fold, extending its half-life; the only positive complement regulator. Its established role is stabilization of a convertase that has already formed; a primary surface-recognition role is debated
X-linked properdin deficiency predisposes to fulminant meningococcal disease, often fatal in a first episode. Because the disorder is X-linked, the maternal line should be evaluated: the patient should be vaccinated, maternal male relatives tested and carrier females identified, who can have intermediate levels and rarely symptomatic disease
Binds and stabilizes surface C3bBb → Extends the half-life of C3bBb (and C3bBbC3b)Level / assay: Typical adult serum about 5–25 mg/L. Deficiency occurs in three types: I (absent), II (low) and III (dysfunctional with a normal antigenic level), so a normal concentration does not exclude it
Cytokine control: Released from neutrophil granules on activation rather than transcriptionally controlled
Scene 30

Complement: terminal pathway (2)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
C5
C5
Complement
Hepatocytes; also macrophagesCleaved by the C5 convertase into C5a and C5b; C5b initiates membrane-attack-complex assembly
C5 deficiency causes recurrent Neisseria infection; eculizumab and ravulizumab block C5 cleavage and create the same acquired risk, so both MenACWY and MenB vaccination are required at least two weeks before the first dose, risk is reduced rather than abolished (non-groupable Neisseria included) and many centres add continuous antibacterial prophylaxis
C5b binds C6 to begin the terminal pathway → The C5 convertase is the C3 convertase plus an additional C3b, forming C4b2a3b (classical/lectin) or C3bBb3b (alternative), which repositions C5; C5 → C5b + C5a, and C5b6789 = MACLevel / assay: Typical adult serum about 0.07–0.09 g/L; deficiency presents as an absent CH50 and AH50 with normal C3 and C4
Cytokine control: Hepatic acute-phase production with IL-6
Scene 30
C6 / C7 / C8 / C9 (MAC)
C6, C7, C8A/B/G, C9 — the membrane attack complex
Complement
Hepatocytes mainlyAssemble on C5b into the C5b-9 pore that lyses Neisseria and other susceptible cells; sublytic MAC also activates endothelium and the NLRP3 inflammasome
Terminal-pathway (C5–C9) and properdin deficiencies predispose to recurrent Neisseria meningitidis disease, often with unusual serogroups; CH50 and AH50 should be tested in any patient with a second meningococcal episode. C9 deficiency is common in Japan and relatively mild because C5b-8 retains some lytic activity, and complete C6 deficiency is the more frequent terminal-component defect in individuals of African ancestry
Inserts directly into the lipid bilayer; blocked by CD59 on host cells → C5b + C6 + C7 → membrane insertion; C8 then multiple C9 form the poreLevel / assay: Screened functionally, and the pair of assays localizes the defect: an absent CH50 with a normal AH50 indicates a C1, C2 or C4 defect; a normal CH50 with an absent AH50 indicates a factor D, factor B or properdin defect; and absence of both indicates a C3 or terminal-component defect. Complement function is labile in vitro, so a spuriously absent CH50 usually reflects delayed separation or warm storage rather than deficiency; serum should be separated promptly and stored at −70 °C
Cytokine control: Hepatic production rises modestly in the acute-phase response
Scene 30

Complement: regulators (5)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
C1 inhibitor
SERPING1 (C1-INH)
Complement
Hepatocytes mainly; also monocytes and endotheliumSerpin that inactivates C1r/C1s and MASP-1/2, and is the principal inhibitor of plasma kallikrein and factor XIIa; its loss therefore causes bradykinin angioedema rather than a complement-deficiency syndrome
Hereditary angioedema types I and II: low C4 between attacks is the best screening test, with a normal C3; acquired C1-INH deficiency (low C1q) accompanies lymphoproliferative disease. Hereditary angioedema with normal C1-INH (F12, PLG, ANGPT1, KNG1, MYOF) is a recognized diagnostic difficulty, since C4 and C1-INH are both normal and the low-C4 screen is uninformative. Attacks do not respond to antihistamines, corticosteroids or adrenaline: on-demand treatment includes C1-INH concentrate, icatibant and ecallantide (marketed in the United States but not in Canada), and first-line long-term prophylaxis includes plasma-derived C1-INH concentrate, lanadelumab and berotralstat, with danazol a second-line option that is not recommended in children and adolescents before Tanner stage V
Covalently traps the target proteases → Inhibits C1r, C1s, MASP-1, MASP-2, kallikrein, factor XIIaLevel / assay: Typical adult antigenic level 0.15–0.35 g/L with function above about 68% of normal; a function under 50% supports hereditary angioedema and 50–68% is indeterminate and should be repeated. Type II disease has a normal antigenic level and low function, so the functional assay is always required
Cytokine control: Hepatic production rises with IFN-γ; attenuated androgens raise C1-INH and C4 levels by an incompletely understood mechanism (the basis of danazol prophylaxis)
Scene 31
Factor H
CFH (with the CFHR proteins)
Complement
Hepatocytes mainly; also retinal pigment epithelium, endothelium and platelets locallyThe principal fluid-phase and host-surface inhibitor of the alternative pathway: accelerates decay of C3bBb and acts as a cofactor for factor I to cleave C3b; it recognizes host sialic acid and glycosaminoglycans, which is the basis on which host surfaces are spared
Loss-of-function CFH variants and anti-factor-H autoantibodies (often with CFHR1/3 deletion) cause atypical haemolytic uraemic syndrome; the Y402H variant is a major age-related macular degeneration risk allele; complete deficiency results in complete consumption of C3. The phenotype follows the genotype: aHUS mutations cluster in the C-terminal surface-recognition domains (SCR19-20), while C3 glomerulopathy follows loss of N-terminal regulatory function or CFH–CFHR hybrid genes. Eculizumab is first-line for aHUS, and anti-factor-H-antibody disease additionally requires plasma exchange and immunosuppression
Binds C3b with host surface polyanions → Decay acceleration of C3bBb plus factor-I cofactor activityLevel / assay: Typical adult serum 0.2–0.7 g/L; measured with C3, factor I and anti-factor-H antibodies when C3 is low in isolation
Cytokine control: Hepatic production rises with IFN-γ and IL-6
Scene 31
Factor I
CFI
Complement
Hepatocytes; also monocytes and endotheliumThe protease that permanently inactivates C3b to iC3b and C4b to C4c/C4d, using factor H, C4BP, CR1 or MCP as cofactor
Factor I deficiency results in C3 depletion (secondary C3 deficiency) and susceptibility to pyogenic infection; partial defects cause atypical haemolytic uraemic syndrome
Requires a cofactor for activity; iC3b remains a CR3 ligand, so cleavage converts activation into opsonization → C3b → iC3b with factor H, MCP or CR1; the second cleavage of iC3b to C3c plus C3dg (the CR2 ligand) requires CR1 specifically; factor H and MCP cannot serve as cofactors for itLevel / assay: Typical adult serum 0.03–0.06 g/L
Cytokine control: Hepatic acute-phase production with IL-6 and IFN-γ
Scene 31
C4BP / MCP / DAF
C4BPA (C4b-binding protein), CD46 (MCP), CD55 (DAF)
Complement
C4BP from hepatocytes; MCP (CD46) and DAF (CD55) on almost every host cell membranePrevent activation on host surfaces: C4BP is the cofactor for C4b (weakly for C3b) and MCP for both C3b and C4b; DAF dissociates both C3 convertases
CD46 loss of function causes atypical haemolytic uraemic syndrome; an acquired somatic PIGA mutation in an expanded haematopoietic stem-cell clone eliminates DAF and CD59 together in paroxysmal nocturnal haemoglobinuria, where the haemolysis is predominantly CD59-dependent; isolated inherited CD55 loss instead causes CHAPLE disease (protein-losing enteropathy with thrombosis), treated with terminal-pathway blockade (pozelimab). CD46-associated aHUS has the best renal and post-transplant prognosis of the aHUS genotypes
Membrane-anchored (MCP is transmembrane, DAF is GPI-anchored); CD46 is also the receptor for vaccine and laboratory-adapted measles strains (wild-type measles uses CD150/SLAM and nectin-4) and a T-cell co-stimulatory receptor → Decay acceleration (DAF) and factor-I cofactor activity (C4BP, MCP)Level / assay: Membrane regulators are measured by flow cytometry (the PNH panel), not by serum level
Cytokine control: CD46 and CD55 expression rises on activated endothelium and epithelium
Scene 31
CD59
CD59 (protectin, MAC-inhibitory protein)
Complement
GPI-anchored on essentially all host cells, including red cellsBlocks C9 recruitment so the membrane attack complex cannot complete on host membranes
Isolated inherited CD59 deficiency causes haemolysis with childhood neuropathy; with CD55 loss in PNH it causes the intravascular haemolysis that eculizumab prevents
Binds C8 and C9 within the forming complex → Prevents conversion of C5b-8 to a C5b-9 poreLevel / assay: Measured by flow cytometry (FLAER / CD55 and CD59 on red cells and granulocytes)
Cytokine control: Expression rises on endothelium after inflammatory stimuli
Scene 31

Complement: receptors (4)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
CR1 (CD35)
CR1 — complement receptor 1
Complement
Erythrocytes (the largest pool), neutrophils, monocytes, macrophages, B cells, follicular dendritic cells, podocytesImmune-complex clearance: red-cell CR1 transports C3b/C4b-coated complexes to liver and spleen; on phagocytes it binds C3b and C4b for ingestion; it is also a factor-I cofactor and decay accelerator
Low erythrocyte CR1 impairs immune-complex clearance in lupus; CR1 is the Plasmodium falciparum rosetting receptor
Binds C3b and C4b; low-affinity iC3b binding is reported in the primary literature but disputed, and iC3b is the established ligand of CR3, CR4 and CRIg → Phagocytosis with FcγR co-signalling; regulator activity on the same moleculeLevel / assay: Red-cell CR1 copy number is measured in research settings; low in lupus, partly acquired
Cytokine control: Neutrophil surface CR1 rises rapidly on degranulation after C5a, GM-CSF or TNF
Scene 32
CR2 (CD21)
CR2 — complement receptor 2
Complement
B cells and follicular dendritic cellsLowers the B-cell activation threshold by one to three orders of magnitude in model systems (reported 10- to 1000-fold): C3d on antigen co-ligates CR2 with the BCR (the CD19/CD21/CD81 complex); FDC CR2 retains antigen in germinal centres
Human CR2 deficiency is very rare: the first reported patient presented with CVID-like hypogammaglobulinaemia and poor vaccine responses, and a second had a milder phenotype; CD21 is the Epstein–Barr-virus receptor, which links complement to EBV entry
Binds C3dg and C3d, and iC3b (the end-products of C3b breakdown) → CD19 phosphorylation → PI3K with BCR signallingLevel / assay: Assessed by flow cytometry; CD21-low B cells are a recognized CVID phenotype
Cytokine control: IL-21 with TLR9 and chronic B-cell-receptor stimulation drives the CD21-low phenotype
Scene 32
CR3 / CR4
ITGAM/ITGB2 (CD11b/CD18, Mac-1) and ITGAX/ITGB2 (CD11c/CD18)
Complement
Neutrophils, monocytes, macrophages, NK cells, dendritic cells (CR4)The main phagocytic receptor for iC3b-opsonized particles; also the neutrophil adhesion integrin for firm arrest on endothelium
CD18 deficiency (leukocyte adhesion deficiency type 1) causes delayed cord separation, absent pus formation, severe bacterial infection with a high blood neutrophil count; the ITGAM R77H variant is an established lupus risk allele
Binds iC3b, and also ICAM-1, fibrinogen and β-glucan; fibrinogen is a CR3 ligand, through which the acute-phase protein of Scene 36 engages this receptor → Inside-out activation by C5a and chemokines; outside-in signalling → phagocytosis, oxidative burstLevel / assay: Measured as CD18/CD11b expression by flow cytometry in the evaluation of leukocyte adhesion deficiency
Cytokine control: Surface CR3 rises within minutes of C5a, IL-8, TNF or GM-CSF exposure as granules mobilize
Scene 32, 33
C3aR / C5aR1
C3AR1 and C5AR1 (CD88); with C5aR2 (C5L2)
Complement
Neutrophils, monocytes, macrophages, mast cells, basophils, eosinophils; also epithelium and endotheliumConvert complement activation into cell behaviour: chemotaxis, adhesion, degranulation and oxidative burst, and mast-cell mediator release
Avacopan (C5aR1 antagonist) is approved for ANCA-associated vasculitis; C5aR1 blockade spares the membrane-attack complex, unlike anti-C5
Bind C3a and C5a respectively; C5aR2 is non-G-protein-coupled and modulates signalling → Gi-coupled GPCRs → PI3K, Rho GTPases, Ca²⁺ flux (the same signalling pathway as the chemokine receptors of Scene 6)Level / assay: Not a serum measurement; receptor expression falls on neutrophils during sepsis
Cytokine control: C5aR1 expression rises on epithelium and endothelium with IL-1, TNF and IFN-γ
Scene 32, 33

Neutrophil regulation (4)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
Granulopoiesis
marrow production of neutrophils (myeloblast to segmented neutrophil)
Neutrophil
Bone marrow: GMP progenitors under G-CSF, with GM-CSF, IL-3 and SCF; IL-17 and IL-23 raise G-CSF when neutrophils are consumedDetermines the size of the marrow pool: about 6 days from myeloblast to mature neutrophil by modern labelling studies (classical kinetic estimates put the whole sequence nearer 10–14 days), shortened by G-CSF (measured postmitotic marrow transit from about 6.4 to 2.9 days; textbooks commonly quote 1–3 days)
ELANE (most common), HAX1, G6PC3, SRP54, GFI1, JAGN1, VPS45 and gain-of-function WAS (X-linked neutropenia) cause severe congenital neutropenia with promyelocyte maturation arrest in the marrow, usually G-CSF-responsive; acquired CSF3R truncation and RUNX1 mutations identify patients who progress to MDS or AML: cumulative incidence about 22% at 15 years on G-CSF (SCNIR), the annual risk plateauing near 2.3%/year after 10 years, so counts and marrow are monitored
G-CSFR (CSF3R) on progenitors; KIT for SCF; GM-CSFR → G-CSFR → JAK2 / STAT3 (with STAT5) → proliferation and maturationDefining factor: C/EBPα for steady state, C/EBPβ for emergency granulopoiesis; Gfi-1, PU.1Scene 33
Marrow retention and release
the CXCR4 / CXCR2 balance that holds or frees neutrophils
Neutrophil
Marrow stroma produces CXCL12 (SDF-1), which retains CXCR4+ neutrophils; G-CSF lowers CXCL12 and raises CXCR2 ligands (IL-8, GRO-α, ENA-78), releasing themRegulates the blood count from minute to minute: roughly 90% of the body’s neutrophils reside in the marrow reserve, and only a few per cent circulate
WHIM syndrome (gain-of-function CXCR4) retains neutrophils in the marrow, causing myelokathexis with warts and hypogammaglobulinaemia; mavorixafor, an oral CXCR4 antagonist approved by the FDA in 2024 for WHIM from age 12 (not approved in Canada), raises neutrophil and lymphocyte counts, and plerixafor releases them acutely; steroid-induced neutrophilia from demargination and release is the commonly encountered counterpart
CXCR4 (retention) opposed by CXCR2 (release) on the neutrophil surface → Both are Gi-coupled GPCRs (Scene 6); the balance between the two determines whether the cell is retained or releasedDefining factor: Not transcription-factor driven: a receptor-balance switchScene 33
Recruitment to tissue
rolling, arrest and transmigration
Neutrophil
Endothelium activated by TNF-α and IL-1β expresses E- and P-selectin and the chemokines IL-8, GRO-α and ENA-78; C5a is generated by complement activationRecruits neutrophils from blood within minutes: selectin rolling, chemokine- and C5a-triggered integrin activation, firm arrest, then crawling and diapedesis
LAD-1 (ITGB2/CD18) causes delayed cord separation and infection without pus formation; LAD-2 (SLC35C1) adds the growth and developmental delay and Bombay (hh) phenotype of a glycosylation disorder and responds partially to oral fucose; LAD-3 (FERMT3, kindlin-3) adds a Glanzmann-like bleeding diathesis, the clinical discriminator. In all three the blood neutrophil count is elevated because the cells cannot leave the circulation
PSGL-1 and L-selectin for rolling; CXCR1, CXCR2 and C5aR1 for activation; LFA-1 (CD11a/CD18) and Mac-1 / CR3 (CD11b/CD18) for arrest → GPCR → inside-out integrin activation → firm adhesion; outside-in signalling for crawlingDefining factor: Not applicable: a surface-receptor cascadeScene 33
Resolution and clearance
apoptosis, efferocytosis and the end of the response
Neutrophil
Neutrophils die by apoptosis after roughly a day in blood (circulating half-life about 8–19 hours; published estimates range from ~6 hours to several days) and longer in tissue; GM-CSF, G-CSF and IL-8 delay it, whereas loss of survival signal and phagocytosis accelerate itMacrophages ingest apoptotic neutrophils (efferocytosis), which switches the macrophage to a TGF-β and IL-10 programme and terminates recruitment, while the eicosanoid class switch to lipoxins, resolvins and protectins actively terminates the response; when few apoptotic neutrophils are cleared in tissue, macrophage IL-23 production rises and induces IL-17 (largely from γδ T, ILC3 and MAIT cells), which in turn raises G-CSF
Failed apoptotic-cell clearance (C1q deficiency) causes lupus; the IL-23 / IL-17 / G-CSF loop accounts for the rise in G-CSF in neutropenia and for the mild reduction in neutrophil counts with anti-IL-17 agents
Phosphatidylserine on the apoptotic neutrophil recognized by macrophage MerTK (bridged by Gas6 and protein S) and by scavenger receptors; C1q and C3b bridge separately to CR1, CR3 and calreticulin-LRP1 → Efferocytosis → macrophage IL-10 and TGF-β, suppressing IL-23Defining factor: Not applicable
Makes: IL-10
Scene 33, 34

Neutrophil function (3)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
Phagocytosis and killing
opsonin-dependent ingestion, oxidative burst and granules
Neutrophil
Opsonins determine which targets are ingested: IgG through FcγRIIa and FcγRIIIb, and C3b/iC3b through CR1 and CR3; IFN-γ and GM-CSF prime the burstIngests opsonized organisms into a phagosome, assembles NADPH oxidase for superoxide, and discharges primary (myeloperoxidase, elastase), secondary (lactoferrin) and tertiary (gelatinase, MMP-9) granules into it
Chronic granulomatous disease (CYBB, NCF1, NCF2, CYBA, NCF4, CYBC1/EROS) abolishes the burst and predisposes to Staphylococcus aureus, Serratia, Burkholderia cepacia complex, Nocardia and Aspergillus infection with sterile granulomas and colitis (the former catalase-positive rule has been experimentally refuted). Dihydrorhodamine flow cytometry is the diagnostic test and identifies X-linked carriers by its bimodal pattern; residual oxidase activity predicts survival. Myeloperoxidase deficiency is usually benign but gives a falsely abnormal DHR result, because dihydrorhodamine oxidation is itself MPO-dependent; the NBT test remains normal
FcγRIIa (CD32a), FcγRIIIb (CD16b, GPI-anchored and lacking an ITAM; it signals through FcγRIIa and CR3), FcγRI (CD64, induced by IFN-γ or G-CSF), FcαRI (CD89) for IgA, CR1 (CD35), CR3 (CD11b/CD18), C5aR1, fMLP receptor → ITAM → Syk → PI3K and PKC → p47phox, p67phox, p40phox and Rac2 assemble on the membrane flavocytochrome gp91phox (NOX2) with p22phoxDefining factor: Granule contents are preformed and require no transcription; the cytokine output below is transcriptionally induced and modest relative to that of a monocyte
Makes: IL-8, TNFα, BAFF, IL-1RA, IL-1β
Scene 34
NET formation
neutrophil extracellular traps
Neutrophil
Triggered by immobilized antigen, PMA, IL-8, C5a, activated platelets and some bacteria; in many settings it requires NADPH-oxidase-derived ROS and PAD4-driven histone citrullinationReleases chromatin bearing elastase, myeloperoxidase and histones, which traps extracellular organisms; also a source of autoantigen and a driver of thrombosis
NETs externalize MPO and PR3 (the ANCA antigens) and DNA and nucleosomes in lupus, whereas citrullinated histones from the same process are a source of the ACPA antigens of rheumatoid arthritis; NET clearance depends on DNase I and DNASE1L3, and DNASE1L3 loss causes lupus and hypocomplementaemic urticarial vasculitis. NOX2-deficient (CGD) neutrophils form NETs poorly, a defect corrected by gene therapy. NETs also contribute to immunothrombosis in sepsis and severe COVID-19
Downstream of FcγR, CR3, C5aR1 and TLR signalling → ROS and PAD4 → chromatin decondensation → extracellular releaseDefining factor: Not applicableScene 34
Opsonin recognition
what decides whether a neutrophil ingests something
Neutrophil
Opsonins deposited by the adaptive and innate systems: IgG1 and IgG3 (and IgA1 in complexes) from plasma cells, and C3b and iC3b from complement activationBinds opsonized organisms and extends the membrane around them; unopsonized organisms are largely not recognized, so antibody and complement determine which organisms a neutrophil can kill
Neutrophil CD64 rises within hours of bacterial infection and is used as a sepsis marker, especially in neonates; IgA complexes acting on CD89 drive the neutrophil injury of IgA vasculitis
FcγRIIa (CD32a), FcγRIIIb (CD16b, GPI-anchored and lacking an ITAM; it signals through FcγRIIa and CR3), FcγRI (CD64, induced by IFN-γ or G-CSF), FcαRI (CD89) for IgA, CR1 (CD35) for C3b, CR3 (CD11b/CD18) for iC3b → ITAM → Syk → PI3K and PKC; C5a and chemokines activate CR3 by inside-out signallingDefining factor: Not transcription-dependent: the receptors are constitutively expressed on the surfaceScene 34

Acute-phase response: positive reactants (5)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
CRP
C-reactive protein (CRP); a pentameric short pentraxin
Acute-phase
Hepatocytes almost exclusively, driven by IL-6 through STAT3 with IL-1β as a co-signal; transcription rises within hours of the stimulusBinds phosphocholine exposed on damaged membranes, on apoptotic cells and on the pneumococcal C-polysaccharide, then activates the classical complement pathway through C1q and opsonizes the target for FcγRI and FcγRIIa; it is an antibody-independent opsonin
A CRP over about 100 mg/L favours bacterial infection or an abscess, and viral illness is usually lower, but no cut-off separates them reliably and the threshold is population-specific: paediatric febrile-infant rules use the markers only as components of a complete rule. Step-by-Step classifies an infant as low risk only if the child appears well, is older than 21 days, has a negative urine leukocyte esterase, PCT under 0.5 µg/L, CRP 20 mg/L or below and ANC 10 ×10⁹/L or below, so the CRP and PCT thresholds alone do not stratify risk; neonatal sepsis screens use 10 mg/L. Because CRP lags the stimulus by hours, a low value sampled early does not exclude bacterial infection. Newborns have a physiological rise over the first 24–48 hours of life, parallel to PCT, and that response is gestational-age dependent (preterm infants mount a lower and shorter rise), so a neonatal CRP requires both an hour-of-life and a gestation-matched reference. Negative findings are equally informative: CRP remains relatively low in many lupus flares (serositis excepted), which assists in distinguishing flare from infection; it cannot rise during IL-6 blockade, in IL6R or STAT3 defects, or in liver failure, so a normal CRP in those settings provides no information about infection
Recognized by C1q (classical pathway) and by FcγRI and FcγRIIa on phagocytes → IL-6 → JAK1 → STAT3 on the CRP promoter, with NF-κB from IL-1βLevel / assay: Typical adult under about 5 mg/L (laboratories quote 3, 5 or 8); high-sensitivity CRP is the same analyte on a lower-range assay, interpreted as under 1 (low), 1–3 (average) and over 3 mg/L (high) for cardiovascular risk; the 2003 AHA/CDC statement that defined those bands specifies the average of two samples about two weeks apart and regards a value over 10 mg/L as an indication to seek an acute cause rather than as a risk category
Half-life about 19 hours and constant, so the level reflects the current rate of synthesis: it begins to rise by 4–6 hours, doubles roughly every 8 hours, peaks at 36–50 hours, and falls rapidly once the stimulus ceases
Cytokine control: IL-6 is the dominant driver (with IL-1β); IL-6 blockade with tocilizumab or sarilumab abolishes the CRP response
Scene 35, 36
SAA
serum amyloid A (SAA1/SAA2)
Acute-phase
Hepatocytes under IL-1β, IL-6 and TNF-α togetherAn apolipoprotein that redistributes cholesterol during inflammation and recruits monocytes; chronically raised SAA is the precursor protein of AA amyloid, which deposits in kidney, gut and liver
The clinically relevant marker in the periodic fevers: sustained SAA elevation in untreated familial Mediterranean fever, TRAPS or CAPS causes AA amyloidosis, so where the assay is available it is used to confirm that colchicine or anti-IL-1 treatment is adequate between attacks; a normal CRP between attacks does not establish that inflammation is controlled
Binds HDL; signals through FPR2 and TLR2 on monocytes → NF-κB and STAT3 on the SAA promotersLevel / assay: Typical adult under about 10 mg/L, but the assay is not universally available
Among the fastest of the acute-phase rises: up to about 1000-fold within roughly 24 hours, as can CRP, and on serial measurement it rises earlier and falls more rapidly than CRP (human SAA half-life figures are not well established, so the comparison is kinetic rather than pharmacokinetic)
Cytokine control: Driven by IL-1β, IL-6 and TNF-α; anti-IL-1 treatment lowers it markedly in the inflammasome diseases
Scene 35, 36
Fibrinogen
fibrinogen (FGA / FGB / FGG) — a type 2 acute-phase protein
Acute-phase
Hepatocytes under IL-6 through STAT3; a type 2 acute-phase protein, driven by IL-6-family (gp130) signals alone: IL-1β and TNF-α do not add to the IL-6 effect and IL-1β negatively modulates it, unlike CRP, SAA and complement C3, which are type 1 and respond to both. Human haptoglobin is type 2 with fibrinogen, so IL-1β also adds little to it; the type 1 / type 2 distinction is species-dependent and the rat assignments do not apply to humans. A two- to four-fold rise over days rather than hoursThe clotting substrate for thrombin, and the principal protein causing red cells to form rouleaux, which is the phenomenon measured by the ESR
Because fibrinogen determines the ESR, any condition in which it is consumed or not produced (disseminated intravascular coagulation, liver failure, congenital hypo- or dysfibrinogenaemia, thrombolysis) can suppress the ESR despite active inflammation
Binds integrin αIIbβ3 on platelets and CR3 (CD11b/CD18) on neutrophils → IL-6 → STAT3 on the fibrinogen genesLevel / assay: Typical adult 2–4 g/L; rises to 6–10 g/L in sustained inflammation; neonatal values are lower than adult, and in a child with systemic JIA a fibrinogen of ≤3.6 g/L is classified as abnormally low in the 2016 MAS criteria because the acute-phase response would be expected to have raised it
Slow: rises over 24–48 hours and falls over days to weeks, which accounts for the lag of the ESR behind the CRP in both directions
Cytokine control: IL-6-driven, so IL-6 blockade lowers fibrinogen and with it the ESR. At the hepatocyte IL-1β does not add to the IL-6 signal and transiently antagonises it at the promoter, but this does not reverse the clinical direction: because IL-1β drives IL-6, IL-1 blockade also lowers fibrinogen (canakinumab reduced fibrinogen as well as IL-6 and CRP in the CANTOS phase IIb trial), so a falling fibrinogen on anti-IL-1 treatment is expected and not paradoxical
Scene 35, 36, 37
Procalcitonin
procalcitonin (PCT), the prohormone of calcitonin (CALCA)
Acute-phase
Normally only thyroid C cells, which cleave it to calcitonin; in systemic bacterial infection almost every parenchymal tissue transcribes CALCA under IL-1β, TNF-α and IL-6 and releases the uncleaved prohormoneNo established physiological role at these concentrations; it is used as a marker because bacterial products induce it whereas interferon suppresses it
Discriminates bacterial from viral infection better than CRP and is the only marker in this group that IL-6 blockade does not abolish, so it remains interpretable on tocilizumab. It is also raised without infection after major surgery, trauma, burns, cardiac arrest and in medullary thyroid carcinoma
No defined receptor for the prohormone → NF-κB from TLR and IL-1 signalling; type I and type II interferon suppress itLevel / assay: Typical adult under 0.1 µg/L; above about 0.5 µg/L suggests bacterial infection and above 2 µg/L suggests sepsis. Healthy newborns have a large physiological peak at about 24 hours of life (roughly the 18–36 hour window); the 95th centile reaches roughly 20 µg/L in term infants, far above the adult bacterial cut-off, and values return to the adult range by about 48–72 hours on the classic term nomograms, although some series show a slower fall. The fall is later still in preterm infants, in whom values are interpreted against a gestation- and hour-matched nomogram; their peak is reported between 24 and 48 hours (averaging about 36) in preterm reference series, although Chiesa 2011 found an earlier one. It is agreed that the peak resolves more slowly at lower gestational ages; the peak magnitude is disputed, since preterm series report peaks both above and below the term value, with the lowest values in the lowest-birth-weight infants, while their CRP response is correspondingly lower and shorter, so gestational age as well as hour of life must be matched. Within that window PCT must therefore be interpreted against an hour-of-life nomogram and not the adult cut-offs
Half-life about 24 hours; it rises within 3–6 hours and peaks at about 6–24 hours, so it rises earlier than CRP and falls predictably when the infection is treated
Cytokine control: Induced by IL-1β, TNF-α and IL-6; suppressed by IFN-γ and type I interferon, which accounts for comparatively low values in viral illness
Scene 35, 36
Haptoglobin
haptoglobin (HP)
Acute-phase
Hepatocytes under IL-6 through STAT3; a type 2 reactant in humans; a modest two- to three-fold riseBinds free haemoglobin released from lysed red cells and delivers it to macrophage CD163 for clearance
The two effects oppose each other: haemolysis consumes haptoglobin whereas inflammation raises its synthesis, so a normal haptoglobin in an inflamed patient does not exclude haemolysis
Haptoglobin–haemoglobin complexes are cleared by CD163 on macrophages → STAT3 and NF-κB on the HP promoterLevel / assay: Typical adult 0.3–2.0 g/L. Age caveat: newborns usually have no measurable haptoglobin and a low value is physiological through the first 3–6 months, with adult levels reached around 6 months, so haptoglobin cannot be used to assess haemolysis in young infants
Rises over 24–48 hours; falls within hours during brisk haemolysis as it is consumed
Cytokine control: IL-6-driven
Scene 35

Acute-phase response: negative reactants (2)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
Albumin
albumin (ALB) — a negative acute-phase reactant
Acute-phase
Hepatocytes; IL-6 and TNF-α suppress transcription, so the level falls as the positive reactants rise, and capillary leak and expanded plasma volume lower it furtherOncotic pressure and carriage of drugs, calcium, bilirubin and hormones; its fall during inflammation is a marker of the response, not of nutrition alone
A low albumin in an inflamed patient is usually the acute-phase response rather than malnutrition; causes of true protein loss (nephrotic syndrome, protein-losing enteropathy, including the CD55 deficiency of CHAPLE disease) should be excluded before it is attributed to nutrition
No receptor relevant here; FcRn recycles albumin alongside IgG → IL-6 and TNF-α suppress the ALB promoterLevel / assay: Typical adult 35–50 g/L. The effect of age is contrary to expectation: values in term and preterm neonates are lower (term 24–40 g/L in the first week, preterm from about 21 g/L), but from mid-infancy through childhood albumin is at or slightly above the adult interval (about 39–50 g/L), so a borderline-low albumin in a 4-year-old is not an age effect
Long (about 20 days), so a fall is slow and a rise after recovery is slower
Cytokine control: Suppressed by IL-6 and TNF-α
Scene 35
Transferrin and transthyretin
transferrin (TF) and transthyretin / prealbumin (TTR) — negative reactants
Acute-phase
Hepatocytes; both are suppressed by IL-6 and TNF-α during inflammationTransferrin carries iron to the transferrin receptor; transthyretin carries thyroxine and retinol-binding protein. Both fall in inflammation, which distorts the panels in which they are included
A low transferrin during inflammation is not iron overload, and a low transthyretin is not by itself evidence of malnutrition; both reflect the inflammation. When ferritin is uninterpretable, the soluble transferrin receptor (or the sTfR/log-ferritin index) remains a valid measure: transferrin saturation is itself lowered by inflammation, so a low saturation does not establish iron deficiency
Transferrin is recognized by TfR1 (CD71) on erythroid precursors and activated lymphocytes → IL-6 and TNF-α suppress both promotersLevel / assay: Transferrin typically 2.0–3.6 g/L in adults but lower in the neonate (mean about 2.0–2.15 g/L, roughly 1.3–2.8 g/L), exceeding the adult mean by about 10 months and remaining at or slightly above adult values for the rest of childhood; transthyretin typically 0.14–0.35 g/L in adults, about 0.11–0.26 g/L from one month to 12 years and 0.13–0.32 g/L in adolescence, with a wide newborn interval (0.07–0.39 g/L)
Transferrin about 8 days; transthyretin about 2 days, which accounts for its being the most rapidly falling of the negative reactants
Cytokine control: Suppressed by IL-6 and TNF-α
Scene 35, 38

Acute-phase response: iron axis (2)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
Ferritin
ferritin (FTL / FTH1), the iron-storage protein
Acute-phase
Hepatocytes and macrophages; IL-6 and IL-1β raise transcription, and iron raises translation through the iron-responsive elementStores iron in a non-toxic form within cells; the serum form is a secondary marker that rises both with iron stores and with inflammation, which accounts for the difficulty of its interpretation
A normal or high ferritin does not exclude iron deficiency when CRP is raised; transferrin saturation is not a suitable alternative, because it is lowered by inflammation independently, and the soluble transferrin receptor or the sTfR/log-ferritin index, interpreted against a paediatric interval, is used instead. A very high ferritin should prompt consideration of haemophagocytosis, macrophage activation syndrome, Still disease, iron overload or liver injury rather than being interpreted as replete iron stores
Serum ferritin is largely iron-poor L-chain; scavenger receptor SCARA5 (L-ferritin) and TfR1 (CD71), the human H-ferritin receptor, bind ferritin; the murine H-ferritin receptor TIM-2 has no human ortholog → STAT3 and NF-κB on the ferritin genes; IRP1/IRP2 control translationLevel / assay: Wide and laboratory-specific; WHO defines under 12 µg/L below 5 years and under 15 µg/L from 5 years as depleted stores, and under 30 µg/L below five years and under 70 µg/L from five years when inflammation is present (the WHO recommendation text says 30 in children and 70 in adults, but the WHO cut-off table bands the 70 µg/L figure from five years up, adolescents included). The ASH 2026 guideline (Powers, Blood Adv) raises the non-inflamed cutoffs: 20 µg/L or below from 9 months to 4 years (replacing 12), 20 µg/L by indirect evidence from 4 years to adolescence, and 30 µg/L or below in adolescents and adults, including menstruating and pregnant individuals; in adults with anaemia of inflammation it suggests ferritin under 100 µg/L or a transferrin saturation under 20%. It makes no recommendation for children with inflammation, so the WHO 30 µg/L figure continues to apply in that setting; ferritin is very high in the first weeks of life (roughly 150–950 µg/L in the first month) and then falls below the adult interval for the rest of childhood (about 6–110 µg/L from 6 months to adolescence, laboratory-dependent), so it must be interpreted against an age-banded interval in both directions: a value normal for an adult can represent depletion in a neonate, whereas an adult low-normal value may be normal for a 3-year-old. Clinically relevant thresholds: ferritin of 500 µg/L or more is one of the eight HLH-2004 criteria (sensitive, poorly specific); in systemic JIA the 2016 EULAR/ACR/PRINTO criteria classify MAS on ferritin >684 µg/L plus two of platelets ≤181 ×10⁹/L, AST >48 U/L, triglycerides >1.76 mmol/L or fibrinogen ≤3.6 g/L; these criteria apply only to a febrile child with known or suspected systemic JIA, and classify rather than diagnose (sensitivity 0.73, specificity 0.99); and among children whose ferritin was already above 500 µg/L at a single paediatric centre, a ferritin over 10,000 µg/L was 90% sensitive and 96% specific for HLH (Allen 2008, 10 HLH cases in 330 patients); the denominator was selected, so the specificity does not apply to an unselected febrile child, in whom sepsis, haematological malignancy, renal failure and hepatocellular injury account for many values above that level. Values in the tens of thousands are common in MAS but are not the classification threshold
Rises over 24–48 hours with inflammation and falls over days to weeks
Cytokine control: IL-6 and IL-1β raise it independently of iron stores
Scene 35, 38
Hepcidin
hepcidin (HAMP)
Acute-phase
Hepatocytes under IL-6 through STAT3, with the BMP6–SMAD pathway sensing iron storesThe principal iron-regulatory hormone: it degrades ferroportin on enterocytes and macrophages, so dietary iron absorption ceases and iron is sequestered within macrophages, which is the mechanism of the anaemia of inflammation
Accounts for the laboratory pattern of anaemia of inflammation (low serum iron, low transferrin saturation, low or normal transferrin and a normal or high ferritin) and for the poor response to oral iron until the inflammation is treated
Binds and degrades ferroportin (SLC40A1) → IL-6 → STAT3 and BMP6 → SMAD1/5/8 on the HAMP promoterLevel / assay: No universally standardised assay or reference range; interpreted in research and specialist settings rather than routinely
Short, with a rise within hours of an IL-6 signal
Cytokine control: IL-6 is the inflammatory driver; erythropoietic drive through erythroferrone suppresses it
Scene 35, 38

Acute-phase response: tests and indices (1)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
ESR
erythrocyte sedimentation rate (Westergren method) — a physical index, not a protein
Acute-phase
Not synthesised: it is the distance red cells fall in a vertical tube in one hour, and it rises when plasma proteins (chiefly fibrinogen, and to a lesser extent immunoglobulins) bridge red cells into rouleaux that sediment more rapidlyMeasures the net effect of fibrinogen and immunoglobulin on red-cell aggregation, so it is an indirect and slow index of inflammation rather than a mediator
The ESR is interpreted together with the CRP and not as a substitute for it. A high CRP with a normal ESR suggests early inflammation; a high ESR with a normal CRP suggests resolving inflammation, a paraprotein or polyclonal hypergammaglobulinaemia, or anaemia. Raised without inflammation by anaemia, pregnancy, female sex, older age, obesity and renal failure; lowered by polycythaemia, severe hypofibrinogenaemia, and red-cell shape changes such as sickle cells, spherocytes and marked microcytosis. An ESR over 100 mm/h suggests infection, myeloma or another malignancy, giant-cell arteritis, tuberculosis or nephrotic-range renal disease in adults; in children the same value more often indicates osteomyelitis or septic arthritis, Kawasaki disease, systemic JIA and inflammatory bowel disease rather than myeloma or giant-cell arteritis
No receptor: a laboratory measurement → Depends on fibrinogen (IL-6-driven) and on immunoglobulin concentrationLevel / assay: Age- and sex-dependent: Westergren upper limits in adults are under about 15 mm/h for men and 20 mm/h for women below 50 years, rising to about 20 and 30 mm/h over 50, which is approximated by the adult age correction (age ÷ 2 for men, (age + 10) ÷ 2 for women). That formula does not apply to children: paediatric limits are about 0–13 mm/h to age 12 (newborns 0–2 mm/h), with adult limits from around puberty
Rises over 24–48 hours and falls over days to weeks, lagging the CRP in both directions because it follows fibrinogen
Cytokine control: Only indirectly: IL-6 raises fibrinogen, which raises the ESR; IL-6 blockade lowers both
Scene 36, 37

Type 2 and allergic disease (7)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
Omalizumab
omalizumab (Xolair) — humanised anti-IgE IgG1
Biologic or targeted agent
Administered therapeutically; not produced endogenouslyBinds the Cε3 domain of free IgE at the site used by FcεRI, so IgE can no longer bind to mast cells and basophils; receptor-bound IgE is not displaced, so the effect results from the slow loss of surface IgE as receptors turn over, and FcεRI density on basophils and mast cells falls over weeks
Carries a boxed warning for anaphylaxis, which has occurred after a first dose and after more than a year of uneventful treatment: it is administered in a healthcare setting with observation, and for the food-allergy indication an adrenaline auto-injector is prescribed. Licensed for allergic asthma from 6 years, chronic spontaneous urticaria from 12 years, chronic rhinosinusitis with nasal polyps in adults, and, in the USA only, for IgE-mediated food allergy from one year, where it raises the reaction threshold rather than conferring tolerance, so avoidance continues. Also used off-label as adjunctive cover during oral immunotherapy build-up.
IgE → Free IgE falls within hours; surface FcεRI density falls over 1–3 months, which accounts for the delay between dosing and clinical effectWhat it does to the tests: Total IgE rises, often several-fold, and remains elevated for a year or more: the assay measures omalizumab–IgE complexes as well as free IgE, so a rising total IgE on treatment is expected and is not treatment failure. Free IgE is the analyte that falls, and it is not routinely available. Blood eosinophils fall modestly. Skin prick tests and basophil activation tests become unreliable while surface IgE is depleted, and specific IgE in serum is unaffected by the drug but is interpreted against a distorted total.
Made uninterpretable: Total IgE and skin prick testing. For asthma, nasal polyps and food allergy the dose and interval are determined from the pre-treatment total IgE and body weight, so the baseline must be recorded before the first dose and a total IgE measured on treatment cannot be used to revise the dose. Chronic spontaneous urticaria is the exception: dosing is fixed at 150 or 300 mg every four weeks and requires neither value, so treatment should not be delayed to obtain them. If skin testing is required, it must precede treatment or follow a washout of several months.
Canada and the United States: Canada (Xolair, PM Feb 2025; biosimilar Omlyclo): allergic asthma from 6 years, chronic idiopathic urticaria from 12 years, nasal polyps in adults. Asthma dosing is a two-variable lookup on pre-treatment total IgE × weight, 75–375 mg q2w or q4w; the adolescent table starts at 20 kg. United States: the same three indications at the same ages, and the 6–11-year asthma table is identical cell for cell, but the adolescent table starts at 30 kg and adds IgE-mediated food allergy from 1 year (75–600 mg, 10–12 kg upward, IgE 30–1850 IU/mL). Different: food allergy is not authorised in Canada for either Xolair or Omlyclo, so a Canadian prescription for it is off-label with no Canadian dosing table; the US table is the only published authority. Anaphylaxis is boxed in both countries. Devices differ: in Canada the 300 mg syringe and every pen strength are for 12 years and over, so a 6–11-year-old requires the 75 or 150 mg syringe or the vial.
Scene 39
Dupilumab
dupilumab (Dupixent) — human anti-IL-4Rα IgG4
Biologic or targeted agent
Administered therapeutically; not produced endogenouslyBinds IL-4Rα, so it blocks the type I receptor (IL-4Rα + γc, used by IL-4 alone) and the type II receptor (IL-4Rα + IL-13Rα1, used by both IL-4 and IL-13): a single antibody blocks the entire STAT6 arm of type 2 immunity
Atopic dermatitis from 6 months, eosinophilic asthma from 6 years, chronic rhinosinusitis with nasal polyps from 12 years, eosinophilic oesophagitis from 1 year and 15 kg, chronic spontaneous urticaria from 2 years in the USA but only from 12 years in Canada, allergic fungal rhinosinusitis from 6 years with prior sino-nasal surgery and bullous pemphigoid in adults in the USA only, and prurigo nodularis and COPD with type 2 inflammation in adults. Head and neck erythema and conjunctivitis are the characteristic adverse effects; arthralgia and psoriasiform eruptions are recognised.
IL-4; IL-13 → Blocks IL-4 and IL-13 signalling through STAT6; IL-13 can still bind the decoy IL-13Rα2, which partly accounts for the rise in free IL-13 in the bloodWhat it does to the tests: Blood eosinophils often rise in the first weeks to months and then decline; this is the expected result of blocking eotaxin-driven tissue recruitment while IL-5-driven marrow release continues, so the cells remain in the circulation. A rise does not represent treatment failure and is not by itself an indication for discontinuation; a sustained count over about 1.5 × 10⁹/L, and any count with new systemic symptoms, requires evaluation for eosinophilic granulomatosis with polyangiitis or hypereosinophilic disease. FeNO and total IgE fall slowly over months. TARC (CCL17) falls and correlates with atopic-dermatitis activity. CRP and ESR are unaffected and remain interpretable.
Made uninterpretable: Blood eosinophils in the first months, and total IgE as a measure of disease activity.
Canada and the United States: Canada (PM Oct 2026): atopic dermatitis from 6 months, asthma from 6 years, nasal polyps from 12 years, eosinophilic oesophagitis from 1 year and 15 kg, chronic spontaneous urticaria from 12 years, prurigo nodularis and COPD in adults. United States (label Apr 2026): the same, except urticaria from 2 years, plus allergic fungal rhinosinusitis from 6 years with prior sino-nasal surgery and bullous pemphigoid in adults, none of which Canada has authorised. Same: the dermatitis, polyp, oesophagitis, prurigo and COPD ages, the weight bands and the loading rules all match exactly, as do the device age limits (pen from 2 years, syringe from 6 months; under 12 a caregiver injects). Different also in asthma wording: Canada licenses severe type 2 asthma, the USA moderate-to-severe, and Canada alone offers 200 mg q2w or 300 mg q4w for a 30–60 kg child aged 6–11. No boxed warning in either country. Potential source of error: the loading dose is age-dependent and not weight-dependent; there is none under 6 years and none for 6–11-year asthma, but a 6–11-year-old with dermatitis receives a loading dose.
Scene 39
Tralokinumab and lebrikizumab
tralokinumab (Adbry/Adtralza) and lebrikizumab (Ebglyss) — anti-IL-13 IgG4
Biologic or targeted agent
Administered therapeutically; not produced endogenouslyNeutralise IL-13 itself rather than the shared receptor chain, so IL-4 signalling through the type I receptor remains intact; the blockade is narrower than that of dupilumab
Atopic dermatitis in adolescents from 12 years and in adults; the adolescent tralokinumab dose is twice as high in Canada as in the USA (see the licensing note). Useful where dupilumab-associated conjunctivitis or head-and-neck erythema is limiting, since IL-4 signalling is preserved.
IL-13 → Tralokinumab blocks IL-13 binding to both IL-13Rα1 and IL-13Rα2; lebrikizumab blocks the IL-13Rα1 heterodimer while leaving IL-13Rα2 decoy clearance intactWhat it does to the tests: Changes are in the same direction as with dupilumab but are smaller: FeNO and TARC fall, and eosinophils change little. Conjunctivitis occurs but less often than with dupilumab.
Canada and the United States: Tralokinumab: the adolescent dose differs by a factor of two between the two countries, and both positions are current. Canada (Adtralza, PM Mar 2026), 12 years and over: 600 mg load, then 300 mg q2w, which is the full adult dose. United States (Adbry, label Dec 2025), 12–17 years: 300 mg load, then 150 mg q2w, by prefilled syringe only, since the 300 mg autoinjector cannot deliver it. Dosing a Canadian adolescent from an American source, or the reverse, results in a twofold error. The indication and the 12-year floor are the same; Canada permits the q4w step-down in any responder, the USA only in adults under 100 kg. Lebrikizumab (Ebglyss) is the same in the two countries: 12 years and 40 kg, 500 mg at weeks 0 and 2, then 250 mg q2w to week 16; a 12-year-old under 40 kg is off-label in both countries. Different only in maintenance: the USA added 250 mg q8w in June 2026, Canada authorises q4w alone. Neither drug is authorised below 12 years in either country, and Health Canada notes that no paediatric data were submitted for tralokinumab, so there is no Canadian basis for extrapolation to younger ages. No boxed warning.
Scene 39
Mepolizumab and reslizumab
mepolizumab (Nucala) and reslizumab (Cinqair) — anti-IL-5 IgG
Biologic or targeted agent
Administered therapeutically; not produced endogenouslyNeutralise circulating IL-5, so eosinophil production, release from the marrow and survival in tissue all fall; the cells are not killed directly, so the count falls but is not abolished
Mepolizumab: severe eosinophilic asthma from 6 years, hypereosinophilic syndrome from 12 years in the USA but adults only in Canada, and eosinophilic granulomatosis with polyangiitis, chronic rhinosinusitis with nasal polyps and COPD in adults. Reslizumab is intravenous and adults only. Baseline eosinophil count predicts response, so it must be measured before the first dose.
IL-5 → Free IL-5 is neutralised; eosinophil IL-5Rα signalling (JAK2/STAT5) is lostWhat it does to the tests: Blood eosinophils fall by roughly 80–90% within weeks but do not reach zero; tissue eosinophils fall more slowly. CRP, ESR and IgE are unaffected. A persistently normal eosinophil count on treatment does not establish tissue control.
Made uninterpretable: The blood eosinophil count as a measure of disease activity, since on treatment it reflects the drug effect.
Canada and the United States: Mepolizumab (Nucala): asthma is fully concordant, from 6 years in both countries, 40 mg q4w at 6–11 years and 100 mg q4w from 12, and the 40 mg syringe is marketed in Canada. Nasal polyps, COPD and EGPA are adults-only in both. Different: hypereosinophilic syndrome is licensed from 12 years in the USA and in adults only in Canada, so use in an adolescent with idiopathic HES is off-label in Canada. Canada also specifies an eligibility threshold that the US label omits (eosinophils at or above 150/µL at initiation or 300/µL within the past year) and sets a lower inhaled-steroid floor for 6–17-year-olds than for adults. Potential source of error: the asthma dose changes in a single step at the twelfth birthday and is not weight-scaled, and the 100 mg devices cannot deliver a 40 mg dose, so an autoinjector prescribed for a 9-year-old delivers a two-and-a-half-fold overdose. The EGPA and HES dose of 300 mg is given as three separate 100 mg injections. Reslizumab (Cinqair) is identical in the two countries: adults only, 3 mg/kg intravenously q4w over 20–50 minutes, in a setting prepared for anaphylaxis, which is boxed in both countries. It is the only weight-based and only intravenous agent here and the only one with no paediatric licence in either country; the mg/kg dosing does not imply suitability for paediatric use. A malignancy warning appears in the US label; whether the Canadian monograph carries an equivalent was not confirmed.
Scene 39
Benralizumab
benralizumab (Fasenra) — afucosylated anti-IL-5Rα IgG1
Biologic or targeted agent
Administered therapeutically; not produced endogenouslyBinds IL-5Rα, the receptor on the eosinophil, and not the cytokine: the target shown for this entry is IL-5 because the eosinophil is not a catalogued entity in this reference, but the drug leaves IL-5 itself in the circulation and depletes the cell that responds to it. Because the Fc is afucosylated and binds FcγRIIIa with very high affinity, it recruits NK-cell antibody-dependent cellular cytotoxicity: the eosinophil is killed rather than deprived of its survival signal. Basophils, which also express IL-5Rα, are depleted with them
Severe eosinophilic asthma from 6 years in the USA but adults only in Canada, hypereosinophilic syndrome from 12 years (Canada also requires 40 kg), and eosinophilic granulomatosis with polyangiitis in adults. Strongyloides should be screened for and treated before initiation, as with any agent that depletes eosinophils.
IL-5 → Antibody-dependent cellular cytotoxicity through FcγRIIIa on NK cells, in addition to receptor blockadeWhat it does to the tests: Blood eosinophils fall to zero by the first on-treatment measurement at four weeks (and within about a day in the bronchoscopy studies of the mechanism) and remain at zero; depletion is complete, unlike that with the anti-IL-5 antibodies. Basophils also fall. A zero eosinophil count is the expected on-treatment finding and is not in itself a cause for concern, but the count can no longer be used diagnostically, including for the eosinophilia that would otherwise indicate drug reaction, parasitic infection or adrenal insufficiency.
Made uninterpretable: The eosinophil count, for the duration of treatment.
Canada and the United States: The asthma licence differs by twelve years. United States (label May 2026): severe eosinophilic asthma from 6 years (10 mg q4w under 35 kg and 30 mg q4w at or above it for 6–11-year-olds), then 30 mg q4w × 3 doses followed by q8w from 12 years. Canada (PM Aug 2026): asthma in adults only; Health Canada states efficacy and safety are not established below 18 years. Benralizumab for a 9-year-old is therefore on-label in the United States and off-label in Canada; the 10 mg paediatric syringe is not marketed in Canada, so the US dose cannot be delivered from Canadian stock (the 30 mg/mL syringe cannot be divided reliably). EGPA is adults-only in both, 30 mg q4w. Hypereosinophilic syndrome is from 12 years in both, but Canada additionally requires 40 kg, so a 13-year-old of 35 kg is on-label in the USA and off-label in Canada. No boxed warning in either country. Potential source of error: the q4w × 3 then q8w loading pattern applies to asthma only; EGPA and HES remain q4w indefinitely. In the USA the syringe is for clinic use and only the pen is supplied for home use; Canada permits either to be self-administered or administered by a caregiver.
Scene 39
Tezepelumab
tezepelumab (Tezspire) — human anti-TSLP IgG2
Biologic or targeted agent
Administered therapeutically; not produced endogenouslyBlocks TSLP at the origin of the epithelial alarmin cascade, upstream of the type 2 cytokines, so it is effective in asthma independent of eosinophil count or allergic status; it is the only type 2 agent that is not restricted to a type 2 phenotype
Severe asthma from 12 years regardless of phenotype, including low-eosinophil disease, and chronic rhinosinusitis with nasal polyps from 12 years in the USA but adults only in Canada. Because it acts upstream of IL-5 and IL-13, it attenuates several of the markers used to phenotype the patient, so phenotyping must precede treatment.
TSLP → Prevents TSLP binding TSLPR + IL-7Rα, so the downstream OX40L, IL-4, IL-5 and IL-13 programme is not initiatedWhat it does to the tests: Blood eosinophils, FeNO and total IgE all fall. IL-5 and IL-13 in blood fall. Airway hyperresponsiveness falls, an effect not reliably achieved by the other agents.
Canada and the United States: Asthma is identical in the two countries and is among the most complete concordances in this reference: severe asthma from 12 years, 210 mg subcutaneously q4w, flat dose, no loading dose, no weight band and no biomarker threshold. Different for nasal polyps: licensed from 12 years in the USA since October 2025, and in adults only in Canada, which added the indication four months later and still restricted it (a deliberate divergence rather than a delay), so a 15-year-old with refractory polyposis is off-label in Canada. Canada also requires that polyps be inadequately controlled by systemic corticosteroids or surgery. No boxed warning in either country. Devices differ: in the USA the vial and syringe are for clinic administration and only the pen is supplied for home use, whereas Canada permits self- or caregiver-injection generally and does not market the vial; a Canadian adolescent may therefore receive for home use a syringe that in the United States would require clinic attendance.
Scene 39
Nemolizumab
nemolizumab (Nemluvio) — anti-IL-31RA IgG2
Biologic or targeted agent
Administered therapeutically; not produced endogenouslyBlocks the IL-31 receptor A chain on sensory neurons, keratinocytes and immune cells, interrupting the itch signal rather than the inflammation that produced it
Prurigo nodularis in adults, and atopic dermatitis from 12 years. Because it targets the itch pathway specifically, the skin signs can lag the symptomatic response.
IL-31 → Blocks IL-31 signalling through IL-31RA + OSMRβWhat it does to the tests: No reliable effect on eosinophils, IgE or the acute-phase markers, so there is no characteristic laboratory change to monitor. Arthralgia, myalgia and headache are the labelled adverse reactions.
Canada and the United States: The same in the two countries, with no divergence found: atopic dermatitis from 12 years (60 mg as two 30 mg injections at the first visit, then 30 mg q4w, reducing to q8w after 16 weeks in responders, used with a topical steroid or calcineurin inhibitor) and prurigo nodularis in adults only, weight-banded at 90 kg (30 mg q4w below, 60 mg q4w at or above). No weight adjustment for adolescents in either country. No boxed warning. Canada authorised it in December 2025 and the USA in August 2024 for prurigo with dermatitis following that December. Potential sources of error: prurigo is weight-banded and dermatitis is not, so the dose rule changes with the indication in the same patient; the device requires reconstitution, unlike every other subcutaneous agent listed; and although the Canadian monograph describes a prefilled syringe, that presentation was cancelled before marketing, so only the pen is available in Canada.
Scene 39

TNF blockade (2)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
Etanercept
etanercept (Enbrel) — soluble TNFR2 (p75) — Fc fusion protein
Biologic or targeted agent
Administered therapeutically; not produced endogenouslyA decoy receptor rather than an antibody: it binds soluble TNF-α and lymphotoxin-α (TNF-β), which the monoclonal antibodies do not. It binds transmembrane TNF without the sustained cross-linking produced by the monoclonal antibodies, which is the usual, although not established, explanation for its lack of efficacy in granulomatous bowel disease and its lower rate of tuberculosis reactivation
Carries the class boxed warning: serious infection including tuberculosis (testing for latent disease is required before and during treatment), invasive fungal infection (histoplasmosis, coccidioidomycosis and pneumocystosis, where the histoplasma antigen test may be negative), and lymphoma and other malignancies, some fatal, reported in children and adolescents treated with TNF blockers. Screening for latent tuberculosis and hepatitis B is required before initiation. Licensed in the USA for polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis from 2 years and for paediatric plaque psoriasis from 4 years; in Canada for polyarticular juvenile idiopathic arthritis from 4 to 17 years after an inadequate response to a disease-modifying antirheumatic drug and for chronic severe paediatric plaque psoriasis from 4 to 17 years, with no juvenile psoriatic arthritis indication. The paediatric dose in both countries is 0.8 mg/kg weekly to a maximum of 50 mg. In adults it is licensed in both countries for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and plaque psoriasis. It is not effective in Crohn disease, uveitis or sarcoidosis, which is the clearest example in this class that two drugs against the same cytokine are not interchangeable.
TNFα; TNFβ → Neutralises soluble TNF-α and TNF-β before they reach TNFR1 and TNFR2What it does to the tests: CRP, ESR, SAA and fibrinogen all fall, and so does the platelet count; the anaemia of inflammation improves, so haemoglobin rises. Ferritin falls. Because it attenuates the entire acute-phase response, a normal CRP on treatment cannot be used to exclude infection. Anti-nuclear and anti-dsDNA antibodies appear in a minority without clinical lupus.
Made uninterpretable: CRP and ESR as infection markers.
Canada and the United States: Canada (Enbrel, monograph May 2025, plus three biosimilars that carry the same indications and are not restricted): polyarticular JIA from 4 years, paediatric plaque psoriasis from 4 years, and rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and adult psoriasis in adults. United States: polyarticular JIA from 2 years and juvenile psoriatic arthritis from 2 years, neither of which is authorised in Canada, where psoriatic arthritis is an adult-only indication. Paediatric plaque psoriasis is from 4 years in both. Same: the paediatric dose is identical, 0.8 mg/kg weekly to a 50 mg ceiling, as is every adult regimen. A three-year-old with polyarticular JIA is therefore on-label in the USA and off-label in Canada, although the dose is the same in either case. Boxed in both countries, and substantively identical: serious infection and malignancy, with paediatric malignancy named explicitly, namely lymphoma and other malignancies, some fatal, reported in children and adolescents on TNF blockers.
Scene 40
Infliximab, adalimumab and golimumab
infliximab (Remicade), adalimumab (Humira), golimumab (Simponi), certolizumab pegol (Cimzia) — anti-TNF-α monoclonals
Biologic or targeted agent
Administered therapeutically; not produced endogenouslyNeutralise TNF-α only, and bind transmembrane TNF with sustained cross-linking, which delivers reverse signalling and, for the IgG1 agents, complement- and cell-mediated killing of TNF-bearing cells. This accounts for their efficacy in granulomatous disease, in which etanercept is not effective, and for their higher tuberculosis risk
Carries the same class boxed warning as etanercept (serious infection including tuberculosis, invasive fungal infection, and lymphoma and other malignancies reported in children and adolescents). These agents carry the higher tuberculosis risk, as described above, so latent tuberculosis and hepatitis B screening before initiation, with repeat tuberculosis testing on treatment, is of particular importance. Licensed across Crohn disease, ulcerative colitis, juvenile idiopathic arthritis, uveitis and hidradenitis; Behçet disease is not a labelled indication for any of the four agents in Canada or the USA, so that use is off-label. The paediatric licences differ by country. Infliximab: Crohn disease from 9 years in Canada and from 6 years in the USA, and ulcerative colitis from 6 years in both. Adalimumab: polyarticular juvenile idiopathic arthritis from 2 years and ulcerative colitis from 5 years in both countries; Crohn disease from 13 years and 40 kg in Canada but from 6 years in the USA; hidradenitis suppurativa from 12 years, dosed from 30 kg, in both; and uveitis from 2 years, as chronic non-infectious anterior uveitis with methotrexate in Canada and as non-infectious intermediate, posterior and panuveitis in the USA. Golimumab: polyarticular juvenile idiopathic arthritis from 2 years by the intravenous route in both countries, with ulcerative colitis from 15 kg by the subcutaneous route and paediatric psoriatic arthritis from 2 years by the intravenous route in the USA only; the subcutaneous product has no paediatric indication in Canada. Certolizumab: polyarticular juvenile idiopathic arthritis from 2 years in the USA, with no paediatric indication in Canada. Certolizumab has the least placental transfer (negligible in most infants at birth and low in the remainder), so it is the agent that can be continued latest in pregnancy; the IgG1 agents cross from the second trimester, and a live vaccine in an exposed infant, in practice rotavirus or BCG, is deferred, usually to 6 months.
TNFα → Neutralise soluble and transmembrane TNF-α; certolizumab is a PEGylated Fab with no Fc, so it causes no Fc-mediated killing and crosses the placenta minimallyWhat it does to the tests: As for etanercept with respect to the acute-phase markers: CRP, ESR, SAA, fibrinogen, ferritin and the platelet count all fall, and the anaemia of inflammation improves. Faecal calprotectin falls in bowel disease. Anti-drug antibodies develop, particularly with infliximab, and drug levels with anti-drug antibodies are the standard means of investigating loss of response; concomitant methotrexate reduces them.
Made uninterpretable: CRP and ESR as infection markers.
Canada and the United States: Infliximab: paediatric Crohn disease is from 9 years in Canada and 6 years in the USA, so a seven-year-old is on-label in the United States and off-label in Canada, a three-year difference for the most common paediatric indication in this group. Paediatric ulcerative colitis is from 6 years in both countries, and the dose is identical for both bowel indications: 5 mg/kg intravenously at weeks 0, 2 and 6, then eight-weekly. Ankylosing spondylitis maintenance is six- to eight-weekly in Canada and six-weekly in the USA, and Canada alone advises trough-level and antibody measurement when escalating. Boxed in both countries and substantively identical for the whole class: serious infection and tuberculosis, paediatric malignancy by name, and hepatosplenic T-cell lymphoma; almost all reported cases were on concomitant azathioprine or 6-mercaptopurine, and most were adolescent or young adult males with Crohn disease or colitis. This is the boxed statement of greatest paediatric relevance in either country's labelling and should be considered when combination therapy is planned. Certolizumab is the exception in this entry: no paediatric indication in either country.
Scene 40

IL-1 blockade (2)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
Anakinra
anakinra (Kineret) — recombinant human IL-1 receptor antagonist
Biologic or targeted agent
Administered therapeutically; not produced endogenouslyThe recombinant form of the natural antagonist catalogued in this reference as IL-1RA: it occupies IL-1R1 without signalling, so it blocks both IL-1-α and IL-1-β; this is broader than the anti-IL-1β antibodies, which is relevant where IL-1α drives the disease
Licensed in the US for NOMID (neonatal-onset multisystem inflammatory disease) and for deficiency of the IL-1 receptor antagonist (DIRA) with no age or weight floor in either indication. The DIRA cohort started treatment from one month of age, which is relevant because DIRA presents in the neonatal period: the only practical lower bound is the prefilled syringe, which cannot deliver under 20 mg. Rheumatoid arthritis is the adult indication. The floor of 8 months and 10 kg is the European figure and is also the Health Canada NOMID floor, stated in the Canadian indication itself, so in Canada it governs. See the licensing note. Its wide use in systemic JIA and Still disease, macrophage activation syndrome, colchicine-resistant familial Mediterranean fever and recurrent pericarditis is off-label in the US, although well supported and recommended in the 2025 inborn-errors practice parameter for several inflammasome disorders (Scene 45). The short half-life of 4 to 6 hours is an advantage in an acutely unwell child; its effect ceases within a day of discontinuation.
IL-1α; IL-1β → Competitive blockade of IL-1R1, preventing recruitment of IL-1RAcP and NF-κB signallingWhat it does to the tests: CRP, SAA, ferritin and the ESR fall rapidly, often within days; the response is sufficiently rapid to be used diagnostically in suspected macrophage activation syndrome and in the periodic fevers. Neutropenia occurs in a few per cent and requires monitoring. Injection-site reactions are almost universal early in treatment and subsequently resolve.
Made uninterpretable: CRP and SAA as infection markers.
Canada and the United States: The Canadian and US labels differ in their lower age and weight limits. Canada (monograph Aug 2025): NOMID from 8 months and 10 kg (the floor is in the indication itself and not in a footnote) and rheumatoid arthritis in adults. United States (label Oct 2025): NOMID with no age and no weight floor stated, and DIRA likewise with no floor, the DIRA cohort having started from one month of age. DIRA is not an authorised indication in Canada; the term does not appear in the Canadian monograph. In Canada, therefore, both DIRA and any NOMID use below 8 months or 10 kg are off-label, and NOMID typically presents within that age range. In both countries the CAPS licence covers NOMID only: treatment of familial cold autoinflammatory syndrome or Muckle-Wells syndrome with anakinra is off-label in either country. Dosing is numerically identical (start 1–2 mg/kg/day, usual maintenance 3–4, ceiling 8), and Canada alone states the maintenance range and the caveat that data above 5 mg/kg are very limited. Initiation and continuation at 1–2 mg/kg results in under-treatment. The practical lower limit in neonatal DIRA is the syringe: it is graduated 20–100 mg, so a 4 kg neonate requiring 4–8 mg cannot be dosed from it, as both labels state explicitly; this should be addressed at the outset of any neonatal treatment plan. Canada carries a Serious Warnings box (serious infections, anaphylaxis) where the USA has no boxed warning, and Canada has recently added amyloidosis and DRESS to its warnings.
Scene 40
Canakinumab and rilonacept
canakinumab (Ilaris) — anti-IL-1β IgG1; rilonacept (Arcalyst) — IL-1 Trap, which also binds IL-1RA
Biologic or targeted agent
Administered therapeutically; not produced endogenouslyCanakinumab neutralises IL-1β only and has a half-life of 22.9 to 25.7 days, so it provides sustained control with monthly dosing. Rilonacept is a fusion of the IL-1R1 and IL-1RAcP extracellular domains to an Fc, trapping IL-1β with high affinity, IL-1α with lower affinity and the natural antagonist IL-1RA as well, dosed weekly
US labelling: canakinumab covers CAPS from 4 years, limited to familial cold autoinflammatory syndrome and Muckle-Wells syndrome, Still disease including systemic JIA from 2 years and 7.5 kg, and familial Mediterranean fever, TRAPS and hyper-IgD syndrome / mevalonate kinase deficiency in adult and paediatric patients without a stated age; in the USA the 2-year floor applies to Still disease and not to CAPS, and the two are readily transposed. Canadian labelling: CAPS from 2 years, dosed from 15 kg, naming familial cold autoinflammatory syndrome and Muckle-Wells syndrome and permitting use in NOMID/CINCA with the statement that improvement in central nervous system symptoms has not been confirmed; TRAPS, hyper-IgD syndrome / mevalonate kinase deficiency and familial Mediterranean fever, not recommended under 2 years; and Still disease including systemic JIA from 2 years and over 9 kg. In the EU canakinumab is licensed for CAPS from 2 years and 7.5 kg. Rilonacept is licensed in the USA from 12 years for CAPS (familial cold autoinflammatory syndrome and Muckle-Wells syndrome) and for recurrent pericarditis, and for maintenance of remission in deficiency of the IL-1 receptor antagonist from 10 kg; it is not authorised in Canada. The long half-life that makes canakinumab convenient is a disadvantage if infection supervenes.
IL-1β → Canakinumab neutralises free IL-1β; rilonacept traps IL-1β and, less avidly, IL-1αWhat it does to the tests: CRP and SAA fall to normal and remain normal; SAA is the marker used to confirm that control is adequate between attacks in the periodic fevers, because a normal CRP alone does not establish it. Ferritin falls. Neutropenia is less common than with anakinra.
Made uninterpretable: CRP and SAA as infection markers.
Canada and the United States: The CAPS ages and dose ceilings for canakinumab differ, and the difference is large. Cryopyrin-associated periodic syndrome: from 2 years in Canada and 4 years in the USA, and Canada explicitly permits NOMID and CINCA with a CNS caveat while the US CAPS indication does not include them. The escalation ceiling diverges further: Canada allows up to 600 mg above 40 kg or 8 mg/kg between 15 and 40 kg, compared with a US paediatric ceiling of 3 mg/kg, roughly a 2.7-fold difference. Still's disease and systemic JIA are from 2 years in both countries, at 4 mg/kg to a 300 mg maximum four-weekly (identical), but the weight floor differs: above 9 kg in Canada, 7.5 kg and above in the USA. TRAPS, hyper-IgD syndrome and familial Mediterranean fever carry the same dosing in both, with Canada advising against use below 2 years and the USA stating no floor. Gout flares are a US-only indication. The CAPS and Still's disease ages must not be transposed; they differ within each country as well as between them. Neither country applies a boxed warning to canakinumab: no US boxed warning and no Canadian Serious Warnings box, with serious infection leading the ordinary warnings in both. Canada added DRESS in June 2025.
Scene 40

IL-6 blockade (2)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
Tocilizumab and sarilumab
tocilizumab (Actemra) and sarilumab (Kevzara) — anti-IL-6R IgG1
Biologic or targeted agent
Administered therapeutically; not produced endogenouslyBlock the IL-6 receptor, so both classical signalling (membrane IL-6R on hepatocytes and leucocytes) and trans-signalling (soluble IL-6R on any gp130-bearing cell) are inhibited. Because the hepatocyte acute-phase programme is IL-6-dependent, blockade abolishes the laboratory acute-phase response
The two are not interchangeable in children. Tocilizumab covers systemic JIA and polyarticular JIA from 2 years, giant-cell arteritis and rheumatoid arthritis in both countries. For CAR T-cell-induced cytokine release syndrome the US licence is from 2 years, whereas the Canadian indication follows the populations of the authorised CAR T-cell products and safety and efficacy are stated not to be established under 3 years. For COVID-19 in hospitalised patients receiving systemic corticosteroids the US licence is from 2 years and the Canadian licence is for adults only. Sarilumab has no systemic JIA indication; its only paediatric licence is polyarticular JIA at 63 kg and above, in the USA, with no paediatric indication in Canada, and it holds no giant-cell arteritis, cytokine release syndrome or COVID-19 indication. Bowel perforation is the characteristic serious risk and presents without the CRP rise that would normally accompany it; abdominal pain on tocilizumab requires imaging rather than repeat CRP measurement.
IL-6 → Blocks IL-6 binding to IL-6Rα, so gp130 is not recruited and JAK1 → STAT3 signalling does not occurWhat it does to the tests: CRP falls to normal within days and cannot be relied on to rise during treatment, irrespective of the clinical state; the same applies to ESR (through fibrinogen), SAA, haptoglobin, fibrinogen and ferritin. This is among the most consequential laboratory interactions described in this reference: a normal CRP in a child on tocilizumab provides almost no information about infection. Procalcitonin is the least affected and is the preferred marker for monitoring, because bacterial products induce CALCA through pathways that do not require IL-6; this rests, however, on observational data in cytokine release syndrome and COVID-19 rather than on the label, and procalcitonin also rises in non-infectious cytokine release syndrome, so it is the best available marker rather than a specific one. Neutropenia is common and is not usually infection-related. Transaminases rise. Lipids rise. Hepcidin falls, so the anaemia of inflammation improves and iron studies become interpretable. Measured total IL-6 rises on receptor blockade, because the cytokine is no longer cleared through its receptor; a high IL-6 on tocilizumab reflects the pharmacological effect of the drug and not failure of disease control, and for this reason interpretation in this reference is based on the treatment rather than the measured level.
Made uninterpretable: CRP, ESR, SAA, fibrinogen, haptoglobin and ferritin, for the duration of treatment. Procalcitonin, clinical assessment and imaging are used instead.
Canada and the United States: Sarilumab has no paediatric licence in Canada; Health Canada states that no paediatric data have been submitted. Its entire paediatric licence is American and consists solely of a weight band with no stated age: polyarticular JIA at 63 kg or more, which excludes most children who have the disease and exists because the fixed 200 mg syringe cannot be subdivided. The 63 kg indication therefore does not permit on-label prescription of sarilumab to a 65 kg adolescent in Canada. A paediatric indication cannot be inferred from the polymyalgia indication, which is authorised in Canada. Adult rheumatoid arthritis and polymyalgia rheumatica at 200 mg fortnightly are identical in both countries, and neither country licenses systemic JIA, giant-cell arteritis or cytokine release syndrome; these indications are absent in both jurisdictions. Serious infection is boxed in the USA and appears in a Serious Warnings box in Canada, which is substantively the same. The 63 kg threshold is the same value as that for etanercept, for the same device-related reason, which may cause confusion between the two drugs.
Scene 40
Siltuximab
siltuximab (Sylvant) — chimeric anti-IL-6 IgG1
Biologic or targeted agent
Administered therapeutically; not produced endogenouslyNeutralises IL-6 itself rather than its receptor, so the same acute-phase consequences follow; it does not bind viral IL-6, and it is therefore used in HHV-8-negative rather than HHV-8-associated Castleman disease
Idiopathic multicentric Castleman disease in adults; safety and efficacy in children are not established; it is not used in HHV-8-associated disease, because it does not bind viral IL-6. The same loss of infection markers as with tocilizumab applies.
IL-6 → Neutralises free IL-6 before it reaches IL-6RWhat it does to the tests: Identical to tocilizumab: CRP, ESR, fibrinogen, haptoglobin and ferritin are all suppressed and uninterpretable; procalcitonin is preserved.
Made uninterpretable: CRP, ESR and the other IL-6-driven acute-phase markers.
Canada and the United States: Identical in both countries in every respect, and the only agent in this group with no Canada/USA divergence: idiopathic multicentric Castleman disease in patients who are HIV-negative and HHV-8-negative, 11 mg/kg intravenously every three weeks, the same laboratory treatment and retreatment criteria, no dose reduction permitted, no paediatric indication, and no boxed warning in either country. Although the disease occurs in children and adolescents, there is no paediatric indication in either country and the labels contain no paediatric dose or pharmacokinetic guidance, so paediatric use is entirely off-label and without labelled guidance. Both labels require permanent discontinuation, without re-institution, after a severe infusion reaction, anaphylaxis or cytokine release syndrome. Both warn that it masks acute inflammation and suppresses fever and CRP, which is the principal difficulty in assessing a febrile immunosuppressed child.
Scene 40

IL-12, IL-23 and IL-17 blockade (3)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
Ustekinumab
ustekinumab (Stelara) — anti-p40 IgG1
Biologic or targeted agent
Administered therapeutically; not produced endogenouslyBinds the p40 subunit shared by IL-12 and IL-23, so it blocks both the Th1 axis (IL-12 → STAT4 → IFN-γ) and the Th17 axis (IL-23 → STAT3 → IL-17); a single antibody thus blocks two pathways, which accounts for the difference between its infection profile and that of the p19-selective agents
In the USA: plaque psoriasis from 6 years, psoriatic arthritis from 6 years, and Crohn disease and ulcerative colitis from 2 years, dosed from 10 kg; the US paediatric licence thus covers all four indications and not psoriasis alone. In Canada the paediatric licence is for plaque psoriasis alone, from 6 to 17 years where other systemic therapy or phototherapy has given inadequate control or is not tolerated; psoriatic arthritis, Crohn disease and ulcerative colitis are adult indications. Blockade of IL-12 as well as IL-23 distinguishes it from the newer p19 agents; the p19 agents are at least as effective in psoriasis, so the broader blockade is no longer regarded as a clinical advantage.
IL-12p40; IL-12p70; IL-23 → Prevents p40-containing cytokines binding IL-12Rβ1What it does to the tests: CRP and ESR fall where they were elevated by disease activity. No characteristic haematological change. The combined IL-12 and IL-23 blockade resembles inherited IL-12Rβ1 deficiency, so mycobacterial and salmonella susceptibility is the theoretical concern, although it is rarely observed in practice.
Canada and the United States: Canada (Stelara, monograph Aug 2024, and nine biosimilars): plaque psoriasis from 6 years; psoriatic arthritis, Crohn disease and ulcerative colitis in adults only. Health Canada states explicitly that paediatric Crohn and colitis are not established, and Stelara I.V. has not been studied in Canadian children. United States: psoriasis from 6 years, psoriatic arthritis from 6 years, and Crohn disease and ulcerative colitis from 2 years (10 mg/kg intravenous induction in a 10–25 kg child, then 2.5 mg/kg subcutaneously), bands that appear in no Canadian monograph. Different: paediatric inflammatory bowel disease is the principal and substantial difference; American IBD guidance provides paediatric dosing that has no Canadian authorisation, and no Canadian product, originator or biosimilar, covers it. Same: the psoriasis ages and weight bands match, and neither country has a boxed warning. Health Canada's authorisation of a biosimilar is not a declaration of equivalence, and interchangeability is a provincial decision, so substitution in each province follows the provincial formulary and not the federal licence.
Scene 41
Guselkumab, risankizumab and tildrakizumab
guselkumab (Tremfya), risankizumab (Skyrizi), tildrakizumab (Ilumya) — anti-IL-23 p19 IgG1
Biologic or targeted agent
Administered therapeutically; not produced endogenouslyBind the p19 subunit unique to IL-23, leaving IL-12 and the Th1 axis intact; the blockade is narrower than that of ustekinumab and targets the relevant cytokine, since IL-23 maintains pathogenic Th17 cells after their induction
The three are not equivalent: risankizumab covers plaque psoriasis, psoriatic arthritis, Crohn disease and ulcerative colitis, guselkumab the same four indications in both countries, but tildrakizumab is licensed in adults only, for plaque psoriasis in Canada and for plaque psoriasis and psoriatic arthritis in the USA. Guselkumab and risankizumab hold paediatric licences for plaque psoriasis and psoriatic arthritis from 6 years: guselkumab in Canada with weight-banded doses from 12 kg to under 40 kg and the adult dose from 40 kg, but in the USA only at 40 kg or more; risankizumab in both countries at 55 mg under 40 kg and 150 mg at 40 kg or more. The bowel indications of both, and all tildrakizumab indications, are adult only. Preferred over ustekinumab in psoriasis on efficacy, and the preserved IL-12 arm is a theoretical safety advantage.
IL-23 → Prevent IL-23 binding IL-23R, so STAT3-driven RORγt maintenance of Th17 is lost while IL-12 → STAT4 is preservedWhat it does to the tests: CRP and ESR fall where they were elevated by disease activity. Candida infection is less frequent than with the IL-17 agents: IL-23 blockade leaves IL-17 signalling at the receptor intact and spares the IL-17 already produced by differentiated and innate sources, rather than removing the cytokine itself.
Canada and the United States: Guselkumab (Tremfya): Canada has the broader licence. Both countries license psoriasis and psoriatic arthritis from 6 years, but the USA additionally requires 40 kg and has no dose below it, whereas Canada covers 12–39 kg with the variable-dose injector (20 mg at 12–15 kg rising to 45 mg at 31–39 kg). A 25 kg seven-year-old with severe psoriasis can therefore be dosed on-label in Canada and is off-label in the USA. Crohn disease and colitis are adults-only in both, with identical regimens. Canada contraindicates clinically important active infection; the USA does not. Risankizumab (Skyrizi): paediatric psoriasis and psoriatic arthritis from 6 years are identical in the two countries (55 mg under 40 kg, 150 mg at or above, weeks 0 and 4 then q12w), and paediatric IBD is authorised in neither country, despite extensive adult use. Adult Crohn differs: the USA offers an all-subcutaneous induction and 180 or 360 mg maintenance, Canada 360 mg only. Tildrakizumab (Ilumya): adults only in both countries and the only agent in this group with no paediatric authorisation in either country, so it is not a substitute for the other two in a child; psoriatic arthritis was added in the USA in late October 2026 and is not authorised in Canada. No boxed warning on any of the three in either country.
Scene 41
Secukinumab, ixekizumab and bimekizumab
secukinumab (Cosentyx) and ixekizumab (Taltz) — anti-IL-17A; bimekizumab (Bimzelx) — anti-IL-17A and IL-17F; brodalumab (Siliq) — anti-IL-17RA
Biologic or targeted agent
Administered therapeutically; not produced endogenouslyNeutralise IL-17A (and, for bimekizumab, IL-17F as well; brodalumab blocks the receptor and therefore A, F, C, E and the A/F heterodimer). IL-17 induces epithelial antimicrobial peptides, CXCL8 and G-CSF, so its blockade predictably impairs mucosal antifungal defence
Secukinumab has the widest paediatric licence of any agent in these scenes. In the USA: plaque psoriasis from 6 years, psoriatic arthritis from 2 years, enthesitis-related arthritis from 4 years, and ankylosing spondylitis and hidradenitis from 12 years. In Canada: plaque psoriasis, enthesitis-related arthritis and juvenile psoriatic arthritis from 6 years, with ankylosing spondylitis, non-radiographic axial spondyloarthritis and hidradenitis in adults only. Ixekizumab covers psoriasis from 6 years in both countries; bimekizumab and brodalumab are adults only. Mucocutaneous candidiasis is the characteristic adverse effect and is the acquired phenocopy of inherited IL-17 pathway defects (IL17RA, IL17F, ACT1, and the chronic mucocutaneous candidiasis of STAT1 gain-of-function and AIRE autoantibodies). With respect to inflammatory bowel disease the class is not uniform: for secukinumab, ixekizumab and bimekizumab new or worsening disease is a labelled caution rather than a contraindication, so an effective drug need not be withheld from a child with quiescent disease, whereas for brodalumab Crohn disease is a contraindication. Brodalumab also carries a boxed warning for suicidal ideation and behaviour including completed suicides, and is available only through a restricted programme.
IL-17A; IL-17F → Neutralise IL-17A / IL-17F, or block IL-17RA, removing the ACT1 → NF-κB signal in epithelium and stromaWhat it does to the tests: Mild falls in the neutrophil count are expected and follow from the IL-23 / IL-17 / G-CSF loop: reduced IL-17 lowers G-CSF and therefore the neutrophil count; this does not represent drug toxicity and is rarely clinically significant. CRP and ESR fall with disease control.
Canada and the United States: Secukinumab diverges more than any other agent in this reference. Plaque psoriasis is identical: from 6 years, 75 mg under 50 kg and 150 mg at or above, loaded weekly at weeks 0 to 4. All other indications differ: psoriatic arthritis is from 2 years and 15 kg in the USA and 18 years in Canada (Canada names juvenile psoriatic arthritis separately, from 6 years); enthesitis-related arthritis from 4 years in the USA and 6 in Canada; ankylosing spondylitis from 12 years in the USA and 18 in Canada; hidradenitis from 12 years and 30 kg in the USA and 18 in Canada. The intravenous route is not available in Canada, and Canada alone requires prior hepatitis B screening. Use in a four-year-old with enthesitis-related arthritis, as described in American publications, is off-label in Canada. In addition, the US paediatric bands carry a 15 kg lower bound whereas the Canadian juvenile bands state none, so ‘under 50 kg, 75 mg’ could be misinterpreted as applying to a toddler. Ixekizumab (Taltz): paediatric psoriasis from 6 years in the two countries, with the same bands; however, only the 80 mg presentation is available in Canada, so the 20 mg and 40 mg paediatric doses must be prepared from it by a health professional at every visit, which precludes home administration below 50 kg in Canada. This is a difference in delivery and not in dose. Bimekizumab (Bimzelx): identical in the two countries, adults only, with no paediatric licence in either; no inference should be drawn from the IL-17A agents. The US label carries a suicidal-ideation warning that the Canadian monograph does not. Brodalumab is a separate case (see its own entry).
Scene 41

T-cell and B-cell directed (3)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
Abatacept
abatacept (Orencia) — CTLA-4-Ig fusion protein
Biologic or targeted agent
Administered therapeutically; not produced endogenouslyBinds CD80 and CD86 on antigen-presenting cells, so the CD28 costimulatory second signal is not delivered and T cells are not fully activated; it acts at the initiation of the response rather than on any single cytokine
In the USA: polyarticular JIA from 2 years (subcutaneously from 2 years, intravenously from 6 years), psoriatic arthritis from 2 years, rheumatoid arthritis in adults, and prophylaxis of acute graft-versus-host disease from 2 years. In Canada: polyarticular JIA from 6 years by intravenous infusion only, with no paediatric subcutaneous indication, rheumatoid arthritis and psoriatic arthritis in adults, and prophylaxis of acute graft-versus-host disease from 6 years. In inborn errors of immunity it is the precision agent for CTLA-4 haploinsufficiency and LRBA deficiency, where it replaces the deficient CTLA-4 inhibitory function (Scene 46). Live vaccines should not be given with it or within three months of stopping, and it should not be combined with a TNF inhibitor. Because it attenuates rather than abolishes responses, infection risk is lower than with the cytokine blockers.
Th1; Th17; Tfh → Competitive blockade of CD28 costimulation, reproducing the physiological inhibition exerted by CTLA-4What it does to the tests: No characteristic laboratory change; CRP and ESR fall with disease control. T-dependent vaccine responses are attenuated, so serological protection cannot be assumed and post-vaccination titres should be measured.
Made uninterpretable: Vaccine serology as proof of protection.
Canada and the United States: The divergence for abatacept is almost entirely paediatric. Adult rheumatoid arthritis and intravenous polyarticular JIA from 6 years at 10 mg/kg are identical. The subcutaneous route in juvenile arthritis, however, is licensed from 2 years in the USA, at 50, 87.5 or 125 mg weekly by weight, and is not authorised at any age in Canada, where the 50 mg and 87.5 mg syringes are not marketed. A Canadian child with polyarticular JIA therefore cannot receive weekly subcutaneous abatacept on-label: monthly infusions from 6 years are the only authorised route. Subcutaneous abatacept in a three-year-old, as assumed in American guidance, is off-label in Canada and the required devices are not available. Psoriatic arthritis is from 2 years in the USA and adults-only in Canada. For acute graft-versus-host disease prophylaxis the regimens differ by age, which is the most important potential source of error: Canada licenses it from 6 years at 10 mg/kg, whereas the USA licenses it from 2 years and specifies a higher regimen for 2–under-6-year-olds, 15 mg/kg then 12 mg/kg × 3; use of the 10 mg/kg dose in a three-year-old is therefore an under-dose relative to the only label that studied that age. Infusion time is 30 minutes for arthritis and 60 for graft-versus-host disease in both countries. Warnings differ in the opposite direction to that usually seen: Canada has a Serious Warnings box (anaphylaxis, infection, tuberculosis) and contraindicates use in HIV-positive and immunocompromised patients, while the US label has no boxed warning and states no contraindications.
Scene 41
Rituximab
rituximab (Rituxan/MabThera) — chimeric anti-CD20 IgG1
Biologic or targeted agent
Administered therapeutically; not produced endogenouslyDepletes CD20-positive B cells from the pre-B stage to the memory B cell by complement-dependent and antibody-dependent killing. CD20 is lost as the cell differentiates into an antibody-secreting cell (it is low and variable on plasmablasts and absent from long-lived plasma cells), so existing antibody is initially spared and the fall in immunoglobulin is gradual; the long-lived plasma cell compartment maintains vaccine-derived antibody
Carries a boxed warning with four parts: fatal infusion reactions, most often with the first infusion; severe and sometimes fatal mucocutaneous reactions; hepatitis B reactivation, which makes screening mandatory; and progressive multifocal leukoencephalopathy, including fatal cases, which is the risk of greatest importance to disclose when obtaining consent from a family. Licensed in the USA for mature B-cell non-Hodgkin lymphoma and mature B-cell acute leukaemia from 6 months, for ANCA-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis) from 2 years, and in adults for non-Hodgkin lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis and pemphigus vulgaris. In Canada the reference product is licensed in adults only, for non-Hodgkin lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis and induction of remission in granulomatosis with polyangiitis and microscopic polyangiitis; it has no paediatric indication and no pemphigus vulgaris indication, so those uses are off-label in Canada. Used off-label in both countries for nephrotic syndrome, autoimmune cytopenias and neuromyelitis optica. Immunoglobulins and B-cell numbers should be measured before each course and monitored afterwards.
Transitional B cell; Naive follicular B cell; Memory B cell; Germinal-centre B cell → Complement-dependent cytotoxicity and FcγRIIIa-mediated killing of CD20+ B cellsWhat it does to the tests: B cells are depleted from the blood within days and return at 6 to 12 months. IgM falls first and to the greatest extent; IgG falls later and in a minority remains low for years (persistent hypogammaglobulinaemia, more likely with repeated courses, with prior immunosuppression, and in children). Specific antibody titres fall. Vaccine responses are lost while B cells are absent, so immunisation must precede treatment by at least 4 weeks where possible, and live vaccines are contraindicated. Late-onset neutropenia can occur months after the last dose.
Made uninterpretable: Vaccine serology, B-cell-dependent diagnostic testing, and any attempt to diagnose an antibody deficiency while the drug is active; the immunological evaluation must precede treatment.
Canada and the United States: Canada (Rituxan, monograph Jun 2023; Rituxan SC also marketed): adult lymphoma and leukaemia, adult rheumatoid arthritis after a TNF inhibitor, and ANCA-associated vasculitis in adults, induction only. United States: the same adult indications plus paediatric mature B-cell lymphoma and B-cell acute leukaemia from 6 months at 375 mg/m² with chemotherapy, granulomatosis with polyangiitis and microscopic polyangiitis from 2 years with a defined follow-up regimen (250 mg/m² in children), and pemphigus vulgaris in adults, none of which Canada has authorised. Different also in what is boxed: the USA boxes severe mucocutaneous reactions and hepatitis B reactivation alongside infusion reactions and PML, while Canada boxes infusion reactions, PML and an experienced-prescriber requirement but neither of the other two, although hepatitis B screening appears elsewhere in the monograph. Canada contraindicates prior or current PML and hypersensitivity to murine protein; the US label states no contraindications. Same: neither country restricts distribution. Hypogammaglobulinaemia that can persist for years and prolonged B-cell aplasia are recognised in children; immunoglobulins should be measured before and after treatment in either country.
Scene 41
Belimumab
belimumab (Benlysta) — human anti-BAFF (BLyS) IgG1
Biologic or targeted agent
Administered therapeutically; not produced endogenouslyNeutralises soluble BAFF, the survival factor on which transitional and naive B cells depend, so the autoreactive transitional cells that normally die at that checkpoint are not rescued; the effect is selective pressure on the newly formed B-cell pool rather than depletion
Systemic lupus erythematosus from 5 years and lupus nephritis from 5 years in both countries. The licensed routes differ: in Canada paediatric lupus nephritis is treated by the intravenous route only, subcutaneous use in lupus nephritis being restricted to adults, while subcutaneous use in paediatric systemic lupus erythematosus is from 15 kg; in the USA subcutaneous dosing from 15 kg is licensed from 5 years for both indications. The complement and anti-dsDNA response is used to monitor treatment.
BAFF → Neutralises BAFF before it reaches BAFF-R, TACI and BCMAWhat it does to the tests: Naive and transitional B cells fall over months; memory B cells and plasma cells are relatively spared, so immunoglobulins fall only modestly. Anti-dsDNA titres fall and complement C3 and C4 rise towards normal as consumption diminishes; this is one of the few agents listed that raises complement levels.
Canada and the United States: The same in the two countries for the relevant ages: systemic lupus from 5 years, and 10 mg/kg intravenously every two weeks for three doses then monthly. The subcutaneous paediatric bands represent a true difference in dosing and not a difference in wording: Canada has three (weekly at 50 kg and above, every ten days at 30–under-50 kg, fortnightly at 15–under-30 kg) and the USA has two (weekly at 40 kg and above, fortnightly at 15–under-40 kg). A 35 kg eleven-year-old is dosed every ten days in Canada and every fourteen in the USA. Lupus nephritis also diverges: it is licensed subcutaneously from 5 years in the USA and not below 18 years in Canada, so a Canadian child with nephritis remains on monthly infusions. Warnings again differ in the opposite direction: Canada boxes infusion reactions, serious infection including PML, and depression and suicidality, whereas the USA has no boxed warning but includes an instruction to assess for depression and suicide risk before initiation and to monitor during treatment. Since August 2026 the USA contraindicates prior anaphylaxis, Stevens-Johnson syndrome or toxic epidermal necrolysis to belimumab; Canada does not list these.
Scene 41

Interferon blockade (2)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
Anifrolumab
anifrolumab (Saphnelo) — anti-IFNAR1 IgG1
Biologic or targeted agent
Administered therapeutically; not produced endogenouslyBlocks the type I interferon receptor, so the type I interferons (the IFN-α subtypes, IFN-β, IFN-ω and the less-studied IFN-κ and IFN-ε) are blocked together. The interferon signature that defines a large subgroup of lupus is suppressed
Moderate-to-severe systemic lupus erythematosus in adults; no paediatric licence. Its mechanism is the converse of that of the type I interferonopathies (STING, TREX1, IFIH1), in which the same pathway is pathologically activated.
IFNα2; IFNβ; IFNω → Blocks IFNAR1, preventing JAK1/TYK2 → STAT1/STAT2/IRF9 (ISGF3) assemblyWhat it does to the tests: The 21-gene interferon signature is neutralised by at least 80% from about week 4 and through the first year, which is the pharmacodynamic measure reported in the label; where the assay is available it is the marker used for monitoring. Anti-dsDNA falls and C3 and C4 rise with disease control. Herpes zoster is the characteristic infection and respiratory viral infections are more frequent, which is the predictable consequence of type I interferon blockade.
Made uninterpretable: The interferon signature as a measure of disease rather than of drug.
Canada and the United States: The same in the two countries: adults only, for active autoantibody-positive systemic lupus on standard therapy, 300 mg intravenously over 30 minutes every four weeks, with a subcutaneous option of 120 mg weekly by autoinjector added in 2026 (April in the USA, March in Canada). Health Canada states that no paediatric data are available to it, so no paediatric indication exists; the USA likewise has not established paediatric use. Neither country recommends it in severe active lupus nephritis or severe CNS lupus. No boxed warning in either country. Switching between routes requires a washout in either country: about two weeks from the last infusion before the first injection, and three to four weeks in the reverse direction.
Scene 42
Emapalumab
emapalumab (Gamifant) — anti-IFN-γ IgG1
Biologic or targeted agent
Administered therapeutically; not produced endogenouslyNeutralises free and receptor-bound IFN-γ, the cytokine that drives the macrophage activation of haemophagocytic lymphohistiocytosis; it is the only agent in this reference directed at that final common pathway
Licensed in the USA only; it is not authorised in Canada, where the submission was withdrawn by the sponsor in January 2021 before a decision was issued. Primary haemophagocytic lymphohistiocytosis refractory to, intolerant of or recurrent on conventional therapy, from birth, and also HLH / macrophage activation syndrome in known or suspected Still disease where glucocorticoids have failed or MAS has recurred, which makes it directly relevant to systemic JIA as described elsewhere in this reference. The label names the organisms favoured by neutralisation of IFN-γ as mycobacteria, herpes zoster and Histoplasma capsulatum: latent tuberculosis is evaluated and tested for before initiation and treated if present, and prophylaxis is given against herpes zoster, Pneumocystis jirovecii and fungal infection. Salmonella susceptibility is a feature of the inherited IFN-γ-axis phenotype rather than of this drug.
IFNγ → Neutralises IFN-γ before and after it engages IFN-γR1What it does to the tests: CXCL9 (MIG) falls and is the marker used for monitoring; CXCL9 is interferon-induced and reflects IFN-γ activity better than ferritin. Total IFN-γ measured by immunoassay rises, because the drug–cytokine complex is still detected; this is expected and is not treatment failure. Ferritin, soluble CD25 and the transaminases fall with response.
Made uninterpretable: Measured IFN-γ levels. CXCL9 is used instead.
Canada and the United States: Not authorised in Canada; the product was not left unexamined: the submission for primary haemophagocytic lymphohistiocytosis was cancelled by the sponsor in January 2021 before Health Canada issued a decision, with clinical deficiencies identified that would have prevented approval. No Canadian decision was issued, so Canadian access is through the Special Access Programme only, which is the most important consideration regarding this drug in Canadian paediatric immunology practice. Whether a new submission has been filed since, and current Special Access availability, were not confirmed. United States (label Mar 2026): primary HLH in adults and children of any age with refractory, recurrent or progressive disease or intolerance of conventional therapy, and (added June 2025) HLH/macrophage activation syndrome in known or suspected Still's disease including systemic JIA, where glucocorticoids have failed or MAS has recurred. The two indications use different regimens, which is a potential source of prescribing error. Zoster, Pneumocystis and fungal prophylaxis are given, and the IFN-γ-dependent tests become uninterpretable.
Scene 42

Complement blockade (4)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
Eculizumab and ravulizumab
eculizumab (Soliris) and ravulizumab (Ultomiris) — anti-C5; pozelimab (Veopoz) — anti-C5, licensed for CHAPLE disease alone
Biologic or targeted agent
Administered therapeutically; not produced endogenouslyBind C5 and prevent its cleavage, so neither the C5a anaphylatoxin nor the C5b that nucleates the membrane attack complex is generated. All upstream events (C3 cleavage, C3b opsonisation, the amplification loop) continue unaffected
Eculizumab and ravulizumab: paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome, and generalised myasthenia gravis and NMOSD in adults. Paediatric cover differs by agent and country: ravulizumab is licensed for both haemolytic indications from one month of age in both countries; eculizumab is licensed for both in children from 5 kg in Canada, whereas in the USA its paediatric use is established for atypical haemolytic uraemic syndrome and for generalised myasthenia gravis from 6 years, and paediatric safety and effectiveness in paroxysmal nocturnal haemoglobinuria are not established. Pozelimab is not interchangeable with them: its only licensed indication is CD55-deficient protein-losing enteropathy (CHAPLE disease) from one year of age, the condition described in this reference under the complement regulators, and it has none of the other three indications; it is licensed in the USA and is not authorised in Canada. All three carry a boxed warning for serious meningococcal infection and are available only through a restricted programme. The class creates an acquired terminal-pathway defect, so meningococcal ACWY and B vaccination at least two weeks before initiation, with antibiotic prophylaxis, is mandatory; these are the same precautions described in this reference for inherited C5 to C9 deficiency. Vaccination does not eliminate the risk; breakthrough meningococcal disease occurs in vaccinated patients.
C5; C5a → Blocks C5 convertase cleavage of C5; ravulizumab adds pH-dependent recycling for 8-weekly dosingWhat it does to the tests: CH50 and AH50 both become undetectable: C5 is a terminal component and both haemolytic assays require C5 to C9, so its blockade abolishes both; this finding confirms adequate blockade and does not indicate a complement deficiency. C3 and C4 are unchanged, because the blockade is distal to them, so a normal C3 and C4 on treatment provides no information about drug effect. Free eculizumab levels and the modified Ham test are used where available. LDH falls in paroxysmal nocturnal haemoglobinuria; extravascular haemolysis with C3 loading on red cells may continue.
Made uninterpretable: CH50 as a test for complement deficiency, and C3/C4 as a measure of blockade.
Canada and the United States: Eculizumab shows the most marked reversal of the usual pattern in this reference, in the direction opposite to that generally assumed. Paroxysmal nocturnal haemoglobinuria: Canada has a paediatric indication, down to 5 kg since August 2025, and the USA does not; US paediatric PNH use is off-label. Generalised myasthenia gravis differs in the opposite direction: from 6 years in the USA, adults only in Canada. Atypical HUS is the same in both, with identical weight bands from 5 kg and STEC-HUS excluded; neuromyelitis optica is adults only in both. Ravulizumab is identical in the two countries (PNH and atypical HUS from one month, myasthenia and neuromyelitis optica in adults, with every weight band, loading dose and interval matching), except that IgA nephropathy is a US-only accelerated approval in adults. Pozelimab is not authorised in Canada: no Health Canada record exists under any status, so a Canadian child with CHAPLE disease requires the Special Access Programme. In the USA it is licensed for CHAPLE only, from one year. Vaccination: meningococcal ACWY and B at least two weeks before the first dose in both countries, with antibiotic cover if treatment cannot be delayed; Canada additionally mandates prophylaxis for every child under two years until two weeks after vaccination, which the US label does not. Two eculizumab biosimilars are marketed in the USA and none in Canada.
Scene 42
Pegcetacoplan
pegcetacoplan (Empaveli in Canada and the USA; Aspaveli elsewhere) — PEGylated C3-binding peptide
Biologic or targeted agent
Administered therapeutically; not produced endogenouslyBinds C3 and C3b, blocking cleavage at the level of the convertase itself, so it inhibits the alternative amplification loop as well as the terminal pathway; this proximal blockade also prevents the C3 loading responsible for extravascular haemolysis on C5 inhibitors
Carries a boxed warning for serious infection caused by encapsulated bacteria and is available only through a restricted programme. Licensed for paroxysmal nocturnal haemoglobinuria in adults, and for C3 glomerulopathy and primary immune-complex MPGN from 12 years. Blockade at C3 abolishes opsonisation as well as the terminal pathway, so the encapsulated-organism risk is broader than with C5 blockade: pneumococcal, meningococcal and Haemophilus influenzae type b vaccination are all required.
C3 → Binds C3/C3b, preventing convertase cleavage of C3What it does to the tests: Measured C3 rises steeply, which is the most common source of misinterpretation with this drug: with convertase cleavage blocked, C3 is no longer consumed, and drug-bound C3 accumulates. The label reports a mean rise from 94 mg/dL at baseline to 380 mg/dL by week 16 in paroxysmal nocturnal haemoglobinuria, and from 62 to 371 mg/dL by week 26 in C3 glomerulopathy. A C3 of several hundred mg/dL on this drug reflects the pharmacological effect of treatment and is neither an artefact nor evidence of a different diagnosis. CH50 and AH50 both fall. Haemoglobin rises further than on C5 blockade in paroxysmal nocturnal haemoglobinuria, because extravascular haemolysis is also prevented.
Made uninterpretable: The C3 level as a measure of disease, and both pathway assays.
Canada and the United States: The same in the two countries for the relevant age: C3 glomerulopathy and immune-complex MPGN from 12 years, and paroxysmal nocturnal haemoglobinuria in adults with no paediatric indication in either. Trade names differ: Empaveli in the USA, Aspaveli elsewhere. Vaccination is broader than for the anti-C5 agents because blockade of C3 abolishes opsonisation as well as the terminal pathway: pneumococcal and meningococcal ACWY and B at least two weeks before the first dose in both countries, and Canada additionally requires Haemophilus influenzae type b per NACI. The direction of the C3 result should be noted: C3 rises steeply on treatment, because the drug prevents consumption, so a rising C3 is the expected response and does not represent treatment failure.
Scene 42
Iptacopan and danicopan
iptacopan (Fabhalta) — factor B inhibitor; danicopan (Voydeya) — factor D inhibitor
Biologic or targeted agent
Administered therapeutically; not produced endogenouslyOral small molecules that block the alternative pathway specifically, at factor B or at factor D, the two components of the amplification loop, leaving the classical and lectin pathways functional
Adults only. Paroxysmal nocturnal haemoglobinuria (iptacopan as monotherapy, danicopan added to a C5 inhibitor for extravascular haemolysis), and C3 glomerulopathy for iptacopan in both countries, with IgA nephropathy for iptacopan in the USA only. Both carry a boxed warning for serious infection with encapsulated organisms and both are available only through a restricted programme; vaccination against meningococcus, pneumococcus and Haemophilus influenzae type b is required before initiation, as for any alternative-pathway blockade.
Factor B; Factor D → Inhibit factor B or factor D, preventing assembly and activity of the alternative C3 convertase C3bBbWhat it does to the tests: AH50 falls to near zero while CH50 is relatively preserved, the converse of classical-pathway blockade with sutimlimab, in which CH50 falls and C4 recovers. It is not the converse of C5 blockade: C5 is a terminal component and both haemolytic assays require C5 to C9, so a C5 inhibitor abolishes CH50 and AH50 together (Scene 30). Measured C3 also rises as consumption ceases (the iptacopan label reports 23 to 80 mg/dL by day 14 in C3 glomerulopathy), although less steeply than on pegcetacoplan. The near-zero AH50 is inferred from the pathway as described in this reference rather than taken from the label, which uses an alternative-pathway activity assay and plasma Bb as its pharmacodynamic markers.
Made uninterpretable: AH50, and the C3 level as a measure of disease.
Canada and the United States: Iptacopan (Fabhalta) is the same in the two countries: paroxysmal nocturnal haemoglobinuria and C3 glomerulopathy in adults at 200 mg twice daily, with no paediatric indication at any age in either. Different: IgA nephropathy is a US-only indication (full approval July 2026) and is not authorised in Canada. Danicopan (Voydeya) is identical in the two countries: add-on to ravulizumab or eculizumab in adults with residual extravascular haemolysis, 150 mg rising to 200 mg three times daily, with no paediatric use in either country. Different only in risk-management arrangements: the USA operates a formal risk-management programme for danicopan and the Canadian monograph describes none, whereas Canada alone instructs tapering on discontinuation and names Haemophilus influenzae type b in its warnings box. Each requires pneumococcal and meningococcal vaccination two weeks beforehand, with Hib recommended in Canada. Neither is currently authorised for children, which is the relevant consideration in paediatric practice.
Scene 42
Avacopan and sutimlimab
avacopan (Tavneos) — C5aR1 antagonist; sutimlimab (Enjaymo) — anti-C1s IgG4
Biologic or targeted agent
Administered therapeutically; not produced endogenouslyAvacopan blocks C5aR1, the C5a receptor on the neutrophil, rather than C5a itself (the target shown is C5a because that is the catalogued entity), so the chemotactic and priming signal is lost while the membrane attack complex is preserved; the terminal-pathway infection risk is therefore not created. Sutimlimab blocks C1s and so inhibits the classical pathway at its first enzyme
Avacopan: ANCA-associated vasculitis in adults, where it allows steroid sparing; hepatotoxicity requiring scheduled liver-function monitoring, hepatitis B reactivation and angioedema are its labelled cautions. Sutimlimab: cold agglutinin disease in adults, licensed in the USA and not authorised in Canada; it carries the same encapsulated-organism requirement as the other complement agents, namely vaccination against Streptococcus pneumoniae, Haemophilus influenzae type b and Neisseria meningitidis serogroups A, C, W, Y and B at least two weeks before the first dose, because blockade of C1s abolishes classical-pathway opsonisation, and vaccination does not eliminate the risk. Avacopan is the only complement agent listed that does not create a terminal-pathway defect.
C5a; C1r / C1s → Avacopan: competitive antagonism of C5aR1. Sutimlimab: blocks C1s protease activity in the C1 complexWhat it does to the tests: Avacopan: no routine complement assay changes, since C5 cleavage is unaffected and CH50 remains normal; liver enzymes require scheduled monitoring. Sutimlimab: C4 rises towards normal as classical-pathway consumption ceases (the label reports a return to about 0.2 g/L within a week), and CH50 falls; haemolysis markers improve in cold agglutinin disease.
Made uninterpretable: For sutimlimab, CH50 and C4 as measures of disease.
Canada and the United States: Avacopan (Tavneos) is identical in the two countries: adults with severe active ANCA-associated vasculitis, 30 mg twice daily with food, no paediatric indication, no boxed warning and no restricted programme in either country, and four-weekly liver tests for the first six months. The discontinuation thresholds are expressed differently: Canada specifies interruption at three to five times the upper limit and consideration of discontinuation above eight times, whereas the USA adds an explicit alkaline-phosphatase and bilirubin trigger and an intensified monitoring schedule for patients of Japanese descent. Canada alone recommends Pneumocystis prophylaxis. Sutimlimab is not authorised in Canada (no Health Canada record under any status), so cold agglutinin disease has no authorised complement inhibitor in Canada and access is through the Special Access Programme. In the USA it is adults only. Mechanistically it differs from the other agents: it inhibits C1s, so it is the only proximal classical-pathway agent listed; it leaves the alternative pathway and the AH50 intact and does not carry the terminal complement meningococcal risk profile, but its label nevertheless requires full meningococcal and pneumococcal cover.
Scene 42

JAK inhibition (oral small molecules) (1)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
JAK inhibitors
tofacitinib (Xeljanz), baricitinib (Olumiant), upadacitinib (Rinvoq), abrocitinib (Cibinqo), ruxolitinib (Jakafi/Opzelura) — oral JAK inhibitors
Biologic or targeted agent
Administered therapeutically; not produced endogenouslyNot biologics, but agents that act on the same pathways at the intracellular side of the membrane: every cytokine in this reference that signals through JAK-STAT is blocked simultaneously, according to the JAK selectivity of the drug. Ruxolitinib and baricitinib are JAK1/2-selective, tofacitinib JAK1/3, upadacitinib and abrocitinib JAK1-selective; the TYK2 arm is blocked only partially by these agents, and the selective TYK2 inhibitor deucravacitinib is not included here. Cytokines that use other receptor families (TNF, IL-1, IL-17, IL-18) are not affected
Paediatric licences exist across the class and differ by country. Tofacitinib: polyarticular-course JIA and psoriatic arthritis from 2 years and 10 kg in the USA, with an oral solution for children under 40 kg; in Canada polyarticular JIA and juvenile psoriatic arthritis only in children of 40 kg or more, with the 5 mg tablet. Abrocitinib: atopic dermatitis from 12 years in both countries. Upadacitinib: atopic dermatitis from 12 years and 40 kg in both countries, with polyarticular JIA and psoriatic arthritis from 2 years in the USA only. Baricitinib: severe alopecia areata from 12 years in the USA, and adults only in Canada. Topical ruxolitinib: atopic dermatitis from 2 years and nonsegmental vitiligo from 12 years in both countries. Systemic ruxolitinib covers myelofibrosis, polycythaemia vera and acute and chronic graft-versus-host disease (from 12 years) in both countries, with haemophagocytic lymphohistiocytosis off-label. The class boxed warning covers serious infection, mortality from any cause, malignancy including lymphoma, major adverse cardiovascular events and thrombosis, and derives from an adult rheumatoid-arthritis safety trial in patients over 50 with a cardiovascular risk factor, so it applies to children with caution rather than directly. In inborn errors of immunity these are the precision agents for the JAK/STAT gain-of-function disorders and the interferonopathies (Scene 44): ruxolitinib or baricitinib for STAT1 gain-of-function, ruxolitinib or tofacitinib for STAT3 gain-of-function, baricitinib or tofacitinib for SOCS1 haploinsufficiency, and ruxolitinib, baricitinib or tofacitinib for CANDLE, SAVI, Aicardi-Goutières syndrome and USP18 deficiency.
IL-6; IFNγ; IFNα2; IL-4; IL-13; IL-2; IL-23 → Inhibit JAK1, JAK2, JAK3 or TYK2 kinase activity, so STAT phosphorylation does not occur downstream of the γc, gp130, type I and type II interferon and IL-12-family receptorsWhat it does to the tests: CRP and ESR fall through the IL-6/gp130 arm, so the same loss of infection markers as with tocilizumab applies, although less completely. Haemoglobin, neutrophils, lymphocytes and platelets all fall through the JAK2 arm (erythropoietin and thrombopoietin signalling) and the γc arm. NK and B-cell numbers fall. Lipids and CK rise. Herpes zoster reactivation is the characteristic infection and is the predictable consequence of simultaneous blockade of type I and type II interferon signalling.
Made uninterpretable: CRP and ESR, partially, as infection markers.
Canada and the United States: Abrocitinib (Cibinqo) is among the most complete concordances in this reference: atopic dermatitis from 12 years in both countries, with the same dose options, the same dose reduction at age 65 and the same risk-stratified 100 mg starting dose. Oral ruxolitinib: acute and chronic graft-versus-host disease from 12 years in the two countries, myelofibrosis and polycythaemia in adults in the two countries, and no indication below 12 in either. The brand differs (Jakavi in Canada, Jakafi in the USA), Canada carries an infection-focused Serious Warnings box where the US label has no boxed warning, and the extended-release form has no Canadian counterpart. Topical ruxolitinib (Opzelura): atopic dermatitis from 2 years and vitiligo from 12 years in both countries, the ages now being identical; the US indication, however, restricts dermatitis use to non-immunocompromised patients and to short-term non-continuous use, a restriction absent from the Canadian indication. In paediatric immunology this is the material difference: in the USA topical ruxolitinib is explicitly off-label in an immunocompromised child. Deucravacitinib (Sotyktu) is a TYK2 allosteric inhibitor rather than a classical jakinib, adults only in both, and psoriatic arthritis is not in the Canadian monograph. The class warnings (serious infection, mortality, malignancy, major cardiovascular events, thrombosis) appear in both countries, boxed in the USA and in a Serious Warnings box in Canada, with four Canadian headings against five American.
Scene 42

Marrow and homing (2)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
Mavorixafor and plerixafor
mavorixafor (Xolremdi) and plerixafor (Mozobil in the USA; generic Plerixafor Injection in Canada) — CXCR4 antagonists
Biologic or targeted agent
Administered therapeutically; not produced endogenouslyBlock CXCR4, the receptor and not the ligand: the target shown for this entry is SDF-1 because that is the catalogued entity, but the drug binds CXCR4 and does not affect SDF-1 itself. CXCR4 retains mature neutrophils and stem cells in the marrow against the SDF-1 (CXCL12) gradient. Release from this retention is the treatment of WHIM syndrome, in which a truncated CXCR4 cannot be inactivated and the cells are retained; this myelokathexis is a defect of retention and not of production
Mavorixafor is licensed in the USA for WHIM syndrome from 12 years and is not authorised in Canada; plerixafor is licensed for stem-cell mobilisation, in adults in both countries and in Canada also in children from 1 year with lymphoma or solid malignant tumours, whereas paediatric safety and effectiveness are not established in the USA, and is used off-label in WHIM. In Canada the Mozobil brand was cancelled after marketing on 31 October 2025 and plerixafor is supplied as generic Plerixafor Injection. Both are teratogenic, so pregnancy must be excluded and contraception used. The 2025 inborn-errors practice parameter recommends both for WHIM with the blood count as the monitoring marker. The mechanism is the direct converse of the WHIM defect, which accounts for the rapidity of the response.
SDF-1 → Competitive antagonism of CXCR4, so the SDF-1 retention signal is lost and cells leave the marrowWhat it does to the tests: The absolute neutrophil count and the lymphocyte count rise within hours of dosing, because the cells were present but retained in the marrow. A normal count on treatment therefore reflects release and not production.
Canada and the United States: Mavorixafor is not authorised in Canada (no Health Canada record under any status and no filing found), so a Canadian patient with WHIM syndrome can obtain it only through the Special Access Programme. In the USA it is licensed for WHIM from 12 years; the dose is banded at 50 kg rather than by age, and the requirement for an overnight fast with no food for half an hour afterwards is a significant barrier to adherence in an adolescent. Plerixafor shows the other major reversal of the usual pattern in this reference, with the broader authorisation in Canada: Health Canada has an authorised paediatric indication (1 to under 18 years, lymphoma or solid tumours, 0.24 mg/kg eight to twelve hours before apheresis for up to three days), whereas the US label states that paediatric safety and effectiveness are not established and records that effectiveness was not demonstrated in its paediatric trial. Reliance on the FDA position that effectiveness is not established in children would lead to incorrect refusal of a therapy that is on-label in Canada. The paediatric timing window and duration also differ from the adult eight-to-twelve hours and three days against ten to eleven hours and four days, and the US indication covers only lymphoma and myeloma where Canada's paediatric one includes solid tumours. Adult mobilisation dosing is the same in both.
Scene 43
G-CSF (filgrastim)
filgrastim, pegfilgrastim, lenograstim — recombinant G-CSF
Biologic or targeted agent
Administered therapeutically; not produced endogenouslyThe only agent listed that supplies a cytokine rather than blocking one: recombinant G-CSF drives granulopoiesis, shortens marrow transit and releases the marrow reserve, which accounts for its efficacy in severe congenital neutropenia, in cyclic neutropenia and after chemotherapy
Severe chronic neutropenia, whether congenital, cyclic or idiopathic, and chemotherapy-induced neutropenia are the labelled uses of filgrastim in both countries; autoimmune neutropenia is not a labelled indication in either, and in Canada efficacy in autoimmune neutropenia of infancy is stated not to have been established, so that use is off-label. The labelled starting dose in congenital neutropenia is 12 micrograms/kg daily, as a single or divided dose, in Canada and 6 micrograms/kg twice daily in the USA; in cyclic or idiopathic neutropenia it is 5 micrograms/kg daily in both. Pegfilgrastim has no paediatric indication in Canada. In severe congenital neutropenia the long-term MDS/AML risk (about 22% at 15 years, with a hazard of about 2.3% per year after the first 10 years) is the reason for annual marrow surveillance, and a higher G-CSF requirement indicates higher risk; whether G-CSF causes the transformation or is a marker of the more severe underlying defect is not established.
G-CSF → Agonist at G-CSFR (CSF3R) → JAK2 → STAT3/STAT5, the same receptor shown in the granulopoiesis sceneWhat it does to the tests: The neutrophil count rises within 24 to 48 hours, with a left shift and toxic granulation that can be mistaken for sepsis. Alkaline phosphatase, LDH and uric acid rise. The CD64 index on neutrophils rises, so neutrophil CD64 as a sepsis marker is confounded during G-CSF treatment. Bone pain is common.
Made uninterpretable: Neutrophil CD64 as a sepsis marker; the blood film, which has a reactive appearance as an expected effect of treatment.
Canada and the United States: Filgrastim is substantively the same in the two countries, including paediatric use in severe chronic neutropenia at the same starting doses: 12 µg/kg/day in congenital, 5 µg/kg/day in cyclic or idiopathic disease and 5 µg/kg/day for chemotherapy-induced neutropenia. Canada alone specifies the exclusions of neonates and autoimmune neutropenia of infancy; the USA alone licenses the acute radiation syndrome, and Canada alone an HIV-associated neutropenia indication. Pegfilgrastim is the difference carrying the greatest risk: the US label contains a full paediatric weight-band table from under 10 kg and establishes effectiveness from 8 months, whereas the Canadian monographs for both the originator and its biosimilar state that Health Canada has not authorised a paediatric indication and contain no paediatric dose. Pegfilgrastim in a Canadian child is entirely off-label, and use of the US weight bands constitutes a regimen with no supporting Canadian label. Lenograstim is marketed in neither country (no Health Canada record under any status and no US licensed biologic), so it is a European and Japanese agent and any dose quoted from that literature has no supporting North American label; Canadian practice is filgrastim and pegfilgrastim only. Splenic rupture and sickle-cell crisis appear in a formal Canadian Serious Warnings box and in ordinary warnings in the USA, with the same content but different prominence. Long-term counselling regarding myelodysplasia and leukaemic transformation in congenital neutropenia is required, which the US label places in its paediatric section.
Scene 43

IEI: JAK/STAT gain-of-function and interferonopathies (1)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
JAK inhibitors in JAK/STAT gain-of-function
ruxolitinib, baricitinib and tofacitinib used as precision therapy in inborn errors of immunity
Precision therapy for inborn errors of immunity
Administered therapeutically, matched to the molecular defectThe same drugs as in Scene 42, used for a different purpose: correction of a signalling defect rather than suppression of an inflammatory disease. In a JAK/STAT gain-of-function disorder the pathway is constitutively active, so inhibition of the kinase upstream of the STAT restores near-normal signalling; this is the only medical therapy, other than transplantation, that addresses the underlying lesion
Dosing in these disorders is not established by trial and is taken from cohort experience; none of these uses is licensed in Canada or the USA. Ruxolitinib: in the published cohort of STAT1 and STAT3 gain-of-function disease the dose was 0.4 to 2 mg/kg/day, or 15 mg/m² per dose twice daily, started at half the goal dose and increased by 25% weekly until the goal dose was reached (Forbes LR et al. J Allergy Clin Immunol 2018;142:1665-1669). On the basis of retrospective experience, escalation to 30 mg/m² twice daily, to a maximum of 25 mg twice daily, is also described; 50 mg/m² per dose has been tolerated in children, but long-term data at that dose are inadequate. Tofacitinib: the one patient treated in that cohort was dosed as labelled for rheumatoid arthritis. Baricitinib: the published proposal for CANDLE and SAVI is by body weight and renal function (Kim H et al. Clin Pharmacol Ther 2018;104:364-373). With an estimated glomerular filtration rate of 120 mL/min/1.73 m² or more, the initial dose is 2 mg three times daily under 20 kg, 3 mg twice daily at 20 to 40 kg and 4 mg twice daily over 40 kg; the first escalation is to 2 mg four times daily, to 3 mg, 2 mg and 3 mg as three daily doses, and to 5 mg twice daily respectively; and a second escalation, to 6 mg twice daily, is proposed only over 40 kg. With a lower filtration rate the initial dose is 2 mg twice daily at all weights. Mean exposure at the doses reached was 1.83 times that of adults taking 4 mg daily for rheumatoid arthritis. A regimen of 2 mg daily, increased to 4 mg daily within 4 to 6 weeks according to clinical response and tolerance, with 2 mg daily in children under 9 years, may also be used. The dose is titrated every 4 to 6 weeks according to clinical response. Aciclovir prophylaxis is suggested because of the herpesvirus risk, with review every 4 to 6 months for opportunistic infection, cardiovascular and thromboembolic disease, malignancy and liver disease. Treatment is lifelong or until transplant. Early introduction may determine whether the disease resolves.
IFNγ; IFNα2; IFNβ; IL-6 → Inhibit the JAK upstream of the overactive STAT, lowering STAT phosphorylation to nearer normalFor: STAT1 gain-of-function (ruxolitinib or baricitinib); STAT3 gain-of-function (ruxolitinib or tofacitinib); STAT4 gain-of-function and STAT5b gain-of-function (ruxolitinib); SOCS1 haploinsufficiency (baricitinib or tofacitinib); and the interferonopathies: USP18 deficiency, SAVI, Aicardi-Goutières syndrome and CANDLE (ruxolitinib, baricitinib or tofacitinib)
Follow: CXCL9 and Th17 numbers in STAT1 gain-of-function; double-negative T cells in STAT3 gain-of-function; IL-6 in STAT4; eosinophilia in STAT5b; CXCL9 in SOCS1 deficiency; and an interferon-activity score in the interferonopathies. CXCL9 (MIG) is an interferon-induced chemokine and therefore reflects IFN-γ activity better than ferritin
Graded: Strong recommendation for STAT3 gain-of-function, SOCS1 deficiency and the interferonopathies; conditional for STAT1, STAT4 and STAT5b gain-of-function. Certainty of evidence moderate to very low; there are no clinical trials in these disorders, and the evidence is at cohort and case-report level throughout
What it does to the tests: The biomarkers listed above fall with response and are those recommended for monitoring. The laboratory adverse effects are those of the class: cytopenias, raised transaminases and raised triglycerides, so a blood count with differential, a liver panel and a chemistry panel are monitored, with viral PCR for reactivation. Because these agents also block IL-6 signalling, the CRP response is attenuated, as with tocilizumab.
Made uninterpretable: CRP and ESR, partially, as infection markers.
Scene 44

IEI: inflammasome and IL-1-mediated disorders (1)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
IL-1 blockade in the inflammasomopathies
anakinra, rilonacept and canakinumab used as precision therapy in inborn errors of immunity
Precision therapy for inborn errors of immunity
Administered therapeutically, matched to the molecular defectThe three IL-1 agents of Scene 40, matched here to the defects that drive IL-1 production. They are not equivalent: anakinra blocks IL-1α as well as IL-1β and has a terminal half-life of 4 to 6 hours with probably better central nervous system penetration; rilonacept traps IL-1β and, less avidly, IL-1α and the natural antagonist IL-1RA, with a half-life of about 7 days; canakinumab neutralises IL-1β alone with a half-life of 22.9 to 25.7 days
Children generally require higher doses than adults, and patients with severe phenotypes require higher doses than those with mild disease. In familial Mediterranean fever, raising canakinumab from 150 mg to 300 mg every 4 weeks converted many partial responses into complete responses, and dose escalation also improved response in TRAPS and in mevalonate kinase deficiency. IL-1 blockade also reduces proteinuria. In milder disease with normal markers between episodes, on-demand anakinra can shorten or prevent attacks rather than continuous treatment. Data in pregnancy and breastfeeding are limited for all three. Treatment is lifelong.
IL-1α; IL-1β → Receptor blockade (anakinra), ligand trapping (rilonacept) or neutralisation of IL-1β (canakinumab)For: CAPS (familial cold autoinflammatory syndrome, Muckle-Wells syndrome and NOMID/CINCA, from NLRP3) with all three agents in practice, although the licences are narrower: anakinra is licensed for NOMID alone in both countries (in Canada from 8 months and 10 kg), canakinumab for familial cold autoinflammatory syndrome and Muckle-Wells syndrome (from 4 years in the USA; from 2 years in Canada, where use in NOMID/CINCA is also permitted), and rilonacept for familial cold autoinflammatory syndrome and Muckle-Wells syndrome from 12 years in the USA only, so the remaining uses are off-label; TRAPS (TNFRSF1A), familial Mediterranean fever (MEFV) and mevalonate kinase deficiency (MVK) with canakinumab; deficiency of the IL-1 receptor antagonist (DIRA, IL1RN) with anakinra or rilonacept, both licensed for this in the USA only, anakinra being off-label for DIRA in Canada and rilonacept not authorised there; PAPA syndrome (PSTPIP1), FCAS2 (NLRP12) and Majeed syndrome (LPIN2) with anakinra or canakinumab; NOCARH (CDC42) with anakinra; FCAS4 (NLRC4) with canakinumab; the uses in PAPA syndrome, FCAS2, Majeed syndrome, NOCARH and FCAS4 are off-label in both countries
Follow: CRP and serum amyloid A throughout, with the white cell and neutrophil count and proteinuria in CAPS, TRAPS, FMF and mevalonate kinase deficiency, and ferritin added in NOCARH and NLRC4 disease. Serum amyloid A is the relevant marker between attacks: a normal CRP does not establish that inflammation is controlled, and sustained SAA elevation is the precursor of AA amyloid
Graded: Strong recommendation with high certainty for CAPS, TRAPS, FMF and mevalonate kinase deficiency; strong with moderate certainty for DIRA; conditional with low certainty for PAPA, FCAS2, Majeed syndrome, NOCARH and FCAS4
What it does to the tests: CRP, SAA, the neutrophil count and proteinuria all fall, often within days; the response is sufficiently rapid that a trial of IL-1 blockade is used diagnostically while a molecular diagnosis is awaited, in preference to awaiting genetic results and accepting the morbidity of the delay. Anakinra causes neutropenia in a few per cent. Injection-site reactions are almost universal early in anakinra treatment and subsequently resolve.
Made uninterpretable: CRP and SAA as infection markers.
Scene 45

IEI: other precision agents (6)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
Leniolisib
leniolisib (Joenja) — oral selective PI3Kδ inhibitor
Precision therapy for inborn errors of immunity
Administered therapeutically, matched to the molecular defectThe first drug developed for a single inborn error of immunity. In activated PI3K-delta syndrome a gain-of-function in PIK3CD, or loss of its regulatory subunit in PIK3R1, renders PI3Kδ constitutively active; leniolisib inhibits that catalytic subunit selectively and restores the lymphocyte compartment towards normal
Fetal harm is possible, and medication interactions occur, so concurrent drugs should be reviewed. Treatment is lifelong. The randomised trial enrolled patients of 12 to 75 years, and the original 2023 licence followed it. The US licence was extended in September 2026 down to 4 years at 27 kg or more, with weight-banded dosing: 40 mg twice daily at 27 to under 38 kg, 50 mg twice daily at 38 to under 45 kg, and 70 mg twice daily at 45 kg and above and for all patients of 12 years and over. The Canadian licence was not extended: it remains 12 years and 45 kg, with only the 70 mg strength authorised, which is recorded as approved but not yet as marketed, and no weight bands (see the licensing note before an age is quoted). Children under 27 kg have no approved dose in either country; a US supplemental application for children of 4 years and over weighing 13 to under 27 kg has been accepted for priority review, with a target action date of 30 January 2027, and remains pending, so no dose can currently be quoted for that band.
IgM; Transitional B cell; Plasmablast; CD8 Tem / Temra → Selective inhibition of the PI3Kδ catalytic subunit p110δ, lowering AKT–mTOR signalling in lymphocytesFor: Activated PI3K-delta syndrome, both APDS1 (PIK3CD gain-of-function) and APDS2 (PIK3R1 loss); from 4 years and 27 kg in the USA, but from 12 years and 45 kg in Canada, which requires both
Follow: Serum IgM, which is characteristically high in APDS and falls markedly on treatment; transitional B cells; and CD8 and CD4 terminally differentiated effector memory (TEMRA) cells
Graded: Strong recommendation, high certainty; one of two agents in this group, with interferon gamma-1b in chronic granulomatous disease (PMID 1846940), supported by a randomised placebo-controlled trial
What it does to the tests: In the phase 3 trial, lymphadenopathy and spleen size fell, as did transitional B cells, CD38+ plasmablasts, switched and unswitched memory B cells, CD57+ senescent CD8 T cells and CD8 TEMRA cells, while total CD4 counts rose and CD4 TEMRA cells fell. Serum IgM fell markedly. A blood count and immunoglobulins are the monitoring specified in the label.
Made uninterpretable: Serum IgM as a measure of disease rather than of treatment.
Canada and the United States: The Canadian and US criteria differ. Canada: activated PI3K-delta syndrome from 12 years and 45 kg (both conditions are required); only the 70 mg strength is authorised, and it is recorded as approved but not yet as marketed, so there is no weight-banded dosing in Canada. United States (label Sep 2026): from 4 years and 27 kg, with 40, 50 and 70 mg tablets and weight bands (40 mg twice daily at 27 to under 38 kg, 50 mg at 38 to under 45 kg, 70 mg at 45 kg and above, and 70 mg twice daily for any patient aged 12 or over). Two specific consequences follow. A 13-year-old weighing 40 kg is on-label in the USA and off-label in Canada, because Canada requires both the age and the weight. A 7-year-old of 30 kg cannot be treated according to the label in Canada and cannot receive a reduced dose of the Canadian product, because the 70 mg tablet is film-coated and oval with no scoring or splitting instructions in either monograph. To obtain the paediatric strengths, a Canadian prescriber would apply to the Health Canada Special Access Programme for the US 40 mg or 50 mg tablets, documenting the weight band and the absence of an authorised Canadian 40 mg or 50 mg product. A further US supplemental application, for lower doses in children of 4 years and over weighing 13 to under 27 kg, has been accepted for priority review with a target action date of 30 January 2027; no dose for that band is authorised. A Canadian reimbursement recommendation could not be verified: the review page of Canada's Drug Agency, last updated October 2024, records the review as suspended, whereas a BC PharmaCare call for public input (29 July to 25 August 2026) states that the drug has been or will be reviewed by Canada's Drug Agency.
Scene 46
Abatacept and belatacept in CTLA-4 and LRBA disease
abatacept (Orencia) and belatacept (Nulojix) — CTLA-4-Ig fusion proteins
Precision therapy for inborn errors of immunity
Administered therapeutically, matched to the molecular defectReplacement of a deficient inhibitory mechanism rather than suppression of a normal one. CTLA-4 competes with CD28 for CD80 and CD86; LRBA is required to recycle CTLA-4 rather than direct it to degradation, so loss of either leaves CD28 costimulation unopposed. A CTLA-4–Ig fusion protein supplies the missing competitor
Live vaccines must not be given during treatment or within three months of stopping, and it should not be combined with a TNF inhibitor. Treatment is lifelong. It controls the disease and is not curative: transplantation remains the curative option in severe disease.
Tfh → Binds CD80 and CD86, restoring the competition for CD28 that is lost as a result of the defectFor: CTLA-4 haploinsufficiency and LRBA deficiency: the lymphoproliferation, enteropathy, autoimmune cytopenias and interstitial lung disease of those disorders
Follow: Circulating T follicular helper cells and soluble CD25, both of which fall on treatment in most patients
Graded: Strong recommendation, moderate certainty
What it does to the tests: Circulating Tfh and soluble CD25 fall. In LRBA deficiency with refractory interstitial lung disease, lung function improved within six months of initiation; chronic diarrhoea, lymphoproliferation and autoimmune cytopenias improved on long-term follow-up. The label specifies no monitoring blood tests.
Made uninterpretable: Vaccine serology as proof of protection, as with abatacept in any indication.
Scene 46
Elapegademase
elapegademase (Revcovi) — PEGylated recombinant bovine adenosine deaminase
Precision therapy for inborn errors of immunity
Administered therapeutically, matched to the molecular defectEnzyme replacement rather than a signalling inhibitor. In adenosine deaminase deficiency the toxic substrates deoxyadenosine and dAXP accumulate and are toxic to lymphocytes; enzyme replacement clears them, and lymphocyte counts, neutrophil counts and infection frequency improve
Licensed in the USA for adenosine deaminase severe combined immune deficiency in paediatric and adult patients; it is not authorised in Canada. Treatment is started as soon as absent enzyme activity is demonstrated, without awaiting the genetic result. Initial dosing in the parameter is 0.4 mg/kg/week intramuscularly, divided into two doses, for infants and 0.2 mg/kg/week for older children and adolescents, which may be given weekly; the label applies the same two figures to a different distinction (0.4 mg/kg/week, calculated on ideal or actual body weight, whichever is greater, and divided twice weekly for a minimum of 12 to 24 weeks until immune reconstitution, for any patient new to enzyme replacement irrespective of age, and 0.2 mg/kg/week as the minimum starting dose for those transitioning from pegademase at a weekly dose of 30 U/kg or less or of unknown size), so a late-diagnosed older child started at 0.2 would be underdosed. Treatment history as well as age should determine the dose. The dose is increased by 0.033 mg/kg/week if the trough plasma ADA remains under 30 mmol/h/L or trough dAXP exceeds 0.02 mmol/L; higher doses may be needed in ADA-associated pulmonary alveolar proteinosis or hepatitis. The parameter names vidarabine and deoxycoformycin as interacting; the label states that interaction potential has not been studied. Enzyme replacement does not fully reconstitute immunity, so antimicrobial prophylaxis and immunoglobulin replacement usually continue, and it is a bridging therapy to transplantation or gene therapy rather than definitive treatment.
No catalogued node is acted on directly → Replaces adenosine deaminase activity in plasma, clearing plasma deoxyadenosine and lowering erythrocyte deoxyadenosine nucleotides (dAXP)For: Adenosine deaminase deficiency, including ADA-SCID
Follow: Plasma ADA activity and erythrocyte dAXP, with blood counts and lymphocyte subsets
Graded: Strong recommendation, high certainty
What it does to the tests: Lymphocyte and neutrophil counts rise and infections decrease; trough erythrocyte dAXP (deoxyadenosine nucleotides) falls below 0.02 mmol/L within 3 to 6 months, and a trough dAXP above 0.02 mmol/L is an indication for dose escalation. The US label specifies that trough erythrocyte dAXP is maintained below 0.02 mmol/L from two months after the start of treatment and monitored at least twice a year. Plasma ADA, erythrocyte dAXP, blood counts and lymphocyte subsets are measured at least every 6 months. Antibody function can wane on long-term therapy, in part from neutralising antibodies to the drug.
Scene 46
Interferon gamma-1b
interferon gamma-1b (Actimmune) — recombinant human IFN-γ
Precision therapy for inborn errors of immunity
Administered therapeutically, matched to the molecular defectThe converse of emapalumab: a cytokine supplied rather than blocked. In chronic granulomatous disease it reduces the frequency and severity of serious infection without restoring the oxidative burst, and in the IFN-γ-axis defects it supplies or augments the signal that the defect has weakened
Dosing is by body surface area, and the rule for small infants is the most frequent source of error: 50 micrograms/m² three times a week where the surface area is above 0.5 m², but 1.5 micrograms/kg per dose three times a week where it is 0.5 m² or below; a young infant dosed by the per-square-metre figure is substantially underdosed. In chronic granulomatous disease it is given alongside trimethoprim-sulfamethoxazole and itraconazole; in disseminated mycobacterial disease the per-square-metre dose is added to antimycobacterial therapy. It does not replace antimicrobial prophylaxis. It is licensed in the USA for chronic granulomatous disease, with paediatric use established from 1 year, and for severe malignant osteopetrosis, from 1 month; its use in Mendelian susceptibility to mycobacterial disease is off-label, and it is not authorised in Canada.
IFNγ → Agonist at the IFN-γ receptor, driving JAK1/JAK2 and STAT1 in macrophagesFor: Chronic granulomatous disease as prophylaxis against all infections, and the Mendelian susceptibility to mycobacterial disease group: IL-12p40, IL-12Rβ1, IL-12Rβ2 and IL-23R deficiency, autosomal dominant partial IFN-γR1 or R2 deficiency, STAT1 loss-of-function, TYK2, IRF8 and ISG15 deficiency, and IFN-γ deficiency itself
Follow: Clinical infection frequency; there is no validated laboratory marker of response
Graded: Strong recommendation in chronic granulomatous disease with moderate certainty; strong with very low certainty in the IFN-γ-signalling defects
What it does to the tests: Raised liver enzymes and renal toxicity are the laboratory adverse effects, with fever; liver enzymes, a chemistry panel and a blood count with differential are monitored. Treatment is lifelong or until transplant.
Scene 46
Oral fucose
oral L-fucose supplementation
Precision therapy for inborn errors of immunity
Administered therapeutically, matched to the molecular defectDirect supplementation of a deficient sugar. Leukocyte adhesion deficiency type II is a defect of GDP-fucose transport, so the selectin ligands on which rolling depends are not synthesised; oral fucose permits their synthesis, and the rolling step of Scene 33 is restored
Not every patient responds, and the neurological features do not improve with the haematological ones. The white cell count is the practical measure of response to supplementation.
No catalogued node is acted on directly → Substrate supplementation restoring fucosylation of selectin ligands, including sialyl-Lewis XFor: Leukocyte adhesion deficiency type II (SLC35C1), which also causes short stature, developmental delay and the Bombay blood phenotype
Follow: The white cell count with differential: the persistent leucocytosis of a rolling defect falls as the ligands return
Graded: Strong recommendation, low certainty; some but not all patients respond
What it does to the tests: Selectin ligands reappear on neutrophils, the white cell count normalises and infections improve in responders. Discontinuation reverses both: the ligands are lost and the leucocytosis returns, which demonstrates the mechanism as clearly as the response itself.
Scene 46
Cobalamin and folate in the transport defects
hydroxocobalamin, cyanocobalamin and high-dose intravenous folinic acid
Precision therapy for inborn errors of immunity
Administered therapeutically, matched to the molecular defectSeveral defects of vitamin B12 and folate transport or metabolism present with the features of severe combined immunodeficiency (poor T-cell proliferation to mitogen, hypogammaglobulinaemia and absent antibody responses) and respond to vitamin replacement, with the best outcomes when treatment begins early. They are the most important treatable mimics in this group
TCN2 deficiency is treated with cyanocobalamin or hydroxocobalamin; SLC46A1 deficiency with high-dose intravenous folinic acid; MTHFD1 deficiency and cblF disease (LMBRD1) with hydroxocobalamin and folinic acid together. Treatment is lifelong. Total plasma homocysteine, methylmalonic acid and folate should be measured before a diagnosis of SCID is made in an infant with an SCID-like presentation.
No catalogued node is acted on directly → Bypasses the defective transporter by supplying the vitamin at a dose that reaches the cellFor: Transcobalamin II deficiency (TCN2); proton-coupled folate transporter deficiency (SLC46A1); MTHFD1 deficiency; and cblF disease (LMBRD1)
Follow: Vitamin B12 and folate levels, total plasma homocysteine and methylmalonic acid, and the blood count
Graded: Strong recommendation, low certainty
What it does to the tests: The immunological abnormalities (low or absent T-cell proliferation, hypogammaglobulinaemia and impaired antibody responses) return to normal with treatment. The blood count, vitamin B12 and folate are monitored, together with total plasma homocysteine and methylmalonic acid.
Scene 46

IEI: the backbone of management (4)

EntityMade / induced byFunction and clinical correlateReceptor → signallingDetailScene
Immunoglobulin replacement
immunoglobulin replacement therapy (IgRT) — intravenous or subcutaneous IgG
Precision therapy for inborn errors of immunity
Administered therapeutically, matched to the molecular defectNot a cytokine therapy, but the treatment received by most patients with the antibody deficiencies described in this reference. It supplies pooled donor IgG and only IgG: it does not replace IgA or IgM, so mucosal protection is not restored and a low IgA is not corrected
The population target is a minimum and not an individual goal: the dose is individualised to the level at which the individual patient ceases to have infections (the biologic trough), which in X-linked agammaglobulinaemia has ranged from 800 to 1300 mg/dL and in common variable immunodeficiency from 500 to 1700 mg/dL. Dose is adjusted for weight change beyond 5%. A low or absent IgA is not a contraindication, and the choice of route is a conditional recommendation made with the patient rather than part of the strong one. Treatment is continuous, and lifelong for most but not all patients: a planned trial off therapy is explicitly permitted in selected cases, specifically specific antibody deficiency in children and transient hypogammaglobulinaemia of infancy, which are the paediatric situations in which the question arises.
IgG1; IgG2; IgG3; IgG4 → Passive replacement of IgG, with the FcRn recycling of Scene 28 conferring the three-week half-life that permits three- to four-weekly dosingFor: Inborn errors with defective humoral immunity: X-linked agammaglobulinaemia, common variable immunodeficiency, class-switch recombination defects, combined immunodeficiencies and others in which antibody production or function is lost
Follow: The serum IgG trough, with a blood count and chemistry panel
Graded: Strong recommendation. Certainty moderate for the starting dose and the monitoring, high for the trough target, low for the recommendation that it is continuous and lifelong
What it does to the tests: The starting dose is 400 to 600 mg/kg per month: intravenously every 3 to 4 weeks, or the same monthly dose divided into weekly or two-weekly subcutaneous infusions (the labelled conversion from the intravenous dose differs by product and by country: in the USA the weekly-equivalent intravenous dose is multiplied by 1.37 for Hizentra, Xembify and subcutaneous Gamunex-C and Gammagard Liquid and by 1.30 for Cuvitru and Cutaquig, to match bioavailability, and is unchanged for facilitated subcutaneous HyQvia; in Canada it is unchanged for Hizentra, Cuvitru and HyQvia, while the Canadian monographs of Xembify and Cutaquig, neither of which is recorded as marketed, apply 1.37 and 1.30; the figures of 1.35 and 1.53 are not labelled conversion factors, 1.53 being the mean individual dose adjustment in the US pharmacokinetic study of Hizentra). The target is a serum IgG above 800 mg/dL: pneumonia falls by about a quarter for every additional 100 mg/dL of trough, and a trough of 500 carries about five times the pneumonia rate of 1000, with no further benefit above 1000. IgG is measured every 6 to 12 months when stable, and monthly when there are breakthrough infections, in pregnancy, with protein loss, on immunosuppression, with significant weight change or where adherence is uncertain. The trough is sampled before the intravenous infusion; on subcutaneous dosing the level peaks at 3 to 5 days and steady state takes 4 to 6 months.
Made uninterpretable: All IgG-based serology, including vaccine responses and infectious serology: the result reflects the donor pool and not the patient. Any assessment of antibody production must precede the first infusion or follow a washout.
Canada and the United States: The monthly dose is concordant; the trough target and the subcutaneous conversion are not, and both are likely sources of error in a Canadian chart. The monthly dose is identical (the practice parameter's 400–600 mg/kg/month is the same as the Canadian 0.4–0.6 g/kg every four weeks), except that Canadian guidance specifies adjusted body weight in adults whereas children are generally dosed on actual weight, which diverges only in the obese adolescent. Trough target: the practice parameter sets above 800 mg/dL (a strong recommendation on high-certainty evidence); Canadian guidance sets ‘at least the lower limit of the age-specific serum IgG reference range’, which in a two-year-old is roughly 500 mg/dL and is substantially lower. Recording 800 as the sole target in a Canadian chart conflicts with the criteria applied by the local transfusion service, so both targets should be known; the American figure is the one supported by outcome evidence. Subcutaneous conversion: the 1.37 factor (1.35–1.53 across products) derives from US labelling. Canadian labelling and Canadian guidance use 1:1: the monthly dose is divided by four for the weekly subcutaneous dose and then titrated to trough. Access differs in kind: in the USA this is a prescription drug supplied through specialty pharmacy; in Canada it is a blood product, free to the patient, released by transfusion medicine against a utilisation guideline, with brand allocation determined by national contracts and shortage plans, so brand continuity cannot be assured, and there is a dedicated national brand-switching statement because switching is expected. Objective measures of effectiveness should be set at the outset and reviewed by six months and at least annually thereafter.
Scene 47
Antimicrobial prophylaxis
targeted antimicrobial prophylaxis in inborn errors of immunity
Precision therapy for inborn errors of immunity
Administered therapeutically, matched to the molecular defectProphylaxis in these disorders is directed at the organisms to which the specific defect confers susceptibility and is not given broadly. The correspondence between defect and organism follows the principle applied throughout this reference: the deficient pathway predicts the infection
Where hypersensitivity to trimethoprim-sulfamethoxazole is suspected, desensitisation is preferred to discontinuation, since the alternatives provide incomplete coverage. The azoles interact with many drugs, including the agents in these scenes. Prophylaxis complements, and does not replace, immunoglobulin replacement or precision therapy.
No catalogued node is acted on directly → Antimicrobial rather than immunologicalFor: Chronic granulomatous disease; SCID and congenital athymia; antibody deficiencies; terminal complement defects and asplenia; STAT3 and IL-6-pathway hyper-IgE syndrome; chronic mucocutaneous candidiasis (STAT1 gain-of-function, APECED, CARD9, IL-17 and IL-17R defects); Mendelian susceptibility to mycobacterial disease; combined immunodeficiency with severe T-cell defects
Follow: Infection frequency; adherence and drug interactions are of greater importance than any laboratory measure
Graded: Strong recommendation, high quality of evidence for the recommendation overall; the individual regimens range from strong with high certainty down to conditional with very low certainty
What it does to the tests: Trimethoprim-sulfamethoxazole for chronic granulomatous disease, covering Staphylococcus aureus, Burkholderia, Nocardia and Serratia: 5 mg/kg of the trimethoprim component, with a maximum dose of 160 mg of trimethoprim twice daily; whether 5 mg/kg is a single or a total daily dose is not specified, and a 2018 review gives 5 mg/kg per day to a maximum of one double-strength tablet (160 mg of trimethoprim) daily. Prophylaxis reduces bacterial infections by approximately half. For Pneumocystis prophylaxis in SCID and congenital athymia the same agent is given two to three times a week (5 mg/kg, maximum 160 mg of trimethoprim), and in combined immunodeficiency with severe T-cell defects twice daily, as a conditional rather than a strong recommendation; pentamidine, atovaquone and dapsone are alternatives. Itraconazole for Aspergillus in chronic granulomatous disease: 5 mg/kg daily, to a maximum of 100 mg daily under 50 kg and 200 mg daily over 50 kg. The placebo-controlled trial, which enrolled patients aged 5 years and over, used fixed doses of 100 mg daily under 13 years of age or under 50 kg and 200 mg daily from 13 years or from 50 kg. Itraconazole has no paediatric indication in Canada or the USA; the oral solution is better absorbed than the tablets, which should be taken with a meal. Fluconazole for Candida at 3 mg/kg in SCID and congenital athymia, or 3 to 6 mg/kg/day in infants with SCID, and at 5 mg/kg in chronic mucocutaneous candidiasis and in hyper-IgE syndrome. In STAT3 hyper-IgE syndrome the named regimen is trimethoprim-sulfamethoxazole at 5 to 6 mg/kg/day of the trimethoprim component divided twice daily, with itraconazole added where pneumatoceles are present; coccidioidomycosis prophylaxis is advised in endemic regions for STAT3 hyper-IgE syndrome and STAT1 gain-of-function. Aciclovir for HSV and VZV, at 12.5 mg/kg twice daily in SCID and congenital athymia before immune reconstitution and at 20 to 40 mg/kg, to a maximum of 400 mg, twice daily in combined immunodeficiency with severe T-cell defects; ganciclovir or valganciclovir is used as treatment rather than as prophylaxis, for established CMV infection or for symptoms consistent with CMV infection while PCR results are pending. Azithromycin 5 mg/kg daily to a maximum of 250 mg, or 500 mg three days a week, for respiratory infection in antibody deficiency and for environmental mycobacteria in MSMD, with amoxicillin or trimethoprim-sulfamethoxazole as alternatives. Daily amoxicillin or penicillin in terminal complement defects and asplenia, to at least 5 years of age and able to be continued for life, particularly after an episode of sepsis; cephalexin or azithromycin is used in penicillin allergy, and an allergy evaluation is preferred before a second-line drug is adopted. Meningococcal and pneumococcal vaccination at diagnosis is at least as important as the antibiotic. Aciclovir should not be given concurrently with ganciclovir or valganciclovir. Perioperative decolonisation for Staphylococcus aureus is advised in chronic granulomatous disease, leukocyte adhesion deficiency and hyper-IgE syndrome.
Canada and the United States: None of these uses is a licensed indication in Canada or the USA; all represent guideline practice and are off-label. Dosing is effectively the same in the two countries because both follow the same guidelines and literature; the paediatric formulations available differ, and this is the principal source of practical risk, so the available suspension should be confirmed before a weight-based dose is prescribed. For trimethoprim-sulfamethoxazole in chronic granulomatous disease, the recommended regimen is 5 mg/kg of the trimethoprim component with a maximum dose of 160 mg twice daily; the recommendation does not state whether 5 mg/kg is a single dose or a total daily dose. A 2018 review of the management of chronic granulomatous disease gives 5 mg/kg per day of the trimethoprim component, to a maximum of one double-strength tablet (160 mg of trimethoprim) daily. Where hypersensitivity to trimethoprim-sulfamethoxazole is a concern, drug desensitisation is suggested; the alternatives, second- or third-generation cephalosporins or trimethoprim alone, leave gaps in the coverage of Staphylococcus aureus, Burkholderia, Nocardia and Serratia.
Scene 47
Vaccination in inborn errors of immunity
live and non-live vaccines in IEI and their household contacts
Precision therapy for inborn errors of immunity
Administered therapeutically, matched to the molecular defectVaccination is not contraindicated as a whole: live replicating vaccines are withheld in severe cellular, phagocytic or humoral defects, whereas non-live vaccines are given and are of value even where the antibody response is expected to be poor, because the T-cell response may be preserved
Household contacts may receive live vaccines, with two exceptions: oral poliovirus vaccine and replication-competent smallpox/mpox vaccine. After a household infant has received oral rotavirus vaccine, hand washing after nappy changes is advised for a month. Contact with a blistering rash after varicella vaccination or shingles should be avoided. COVID-19 vaccination is strongly recommended including on immunoglobulin replacement, where T-cell and serological responses were better than expected; HPV vaccination is recommended for all patients with an inborn error of immunity from 9 to 45 years. The first dose of rotavirus vaccine must be given by 14 weeks and 6 days of age, with the series completed by 8 months, which is often before the immunological diagnosis is established; the question should therefore be resolved early rather than deferred by default. Meningococcal and pneumococcal vaccination is recommended at diagnosis in complement deficiency, asplenia and the TLR-pathway defects, alongside the antibiotic prophylaxis. Seasonal inactivated influenza vaccination is recommended with a standing on-demand antiviral prescription for exposure in patients of 3 months and over. With respect to grading, during immunoglobulin replacement the recommendations for mRNA COVID-19 and inactivated influenza vaccination are conditional with low certainty, and those for recombinant zoster and for HPV conditional with very low certainty, although the narrative text recommends them.
No catalogued node is acted on directly → ImmunisationFor: All inborn errors of immunity, and their household contacts
Follow: Vaccine-specific antibody titres, where immunoglobulin replacement has not made them uninterpretable
Graded: Strong recommendation to follow current public-agency and professional-society schedules, with low certainty, because those schedules change more rapidly than any practice parameter and supersede it
What it does to the tests: All live viral vaccines, including live attenuated influenza and dengue, and all live bacterial vaccines (BCG, typhoid) are contraindicated in severe inborn errors: SCID, congenital athymia, combined immunodeficiency, IFN-α and IFN-γ deficiency, the IL-12 axis defects, antibody deficiencies and chronic granulomatous disease. Chronic granulomatous disease is a clinically important partial exception: the contraindication applies to live bacterial vaccines, and a child with CGD who is not immunosuppressed may receive live viral vaccines, so MMR and varicella are not withheld on the basis of the CGD diagnosis alone. Vaccine-strain rotavirus infection has occurred in newborns with SCID diagnosed before newborn screening, BCG has caused disseminated or localised granulomatous disease in SCID, IFN-γ-pathway defects and chronic granulomatous disease, and vaccine-strain rubella has been found in skin granulomas in ataxia-telangiectasia, combined immunodeficiency and also humoral defects. Isolated T-cell lymphopenia with preserved function is a distinct situation in which live vaccines may be given; the suggested thresholds are CD4 above 400/µL, CD8 above 200/µL, naive CD4 above 20% of CD4, and a protective tetanus response. In a patient who no longer requires immunoglobulin replacement (for example, in transient hypogammaglobulinaemia of infancy), catch-up live viral vaccines are deferred until 8 months after the last infusion (the ACIP interval for a replacement dose of 300–400 mg/kg before a measles- or varicella-containing vaccine), which is also the point at which serology again becomes interpretable.
Made uninterpretable: Vaccine serology in any patient on immunoglobulin replacement.
Scene 47
Immune reconstitution: transplant and gene therapy
allogeneic haematopoietic stem cell transplantation and ex vivo gene therapy
Precision therapy for inborn errors of immunity
Administered therapeutically, matched to the molecular defectThe only curative options. All other treatments in Scenes 44 to 47 control a disease or replace a product; transplantation and gene therapy replace the defective cell itself, and several of the precision agents are accordingly described in the parameter as treatment until transplant rather than as definitive therapy
Timing is among the most important determinants of outcome: survival exceeds 90% when SCID is identified by newborn screening, and transplantation before 3.5 months of age gives better outcomes than later transplantation; this is the rationale for newborn screening and the reason the procedure is urgent rather than elective. Thymus transplantation, rather than haematopoietic transplant, is the procedure for congenital athymia; in the USA allogeneic processed thymus tissue (Rethymic) has been licensed since 8 October 2021 for immune reconstitution in paediatric patients with congenital athymia, and is not indicated for severe combined immunodeficiency, while no such product is authorised in Canada. Gene therapy has been licensed in Europe for adenosine deaminase deficiency (Strimvelis, since May 2016) and in the USA for two further disorders: etuvetidigene autotemcel (Waskyra), approved on 9 December 2025 for Wiskott-Aldrich syndrome with a mutation in the WAS gene, from 6 months of age, where transplantation is appropriate and no suitable HLA-matched related donor is available; and marnetegragene autotemcel (Kresladi), given accelerated approval on 26 March 2026 for paediatric patients with severe leukocyte adhesion deficiency type I due to biallelic ITGB2 variants who have no HLA-matched sibling donor, with continued approval contingent on confirmatory evidence of clinical benefit. None of these gene therapies is authorised in Canada. The parameter lists ADA alongside X-linked SCID, Artemis deficiency and RAG1 deficiency as disorders in which it is accessed through open clinical trials, a statement that predates the two US approvals, so availability depends on location.
No catalogued node is acted on directly → Replacement of the haematopoietic compartment, from a donor or from the patient’s own corrected cellsFor: Severe combined immunodeficiency and congenital athymia; severe combined and phagocyte defects; severe immune dysregulation; and selected disorders in which medical control is inadequate
Follow: Lymphocyte subsets, chimerism and immune reconstitution testing after the procedure
Graded: Strong recommendation with high certainty that SCID is treated by transplant or gene therapy; strong with moderate certainty for cultured thymus tissue implantation in congenital athymia; conditional with moderate certainty that it is done at an experienced centre
What it does to the tests: Blood products given before or around transplant must be irradiated, leucoreduced and CMV-negative (not only CMV-safe), and lymphocyte-depleted; this requirement applies from the time a severe cellular defect is suspected and not from the time it is confirmed.
Scene 47

Source-cell index · what each cell type makes

The catalogue read the other way round: every producing cell type and the mediators it releases. A mediator appears under each of its main sources, so totals exceed 95. The rows added at the end are the cell subsets, antibody-secreting cells, complement-producing tissues and acute-phase outputs of Scenes 19–47.

Source cellMediators producedCount
Monocytes / macrophagesIL-1α, IL-1β, IL-18, TNFα, HMGB1, IL-10, IL-1RA, IL-12p40, IL-12p70, IL-27, IFNα2, IFNβ, IFNω, IL-31, IL-23, IL-20, IL-24, IL-15, IL-6, LIF, GM-CSF, G-CSF, M-CSF, EGF, TGFα, FGF-2, PDGF-AA, PDGF-AB/BB, VEGF-A, BAFF, APRIL, TRAIL, IL-8, GROα, ENA-78, GCP-2, IP-10, MIG, I-TAC, MCP-1, MCP-2, MCP-3, MIP-1α, MIP-1β, MIP-1δ, MPIF-1, RANTES, Eotaxin-2, MCP-4, MDC, I-30951
Dendritic cells (cDC, Langerhans)IL-1β, IL-18, HMGB1, TSLP, IL-10, IL-12p40, IL-12p70, IL-27, IFNβ, IL-28A, IL-29, IL-31, IL-23, IL-20, IL-2, IL-15, IL-6, BAFF, APRIL, MIG, MIP-1α, MIP-1β, MPIF-1, Eotaxin-2, TARC, MDC, MIP-3β, Fractalkine28
Plasmacytoid DCsIFNα2, IFNβ, IFNω, IL-28A, IL-29, TRAIL, Granzyme B7
NeutrophilsIL-1β, IL-1RA, IL-12p40, IL-12p70, VEGF-A, BAFF, APRIL, TRAIL, IL-8, MIP-1α10
EosinophilsIL-17E/IL-25, IL-4, IL-5, TGFα, VEGF-A, APRIL, Eotaxin, IL-168
Mast cells / basophilsTNFα, IL-17E/IL-25, TSLP, IL-10, IL-4, IL-5, IL-9, IL-13, IL-31, IL-3, FGF-2, VEGF-A, sCD40L, Granzyme B, MCP-3, MIP-1α, I-309, IL-1618
Th1 cellsTNFβ, IFNγ, sFasL3
Th2 / Th9 cellsIL-17E/IL-25, IL-10, IL-4, IL-5, IL-9, IL-13, IL-31, IL-24, IL-3, I-30910
Th17 / Th22 / γδ T cellsIL-17A, IL-17F, IL-21, IL-22, IL-24, GM-CSF, MIP-3α, Perforin, Granzyme A, Lymphotactin10
Tfh cellsIL-4, IL-21, BCA-13
Regulatory T / B cellsIL-10, IL-352
Activated T cells (general CD4/CD8)TNFα, IL-2, IL-6, LIF, IL-3, GM-CSF, Flt-3 Ligand, sCD40L, sCD137, sFas, MIP-1α, RANTES, IL-1613
CD8+ cytotoxic T cellsTNFβ, IFNγ, sFasL, TRAIL, Perforin, Granzyme A, Granzyme B, MIP-1β, IL-16, Lymphotactin10
NK / NKT cellsTNFα, TNFβ, HMGB1, IFNγ, IL-4, IL-13, IL-21, IL-2, IL-3, sCD137, sFasL, TRAIL, Perforin, Granzyme A, Granzyme B, MIP-1α, MIP-1β, Lymphotactin18
ILC1IFNγ1
ILC2IL-5, IL-9, IL-133
ILC3TNFβ, IL-17A, IL-17F, IL-224
B cells / plasma cellsTNFβ, Granzyme B, MDC, IL-164
Epithelial cells (airway, gut, glandular)IL-1α, IL-18, IL-33, IL-17E/IL-25, TSLP, IL-1RA, IFNβ, IL-28A, IL-29, IL-17F, IL-7, IL-15, IL-11, GM-CSF, G-CSF, SCF, EGF, TGFα, PDGF-AA, VEGF-A, BAFF, APRIL, IL-8, GROα, ENA-78, GCP-2, IP-10, MCP-1, MIP-1δ, RANTES, Eotaxin, Eotaxin-2, Eotaxin-3, MCP-4, TARC, IL-16, MIP-3α, CCL28, Fractalkine39
KeratinocytesIL-1α, IL-18, TSLP, IL-20, IL-24, IL-7, IL-34, SCF, TGFα, VEGF-A, Granzyme B, IL-8, GROα, IP-10, MIG, I-TAC, MCP-3, Eotaxin-3, TARC, MIP-3α, CTACK21
Endothelial cellsIL-1α, IL-33, IL-6, GM-CSF, G-CSF, M-CSF, SCF, Flt-3 Ligand, FGF-2, PDGF-AB/BB, IL-8, GROα, ENA-78, IP-10, MIG, I-TAC, MCP-1, MCP-2, RANTES, Eotaxin, Eotaxin-3, MCP-4, TARC, I-309, SDF-1, 6Ckine, Fractalkine27
Fibroblasts / smooth muscle / pericytesTSLP, IFNβ, IL-6, IL-11, LIF, GM-CSF, G-CSF, M-CSF, SCF, FGF-2, PDGF-AA, PDGF-AB/BB, IL-8, GROα, ENA-78, GCP-2, IP-10, MCP-1, MCP-2, MCP-3, RANTES, Eotaxin, Eotaxin-2, MCP-424
Platelets / megakaryocytesEGF, PDGF-AA, PDGF-AB/BB, VEGF-A, sCD40L, ENA-78, MCP-3, RANTES8
Liver / kidney (endocrine-like)IL-1RA, IL-28A, IL-29, TPO, EGF5
Bone-marrow and lymphoid stroma (CAR, FRC, FDC, HEV)IL-33, IL-7, IL-15, IL-11, LIF, M-CSF, IL-34, SCF, Flt-3 Ligand, TPO, BAFF, SDF-1, 6Ckine, MIP-3β, BCA-115
Neurons / gliaLIF, IL-34, PDGF-AA, I-TAC, Fractalkine5
Many / any nucleated cells (injury, infection, hypoxia, splicing)IL-1α, HMGB1, IFNα2, IFNβ, VEGF-A, sFas6
Th1 cells (Scene 19)IFNγ, TNFα, TNFβ, IL-2, IL-105
Th2 cells (Scene 19)IL-4, IL-5, IL-13, IL-9, IL-31, IL-10, GM-CSF7
Th17 cells (Scene 19)IL-17A, IL-17F, IL-22, IL-21, GM-CSF, TNFα6
Th9 cells (Scene 19)IL-9, IL-10, IL-213
Th22 cells (Scene 19)IL-22, TNFα2
Tfh cells (Scene 20)IL-21, IL-4, sCD40L, IL-10, BCA-15
Tfr cells (Scene 20)IL-10, IL-352
Thymic (natural) Tregs (Scene 20)IL-10, IL-352
Peripherally induced Tregs (Scene 20)IL-10, IL-352
Tr1 cells (Scene 20)IL-10, IFNγ, Granzyme B3
CD8 cytotoxic T cells (Scene 21)IFNγ, TNFα, Perforin, Granzyme A, Granzyme B, sFasL, Lymphotactin7
CD8 Tc2 / Tc17 cells (Scene 21)IL-4, IL-5, IL-13, IL-17A, IL-22, GM-CSF, Granzyme B7
CD8 memory T cells (Scene 21)IL-2, IFNγ2
CD8 effector-memory and Temra (Scene 21)IFNγ, Perforin, Granzyme B, TNFα4
CD8 tissue-resident memory (Scene 21)IFNγ, Granzyme B, TNFα3
CD8 regulatory T cells (Scene 21)IL-10, Granzyme B2
iNKT cells (Scene 22)IFNγ, IL-4, IL-13, IL-2, TNFα, IL-10, GM-CSF, sCD40L, Granzyme B9
MAIT cells (Scene 22)IFNγ, TNFα, IL-17A, IL-22, Granzyme B5
γδ T cells (Scene 22)IFNγ, IL-17A, IL-17F, TNFβ, Perforin, Granzyme B, IL-227
NK cells (Scene 22)IFNγ, TNFα, Perforin, Granzyme A, Granzyme B, Lymphotactin, GM-CSF7
Marginal-zone B cells (Scene 24)IL-101
B-1 cells (Scene 24)IL-101
Regulatory B cells (Scene 24)IL-10, IL-35, Granzyme B3
Plasmablasts (Scene 25)IgM, IgG1, IgA1, IgE4
Long-lived plasma cells (Scene 25)IgG1, IgG2, IgG3, IgG4, IgA1, IgA26
Neutrophils, on phagocytosis (Scene 34)IL-8, TNFα, BAFF, IL-1RA, IL-1β5
Macrophages clearing apoptotic neutrophils (Scene 33)IL-101
Hepatocytes (complement synthesis, Scenes 29–31)C1r / C1s, C4, C2, C3, C5, C6 / C7 / C8 / C9 (MAC), Factor B, Factor H, Factor I, C1 inhibitor, MBL, MASP-2, C4BP / MCP / DAF13
Hepatocytes (acute-phase output, Scenes 35, 38)CRP, SAA, Fibrinogen, Haptoglobin, Ferritin, Hepcidin, Albumin, Transferrin and transthyretin8
Thyroid C cells and parenchymal tissue (Scene 36)Procalcitonin1
Adipocytes (Scene 30)Factor D1
Monocytes and macrophages (complement synthesis, Scene 29)C1q, C3, Factor B, Factor I4
Neutrophil granules (Scene 30)Properdin1

Text guide

Full explanations for all 47 scenes above, in order. Match the scene title here to the title bar above each diagram.

Scene 1 · Innate alarm and the regulatory brake

A pathogen or damage signal hits a macrophage/dendritic cell. Three receptors from two families — the TNF receptors, plus the IL-1 and IL-18 receptors of the IL-1 family — all converge on the same transcription factor, NF-kB, through different adaptor proteins. IL-1RA physically occupies the IL-1 receptor without triggering it. IL-10 arrives at a completely different receptor; its STAT3 signal switches on a suppressive gene programme that represses NF-kB target genes and destabilizes pro-inflammatory mRNAs — drawn here as a block on the pro-inflammatory genes, not on the adaptors. (IL-10 also induces SOCS3, but its anti-inflammatory effect persists without it.)

Scene 2 · The Th1 amplification core

The macrophage from Scene 1 secretes IL-12 and IL-27. Both, together with IL-23, bind to a T cell or NK cell. IL-12 and IL-23 share the IL-12Rbeta1 chain (and the p40 subunit); IL-27 is a relative that uses its own WSX-1/gp130 receptor. Each fires a different STAT and gene programme: IL-12→STAT4 drives Th1, IL-23→STAT3 expands and stabilizes Th17, and IL-27 first supports Th1 (STAT1/T-bet), then restrains Th17 and induces IL-10. IL-18 arrives through the older, non-JAK IL-1-family route and synergizes with IL-12 on the same IFN-gamma gene. The IFN-gamma that comes out closes two loops at once: a positive loop back to the macrophage that amplifies IL-12, and a negative loop that induces IL-18BP to cap IL-18. Follow both all the way around.

Scene 3 · Th2 / allergic axis

Unlike the Th1 core, the Th2 cytokines mostly act on different target cells rather than converging on one. IL-4 and IL-13 share a receptor chain and the same STAT6 endpoint: on epithelium it drives mucus, eotaxin and periostin; in T and B cells it drives GATA3 and the IgE switch. IL-5 and IL-9 use the same STAT5 machinery as the survival cytokines in Scene 5, but on eosinophils and mast cells respectively. IL-31 is the odd one out — its receptor is expressed on sensory neurons, making it a major driver of Th2-associated itch.

Scene 4 · Th17 axis

IL-6, IL-23 (detailed in Scene 2), and IL-21 all converge on STAT3 to lock in Th17 identity. IL-21 is special: Th17 cells secrete it themselves, and it signals back on the very same cell — a genuine autocrine amplification loop, separate from the IL-12/IL-18/IFN-gamma loop in Scene 2. The two output cytokines, IL-17A and IL-22, land on the same epithelial cell but take completely different routes to get there: IL-17A never touches a JAK.

Scene 5 · Survival signals and antiviral defence

IL-2, IL-7, and IL-15 share the common gamma chain and JAK1/JAK3/STAT5 — the same machinery IL-9 uses in Scene 3. IL-15 is drawn differently on purpose: it is usually trans-presented, held on a dendritic cell's own IL-15Ralpha and handed directly to the responding lymphocyte, rather than floating free like other cytokines. IFN-alpha's antiviral cascade builds a three-part complex (ISGF3) instead of a simple dimer. IL-6's most classic site isn't an immune cell at all — it's the liver. GM-CSF acts on myeloid progenitors, but its non-redundant job is in the lung (alveolar macrophages).

Scene 6 · Chemokine gradients

Everything so far has been one cell secreting, another cell's receptor firing a kinase cascade into its own nucleus. Chemokines do something different: they form a physical concentration gradient in the tissue, and leukocytes read that gradient through a 7-transmembrane GPCR, not a JAK, and crawl up it. Four lanes below show four different cell types reading four different (overlapping) chemokine sets. The fifth vignette, SDF1alpha, is the odd one out — its main job is to hold cells in place and guide homing, rather than inflammatory recruitment.

Scene 7 · Epithelial alarmins and damage signals

The initial signals in an allergic response often originate from damaged epithelium rather than from T cells. IL-33 (an IL-1-family trefoil stored in the nucleus) and IL-25 (an IL-17-family cystine knot produced by tuft cells) both activate ILC2s and Th2 memory cells through NF-κB, so the first IL-5 and IL-13 can appear before any antigen-specific T cell is involved. TSLP signals through the JAK-STAT pathway: STAT5 is its main signal, whereas in the dendritic cell OX40L is induced via NF-κB and CCL17 via STAT6, which together enable the dendritic cell to prime naive T cells toward Th2. HMGB1 is the generic damage signal released by any necrotic cell and feeds back into the innate alarm response of Scene 1.

Scene 8 · Interferons beyond IFN-α: type I and type III

IFN-α (Scene 5) is not the only antiviral interferon. IFN-β and IFN-ω use the same IFNAR receptor and the same ISGF3 programme. IFN-β is the first interferon produced after a virus is sensed, and one of the genes it induces, IRF7, enables virus-sensing cells to produce substantially more IFN-α/β; this positive feedback loop is drawn in pink. The type III interferons IL-28A and IL-29 (IFN-λ2 and IFN-λ1) activate the same ISGF3 programme through a different receptor, IFNLR1 + IL-10R2, which is expressed mainly on barrier epithelium and hepatocytes. They protect the surfaces at which viruses enter while causing less systemic inflammation.

Scene 9 · Regulatory brakes and soluble decoys

Not every member of a cytokine family activates a pathway. Free IL-12p40 (and its p80 homodimer) occupies IL-12Rβ1 without signalling and competes with both IL-12 and IL-23. IL-35, produced by regulatory cells, signals through an unusual STAT1:STAT4 pair to suppress the target T cell and convert it into a new IL-35 producer, so suppression is propagated from cell to cell (infectious tolerance, shown as the pink loop). The two soluble receptors act by ligand capture: sCD137 binds 4-1BB ligand and sFas binds Fas ligand, so the ligand does not reach the receptor on the cell and the signal shown in dashed grey is not transmitted.

Scene 10 · Barrier-tissue and gp130-family cytokines

IL-17F is the less potent counterpart of IL-17A (Scene 4): it uses the same receptor pair and the same Act1/NF-κB pathway and induces a smaller neutrophil programme. IL-20 and IL-24 belong to the IL-10 family and share two receptor combinations on keratinocytes, driving proliferation through STAT3; IL-24, induced by IL-13, also lowers filaggrin, linking Th2 inflammation to the barrier defect of atopic dermatitis. IL-11 and LIF are gp130-family relatives of IL-6. IL-11 is produced by fibroblasts and acts on the same fibroblasts (an autocrine loop), and its fibrotic programme depends largely on ERK. LIF supports mouse embryonic stem cells, implantation, acute-phase proteins and neurons.

Scene 11 · Haematopoietic growth factors

Haematopoiesis in the bone marrow is regulated through two classes of growth-factor receptor. IL-3, G-CSF and TPO use cytokine receptors with JAKs, as do the survival cytokines of Scene 5: IL-3 acts on progenitors, basophils, mast cells and pDCs, G-CSF on neutrophils (it rises when IL-17 is high), and TPO on megakaryocytes and platelets. M-CSF and IL-34 (sharing CSF1R), SCF (KIT) and Flt-3 ligand (FLT3) instead bind receptor tyrosine kinases: the ligand pairs two receptor chains, which phosphorylate each other and activate PI3K/AKT and RAS/MAPK. KIT is the mast-cell receptor mutated in systemic mastocytosis.

Scene 12 · Tissue growth factors and angiogenesis

Tissue repair and remodelling use the same receptor-tyrosine-kinase mechanism. EGF and TGFα share EGFR on epithelium and keratinocytes; FGF-2 requires heparan sulfate as a co-receptor; the PDGFs pair different PDGFR chains (BB binds all three combinations) to recruit fibroblasts, pericytes and smooth muscle; VEGF-A acts on endothelial VEGFR2 to induce new vessel formation and vascular permeability, whereas VEGFR1 acts mainly as a decoy receptor. In the airway these mediators underlie mucus metaplasia, smooth-muscle growth and vascular remodelling.

Scene 13 · TNF superfamily: B-cell survival and co-stimulation

Three TNF-family trimers determine B-cell fate. BAFF maintains survival of naive B cells through BAFF-R, which degrades TRAF3 and releases NIK to activate the non-canonical NF-κB pathway; excess BAFF permits survival of autoreactive B cells (the target of belimumab). APRIL maintains survival of long-lived plasma cells through BCMA and drives IgA switching through TACI. CD40 ligand drives class switching and germinal-centre formation through CD40; most of this help derives from membrane CD40L on T cells, and most circulating soluble CD40L derives from platelets.

Scene 14 · Death ligands and cytotoxic granules

Cytotoxic cells kill by two mechanisms. Death ligands (FasL, TRAIL) bind a death receptor that recruits FADD and caspase-8, which activates caspase-3; soluble FasL is weakly cytotoxic compared with the membrane form. Granule-mediated killing delivers perforin, which inserts into the target membrane in a calcium-dependent manner and forms pores, and granzymes, which enter through those pores. Granzyme B cleaves BID to trigger the mitochondrial pathway and also activates caspase-3 and -7 directly. Granzyme A causes caspase-independent death by a mechanism that is not settled: single-strand DNA nicking after cleavage of the SET complex, and pyroptosis through cleavage of gasdermin B in gasdermin-B-expressing cells such as epithelium, have both been proposed.

Scene 15 · CXC chemokines: neutrophil recruiters and interferon-induced T-cell recruiters

These lanes extend Scene 6. ENA-78 and GCP-2 act with IL-8 and GROα as neutrophil chemoattractants (through CXCR2, and additionally CXCR1 for GCP-2) and are induced by IL-1 and TNF (ENA-78 also by IL-17). MIG and I-TAC act with IP-10 on CXCR3, the receptor that recruits Th1 cells, CTLs and NK cells into tissue; MIG is produced predominantly in response to IFN-γ, and serum CXCL9 is therefore used as a measure of IFN-γ activity.

Scene 16 · Inflammatory CC chemokines: shared receptors

CC chemokines are promiscuous in their receptor usage, so the relationships are presented as a table rather than a diagram. Each row shows every receptor engaged by one chemokine, and each column shows every chemokine to which a given cell type responds. These four chemokines mainly recruit monocytes and T cells through CCR1 and CCR2, and also recruit eosinophils through CCR3. MCP-3 also binds CCR5 but acts as an antagonist at that receptor.

Scene 17 · Allergic-tissue chemokines: eosinophil, Th2 and Treg recruiters

The chemokines of allergic tissue fall into two groups: CCR3 ligands that recruit eosinophils and basophils (the eotaxins and MCP-4), and CCR4 / CCR8 ligands that recruit Th2 cells and Tregs (TARC, MDC, I-309). Eotaxin-3 is also an antagonist at CCR1, CCR2 and CCR5, so it attracts eosinophils while blocking monocyte and Th1 recruitment. IL-16 is included because it attracts CD4+ cells, but it is not a chemokine and signals through CD4.

Scene 18 · Homing and positioning chemokines: tissue addresses

Homeostatic chemokines direct cells to specific tissues. CCR7 ligands recruit naive T cells and mature DCs into the lymph-node T zone; CXCL13 recruits B cells and Tfh cells into follicles; CCL20 recruits CCR6+ cells to epithelia; CCL27 (skin) and CCL28 (mucosa) act through CCR10 to direct memory T cells and IgA plasmablasts to the appropriate barrier. Lymphotactin acts in the opposite direction: an activated CD8 T cell or NK cell recruits an XCR1+ cDC1. Fractalkine is both a chemokine and an adhesion molecule, anchored on inflamed endothelium, where it captures patrolling monocytes.

Scene 19 · CD4 effector T-helper subsets: what induces each and what each makes

The fate of a naive CD4 T cell is not fixed: the cytokines present at priming determine the effector subset, and each subset is defined by a transcription factor, a set of effector cytokines and a homing pattern. IL-12 with IL-18 induces Th1 and IFN-γ; IL-4 induces Th2 and the IL-4, IL-5, IL-13 programme underlying allergic disease; IL-1β with IL-6 and IL-23 induces Th17 and the neutrophil-recruiting IL-17 programme; IL-4 with TGF-β induces Th9; and IL-6 with TNF-α and aryl-hydrocarbon-receptor ligands induces Th22, which produces IL-22 without IL-17. Th9 and Th22 are better regarded as differentiation states than as fixed lineages. The lanes beneath show the cross-regulation: IFN-γ suppresses Th2 and Th17, IL-4 suppresses Th1, and IL-4 is required for Th9 as well as Th2. IL-4 also restrains Th17, which is shown as a suppression marker on the Th17 entry rather than as a lane, and the IL-13-driven keratinocyte IL-24 of Scene 10 is named in the footer because it does not act between two of these cells.

Scene 20 · Regulatory and follicular CD4 T cells

The same naive cell can alternatively differentiate into a helper of B cells or a regulatory cell. In the current working model, Tfh cells are induced in humans mainly by IL-12, although the human inducer is not established, with IL-21 as an autocrine amplifier; they express CXCR5, enter the follicle and deliver IL-21, IL-4 and CD40 ligand, which determine the isotype of the antibody response. Tfr cells are regulatory cells that enter the follicle with them and limit the response. Thymic Tregs depend on IL-2 and STAT5 for FoxP3 stability; peripherally induced Tregs are generated in the gut by TGF-β with retinoic acid and are the population on which oral tolerance and oral immunotherapy depend. Tr1 cells do not express FoxP3: they are induced by IL-27 and IL-10 and suppress through large amounts of IL-10. IL-2 is required for Treg survival but represses Bcl-6, and therefore restrains the follicular programme.

Scene 21 · CD8 T-cell subsets: effector, memory, resident and regulatory

CD8 T cells differentiate along corresponding lines. A cDC1 cross-presenting antigen with IL-12 and type I interferon induces a Tc1 cytotoxic lymphocyte expressing perforin, granzymes, Fas ligand and IFN-γ; IL-4 instead induces Tc2 and IL-6 with IL-23 induces Tc17, which are found in allergic and psoriatic tissue respectively. Memory subsets are distinguished by the signals that maintain them: IL-7 and IL-15 maintain stem-cell-like and central-memory cells, persistent antigen with IL-15 produces effector-memory and terminally differentiated Temra cells, and TGF-β with local IL-15 retains tissue-resident memory cells through CD69 and CD103. These resident cells account for the recurrence of a fixed drug eruption and of a herpes lesion at the same site.

Scene 22 · Innate-like T cells and NK cells

Four lymphocyte populations respond within hours rather than days. Invariant NKT cells recognize lipid presented by CD1d and release IFN-γ, IL-4 and IL-13 together, so they influence the response before any conventional T cell is primed. MAIT cells recognize riboflavin metabolites presented by MR1 and can also be activated by IL-12 with IL-18 alone, without a receptor signal. γδ T cells are not MHC-restricted. NK cells are included for comparison: IL-15 maintains their survival, IL-12 and IL-18 induce IFN-γ, and CD16 allows bound IgG to direct their cytotoxicity, which is the point at which antibody and cellular cytotoxicity converge. PLZF is the shared developmental transcription factor of the innate-like T-cell lineages.

Scene 23 · Which cytokine acts on which lymphocyte subset

This matrix is the index to the four preceding scenes. Each row shows every lymphocyte on which one cytokine acts; each column shows every cytokine to which a subset responds or which it produces. Three entries merit comment. IL-2 both expands effector T cells and sustains the Tregs that restrain them, while repressing Bcl-6 and thereby restraining Th17 and Tfh. IL-10 suppresses Th1 cells and is also produced by them, which constitutes the self-limiting arm of a Th1 response. CD40 ligand appears almost entirely as a product of activated T cells rather than as a signal acting on them, because its targets are the B cell and the dendritic cell.

Scene 24 · B-cell subsets before the germinal centre

A B cell leaving the marrow is transitional and survives only if tonic B-cell-receptor signalling is matched by BAFF; this is the last checkpoint against autoreactivity, and excess BAFF therefore permits survival of autoreactive cells. Surviving cells become naive follicular B cells, the pool from which T-dependent responses arise. Marginal-zone B cells respond to polysaccharide with little or no T-cell help, using the B-cell receptor together with Toll-like receptors and complement receptor CD21; they therefore protect against encapsulated bacteria, and that protection is weak in young children and absent after splenectomy. B-1 cells are the source of natural IgM in mouse; the human equivalent is contested. Regulatory B cells are defined by IL-10 production rather than by lineage.

Scene 25 · The germinal centre and antibody-secreting cells

In the germinal centre a B cell moves between the dark zone, where AID mutates its immunoglobulin genes, and the light zone, where it must capture antigen from follicular dendritic cells and obtain help from a Tfh cell. That help, consisting of CD40 ligand and IL-21, both maintains survival of the cell and selects the isotype. Cells that receive little help become memory cells; those that receive most become plasmablasts; and plasmablasts that reach a CXCL12 marrow niche with APRIL, BAFF and IL-6 become long-lived plasma cells that maintain serum titres for years. The long-lived fraction does not express CD20, and anti-CD20 treatment therefore spares existing antibody while depleting the cells that would generate new specificities.

Scene 26 · Class switching: which signal selects which isotype

Class switching requires two signals: a CD40 signal (or a TACI signal from BAFF or APRIL in the absence of T-cell help) to induce AID, and a cytokine to select the isotype. CD40 ligand is drawn as a ring rather than a filled circle because it permits switching without selecting an isotype. IL-4 and IL-13 open the ε and γ4 regions and therefore induce IgE and IgG4; the addition of IL-10 shifts the same cell from IgE toward IgG4, as occurs during successful allergen immunotherapy. IFN-γ induces IgG1 and IgG3 and suppresses IgE. TGF-β with APRIL or BAFF induces IgA, and gut retinoic acid favours IgA2. Polysaccharide acting through TACI induces IgM and IgG2 without germinal centres; this is the response that matures last in childhood.

Scene 27 · Immunoglobulin isotypes: levels, complement and Fc receptors

Each isotype is defined by the effector functions of its constant region. IgM is the strongest activator of the classical complement pathway, but only after antigen binding converts the pentamer from its planar star form into the staple conformation that exposes its C1q binding sites. Among the IgG subclasses the order of complement activation is IgG3 then IgG1, with IgG2 weak and IgG4 inactive; IgG2 is bound almost exclusively by the H131 allotype of FcγRIIa, which accounts for the relevance of that polymorphism to pneumococcal infection. IgG4 preferentially binds the inhibitory receptor and exchanges half-molecules, so it cannot cross-link antigen, which defines a blocking antibody. IgA engages FcαRI on neutrophils and is transported into secretions by pIgR. IgE engages FcεRI, on which it persists for weeks. Every range in this scene is a typical adult value: in children, the IgG nadir at three to six months, the late maturation of the polysaccharide response and the rise of total IgE through childhood make an age-matched range essential.

Scene 28 · Fc receptors: how antibody becomes cellular action

An antibody exerts effector function only when its Fc is bound by a cellular receptor. FcγRI is the only high-affinity IgG receptor and is therefore occupied by circulating IgG; it is expressed on neutrophils only after IFN-γ or G-CSF, which accounts for the rise in neutrophil CD64 within hours of bacterial infection. FcγRIIa is the main phagocytic receptor. FcγRIIb is the only inhibitory Fc receptor and the only one expressed by B cells, so IgG immune complexes inhibit further antibody production. FcγRIIIa on NK cells is the receptor for antibody-dependent cellular cytotoxicity, and its V158F polymorphism predicts the response to IgG1 therapeutic antibodies. FcεRI retains IgE on mast cells for weeks and triggers immediate hypersensitivity; CD23 regulates the quantity of IgE produced. FcRn and pIgR do not signal; they are transport receptors, which accounts for the three-week half-life of IgG, its transfer across the placenta and the delivery of secretory IgA to the mucosal surface.

Scene 29 · Complement: the classical and lectin pathways

The classical and lectin pathways differ only in the molecule that recognizes the target. C1q binds the Fc of antibody already bound to a surface and activates C1r and then C1s; mannose-binding lectin, a ficolin or collectin-11 binds microbial carbohydrate and activates MASP-2, which has the same function as C1s. Either protease cleaves C4 to C4b, which binds the surface covalently, and C2 to C2a, and C4b with C2a forms the C3 convertase. C1 inhibitor is the inhibitor of both initiating proteases and, of equal importance, of plasma kallikrein and factor XIIa; its loss therefore causes bradykinin angioedema rather than a complement-deficiency syndrome. Low C4 with a normal C3 is the classic screening pattern for that condition, whereas low C4 with low C3 indicates classical-pathway consumption.

Scene 30 · Complement: the alternative pathway, amplification and the terminal pathway

The alternative pathway requires no recognition molecule: C3 hydrolyses spontaneously, factor D cleaves the factor B bound to it, and the resulting convertase cleaves further C3 to C3b. Properdin stabilizes that loop five- to ten-fold, and as a result the alternative pathway generates most of the C3b and membrane attack complex in any response, irrespective of the initiating pathway. A second C3b converts the convertase into a C5 convertase, and C5 is cleaved into C5a, the most potent neutrophil chemoattractant in the body, and C5b, which recruits C6 to C9 to form a pore. Host cells are protected by factor H, factor I, DAF, MCP, CR1 and CD59. The two functional assays together localize a defect: absent CH50 with normal AH50 indicates C1, C2 or C4; the reverse indicates factor D, factor B or properdin; absence of both indicates C3 or a terminal component.

Scene 31 · Complement regulators and the deficiency states that follow

Deficiency of each regulator has a characteristic presentation, and the pattern is usually more informative than the measured level. C1 inhibitor deficiency causes angioedema. In factor H the phenotype depends on the domain affected: C-terminal mutations, which impair host-surface recognition, cause atypical haemolytic uraemic syndrome, whereas loss of N-terminal regulatory function causes C3 glomerulopathy. Factor I deficiency results in complete consumption of C3, so the presentation is secondary C3 deficiency with pyogenic infection. The membrane regulators are lost together in paroxysmal nocturnal haemoglobinuria, in which an acquired PIGA mutation eliminates both DAF and CD59 from a stem-cell clone, and separately in CHAPLE disease, in which inherited CD55 loss causes protein-losing enteropathy. Neonatal complement levels are roughly half to two-thirds of adult levels, so age-matched ranges are as important here as for immunoglobulins.

Scene 32 · Complement receptors: how complement signals to cells

Complement fragments act only when recognized by a cellular receptor, and the fragment present determines which cell responds. CR1 binds intact C3b, and erythrocyte CR1 is the main route by which immune complexes reach the liver and spleen. Once factor I has cleaved C3b, iC3b is the ligand for CR3 and CR4, so that single cleavage transfers the particle from one receptor to another. The final fragment, C3d, is bound by CR2 on B cells, where it lowers the activation threshold by orders of magnitude: this is the point at which innate complement directly amplifies an antibody response, and it is also the receptor by which Epstein–Barr virus enters the cell. The anaphylatoxin receptors are GPCRs of the same family as the chemokine receptors, and C5aR1 on the neutrophil converts complement activation into neutrophil recruitment.

Scene 33 · Neutrophil regulation: production, release, recruitment and resolution

Neutrophil numbers are regulated at four points, each associated with a distinct disease. G-CSF drives production. The marrow then holds about ninety per cent of the neutrophils of the body in reserve, retained by stromal CXCL12 acting on CXCR4 and released when G-CSF lowers CXCL12 and raises the CXCR2 ligands; in WHIM syndrome gain-of-function CXCR4 fixes this balance in favour of retention. In tissue, TNF-α and IL-1β induce selectins and chemokines on endothelium and C5a is generated by complement activation; the cell rolls, adheres firmly through LFA-1 and CR3, and migrates out of the vessel, and the leukocyte adhesion deficiencies disrupt successive steps of this sequence. Finally the cell undergoes apoptosis and is ingested, which switches the macrophage to IL-10 and TGF-β production and actively terminates the response. The number of cells cleared is itself sensed: when few apoptotic neutrophils are ingested, IL-23 rises, IL-17 follows, and IL-17 raises G-CSF, which is the loop that accounts for the rise in G-CSF in neutropenia.

Scene 34 · Neutrophil function: opsonins, the burst, granules and NETs

A neutrophil kills unopsonized targets far less efficiently, although it recognizes some targets directly, including fungal beta-glucan through Dectin-1 and CR3, so antibody and complement largely determine which targets are ingested. IgG is bound by FcγRIIa and FcγRIIIb, and FcγRI is expressed only after IFN-γ or G-CSF. C3b is bound by CR1 and, after cleavage by factor I, iC3b by CR3; C5a activates the same CR3 by inside-out signalling, so complement provides both the activating signal for adhesion and the opsonized particle. Ingestion assembles the NADPH oxidase on the phagosome and discharges the granules into it; in chronic granulomatous disease the oxidase is absent and granulomas form. When the target cannot be ingested the cell can instead release an extracellular trap, which captures organisms but also externalizes the MPO and PR3 of ANCA disease, the nucleosomes of lupus, and the citrullinated histones that are the source of rheumatoid autoantibodies.

Scene 35 · The hepatic acute-phase response: how a cytokine signal becomes a blood test

Almost all inflammatory markers in clinical use are products of a single circuit. Infection, trauma, surgery or autoinflammation activates macrophages and monocytes, which release IL-6 with IL-1-beta and TNF-alpha, and the hepatocyte responds to IL-6 through gp130, JAK1 and STAT3. A coordinated change in plasma-protein synthesis follows: CRP, serum amyloid A, fibrinogen, haptoglobin, ferritin, hepcidin, alpha-1 antitrypsin and ceruloplasmin rise, while albumin, transferrin and transthyretin fall simultaneously and for the same reason. Several complement proteins are also acute-phase reactants, so a C3 or C4 level can be normal during consumption. The dependence on a single signal is of clinical importance: during IL-6 blockade, in IL6R or STAT3 defects, and in liver failure, the IL-6-dependent reactants (CRP, fibrinogen and therefore the ESR, haptoglobin and SAA) cannot rise, so a normal CRP in those settings provides no information about infection. Two markers are exempt and are used instead: procalcitonin still rises, and ferritin can still rise steeply, because it is also driven by IL-1-beta, IFN-gamma and IL-18. A rising ferritin with an unchanged CRP in a child on tocilizumab is a clinically significant finding and not an artefact.

Scene 36 · The markers in common use: CRP, SAA, procalcitonin and fibrinogen

These four markers differ sufficiently in behaviour that their combined measurement is more informative than any single marker. CRP is produced only by hepatocytes, only in response to IL-6, and has a fixed half-life of about nineteen hours, so the level reflects the current rate of synthesis; it is also an effector molecule, binding phosphocholine on damaged membranes and on pneumococcus and then activating complement through C1q, and thus acts as an antibody-independent opsonin. Serum amyloid A rises earlier and falls more rapidly, and can rise about 1000-fold in a day, as can CRP; sustained elevation is the precursor of AA amyloid, which makes SAA, rather than CRP, the marker of adequately treated periodic fever. Procalcitonin is induced by bacterial products and suppressed by interferon, so it discriminates bacterial from viral illness better than CRP, and it is the only marker in this group that IL-6 blockade does not abolish. Fibrinogen rises slowly and is the principal protein determining the ESR.

Scene 37 · The ESR: what it measures, what moves it, and how it differs from CRP

The ESR is not a protein: it is the distance that red cells fall in a tube in one hour. Sedimentation is faster when plasma proteins bridge red cells into rouleaux, and the principal protein responsible is fibrinogen, followed by immunoglobulin. The properties of the test follow from this mechanism. Because fibrinogen takes a day or two to rise and days to weeks to fall, the ESR lags the CRP in both directions. Because any factor that alters red cells or plasma proteins alters sedimentation, the ESR can be high in the absence of inflammation (anaemia, pregnancy, age, any hypergammaglobulinaemia) and can remain normal despite active inflammation when fibrinogen is consumed or the red cells do not form rouleaux, as in sickle-cell disease or disseminated intravascular coagulation. Discordance between the two tests is informative: a high CRP with a normal ESR indicates inflammation of less than a day in duration; a high ESR with a normal CRP indicates a resolving process, a paraprotein, or anaemia. In lupus the two classically diverge, so a high CRP in that setting should raise the possibility of infection rather than flare.

Scene 38 · What inflammation does to iron: hepcidin, ferritin and the anaemia of inflammation

Iron sequestration is a regulated component of the inflammatory response and is mediated by the same IL-6 signal that raises CRP. IL-6 acting through STAT3 raises hepcidin; hepcidin degrades ferroportin, the only route by which iron leaves a cell; dietary iron therefore cannot cross the enterocyte and recycled iron cannot leave the macrophage. Serum iron and transferrin saturation fall, transferrin falls because it is a negative acute-phase protein, and ferritin rises for two unrelated reasons simultaneously: inflammation raises its transcription and retained iron raises its translation. The result is the anaemia of inflammation, and in practice the standard iron panel can no longer be interpreted in the usual way: a normal or high ferritin does not exclude iron deficiency, a low transferrin does not indicate iron overload, and the response to oral iron is poor until the inflammation is treated. A ferritin of several thousand has a different significance and suggests haemophagocytosis or macrophage activation syndrome.

Scene 39 · Type 2 and allergic disease: the agents, and what each one does to the tests

The seven agents differ in the level of the type 2 pathway at which they act. Omalizumab binds free IgE at the site used by FcεRI, so IgE can no longer bind to mast cells; receptor-bound IgE is not displaced, which accounts for an onset of effect over weeks as FcεRI density falls. Dupilumab binds IL-4Rα and thereby blocks IL-4 and IL-13 together, whereas tralokinumab and lebrikizumab block IL-13 alone. Mepolizumab and reslizumab neutralise IL-5 and deprive the eosinophil of its survival signal; benralizumab binds IL-5Rα with an afucosylated Fc and directs NK-cell killing of the eosinophil, so the count falls to zero rather than being reduced. Tezepelumab is the only agent acting upstream of the type 2 cytokines, at TSLP, which accounts for its efficacy in the absence of a type 2 phenotype. Nemolizumab blocks the IL-31 receptor and treats itch rather than inflammation. Two laboratory effects are contrary to expectation and account for most errors of interpretation: total IgE rises on omalizumab, because the assay detects drug–IgE complexes, and blood eosinophils rise in the first months of dupilumab treatment, because marrow release continues while eotaxin-driven tissue entry is blocked.

Scene 40 · TNF, IL-1 and IL-6 blockade: the agents that suppress the acute-phase response

These agents act on the three cytokines that drive the hepatic acute-phase response and therefore share one consequence: they lower the markers used to detect infection. The degree differs, and the difference is clinically relevant. TNF and IL-1 blockade attenuate the response; IL-6 blockade abolishes it, so CRP cannot rise on tocilizumab, sarilumab or siltuximab irrespective of the clinical state. Procalcitonin is the exception and is preserved, because bacterial products induce it independently of IL-6; it is the marker to be used. Within TNF blockade the agents are not interchangeable: etanercept is a decoy receptor that also binds lymphotoxin-α and binds transmembrane TNF without sustained cross-linking, which accounts for its lack of efficacy in granulomatous bowel disease, in which the monoclonal antibodies are effective, and for its lower tuberculosis risk. Anakinra blocks IL-1α as well as IL-1β and has a half-life of hours, which makes it the preferred IL-1 agent in an acutely unwell child; canakinumab persists for weeks, which is a disadvantage if infection supervenes. One agent in this group restores the interpretability of a test rather than removing it: IL-6 blockade lowers hepcidin, so the anaemia of inflammation improves and iron studies become interpretable.

Scene 41 · IL-12, IL-23, IL-17 and the cell-directed agents

Ustekinumab binds the p40 subunit shared by IL-12 and IL-23 and therefore blocks the Th1 and Th17 axes together; guselkumab, risankizumab and tildrakizumab bind p19 and block IL-23 alone, leaving IL-12 intact. The IL-17 agents act one step further downstream, and their adverse effects are predictable from the pathways described in this reference: IL-17 drives the epithelial antimicrobial programme, so mucocutaneous candidiasis is the acquired phenocopy of inherited IL-17 pathway defects, and IL-17 drives G-CSF, so neutrophil counts fall mildly. Inflammatory bowel disease is a labelled caution for secukinumab, ixekizumab and bimekizumab, and a contraindication for brodalumab, which also carries a boxed warning for suicidal ideation and behaviour. The cell-directed agents do not target a cytokine. Abatacept blocks the CD28 second signal, so vaccine responses are attenuated and serological protection cannot be assumed. Rituximab depletes CD20-positive B cells but spares the long-lived plasma cell, so IgM falls first and IgG falls later and in a minority remains low for years; the immunological evaluation and vaccinations must therefore precede the first dose. Belimumab removes BAFF from the newly formed B-cell pool and is one of the few agents listed that raises complement levels, as consumption diminishes.

Scene 42 · Interferon and complement blockade, and the JAK inhibitors

The complement agents are the clearest example in this reference of a drug that reproduces an inherited phenotype: blockade of C5 reproduces terminal-pathway deficiency, with the same meningococcal risk and the same vaccination and prophylaxis requirements, and vaccination does not eliminate the risk. The assay that changes indicates the level of blockade. C5 blockade leaves C3 and C4 unaffected, so a normal C3 on treatment provides no information about drug effect, and because C5 is a terminal component its blockade abolishes CH50 and AH50 together. Iptacopan and danicopan abolish AH50 and spare CH50, which is the converse of classical-pathway blockade with sutimlimab and not of C5 blockade. Measured C3 rises steeply on pegcetacoplan, to several hundred mg/dL, because the C3 bound by the drug is no longer consumed, so a high C3 in that setting reflects the effect of treatment; because that agent abolishes opsonisation, pneumococcal and Hib cover are also required. Sutimlimab raises C4 towards normal and carries the same encapsulated-organism vaccination requirement as the other agents. Avacopan is the exception: blockade of C5aR1 leaves the membrane attack complex intact and creates no terminal-pathway defect. Of the interferon agents, anifrolumab suppresses the lupus interferon signature, and emapalumab neutralises IFN-γ in haemophagocytic lymphohistiocytosis, in which measured IFN-γ rises on treatment because the assay still detects the drug–cytokine complex, so CXCL9 is the marker used for monitoring. The JAK inhibitors are not biologics but block every JAK-STAT cytokine in this reference simultaneously, and do not affect TNF, IL-1, IL-17 and IL-18.

Scene 43 · Agents that act on the neutrophil, and the rule for reading any test on a biologic

The two neutrophil agents have converse actions, corresponding to the defects in Scene 33. Mavorixafor blocks CXCR4 and releases the neutrophils retained in the marrow in WHIM syndrome, so the count rises within hours, because the cells were present but retained. Recombinant G-CSF has the opposite action for the opposite defect and drives production; its effects include a left shift and toxic granulation that can be mistaken for sepsis, and a raised neutrophil CD64 that confounds CD64 as a sepsis marker. The final entry states the principle of which every other entry in these five scenes is an example. A test in a patient receiving a biologic addresses one of three questions, of which only the first concerns the patient: whether the test still reflects the disease, whether it now reflects the drug, or whether the drug has rendered it uninterpretable. A zero eosinophil count on benralizumab, an undetectable CH50 on eculizumab and a rising total IgE on omalizumab are all measures of drug effect. A CRP on tocilizumab cannot answer the clinical question. Two corollaries follow: the baseline should be measured before the first dose, and when a marker is abolished an alternative marker should be specified.

Scene 44 · Precision medicine I: JAK/STAT gain-of-function and the interferonopathies

The agents in Scenes 39 to 43 suppress a pathway that functions normally but is overactive. These four scenes differ: each agent is matched to a molecular defect, in accordance with the 2025 inborn errors of immunity practice parameter. In a JAK/STAT gain-of-function disorder the lesion is a signalling molecule that cannot be inactivated, so inhibition of the upstream kinase restores rather than suppresses signalling; it is the only medical therapy, other than transplantation, that addresses the lesion. Ruxolitinib or baricitinib is used for STAT1 gain-of-function, monitored by CXCL9 and Th17 numbers; ruxolitinib or tofacitinib for STAT3 gain-of-function, monitored by double-negative T cells, with the strongest recommendation in the group; ruxolitinib for STAT4 and STAT5b; and baricitinib or tofacitinib for SOCS1 haploinsufficiency, in which the inhibitor rather than the kinase is deficient but the functional result is the same. The same drugs treat the type I interferonopathies (USP18 deficiency, SAVI, Aicardi-Goutières syndrome and CANDLE), monitored by an interferon-activity score, the measure also used to monitor anifrolumab in lupus. There are no clinical trials in any of these disorders and the evidence is at cohort and case-report level, as the gradings indicate; early introduction may nevertheless determine whether the disease resolves. Dosing is derived from cohort experience, aciclovir prophylaxis is suggested because of the herpesvirus risk, and treatment is lifelong or until transplant. The converse condition should be distinguished: STAT1 loss-of-function affects the same molecule in the opposite direction and is treated with IFN-γ and not with a JAK inhibitor.

Scene 45 · Precision medicine II: the inflammasomopathies and IL-1 blockade

The inflammasome disorders are the clearest example of a disease explained by a single cytokine and controlled by its blockade. The three IL-1 agents are not interchangeable: anakinra blocks IL-1α as well as IL-1β, is cleared in 4 to 6 hours and probably has better central nervous system penetration, which is relevant in NOMID; rilonacept traps both, and IL-1RA as well, with a half-life of about a week; canakinumab neutralises IL-1β alone and persists for 22.9 to 25.7 days, which is convenient unless infection supervenes. All three are strongly recommended with high certainty in CAPS, and canakinumab in TRAPS, familial Mediterranean fever and mevalonate kinase deficiency; anakinra or rilonacept is recommended in deficiency of the IL-1 receptor antagonist, which is the most direct precision therapy in this reference, since anakinra is the molecule that is deficient in the disease. The evidence is weaker but the mechanism is the same in PAPA syndrome, NLRP12 disease, Majeed syndrome, NOCARH and NLRC4 disease. Two practical considerations apply to all of these disorders: the marker for monitoring between attacks is serum amyloid A rather than CRP, because sustained SAA elevation is the precursor of AA amyloid and a normal CRP does not establish control; and because the response is rapid, a trial of IL-1 blockade is used diagnostically without awaiting genetic results.

Scene 46 · Precision medicine III: the defect-specific agents

Six agents are each matched to one lesion. Leniolisib inhibits the PI3K-delta that is constitutively active in activated PI3K-delta syndrome; with interferon gamma-1b in chronic granulomatous disease, it is one of two agents in this group supported by a randomised placebo-controlled trial; it is licensed in the USA from 4 years and 27 kg, with weight-banded dosing under 12 years, and in Canada from 12 years and 45 kg, and its response markers are entities in this reference: serum IgM, which is characteristically high in APDS and falls markedly, transitional B cells, plasmablasts and the CD8 TEMRA compartment. CTLA-4–Ig supplies the inhibitory function lost in CTLA-4 haploinsufficiency and LRBA deficiency, monitored by circulating Tfh cells and soluble CD25; it is the same molecule that, in Scene 41, suppresses a normal immune system. Elapegademase replaces adenosine deaminase and should be started as soon as absent enzyme activity is demonstrated, without awaiting the genetic result, as a bridging therapy to transplantation or gene therapy. Interferon gamma-1b is the converse of emapalumab: the cytokine is administered rather than neutralised, three times a week in chronic granulomatous disease and in the Mendelian susceptibility to mycobacterial disease group. Oral fucose restores the selectin ligands in leukocyte adhesion deficiency type II, and they are lost again on discontinuation. The defects of cobalamin and folate transport and metabolism (TCN2, SLC46A1, MTHFD1 and cblF) can present with a picture resembling severe combined immunodeficiency and respond to cobalamin or folate replacement, most completely when treatment begins early; neurological impairment can persist when treatment is late. Total plasma homocysteine, methylmalonic acid and folate should therefore be measured before a diagnosis of SCID is made in an infant with an SCID-like presentation, because serum vitamin B12 can be normal in transcobalamin deficiency; on treatment, the blood count, vitamin B12 and folate are monitored.

Scene 47 · The backbone: immunoglobulin replacement, prophylaxis, vaccination and cure

Precision agents treat a minority of these patients; the measures described here are those received by the remainder. Immunoglobulin replacement is started at 400 to 600 mg/kg a month, intravenously every three to four weeks or divided into weekly or two-weekly subcutaneous infusions, with a target IgG above 800 mg/dL; pneumonia falls by about a quarter for each additional 100 mg/dL of trough, and a trough of 500 carries about five times the pneumonia rate of 1000, with no further benefit above 1000. The population target is a minimum and not an individual goal: the dose is individualised to the level at which the individual patient ceases to have infections. It supplies IgG only, so mucosal IgA protection is not restored, and all IgG-based serology then reflects the donor pool; the immunological evaluation must therefore precede the first infusion. Prophylaxis is directed at the organisms to which the specific defect confers susceptibility: trimethoprim-sulfamethoxazole and itraconazole with interferon gamma in chronic granulomatous disease, Pneumocystis and Candida cover in severe T-cell defects, azithromycin for respiratory infection in antibody deficiency and for environmental mycobacteria, and daily penicillin or amoxicillin in terminal complement defects and asplenia. Vaccination is not contraindicated as a whole: live replicating vaccines are withheld in severe cellular, phagocytic and humoral defects (vaccine-strain rotavirus, BCG and rubella have all caused disease), but patients with isolated T-cell lymphopenia and preserved function may receive them, household contacts may receive live vaccines other than oral polio and replication-competent smallpox/mpox vaccine, and COVID-19 and HPV vaccination are recommended for all patients. Transplantation and gene therapy are the only curative treatments, and several agents in the earlier scenes are accordingly described as treatment until transplant rather than as definitive therapy.


Master index · feedback loops and regulatory circuits

Seventeen regulatory circuits appear across the scenes above: ten feedback loops, one effector arm, one resolution switch, one coordinated hepatic output, two mutual-antagonism circuits, one competitive block, and the complement amplification loop. A loop means the output of a pathway eventually changes the input to that same pathway — trace each loop back to its start to confirm it closes.

  1. Positive · IL-12/IL-18 → IFN-gamma → IL-12 (Scene 2). IFN-gamma from the T cell or NK cell loops back to the macrophage and increases IL-12 transcription — the engine of the whole network.
  2. Negative · IFN-gamma → IL-18BP → caps IL-18 (Scene 2). The same IFN-gamma output also induces a binding protein that neutralizes free IL-18, capping the loop above from running away unchecked.
  3. Mutual antagonism · IFN-gamma ⊣ Th2, IL-4 ⊣ Th1 (Scenes 2 & 3). Not a single loop but a two-way suppressive circuit — each lineage's signature cytokine actively silences the other.
  4. Positive · IL-21 autocrine amplification (Scene 4). A Th17 cell's own IL-21 output signals back on its own IL-21 receptor, reinforcing its own identity independent of the loop in Scene 2.
  5. Negative · IL-10 and late IL-27 restrain the inflammation that induced them (Scenes 1 & 2). IL-10 → STAT3 switches on a suppressive gene programme that represses NF-kB target genes in the macrophage; late IL-27 restrains the IL-23/Th17 output mainly through STAT1 and by inducing IL-10. SOCS3, induced by both, additionally caps further gp130-family STAT3 signalling (IL-6, IL-27) — not IL-10R.
  6. Regulatory · IL-1RA occupies the IL-1 receptor (Scene 1). Not a transcriptional loop, but a direct competitive block — worth including because it's the fastest-acting brake in the atlas, no gene induction required.
  7. Positive · IFN-β → IRF7 → more IFN-α/β (Scene 8). IFN-β induces IRF7, which lets virus-sensing cells make much more type I interferon.
  8. Self-propagating · IL-35 → iTr35 conversion → more IL-35 (Scene 9). IL-35 converts the T cell it suppresses into a new IL-35 producer (infectious tolerance).
  9. Autocrine · IL-11 in fibroblasts (Scene 10). TGF-β-stimulated fibroblasts make IL-11 and respond to it themselves, sustaining the fibrotic programme.
  10. Amplification · C3b → C3bBb → more C3b (Scene 30). The alternative-pathway loop, stabilized by properdin, makes most of the C3b in any response whichever pathway started it — and factor H, factor I, DAF, MCP and CR1 are the brakes that keep it off host surfaces.
  11. Resolution switch · efferocytosis → IL-10 and TGF-β → less IL-23 (Scenes 33, 34). Eating apoptotic neutrophils switches the macrophage to a suppressive programme, which actively ends the response rather than merely stopping it. Stated on its own this is an arm, not a loop: it closes only by continuing through IL-17 and G-CSF back to granulopoiesis, which is the circuit below.
  12. Effector arm · IL-6 → hepcidin → ferroportin degraded → iron withheld (Scene 38). Iron is pulled out of the plasma to starve organisms of it; sustained, the same axis produces the anaemia of inflammation, and erythroferrone from an expanding erythron is the counter-signal that switches hepcidin back off.
  13. Coordinated output · IL-6 → CRP and SAA, IL-6 ⊣ albumin and transferrin (Scene 35). One hepatocyte programme raises the positive reactants and lowers the negative ones at the same time, which is why a falling albumin and a rising CRP are the same event read twice.
  14. Negative · few apoptotic neutrophils ingested → IL-23 → IL-17 → G-CSF → granulopoiesis (Scene 33). The marrow senses how many apoptotic neutrophils are being ingested; when few are, G-CSF rises — the loop behind the high G-CSF of neutropenia.
  15. Negative · IgG → FcγRIIb → less antibody (Scenes 25, 28). IgG immune complexes co-ligate the inhibitory Fc receptor on the B cell that made them, raising its activation threshold.
  16. Negative · IgE → CD23 → IgE synthesis (Scenes 27, 28). Membrane CD23 feeds back on IgE production, while the shed soluble form can push it either way.
  17. Mutual antagonism · Tfh IL-21 ⊣ Tfr, and Tfr ⊣ Tfh (Scene 20). IL-21 restricts Tfr proliferation by lowering CD25 and IL-2 responsiveness through Bcl-6, while Tfr limits Tfh help in return. Two mutual inhibitions, so the circuit closes with a net positive sign: it sharpens the balance between help and restraint rather than damping it.

JAK-STAT signalling

Most interleukins and interferons in this atlas signal through Janus kinases (JAK1/2/3, TYK2) phosphorylating STAT transcription factors — every blue/purple cascade drawn above. The TNF superfamily, the IL-1 and IL-17 families, the receptor-tyrosine-kinase growth factors (M-CSF, IL-34, SCF, Flt-3L, EGF, TGFα, FGF-2, PDGF, VEGF-A), cytotoxic granule proteins, and all chemokines do not — every amber (NF-κB), olive (receptor tyrosine kinase), red (death receptor / granule), grey (decoy / CD4) or teal (chemokine) cascade above. "Suppression" via JAK-STAT is almost always indirect: a STAT drives transcription of a suppressor gene (most often SOCS1/SOCS3) that then caps further cytokine signalling. The Clinical correlate column below is a compressed pointer, not a full account — for clinical presentation, cytokine profile, and diagnostic workup on each of these, see the companion Pathway → Phenotype Chart.

JAK-STAT-dependent (31 of 95)

CytokineJAKsPrimary STAT(s)Net effectClinical correlate if disruptedMain scene
TSLPJAK1, JAK2STAT5Induction — Th2-priming programme in DCsTezepelumab (anti-TSLP) approved for severe asthma and CRSwNP; TSLP variants associate with asthma; CRLF2 rearrangement in Ph-like ALLScene 7
IL-10JAK1, TYK2STAT3Suppression — STAT3-induced programme represses NF-κB target genesLigand or receptor LOF (IL10, IL10RA, IL10RB) → very early-onset inflammatory bowel diseaseScene 1
IL-35JAK1, JAK2STAT1 + STAT4 heterodimerSuppression — iTr35 conversion, anti-proliferativeNo monogenic disease; constitutive production by human Tregs is still debatedScene 9
IL-12p70JAK2, TYK2STAT4Induction — T-bet, drives Th1LOF (IL12B/IL12RB1) → MSMD; STAT4 GOF → disabling pansclerotic morphea (JAK-inhibitor responsive)Scene 2
IL-27JAK1, JAK2, TYK2STAT1 and STAT3 (dual, sequential)Both — early STAT1 supports Th1; late STAT1+3 suppresses Th17, induces IL-10Biallelic IL27RA LOF → severe but self-limited primary EBV infection (infectious mononucleosis)Scene 2
IFNγJAK1, JAK2STAT1 (GAF)Induction — macrophage activation, IL-12 amplificationReceptor LOF (IFNGR1/2) → MSMD, severity tracks AD-partial vs AR-complete inheritanceScene 2
IFNα2JAK1, TYK2STAT1/STAT2 + IRF9 (ISGF3)Induction — antiviral genesLOF (IFNAR/STAT1/2/IRF9) → severe/fatal viral infection; pathway dysregulation → type I interferonopathies (SAVI, CANDLE, AGS)Scene 5
IFNβJAK1, TYK2STAT1/STAT2 + IRF9 (ISGF3)Induction — antiviral genes; IRF7 amplificationIFN-β therapy for relapsing MS; IFNAR1 / IFNAR2 LOF → severe disease from live vaccines and virusesScene 8
IFNωJAK1, TYK2STAT1/STAT2 + IRF9 (ISGF3)Induction — antiviral genesNeutralizing autoantibodies to IFN-α and/or IFN-ω in ~10–20% of critical COVID-19 pneumonia and in almost all APS-1 (AIRE) patientsScene 8
IL-28AJAK1, TYK2STAT1/STAT2 + IRF9 (ISGF3)Induction — antiviral genes at barriersVariants at the neighbouring IFNL3 (IL28B) / IFNL4 genes, not IL-28A itself, predict spontaneous and treatment-induced hepatitis C clearanceScene 8
IL-29JAK1, TYK2STAT1/STAT2 + IRF9 (ISGF3)Induction — antiviral genes at barriersPegylated IFN-λ1 tested in hepatitis D and COVID-19; no monogenic diseaseScene 8
IL-4JAK1, JAK3 (type I) / JAK1, JAK2, TYK2 (type II)STAT6Induction — GATA3, IgE class switchCommon IL4RA variants (e.g., Q576R; functional effect debated) associate with atopy/asthma; pathway overactivity → atopic dermatitis (dupilumab)Scene 3
IL-5JAK1, JAK2STAT5 (shares beta-c with GM-CSF)Induction — eosinophil genesPathway overactivity → hypereosinophilic syndrome (mepolizumab and benralizumab FDA-approved for HES; benralizumab also approved for EGPA)Scene 3
IL-9JAK1, JAK3STAT5 (also STAT1/3)Induction — mast cell growth genesNo dedicated monogenic disease; shares the γc/JAK3 machinery with the SCID genesScene 3
IL-13JAK1, JAK2, TYK2STAT6Induction — Th2 effector genesSame overactivity axis as IL-4 → atopic dermatitis (dupilumab, tralokinumab, lebrikizumab) and asthma (dupilumab)Scene 3
IL-31JAK1, JAK2STAT3 (mainly; also STAT1/5)Induction — pruritus signalling genesPathway overactivity → chronic pruritus in atopic dermatitis and prurigo nodularis (nemolizumab)Scene 3
IL-21JAK1, JAK3STAT3 (also STAT1)Induction — Th17 autocrine loop, B cell helpIL21R LOF → combined immunodeficiency with Cryptosporidium cholangitis / liver disease; IL21 LOF → very-early-onset IBD with CVID-like featuresScene 4
IL-22JAK1, TYK2STAT3Induction — epithelial antimicrobial genesFalls with broader STAT3 defects; no isolated IL-22 monogenic disease describedScene 4
IL-23JAK2, TYK2STAT3Induction — stabilizes RORγt+ Th17 / ILC3; IL-17 and IL-22 genesPathway overactivity → psoriasis, IBD (guselkumab, risankizumab); IL23R reduced-function variant is protectiveScene 2, 4
IL-20JAK1, TYK2STAT3Induction — keratinocyte proliferationOver-expressed in psoriatic skin and RA synovium; no monogenic diseaseScene 10
IL-24JAK1, TYK2STAT3Induction — keratinocyte proliferation; ↓ filaggrinRaised in atopic-dermatitis and psoriasis lesions; no monogenic diseaseScene 10
IL-2JAK1, JAK3STAT5Induction — proliferation genesIL2RA (CD25) LOF → IPEX-like immune dysregulationScene 5
IL-7JAK1, JAK3STAT5Induction — survival genesIL7R LOF → SCID, T-B+NK+ phenotypeScene 5
IL-15JAK1, JAK3STAT5Induction — NK/memory CD8 survival (trans-presented)No dedicated monogenic disease; shares JAK3 with the SCID genesScene 5
IL-6JAK1, JAK2, TYK2STAT3Induction — acute-phase genes (hepatocyte); Th17 supportSTAT3 node shared with Job syndrome; drives CRP/SAA in autoinflammation; tocilizumab targetScene 4, 5
IL-11JAK1 (JAK2, TYK2)STAT3Induction — fibrotic (largely ERK-dependent) and megakaryocyte genesIL11RA LOF → craniosynostosis with delayed tooth eruption; recombinant IL-11 (oprelvekin) once used for chemotherapy thrombocytopeniaScene 10
LIFJAK1 (JAK2, TYK2)STAT3Induction — mouse ES-cell self-renewal / acute-phase genesLIFR LOF → Stüve–Wiedemann syndrome (bowed long bones, dysautonomia, hyperthermia)Scene 10
IL-3JAK2STAT5Induction — progenitor, basophil, mast-cell genesCD123 targeted by tagraxofusp (BPDCN); no monogenic diseaseScene 11
GM-CSFJAK2STAT5Induction — myeloid genesReceptor LOF or anti-GM-CSF autoantibodies → pulmonary alveolar proteinosisScene 5
G-CSFJAK1, JAK2STAT3 (also STAT5)Induction — neutrophil granule / release genesAcquired CSF3R truncations in severe congenital neutropenia herald AML; CSF3R T618I → chronic neutrophilic leukaemia; filgrastimScene 11
TPOJAK2STAT5 (also STAT3)Induction — megakaryocyte growth genesMPL LOF → congenital amegakaryocytic thrombocytopenia; JAK2 V617F / MPL W515 → ET and myelofibrosis; TPO-receptor agonists for ITPScene 11

Not JAK-STAT (64 of 95) — separate signalling pathways

CytokinePathway classReceptorSignallingClinical correlate if disruptedMain scene
IL-1αNF-κB familyIL-1R1 + IL-1RAcPMyD88 / IRAK4 / TRAF6 → NF-κB, MAPKShares IL-1R1 with IL-1β (anakinra blocks both); MyD88/IRAK4 LOF → pyogenic infection with blunted feverScene 1
IL-1βNF-κB familyIL-1R1 + IL-1RAcPMyD88 / IRAK4 / TRAF6 → NF-κB, MAPKNLRP3 GOF → CAPS (anakinra, canakinumab, rilonacept); IL-1 blockade in Still’s disease and goutScene 1
IL-18NF-κB familyIL-18Rα + IL-18RβMyD88 / IRAK → NF-κBNLRC4 GOF → very high free IL-18 and macrophage activation syndrome; serum IL-18 marks MAS risk in Still’s / sJIAScene 1, 2
TNFαNF-κB familyTNFR1 (p55), TNFR2 (p75)TRADD / TRAF2 / RIPK1 → NF-κB, MAPK; or caspase-8 deathDominant TNFRSF1A mutations → TRAPS; anti-TNF therapy unmasks latent TBScene 1
TNFβNF-κB familyTNFR1, TNFR2, HVEM (and LTβR as LTα1β2)TRADD / TRAF2 → NF-κBLTα / LTβR needed for lymphoid-organ development (mouse knockouts lack lymph nodes); shares TNFR1 with TNF-αScene 1
HMGB1NF-κB familyRAGE; TLR4 (disulfide form); CXCR4 when complexed with CXCL12 (reduced form)TLR4 → MyD88 → NF-κB; RAGE → MAPK / NF-κBLate mediator and biomarker of lethal sepsis and sterile injury; no monogenic diseaseScene 7
IL-33NF-κB familyST2 (IL1RL1) + IL-1RAcP; soluble ST2 is a decoyMyD88 / IRAK → NF-κB, MAPKIL33 and IL1RL1 are leading asthma GWAS loci; anti-IL-33 / anti-ST2 antibodies are in COPD and asthma trialsScene 7
IL-17E/IL-25NF-κB familyIL-17RA + IL-17RBAct1 → TRAF6 → NF-κBNo monogenic disease; raised in asthmatic airways and atopic-dermatitis lesionsScene 7
IL-17ANF-κB familyIL-17RA + IL-17RCAct1 → TRAF6 → NF-κB, C/EBPβReceptor / adaptor LOF (IL17RA, IL17RC, ACT1 / TRAF3IP2) → chronic mucocutaneous candidiasis; overactivity → psoriasis (secukinumab, ixekizumab)Scene 4
IL-17FNF-κB familyIL-17RA + IL-17RC (as homodimer or IL-17A/F heterodimer)Act1 → TRAF6 → NF-κB, C/EBPβDominant IL17F LOF → chronic mucocutaneous candidiasis; bimekizumab blocks IL-17A and IL-17F (psoriasis, hidradenitis)Scene 10
BAFFNF-κB familyBAFF-R (BR3), TACI, BCMATRAF3 degradation → NIK → non-canonical NF-κB (p52 / RelB)TNFRSF13C (BAFF-R) LOF → CVID-like B lymphopenia; belimumab (anti-BAFF) for SLE; BAFF high in SLE and Sjögren’sScene 13
APRILNF-κB familyTACI, BCMA (plus heparan sulfate proteoglycans)TRAF → canonical and non-canonical NF-κBTNFRSF13B (TACI) variants in ~8–10% of CVID (risk modifiers); BCMA is a CAR-T / bispecific target in myeloma; anti-APRIL agents in IgA nephropathyScene 13
sCD40LNF-κB familyCD40 (also αIIbβ3 and Mac-1 integrins)TRAF2/3/5/6 → canonical and non-canonical NF-κBCD40LG LOF → X-linked hyper-IgM syndrome (Pneumocystis, Cryptosporidium cholangitis); plasma sCD40L tracks platelet activationScene 13
IL-1RAAntagonist / decoyIL-1R1 (occupies without recruiting IL-1RAcP)Competitive block — no signalIL1RN LOF → DIRA (neonatal pustulosis, osteitis); anakinra is recombinant IL-1RAScene 1
IL-12p40Antagonist / decoyIL-12Rβ1 (as free p40 or p40 homodimer)Occupies IL-12Rβ1 without STAT activation — competitive antagonist of IL-12 / IL-23 (mainly in mice)IL12B LOF → MSMD (loses IL-12 and IL-23); ustekinumab targets p40 (psoriasis, Crohn’s)Scene 9
sCD137Antagonist / decoyBinds 4-1BBL (CD137L) — decoyNo signal; blocks 4-1BB co-stimulationTNFRSF9 (membrane 4-1BB) LOF → EBV-driven lymphoproliferation; 4-1BB agonists studied in cancer immunotherapyScene 9
sFasAntagonist / decoyBinds FasL — decoyNo signal; blocks Fas-mediated apoptosisRaised in SLE and several cancers; FAS germline / somatic LOF → ALPSScene 9
M-CSFReceptor tyrosine kinaseCSF1R (c-FMS)Receptor tyrosine kinase → PI3K / AKT, ERKCSF1R LOF → adult-onset leukoencephalopathy (ALSP); CSF1R inhibitor pexidartinib for tenosynovial giant-cell tumourScene 11
IL-34Receptor tyrosine kinaseCSF1R (also PTPRZ1, syndecan-1)Receptor tyrosine kinase → PI3K / AKT, ERKNo monogenic disease; raised in RA synoviumScene 11
SCFReceptor tyrosine kinaseKIT (CD117)Receptor tyrosine kinase → PI3K / AKT, MAPK, (STAT)KIT D816V → systemic mastocytosis (avapritinib, midostaurin); KIT LOF → piebaldism; anti-KIT antibody trials in chronic urticariaScene 11
Flt-3 LigandReceptor tyrosine kinaseFLT3 (CD135)Receptor tyrosine kinase → PI3K / AKT, RAS / MAPK, STAT5FLT3-ITD / TKD mutations in ~30% of AML (midostaurin, gilteritinib); serum Flt-3L rises in marrow aplasiaScene 11
EGFReceptor tyrosine kinaseEGFR (ErbB1)Receptor tyrosine kinase → RAS / MAPK, PI3K / AKT, PLCγEGFR LOF → neonatal inflammatory skin and bowel disease; EGFR inhibitors cause acneiform rash and paronychiaScene 12
TGFαReceptor tyrosine kinaseEGFR (ErbB1)Receptor tyrosine kinase → RAS / MAPK, PI3K / AKTADAM17 LOF (cannot shed TGF-α or TNF-α) → neonatal inflammatory skin and bowel disease; over-expressed in psoriasisScene 12
FGF-2Receptor tyrosine kinaseFGFR1–4 + heparan sulfateReceptor tyrosine kinase → RAS / MAPK, PI3K, PLCγRaised in asthmatic airways after allergen challenge; no monogenic diseaseScene 12
PDGF-AAReceptor tyrosine kinasePDGFRα homodimerReceptor tyrosine kinase → PI3K, PLCγ, RAS / MAPKFIP1L1-PDGFRA fusion → myeloid neoplasm with eosinophilia (imatinib-responsive); PDGFRA GOF → GISTScene 12
PDGF-AB/BBReceptor tyrosine kinasePDGFRαα, PDGFRαβ, PDGFRββ (BB binds all three; AB binds αα and αβ)Receptor tyrosine kinase → PI3K, PLCγ, RAS / MAPKPDGFRB fusions (e.g., ETV6-PDGFRB) → myeloid neoplasm with eosinophilia (imatinib-responsive); becaplermin (rhPDGF-BB) for diabetic ulcersScene 12
VEGF-AReceptor tyrosine kinaseVEGFR2 (KDR) + neuropilin-1; VEGFR1 (FLT1) as a high-affinity sinkReceptor tyrosine kinase → PLCγ / ERK, PI3K / AKT / eNOSAnti-VEGF therapy (bevacizumab, intravitreal agents); serum VEGF is a diagnostic marker of POEMS syndromeScene 12
sFasLDeath receptorFas (CD95)FADD → caspase-8 → caspase-3 (soluble form is a weak killer)Serum sFasL >200 pg/mL is a diagnostic biomarker of ALPS; FASLG LOF → ALPS-FASLG; Fas–FasL in SJS/TEN keratinocyte deathScene 14
TRAILDeath receptorDR4 (TRAIL-R1), DR5 (TRAIL-R2); decoys DcR1, DcR2, OPGFADD → caspase-8 → caspase-3; also NF-κBNo monogenic disease; serum TRAIL (with IP-10, CRP) separates viral from bacterial infection in host-response assaysScene 14
PerforinCytotoxic granuleInserts into the target-cell membrane (Ca²⁺-dependent)Forms pores → delivers granzymesBiallelic PRF1 LOF → familial HLH type 2; perforin flow cytometry in the HLH work-upScene 14
Granzyme ACytotoxic granuleEnters through perforin pores (extracellular actions via unknown receptors)Cleaves SET complex → single-strand DNA nicks (caspase-independent); cleaves gasdermin BRaised in sepsis and RA synovial fluid; no monogenic diseaseScene 14
Granzyme BCytotoxic granuleEnters through perforin poresCleaves BID and caspase-3/7 → mitochondrial apoptosisNo monogenic disease; extracellular granzyme B rises with cytotoxic activation (e.g., SJS/TEN blister fluid)Scene 14
IL-8Chemokine GPCRCXCR1, CXCR2Gαi → PI3K, Rho GTPases, Ca²⁺ fluxCXCR2 / IL-8 axis drives neutrophilic airway disease; no monogenic diseaseScene 6
GROαChemokine GPCRCXCR2Gαi → PI3K, Rho GTPases, Ca²⁺ fluxNo monogenic diseaseScene 6
ENA-78Chemokine GPCRCXCR2Gαi → PI3K, Rho GTPases, Ca²⁺ fluxRaised in neutrophilic lung inflammation; no monogenic diseaseScene 15
GCP-2Chemokine GPCRCXCR1, CXCR2Gαi → PI3K, Rho GTPases, Ca²⁺ fluxNo monogenic diseaseScene 15
IP-10Chemokine GPCRCXCR3Gαi → PI3K, Ca²⁺ fluxHost-response marker of viral infection (with TRAIL, CRP); raised in IFN-driven diseasesScene 6
MIGChemokine GPCRCXCR3Gαi → PI3K, Ca²⁺ fluxSerum CXCL9 reflects IFN-γ activity in HLH / MAS and was used to track emapalumab responseScene 15
I-TACChemokine GPCRCXCR3 (highest affinity); ACKR3 scavengerGαi → PI3K, Ca²⁺ fluxRaised in allograft rejection; C57BL/6 laboratory mice lack functional CXCL11Scene 15
MCP-1Chemokine GPCRCCR2Gαi → PI3K, Ca²⁺ fluxNo monogenic disease; the classical-monocyte recruitment axis in atherosclerosis and fibrosisScene 6
MCP-2Chemokine GPCRCCR1, CCR2, CCR3, CCR5 (CCR8 in mice)Gαi → PI3K, Ca²⁺ fluxNo monogenic diseaseScene 16
MCP-3Chemokine GPCRCCR1, CCR2, CCR3 (CCR5 antagonist)Gαi → PI3K, Ca²⁺ fluxNo monogenic diseaseScene 16
MIP-1αChemokine GPCRCCR1, CCR5Gαi → PI3K, Ca²⁺ fluxNo monogenic disease; homozygous CCR5 Δ32 (no surface CCR5) → near-complete R5 HIV-1 resistance; heterozygotes progress more slowlyScene 6
MIP-1βChemokine GPCRCCR5Gαi → PI3K, Ca²⁺ fluxNo monogenic disease; homozygous CCR5 Δ32 → R5 HIV-1 resistanceScene 6
MIP-1δChemokine GPCRCCR1, CCR3Gαi → PI3K, Ca²⁺ fluxNo monogenic diseaseScene 16
MPIF-1Chemokine GPCRCCR1Gαi → PI3K, Ca²⁺ fluxNo monogenic diseaseScene 16
RANTESChemokine GPCRCCR1, CCR3, CCR5Gαi → PI3K, Ca²⁺ fluxNo monogenic disease; CCR5 antagonist maraviroc blocks R5 HIVScene 6
EotaxinChemokine GPCRCCR3Gαi → PI3K, Ca²⁺ fluxNo monogenic diseaseScene 6
Eotaxin-2Chemokine GPCRCCR3Gαi → PI3K, Ca²⁺ fluxRaised in late-phase asthmatic airways; no monogenic diseaseScene 17
Eotaxin-3Chemokine GPCRCCR3 (also a CX3CR1 agonist and a CCR1, CCR2, CCR5 antagonist)Gαi → PI3K, Ca²⁺ fluxCCL26 is the most up-regulated gene in eosinophilic-oesophagitis biopsies; falls with effective therapyScene 17
MCP-4Chemokine GPCRCCR1, CCR2, CCR3Gαi → PI3K, Ca²⁺ fluxRaised in atopic-dermatitis skin and asthmatic airways; no monogenic diseaseScene 17
TARCChemokine GPCRCCR4Gαi → PI3K, Ca²⁺ fluxSerum TARC is the best-validated biomarker of atopic-dermatitis severity; also raised in classic Hodgkin lymphoma and DRESSScene 17
MDCChemokine GPCRCCR4Gαi → PI3K, Ca²⁺ fluxRaised in atopic dermatitis and asthma; mogamulizumab (anti-CCR4) treats mycosis fungoides / Sézary syndrome (ATLL in Japan)Scene 17
I-309Chemokine GPCRCCR8Gαi → PI3K, Ca²⁺ fluxCCR8 is a tumour-Treg depletion target in oncology trials; no monogenic diseaseScene 17
SDF-1Chemokine GPCRCXCR4 (ACKR3 = scavenger)Gαi → PI3K, Ca²⁺ fluxCXCR4 GOF → WHIM syndrome (oral CXCR4 antagonist mavorixafor approved 2024, 12 years and over); plerixafor mobilizes stem cellsScene 6
6CkineChemokine GPCRCCR7Gαi → PI3K, Ca²⁺ flux; integrin activationNo monogenic disease; CCR7 on tumour cells favours lymph-node metastasisScene 18
MIP-3βChemokine GPCRCCR7Gαi → PI3K, Ca²⁺ fluxNo monogenic diseaseScene 18
BCA-1Chemokine GPCRCXCR5Gαi → PI3K, Ca²⁺ fluxPlasma CXCL13 is a germinal-centre activity marker; CSF CXCL13 marks Lyme neuroborreliosis and CNS lymphomaScene 18
MIP-3αChemokine GPCRCCR6 (its only chemokine receptor; β-defensin-2 is also reported to bind CCR6)Gαi → PI3K, Ca²⁺ fluxKeratinocyte CCL20 sustains psoriatic Th17 infiltration; CCR6 variants associate with RAScene 18
CTACKChemokine GPCRCCR10Gαi → PI3K, Ca²⁺ fluxSerum CCL27 tracks atopic-dermatitis severityScene 18
CCL28Chemokine GPCRCCR10, CCR3Gαi → PI3K, Ca²⁺ fluxNo monogenic diseaseScene 18
LymphotactinChemokine GPCRXCR1Gαi → PI3K, Ca²⁺ fluxNo monogenic disease; XCR1 is a target for DC-directed vaccinesScene 18
FractalkineChemokine GPCRCX3CR1Gαi + direct adhesion (membrane-anchored on a mucin stalk; ADAM10/17 shed)CX3CR1 variants (V249I / T280M) associate with atherosclerosis and macular degenerationScene 18
IL-16Other (CD4)CD4 (with CD9) — not a GPCRCD4-associated Lck signalling → migration, IL-2Rα (CD25) expressionRaised in asthmatic airways after allergen challenge; no monogenic diseaseScene 17

The suppression mechanism worth naming explicitly: JAK-STAT cytokines frequently cap their own or each other's signalling by inducing SOCS (suppressor of cytokine signalling) proteins. IFN-gamma induces SOCS1; IL-6, IL-10, and IL-27 induce SOCS3. Once expressed, SOCS proteins bind JAKs or receptor docking sites and block further STAT activation — SOCS3 mainly caps signalling from the gp130 family (IL-6, IL-27), which is why IL-6 and IL-10 give opposite outcomes through the same STAT3. IL-10's own anti-inflammatory effect does not depend on SOCS3: it comes from a STAT3-induced suppressive gene programme (Scene 1).

Glossary

The signalling vocabulary used throughout this atlas. For clinical/genetic terminology (disease names, inheritance patterns, diagnostic tests), see the glossary in the companion Pathway → Phenotype Chart.

JAK — Janus kinase (JAK1, JAK2, JAK3, TYK2); phosphorylates STATs after receptor engagement
STAT — signal transducer and activator of transcription; dimerizes and enters the nucleus after JAK phosphorylation
ISGF3 — interferon-stimulated gene factor 3, the STAT1/STAT2/IRF9 heterotrimer activated by type I and type III interferons
GAF — gamma-activated factor, the STAT1 homodimer activated by IFN-gamma
IRF9 — interferon regulatory factor 9, the DNA-binding partner in ISGF3
SOCS — suppressor of cytokine signalling; a STAT-induced brake that blocks JAKs or receptor docking sites
NF-κB — nuclear factor kappa-light-chain-enhancer of activated B cells; the transcription factor at the centre of Scene 1
TRADD / TRAF2 — adaptor proteins linking TNFR1 to NF-κB (TNFR2 recruits TRAF2 directly, without TRADD)
MyD88 / IRAK — adaptor proteins linking IL-1-family and IL-18 receptors to NF-κB
Act1 — the adaptor linking all IL-17-family receptors (IL-17A, IL-17F, IL-25) to NF-κB and C/EBP, independent of MyD88
GPCR — G-protein coupled receptor; the 7-transmembrane receptor family used by all chemokines
γc — the common gamma chain, shared by the IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 receptors
T-bet — the master transcription factor for Th1 identity, induced downstream of IFN-gamma/STAT1 and IL-12/STAT4
RORγt — the master transcription factor for Th17 identity, induced by IL-6 (or IL-21) plus TGF-β via STAT3; IL-23 stabilizes rather than initiates it
GATA3 — the master transcription factor for Th2 identity, induced downstream of IL-4/STAT6
Trans-presentation — a cytokine (IL-15) held on one cell's receptor and handed directly to a neighbouring cell, rather than freely diffusing
Feedback loop — a pathway whose own output changes the input to that same pathway; marked with ↻ in Scenes 1–6 and drawn as a pink return arrow in Scenes 8–10
RTK — receptor tyrosine kinase; ligand-induced receptor dimers phosphorylate each other and recruit RAS/MAPK, PI3K/AKT and PLCγ (KIT, FLT3, CSF1R, EGFR, FGFR, PDGFR, VEGFR)
gp130 — shared signalling chain of the IL-6 family (IL-6, IL-11, LIF), also used by the IL-12-family cytokines IL-27 and IL-35; pairs with JAK1
βc — common beta chain shared by the IL-3, IL-5 and GM-CSF receptors; signals mainly through JAK2/STAT5 (the IL-5Rα chain also engages JAK1)
ST2 — IL1RL1, the IL-33 receptor; its soluble form (sST2) is a decoy
Non-canonical NF-κB — NIK-driven p52/RelB pathway used by BAFF-R and other TNF-family receptors
BAFF-R / TACI / BCMA — the three B-cell receptors for BAFF; APRIL binds only TACI and BCMA; BCMA dominates on long-lived plasma cells
Decoy receptor — a receptor (often soluble) that binds a ligand without signalling, e.g. sFas, sCD137, sST2, IL-22BP, DcR1/DcR2
FADD / caspase-8 — adaptor and initiator protease downstream of Fas and TRAIL death receptors
Granule exocytosis — release of perforin and granzymes from CTL/NK granules onto a target cell
IFN-λ (type III IFN) — IFN-λ1–4 (IL-29, IL-28A, IL-28B, IFN-λ4); act via IFNLR1/IL-10R2, largely restricted to epithelium and hepatocytes
Alarmin — a mediator stored in, or rapidly released by, damaged or stressed cells that signals danger (IL-33, IL-1α, HMGB1); epithelial TSLP and IL-25 are usually grouped with them
AID — activation-induced cytidine deaminase (AICDA); performs both somatic hypermutation and class-switch recombination in the germinal centre
Class-switch recombination — irreversible DNA recombination that changes the antibody constant region (the isotype) while keeping the same antigen-binding site
Somatic hypermutation — AID-driven point mutation of the immunoglobulin variable region in the germinal-centre dark zone, the basis of affinity maturation
TSDR — Treg-specific demethylated region of FOXP3; demethylation marks a stable thymic regulatory T cell
ITAM / ITIM — activating and inhibitory tyrosine motifs in receptor tails; ITAMs recruit Syk, ITIMs recruit SHIP-1 and raise the activation threshold
Fab-arm exchange — exchange of half-molecules between IgG4 antibodies, which renders IgG4 functionally monovalent and unable to cross-link antigen
Secretory component — the portion of pIgR that remains attached to dimeric IgA after transcytosis; it protects secretory IgA from proteolysis
Convertase — the complement enzyme that cleaves C3 (C4b2a or C3bBb) or C5 (C4b2a3b or C3bBb3b)
Anaphylatoxin — C3a and C5a, the small fragments that act on GPCRs to trigger mast-cell release, vascular leak and (for C5a) neutrophil recruitment
Opsonin — a molecule that coats a target and is recognized by a phagocyte receptor: IgG for FcγR, C3b for CR1, iC3b for CR3
MAC — membrane attack complex, C5b-9; blocked on host cells by CD59
CH50 / AH50 — functional assays of the entire classical and entire alternative pathway; interpreted together they localize a deficiency
Tick-over — spontaneous hydrolysis of C3 in plasma, which initiates the alternative pathway without a recognition molecule
Efferocytosis — phagocytosis of apoptotic cells; it switches the macrophage to an IL-10 and TGF-β programme and resolves inflammation
NET — neutrophil extracellular trap, chromatin bearing granule enzymes that is released to trap organisms, and a source of autoantigen
Myelokathexis — retention of mature neutrophils in the marrow, as in WHIM syndrome
Trm — tissue-resident memory T cell, retained in tissue by CD69 and CD103 and not recirculating
Acute-phase response — the coordinated change in hepatocyte protein synthesis driven mainly by IL-6, with IL-1β and TNF-α; it begins within hours and represents a reprogramming of hepatic protein synthesis rather than a change in a single marker
Positive / negative reactant — a plasma protein whose concentration rises (CRP, SAA, fibrinogen, haptoglobin, ferritin) or falls (albumin, transferrin, transthyretin) during the acute-phase response; both arms are driven by the same signal
hs-CRP — the same analyte as CRP on a lower-range assay, used for cardiovascular risk; the AHA/CDC bands assume two samples two weeks apart, and a value over 10 mg/L is regarded as an indication to seek an acute cause rather than as a risk category
Westergren method — the reference ESR technique: the distance red cells fall in a vertical tube in one hour
Rouleaux — stacking of red cells bridged by fibrinogen and immunoglobulin; it causes the ESR to rise, and red-cell shape changes that prevent it lower the ESR
AA amyloidosis — deposition of SAA-derived fibrils after years of uncontrolled inflammation, classically presenting as proteinuria
Anaemia of inflammation — hepcidin-driven iron restriction: low serum iron and transferrin saturation with a normal or high ferritin, distinguishing it from iron deficiency
← Explorer & search Full atlas Poster